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Head & Neck Cancer
Patients with head & neck cancer (HNC) can have a variety of malignancies which 
originate from the paranasal sinuses, nasal cavity, oral cavity, oro-, naso- or hy-
popharynx, larynx, thyroid gland or from the major or minor salivary glands. Except 
for the thyroid gland, the great majority of these cancers are of squamous cell type 
origin. HNC is the sixth most common type of cancer in humans, representing about 
6% of all malignancies and accounting for an estimated 650,000 new cancer cases 
and 350,000 cancer deaths worldwide, annually. Moreover, an increase in cancers 
of the base of tongue, and tonsillar fossa and/or soft palate has been noted, especi-
ally in young adults in the USA and in some European countries 1. A high number of 
cases are reported in particular areas of the Western world, e.g. in France (oral cavi-
ty tumors), in the Mediterranean basin (cancer of the nasopharynx), and in countries 
like India (oral cavity tumors), and East and South East Asia (Hong Kong, Indonesia; 
cancer of the nasopharynx). This geographical variation is likely to be related to the 
high incidence of risk factors in these areas. Tobacco and alcohol consumption are 
implicated in 75% of all HNC and have a multiplicative combined effect. In non-smo-
kers, substantial alcohol consumption (≥ 3 drinks per day) has been associated with 
increased risk of developing HNC 2. On the other hand, consumption of fruits and ve-
getables has been associated with a reduced risk of HNC. Familial inheritance has 
also been noted as a risk factor. The role of certain viral agents in the pathogenesis 
of HNC is well appreciated (Human papillomavirus (HPV), type 16 and – to a lesser 
extent – type 18). The association between HPV and HNC is strongest for cancers of 
the tonsil, intermediate for the rest of the oropharynx and weakest for the oral cavity 
and larynx. HPV positivity is a favorable prognostic factor in HNC 3. These patients 
respond better to radiotherapy (RT), chemotherapy (CHT) or both. Epstein-Barr vi-
rus (EBV) has long been associated with nasopharyngeal carcinoma. Antibody titers 
to EBV have been found to be elevated in nasopharyngeal carcinoma regardless of 
their ethnic and geographic origin.
The median age of patients with HNC is early 60, with a male predominance. More 
than 50% of the new cases have locally advanced disease and require an aggressive 
combined modality treatment approach. Early recognition of symptoms and signs of 
HNC is important for prompt diagnosis. Accurate staging is in fact the most important 
factor in HNC that guides therapeutic decision making. Distant metastases at initial 
presentation are uncommon, arising in about 10% of the patients 3. Second primary 
tumors develop at a rate of 3–5% every year 4. Surgery is one of the two standard 
treatment options for HNC, but its execution is frequently limited by the anatomical 
extent of the tumor and by the desire to achieve organ (function) preservation.
Radiotherapy
Radiotherapy is next to surgery one of the two most effective modalities for treating 
HNC. In fact, in this era of organ (function) preservation, radiotherapy has even 
replaced surgery with regard to long-term tumor control, cosmesis and quality of 
life (QoL) in some HNC sites (e.g. the oropharynx). Chapter 2 will describe in depth 
the treatment of oropharyngeal cancer, which is taken from our chapter 42 of Perez 
and Brady's Principles and Practice of Radiation Oncology 2007. Due to the routine 
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implementation of sparing techniques, such as IMRT; they play a crucial role in 
the improvement of dose distributions (sparing) and ability to dose escalate bey-
ond dose-levels that are conventionally achieved. Although side-effects (dysphagia 
/ xerostomia / trismus) are not negligible as will described in more detail in chapters 
3-7. 4D treatment plans can now be generated, enabling a dedicated Linac mounted 
on a robotic C-arm, to deliver with sub-millimeter accuracy highly focused doses of 
radiation to a moving target (Cyberknife, Accuray Inc.). Additional ways to apply RT 
are brachytherapy (chapters 8-10) and stereotactic radiotherapy. The introduction of 
chemotherapeutic agents has emerged as the third main treatment mode to a point 
where many, often cisplatin-based regimes, are routinely integrated in the treatment 
protocols in a neoadjuvant and/or concomitant setting. Particularly in academic 
centers, further development in clinical cancer care is increasingly emerging from 
studies in basic sciences, often referred to as translational research. An example 
of this would be the efficacious role of targeted therapy (Cetuximab) in HNC. Howe-
ver, one has to keep in mind that clinical investigators have frequently reported that 
combined treatment can be more expensive and/or results in excess of (late) side 
effects. Between 40% and 60% of HNC will be treated with RT in a curative setting. 
In recent years, noteworthy strategies such as altered fractionation have emerged. 
To obtain better tumor control rates, in recent years more aggressive regimes have 
been implemented in the treatment for cancer of the head and neck. The aggressive 
nature of the treatment modalities is exemplified by using high doses of radiation 
per se, and/or (altered) fractionation regimen. For example, Bourhis et al showed 
in a meta-analyses an increase in local control of 6.4%, and an increase in overall 
survival of 3.4%, by using hyperfractionated or accelerated RT in the cancer of the 
head and neck 5. 
Contouring, Dose Distributions and Quality of Life
Most effective way of improving cure rates is by quality assurance in the prescription 
and delivery of the radiation dose-plan. Questions like ‘How to define the target?’ 
and ‘What are the boundaries of relevant organs at risk (OAR)?’ are of fundamental 
importance from a quality assurance perspective. In chapters 3-7 of this thesis some 
delineation examples are given for ‘new’ organs at risks and dose-effect relation-
ships studies of these OARs are described. A potential solution for these morbidities 
are described in chapters 8 and 10 published before as chapter XI in ‘Function Pre-
servation and Quality of Life in Head and Neck Radiotherapy’, edited by P.M. Harari 
et al. and as chapter 11 of ‘Head and Neck Cancer: Multimodality Management’, 
edited by J. Bernier and in chapter 11 regarding the use of brachytherapy and the 
role of hyperbaric oxygen treatment after radiotherapy in preventing /reducing the 
side-effects.  
Contouring the many described OARs is often a painstaking and time-consuming 
task if clinically used in a radiotherapy department, the time that is needed for con-
touring each IMRT case could entail inaccuracies from the clinician’s side and/or 
lead to cuing in the treatment planning room with increasing waiting times as a con-
sequence. Regarding contouring in head and neck cancer patients for treatment with 
radiotherapy, extensive guidelines are published in the book ‘Contouring in Head 
& Neck Cancer’ from Peter Levendag, Abrahim Al-Mamgani and David Teguh 6. It 
deals with practical issues concerning delineation and contains the original descripti-
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ons by Robbins of surgical boundaries of the neck levels I–VI, the CT based bounda-
ries derived from surgical anatomy for the CTV of neck levels I–VII, and its validation 
of the level-contouring in clinic. The lack of standardization in delineation and dose 
prescription illustrates the need for rigid guidelines. A promising atlas-based auto 
segmentation tool is a welcoming tool for a busy radiotherapy department. This tool 
is described in chapter 14 (ABAS). The fundamentals of non-rigid registration being 
the basis of auto-contouring are reported in chapter 12. Here the non-rigid registra-
tion method is used to quantify the anatomic changes caused by external beam ra-
diotherapy in HNC patients in full three dimensions and to relate the local anatomic 
changes to the planned mean dose. Another application of the non-rigid registration 
tool is to accurately sum different dose distributions from brachytherapy and IMRT 
as described in chapter 13. 
With the current developments in image guided radiotherapy (IGRT), modern linear 
accelerators are equipped with kV imaging devices and cone-beam CT (CBCT). 
With CBCT, not only bony anatomy but also soft tissues are visible. It is now pos-
sible to trace potential changes in patient anatomy due to e.g. weight loss, edema 
or other (medical) reasons. This could lead to the development of on-line positioning 
protocols with smaller PTV margins and thus more sparing of normal tissues. Tools, 
such as functional imaging, non-rigid registration (chapters 12 and 13) and atlas-
based auto-segmentation (chapter 14), play an important role in analyzing the data 
for IGRT. 
Outline Thesis
In summary the current thesis covers a wide range of aspects regarding radiothe-
rapy of cancer in the head and neck. Several aspects were covered:
First, chapter 2 describes the treatment of oropharyngeal cancer. In chapters 3 to 
7 the quality of life (dysphagia and trismus) endpoints and the FEES procedure are 
described in relation to radiation dose to the particular normal tissues. Also site and 
treatment techniques influencing the dose in the normal tissue structures are discus-
sed. Chapters 8 to 10 will describe brachytherapy in oral cavity and oropharyngeal 
cancer. Main focus will be on the quality of life of patients treated by brachytherapy. 
Chapter 11 describes the hyperbaric oxygen trial in reducing late side-effects of ra-
diotherapy. More technical papers regarding adding 3D brachytherapy dose to the 
external beam dose and non-rigid registration being the basis of auto-segmentation 
are described in chapters 12 to 14. 
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Epidemiology
The oropharynx is the posterior continuation of the oral cavity and connects with the 
nasopharynx (above) and laryngopharynx (below). It is located between the soft pa-
late superiorly, and the hyoid bone inferiorly. The main sites of the oropharynx con-
sist of the posterior and lateral pharyngeal wall, faucial arches, tonsillar fossa (TF), 
soft palate (SP), and the base of tongue (BOT). These structures play a crucial role 
in swallowing and speech. By obstructing the “air space” or by infiltrating muscles 
or nerves, locally advanced oropharyngeal tumors can significantly impede these 
functions. The same holds for intensive treatment regimen: it can cause deformities 
and/or impairment of particular functional (sub) units, resulting eventually in severe 
(late) side effects. It has long been known that patients with a history of smoking or 
excessive consumption of alcohol are believed to be at increased risk for developing 
cancer in the oropharynx 31,37. Overall these cancers comprise less than 0.5% of all 
cancers in men in the United States, which amounts to approximately 5000 new 
cases each year 319. According to the Surveillance, Epidemiology, and End Results 
report of the National Cancer Institute, in 2001 the age-adjusted incidence was 1.5 
per 100,000 white men and 3.2 per 100,000 black men 271. These cancers more 
often afflict men (4:1); they are diagnosed most frequently in the sixth and seventh 
decades of life. Oropharyngeal cancers are readily accessible to clinical examina-
tion and staging. Historically, in the early stage and in the moderately advanced 
tumors, radiation therapy (RT) has been the preferred therapy mode because of its 
organ function-preservation properties 300,321. Most (±95%) oropharyngeal cancers 
are squamous cell carcinomas (SCC). Although reports can be found of other histo-
logic subtypes 1,14,72,93,158, such as minor salivary gland tumors, lymphoepitheliomas, 
malignant lymphomas, mesenchymal tumors, or metastases from other extracranial 
tumor sites, these will not be discussed in great detail as they are considered beyond 
the scope of the present chapter.
Anatomy
The SP, anterior faucial pillar, and the retromolar trigone are embryologically con-
nected to the oral cavity. However, because of their clinical behavior, tumors of 
these structures are preferably classified with oropharyngeal malignancies. The in-
ferior part of the TF is referred to as the glossopalatine sulcus (Fig. 1). The lateral 
border of the retromolar trigone extends upward into the buccal mucosa, medially it 
blends with the anterior tonsillar pillar. Its base is formed by the last lower molar and 
the adjacent gingivolingual surface. The lateral walls of the oropharynx are limited 
posteriorly by the TF proper and the posterior tonsillar pillar. The anterior and pos-
terior tonsillar pillars are the folds of mucous membrane that cover the underlying 
glossopalatine and pharyngopalatine muscles, respectively. Deep to the lateral wall 
of the TF are major vessels (Figs. 2 and 3) and muscular components such as the 
superior constrictor muscle, the upper fibers of the middle constrictor muscle, the 
pharyngeus and stylopharyngeus muscles, and the glossopalatine and pharyngo-
palatine muscles. Stratified squamous epithelium covers all of these structures. The 
tonsil has a heavy lymphoid network. The pharyngeal wall is related to the second 
and third cervical vertebrae. Nerve supply is from the cranial nerves IX and X. The 
BOT lies posterior and inferior to the palatoglossal arch. It is bounded anteriorly by 
the circumvallate papillae, laterally by the glossopharyngeal sulci and oropharyn-
Oropharynx
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Figure 1: Anatomy oropharynx Book: Radiation Oncology, Rationale, Techniques, 
Results (Cox, 2003, p.197,  Mosby, St. Louis).
geal, walls and inferiorly by the valleculae and the pharyngoepiglottic fold. Embryo-
logically, its epithelium is derived from the entoderm, unlike that from the oral tongue 
(ectoderm). The body of the BOT is formed by thick muscles, the The genioglossus, 
palatoglossus, and hypoglossus muscles. The muscles originate from the margins 
of the mandible and are attached to the hyoid bone. The blood supply and the inner-
vation are by the lingual arteries and hyoglossal nerve, respectively genioglossus, 
styloglossus, palatoglossus, and hypoglossus muscles. The muscles originate from 
the margins of the mandible and are attached to the bone. The blood supply and hy-
oid the innervation are by the lingual arteries and hypoglossal nerve, respectively.
23
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Figure 2: Cross-section mid-oropharynx. Book: Management of Head and Neck Cancer: a mul-
tidisciplinary  approach.(Million,1994, p.402, figure 17.2 Lippincott Company Philadelphia).
Figure 3: Inside view of lateral oropharangeal wall. Note major vessels in parapharangeal 
Space.Book: Clinically Oriented Anatomy 4th Edition, 1999 (Moore KL, Dalley AF. p.1059, 
Lippincott Williams & Wilkins, Philadelphia)
Figure 4: Neural pathways of referred otalgia. Book: Clinical Radiation Oncology (Leibel, 204, 
p.605, figure 28 7 Lippincott, Williams and Wilkins, Philadelphia)
.
Oropharynx
----------------
24
..........
Natural History
In general, tumors of the anterior tonsillar pillar and soft palate are better differentia-
ted and biologically less aggressive than those of the TF. For example, 50% to 60% 
of patients with primary tumors in the anterior tonsillar pillar, retromolar trigone, and 
SP had necks with clinically negative findings, in contrast to only 24% of those with 
TF primaries 149. Lesions of the TF 231, retromolar trigone 39, and BOT tend to grow 
more extensively. Perez et al. 234 observed that the primary tumor was confined to 
the TF in only 5.4%. Byers et al. 171 described 14% mandibular invasion in carci-
nomas of the retromolar trigone. At diagnosis, 75% of BOT cancers have invaded 
adjacent structures, including the glossopharyngeal sulcus, pharyngeal wall, larynx, 
and/or faucial arches. The most common complaint at presentation of tumors in the 
oropharynx is pain; this pain is either attributed to (severe) mucositis, deep infiltra-
tion of the tumor or is referred (Fig. 4). However, patients with primary tumors of the 
oropharynx can also be asymptomatic or have only vague discomfort at presenta-
tion. BOT tumors, for example, typically grow insidiously. Because the BOT is devoid 
of pain fibers, they are mostly asymptomatic until they have progressed significantly. 
With local advancement and/or with infiltration of the pterygoid muscles, patients 
can experience trismus and, ultimately, bleeding or swallowing problems, or can 
have difficulty with speech. Diagnosis is typically established by clinical examination 
in the outpatient clinic and/or examination under general anesthesia, including mor-
phologic confirmation (biopsy) of the lesion and tattooing of the clinical target volu-
me (CTV). In the Erasmus Medical Center—Daniel den Hoed, Rotterdam (Erasmus 
MC), at the time of diagnosis/staging, with the patient still under general anesthesia, 
the lesion is frequently marked with marker seeds. This enables the extensions of 
the lesion to be visualized on x-ray films. From a series of patients implanted with 
platinum markers, we found, for example, that the TF significantly moves during 
swallowing and even in rest (because of respiration). Maximum excursions in rest 
were found to be 3.6 mm. This type of information contributes to a more accurate 
determination of the planning target volume (PTV) margin (Figs. 5 and 6). Conven-
tionally, platinum (Pt) or gold (Au) marker seeds were used, particularly for those 
patients to be boosted by brachytherapy (BT) 175. Because of significant scattering 
properties on computed tomography (CT), nonmetallic seeds are being tested. Pa-
nendoscopy can reveal synchronous second primaries. Ultrasound fineneedle aspi-
ration biopsy has become an indispensable tool for pro diagnosis and for staging, 
especially where it concerns the lymph nodes. Multislice CT and magnetic resonan-
ce imaging (MRI) scans are now obligatory imaging tools. CT scanning with contrast 
enhancement using 2-mm slices is better for detecting lymph nodes and for bone 
detail. MRI is preferred for the evaluation of the parapharyngeal space. Axial slices 
are usually sufficient; sagittal MRI is helpful for detecting early pre-epiglottic space 
infiltration. CT combined with positron emission tomography scanning seems an ex-
tremely promising, powerful tool for diagnostic and simulation purposes, but is not 
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Figure 5: Motion with swallowing. Lateral fluoroscopic images of two different moments in time 
projected over each other. The patient was instructed to swallow. The images are acquired 
0.5 seconds apart. The colored rectangles indicate the motion of the markers. The arrow indi-
cates the direction of movement (from equilibrium to extreme position during swallowing). For 
the yellow, green and red markers the amplitude in the lateral view was respectively 13.4, 9.3 
and 2.4 mm. For the markers in the blue rectangle the amplitude of the most cranial marker 
was 15.6 mm.
Figure 6: Motion without swallowing. Lateral fluoroscopic images of two different moments 
in time projected over each other. The patient was asked not to swallow. The images are 
acquired 7.5 seconds apart. All markers where stationary except for the marker indicated with 
the red rectangle. The motion of this marker is 2.0 mm in the anterior-posterior direction and 
0.4 mm in the cranial-caudal direction. Based on the  frequency of the observed motion this is 
most probably caused by respiration.
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yet available in every institution. Several textbooks contain helpful overviews 
8,59,123,171,208,232. Tumors are staged according to the American Joint Committee on 
Cancer classification system (Table 1) 6. Dentulous patients are at increased risk 
for caries and osteoradionecrosis from the reduction and qualitative change of sa-
livary flow, change in pH, and proliferation of bacteria believed to be responsible 
for caries. Panorex x-ray films, identification of nonrestorable teeth for pretreatment 
extraction, dental trays for fluoride rinse, protection against scatter radiation, as well 
as education about long-term oral hygiene, should be engaged before RT and/or 
chemotherapy (CHT) is applied. In fact, the quite common development of osteora-
dionecrosis in the past 17 should be prevented by adequate measures. Finally, given 
the complexity of head and neck tumors, all patients should be formally discussed in 
a head and neck tumor board, with or without the patient being present, before the 
initiation of any treatment. 
Table 1: 2002 edition of American Joint-Committee on Cancer Classification of Oropharyn-
geal Cancer. (From: Greene F, Page D, Fleming I, et al. AJCC cancer staging manual, 6th 
ed. New York; Springer-Verlag, 2002) Book Greene F, Page D, Fleming I, et al. AJCC cancer 
staging manual, 6th ed. New York; Springer-Verlag, 2002. 
Lymphatics of the Oropharynx
The lymphatic drainage of the oropharynx and the neck was first described by Rou-
viere 262 in 1938 and has been refined since by others 113,149. The nodal groups in the 
neck were originally described along the lines of lymph node chains, located in par-
ticular anatomic regions and draining specific (sub) sites.  Instead of using the term 
jugular chain nodes, Robbins et al. 255,256,254 proposed the “level system” for classify-
ing the location of lymph nodes in the neck relative to surgical –anatomic landmarks 
(Table 2). The level classification (levels I to VI) was recently refined with the addition 
of sublevels (Ia/Ib, IIa/IIb, and Va/Vb), also using some of the radiologically defined 
landmarks as proposed by Som et al. 283. The probability of lymphatic (regional) me-
tastasis is re lated to size and location of the primary site within the oropharynx. The 
order of progression of metastatic cells is systematic, that is, it usually proceeds from 
the upper jugular chain nodes superiorly (level I/II; first echelon), to midcervical (level 
III) and to lower cervical nodes (level IV), inferiorly. Candela et al. 44, for that pur-
pose , evaluated 333 untreated primary SCCs of the oropharynx and hypopharynx
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Le-
vels Cranial Caudal Anterior(Medial) Posterior (Lateral)
IA Symphysis of madible Body of hyoid
Anterior Belly 
Digastric M
Anterior Belly 
Digastric M
IB Body of madible
Posterior 
Belly of Digastric 
Muscle
Anterior Belly 
Digastric M Stylohoid M
IIA Base of Skull Inferiro Body of Hyoid Stylohyoid M SAN
IIB Base of Skull Inferior Body of Hyoid SAN
Lateral Border 
SCMM
III Inferior Body of Hyoid Inferior Cricoid
Lateral Border
Sternohyoid M
Lateral Border 
SCMM
IV Inferior Body of Hyoid Clavicle
Lateral Border
Sternohyoid M
Lateeral Border 
SCMM
VA
Apex Convergence 
SCMM and Trape-
zius M
Inferior Cricoid Posterior Edge SCMM
Anterior Border
Trapezius M
VB Lower Border Cricoid Clavicle
Posterior Edge 
SCMM
Anterior Border
Trapezius M
VI Hyoid bone Suprasternal notch
Common Carotid 
Artery
Common Carotid 
Artery
Table 2: Anatomical structures defining surgical levels (modified after Robbins, 2002. see 
also references Robbins et al., 1991, 1999). ([SCMM] Sterno-Cleido Mastoid Muscle; [SCJ] 
Sterno Clavicular Joint; [M] Muscle; [SAN] Spinal Accessory Nerve; [RPh] Retropharyngeal; 
[RSS] Retro-Styloid Space; [SCF] Sub-Clavicular Fossa) See also references Robbins et al., 
1991, 1999, 2002.
and ascertained the prevalence of neck node metastasis by neck level. Isolated skip 
metastases occurred in only one patient (0.3%); level I or level V involvement was 
always associated with metastases at other levels. Another important finding is that 
tumors in the midline or of the posterior pharyngeal wall exhibit a higher propensity 
for bilateral lymphadenopathy. 
Delineating and Validation of Neck Node Levels
Node-Negative Neck
From a comprehensive review of the literature regarding the incidence of regional
metastasis 16,40,44,45,52,178,276,277,279, a few observations can be made. First, for most of 
the tumor sites in the oropharynx, when using RT one needs to irradiate the neck 
either electively (46 to 50 Gy node-negative [N0] neck) or boost the lymph nodes 
to high cumulative doses (60 to 70 Gy neck nodes). Second, in organ functionpre-
servation RT, image-based technology has become paramount. Third, in order to 
adequately spare the critical healthy tissues, the clinician needs to be as selective 
as possible with the levels incorporated in the irradiated volumes (standardization 
of treatment volumes; e.g., ipsilateral vs. bilateral neck). Finally, the lymph nodal 
drainage per tumor site follows a predictable pattern, such that the concept of selec-
tive treatment has a legitimate rationale for surgery as well as for RT (Tables 3 and 
4). Nowak et al. 222 reported on an inventory in The Netherlands, showing a lack of 
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standardization even when experienced physicians were asked to delineate the por-
tals designed to cover the primary and neck (Fig. 7). They argued that a more preci-
se three-dimensional definition on CT of the lymph node levels in the neck allows for 
a better standardization of the treatment portals and, in addition, for the development 
and application of more conformal (selective) RT techniques. Conceptually, with the 
radical and modified neck dissection, all lymph nodes are routinely removed 255,256. In 
contrast, selective neck dissection refers to preservation of one or more of the lymph 
node groups (for example, see Table 2 for selective neck dissection levels I, II, and 
III). In order to be as selective as with surgery, first the clinical (research) groups of 
Rotterdam and Brussels have translated the surgical-anatomy boundaries (Table 2) 
to corresponding borders on CT 108,223. 
The Rotterdam guidelines have further evolved into a “simplified version” for 
routine clinical practice (Fig. 8) 318. In fact, the proposed simplified delineation guide-
lines were based on easy-to-identify anatomic landmarks on CT, leading to a simple-
to-execute delineation procedure (“learning curve”). Besides the Rotterdam system 
being more generous, the comparison with the Brussels guidelines revealed small 
but essential discrepancies (Fig. 9). After adjustments, a common set of recom-
mendations for the delineation of neck node levels for the N0 neck was proposed 110. 
This proposal was discussed with major cooperative groups in Europe (DAHANCA, 
EORTC, GORTEC, NCIC, RTOG) and after some minor modifications, it was fully 
endorsed (Table 5, Fig. 10). Finally, a series of clinical experiments was performed
Levels involved (%)
Tumor Site I II III IV V
Oral Cavity 20 17 9 3 0.5
Oropharynx 2 25 19 8 2
Hypopharynx 0 13 13 0 0
Larynx 5 19 20 9 2.5
Table 3: Incidence and distribution of regional metastasis for levels I-V for clinically N0 neck. 
(See references: Bataini, Byers, Candela Chao, Lindberg,, Shah, Shah). Gregoire V, Couche 
E, Cosnard et al, Radiotherapy and Oncology, 2000;56(2):135-150. 
 
Levels Involved (%)
Tumor Site I II III IV V
Oral Cavity 48 39 31 15 4
Oropharynx 15 71 42 27 9
Hypopharynx 10 75 72 45 11
Larynx 6 61 54 30 6
Nasopharynx 13 95 60 21 44
Table 4: Incidence and distribution of regional metastasis for levels I-V for clinically N+ neck. 
(See references: Bataini, Byers, Candela Chao, Lindberg,, Shah, Shah, Sham). Gregoire V, 
Coche E, Cosnard et al, Radiother and Oncology, 2000;56 (2):135-150. 
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to validate the “international consensus guidelines” on the delineation of the CT-
based lymph node levels 174,173. In the first experiment, the superior border of the N0 
neck (cranial border level II) was determined. In 10 consecutive patients, clips were 
placed at the most cranial border of the neck at the time of a neck dissection. Antero-
posterior and lateral x-ray films were obtained intraoperatively. The clips lined up at 
the caudal part of the transverse process of C1 (Fig 11). Thus, the cranial border is 
situated much lower than the base of skull. From the position of the parotid gland, 
one can appreciate that this is of great importance when sparing the major salivary
Figure 7: Due to lack of standardization variation in RT portals as depicted on lateral X-ray 
films by radiation oncologists of different institutions for same clinical indication. Inventory in 
the Netherlands. Radiotherapy and Oncology, volume 43(1)1997:81-86.
Figure 8: Simplified CT-based definition of the lymphnode levels in the superior part of the 
node negative Neck. (middle- and inferior part neck not shown)  Radiotherapy and Oncology 
1999;1:35-42.
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Figure 9: Axial CT slice upper neck region, with levels Ia, Ib, II and V (solid black lines) con-
toured according to Rotterdam (right neck) and Brussels (left neck) delineation protocols. 
Rotterdam and Brussels delineation protocols were meticulously compared and adapted to 
surgical level definitions as defined by 2002 AAO-HNS classification. International consensus 
was reached. Stipulated white lines (both necks) demarcate contours of levels and suble-
vels as defined by international consensus protocol. This figure illustrates contours of levels 
Ia, Ib, IIa, IIb and Va (middle- and inferior neck guidelines not shown). I.J.R.O.Biol. Phys 
2004;58:1:113-123.
IA
IBIIAIIB
IIIVA
VB
IV
VI
Figure 10: Digital Reconstructed Radiograph levels I-VI.
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Le-
vels Cranial Caudal Medial to iCA Posterior Lateral Medial
IA Caudal Madible Body hyoid Platysma, Symp-hysis Body Hyoid
Symphis - Anterior 
Belly DM
IB Cranial SMG, Mylohyoid M
Central hyoid 
bone
Platysma, Symp-
hysis Posterior SMG
Madible, Skin, 
Platysma
Symphysis 
- DM
IIA Transverse Process C1 (caudal border)
Caudal Border 
Hyoid Posterior SMG Posterior IVJ
Medial Edege 
SCMM Medial to ICA
IIB Transverse Process C1 (caudal border)
Caudal Border 
Hyoid Posterior IJV
Posterior Edge 
SCMM
Medial Edege 
SCMM
Deep Cervical 
Mm
III Inferior Hyoid Inferior Cricoid Anterior Edge SCMM
Posterior Edge 
SCMM
Medial Edege 
SCMM
Medial to ICA 
Deep Cervical 
Mm
IV Inferior Cricoid 2 cm Superior SCJ
Anteriomedial 
SCMM
Posterior Border 
SCMM
Medial Edege 
SCMM
Medial to ICA 
Paraspinal Mm
VA Cranial Hyoid Inferior Cricoid Posterior Edge SCMM Al-Trapezius M Skin, Platysma
Deep Paraspi-
nal Mm
VB Inferior Cricoid Transverse Cerv. A.
Posterior Edge 
SCMM
Virtual Line
Al-Trapezius M Skin, Platysma
Deep Paraspi-
nal Mm
VI Caudal Thyroid Sternal Manu-brium Skin
Esophagus/Tra-
chea
Medial Edege 
SCMM, Thyroid G Trachea
RSS Base of skull(jugular foramen)
Upper limit of 
level II
Parapharyngeal 
Space
Vertebra
 Bse of Skull Parotid Space
Retropharyn-
geal nodes
SCF Lower border IV/Vb Sternoclavicular joint
SCMM, Skin, 
Clavicle
Anterior Border
Posterior Scale-
nus M
Lateral Edge
Posterior Scale-
nus M
Trachea/
Thyroid
RPhs Base of skull Cranial Edge Hyoid
Fascia Pharynx 
Mucosa
Longus Coli / 
Capitus M
Medial Edge
 Internal Carotid A Midline
Table 5: International consensus guidelines regarding translation of surgical-anatomy bounda-
ries of lymphnodal levels I-VI in clinically node negative(N0) neck to CT-based borders. Also 
depicted are retrostyloid space, subclavicular fossa and retropharyngeal space (see text). 
([SCMM] Sterno-Cleido Mastoid Muscle; [SCJ] Sterno Clavicular Joint; [RPhS] Retropharyn-
geal Space; [RSS] Retro-Styloid Space; [SCF] Sub-Clavicular Fossa; [C-I] Vertebra Corpus 
C-I; [SMG] Sub-Mandibular Gland; [IJV] Internal Jugular Vein; [Mm] Muscles; [a] artery; [AL-
Trap.M] Antero Lateral Edge Trapezius Muscle; [G] Gland.
Figure 11: Projection of clips (AP and Lateral X-ray films) placed intra-operatively at cranial 
border node negative neck. Clips cluster around caudal border transverse process corpus 
vertebra C-I. See also projection of circumference of parotid gland (PG) as determined by 
CT. 
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gland. In a second series of experiments, the neck levels I-VI in three patients first 
were contoured on preoperative contrast-enhanced CT scans according to the inter-
national consensus guidelines. Of each of these three patients, after placing clips at 
relevant surgical-anatomic–based level boundaries, an intraoperative CT scan was 
also obtained. The preoperative (CTbased delineated boundaries) and intraopera-
tive (surgical-anatomic defined level boundaries) CT scans were then fused. The 
caudal border of level IV can be identified by the clips positioned next to traverse 
cervical artery (Fig. 12). The posterior border of level IV and Vb is determined by a 
virtual line drawn between the heads of the trapezius muscle (Fig. 12). The posterior 
border of surgical level IIa (spinal accessory nerve) did not fully match with posterior 
border of CT-based level IIa (internal jugular vein); the other surgical boundaries and 
CT-based contours were in perfect agreement (Fig. 13). This second series of expe-
riments was also designed to examine whether the subdivision into sublevels IIa and 
IIb, as suggested by Robbins 256, is of any benefit in selective RT. It can be argued 
that because of the heavy infestation of occult metastatic cells in the lymph channels 
around the IJV and carotid artery, the division of level II into radiologic sublevels IIa 
and IIb may not be relevant and may even be risky 174 (Figs. 14 and 15). In contrast 
to CT-based contoured sublevels in cases of selective RT, the division into surgical 
sublevels IIa/IIb makes sense as this could reduce serious morbidity, that is, could 
prevent potential damage to the spinal accessory nerve 174.
tca
a-mhtm
Figure 12: Caudal border level IV (CT-slice at the level of transverse cervical artery [tca]). 
Posterior border level IV and Vb (virtual line anterior medial heads of trapezius muscle [a-
mhtm]).
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Figure 13: Digitally reconstructed radiographs validated the position of clips at cranial border 
IIa, IIb and boundaries level III, Va, and IV, Vb. (left panel).   Digitally reconstructed radio-
graphs validated the position of intra-operatively defined clips, demarcating boundaries of 
levels IIb, Va and Vb, as they were  in good  agreement with previously contoured (and mat-
ched) CT-base boundaries  (right panel). I.J.R.O.Biol. Phys 2005;62:3:690-699.
Figure 14: Photograph and schematic drawing of right upper-neck region in patient with right 
radical neck dissection (RND). Radiopaque surgical clips positioned at the most cranial part of 
the neck, anterior (#1) and posterior (#2) to the internal jugular vein (IJV). Also seen is a clip 
(#3) at the site where the spinal accessory nerve (SAN) enters the sterno cleido mastoid mus-
cle (SCMM). The triangular area, denoted as “no-man’s land”, belongs to either the posterior 
part of surgical level IIa or the ventral (anterior) part of CT-based level IIb. The triangular area 
is formed by SAN, clips #2 and #3, the posterior boundary of the IJV, and part of the hyoid line. 
I.J.R.O.Biol. Phys 2005;62:3:690-699.
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RSS
IIa IIb
IJV
PG
3
1 2
Figure 15: Digitally reconstructed radiograph (left panel) is shown of the computed tomo-
graphy (CT)-based contoured sublevels IIa and IIb, and the  retro-styloidspace (RSS). Right 
panel: superimposed on the delineated sublevels, the contoured IJV and the clips positioned 
intra-operatively at the relevant surgical boundaries of sublevels IIa/IIb and the hyoid (clips #1, 
#2, #3, #5). The stipulated line demarcates the position of the boundary between the surgi-
cally defined sublevels IIa and IIb (SAN). The “no-man’s land” zone is the triangularly shaped, 
cross-hatched area between the posterior border of the surgically defined sublevel IIa (SAN) 
and the posterior border of the CT-based level IIa (posterior boundary of the IJV). I.J.R.O.Biol. 
Phys 2005;62:3:690-699.
Node-Positive Neck
Retrospective intensity-modulated radiation therapy (IMRT) series have reported 
marginal recurrences in the neck of node-positive (N+) patients treated primarily or 
postoperatively with radiotherapy. Eisbruch et al. 74 reported a series of 135 patients 
treated bilaterally from 1994 to 2002 with three-dimensional conformal radiation the-
rapy or IMRT for primary tumors located mainly in the oropharynx. With a median 
follow-up of 32 months, 21 patients had a locoregional recurrence, 4 of which were 
marginal. Some of the marginal recurrences were observed near the base of skull 
above the upper limit of the delineated level II. Thus, it seems reasonable, as a first 
modification in case of infiltration of the upper part of level II, to include in the CTV 
the fatty space around the internal jugular vein and internal carotid artery up to the 
jugular foramen (base of skull) in the N+ neck 109. From an anatomic point of view, 
this space belongs to the upper most part of the retrostyloid space (Fig. 16). Also in-
cluded are the tumor-infiltrated nonlymphoid structures. As a third modification with 
respect to the N+ neck, the guidelines for the caudal limits were modified. For the 
N+ neck, the caudal border was modified basically by lowering it down to the sterno-
clavicular joint. For a boost volume, the involved level and the directly surrounding 
uninvolved neck node levels are used 109. The optimal management of cervical me-
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tastases is still subject to considerable debate. For example, Roy et al. 263 reported 
on patients with TF/SP and BOT tumors and N2 neck disease. After a full course 
of RT, 65% of these patients still had pathologically confirmed disease in cases of 
clinical and/or CT-based evidence of persistent disease. For those patients with no 
evidence of residual disease, 33% still had remaining disease in the neck dissection 
specimen. Their data lend support to a planned neck dissection. In contrast, Su et 
al. 291 argued that for patients with oropharyngeal tumors, a neck dissection only im-
proves regional control for those patients with a complete clinical response. In fact, 
a close follow-up is advocated for this category.
 
IIb IIa
Va III
IVVb
Ib
VI
rss
scF 2 cm
Figure 16: Digital Reconstructial Radiograph with levels Ib-VI, including delineation of the 
Retro-Styloid Space (RSS) and Subclavicular Fossa (SCF).
Postoperative Neck
In cases of postoperative RT (PORT), one relies on the long-established institutional guideli-
nes 24,109. As an example, the routine clinical criterion for PORT as used in the Erasmus MC, 
Rotterdam, and those established by the University of Texas, M.D. Anderson Cancer Center, 
Houston, are summarized in Table 6. Basically, with regard to the tumor bed, if feasible, in 
PORT one tries to mirror the contralateral noninvolved neck. Finally, the previously discussed 
consensus guidelines established for the N0 neck will remain the foundation for PORT (and 
N+ neck).
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PORT: Risk groups
Hard criteria:
Irradical resection
Lym node metastases with ECE
Two or more nodes
High risk 66 Gy (66 Gy EQD2,33) 6 fx/week
Soft criteria:
Perineural growth
Close margins
T3-T4
Intermediate risk 60 Gy (60 Gy EQD2,33) 6 fx/week    
No riskfactors: Low risk No PORT
PORT: Risk groups
High-risk group: >= 2 factors
Oral cavity primary
Mucosal margins close or positive
Nerve invasion
Largest node > 3 cm
>= 2 Positive lymph nodes
Treatment delay greater than 6 weeks
Zubrod performance status >= 2
63 Gy 5 fx/week (53.2 Gy EQD2,33) 
63 Gy 5 fx/week (63 Gy EQD2,33)  3 weeks 1 fx/day,      
  2 wks 2 fx/day
Intermediate-risk:
1 Adverse feature other than ECE
57.6 Gy 5 fx/week (61.8 Gy EQD2,33)
   
Table 6: Indications for postoperative radiation therapy (PORT). Criteria used in Erasmus 
MC – Daniel den Hoed Cancer Center, Rotterdam.(upper panel) and University of Texas, MD 
Anderson Cancer Center, Houston (lower panel).
Clinical Presentation
Patients with carcinoma of the oropharynx present most frequently with a sore thro-
at. They also may complain of difficulty swallowing or pain in the ear, which is related 
to the anastomotic–tympanic nerve of Jacobson. Carcinomas of the tonsil usually 
are ulcerated and sometimes exophytic. They infiltrate the glossopharyngeal sulcus 
and BOT, many times with little or no mucosal involvement. Trismus may be a late 
manifestation of the disease if the masseter or pterygoid muscle is involved. Can-
cers of the BOT, unlike those of the oral tongue, rarely are visualized by the patient 
and may grow to a large size before detection. The patient usually can point to the 
site of pain and the location of the tumor. Difficulty in swallowing because of pain is 
common, but dysphagia and impaired deglutition caused by massive infiltration of 
the tongue by tumor are less so. In advanced tumors that fix the root of the tongue, 
poor articulation is caused by impaired tongue mobility. It is common for patients 
with oropharyngeal cancer to notice a mass in the cervical region, usually subdigas-
tric (jugulodigastric), as the first manifestation of disease. Initially, distant metastases 
are extremely rare.
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Diagnostic Work-Up
The evaluation of patients with carcinoma of the oropharynx always begins with 
a complete history and physical examination. The next step is a comprehensive 
examination of the head and neck, including oral cavity, oropharynx, nasopharynx, 
hypopharynx, and larynx. Mirror or fiberoptic examination of the nasopharynx, hy-
popharynx, and larynx always should be performed to detect any tumor extension 
or associated pathology. In many centers, panendoscopy has become a routine 
procedure because of the risk of second primaries in the upper digestive tract. After 
indirect laryngoscopy, careful digital examination with a gloved finger should eva-
luate submucosal invo.lvement of the glossopalatine sulcus, base of the tongue, 
buccal mucosa, or lateral pharyngeal wall. Direct laryngoscopy under anesthesia 
seldom is required for carcinoma of the faucial arch, but it is very useful to evaluate 
patients with larger tonsillar or BOT lesions. Physical examination should include a 
thorough evaluation of the neck for detection of metastatic lymph nodes as well as 
a search for distant metastases. Examination of the neck should be done with the 
physician standing behind the seated patient. Anatomic position, size, consistency, 
tenderness, and mobility of palpable cervical lymph nodes should be recorded. His-
tologic confirmation of a clinically suspicious malignant lesion always must be ob-
tained, and biopsies should be performed, preferably at the margins of the tumor. 
Incisional or punch forceps biopsies can be performed with local anesthesia on an 
outpatient basis. When a lymphoma is suspected, the lesion may be submucosal; 
a large amount of tissue may be required for electron microscopy and immunologic 
typing of the tumor. Fine-needle aspiration biopsy of suspicious palpable neck nodes 
may be used to make the initial diagnosis. Complete blood counts, chemistry pro-
files, and urinalysis should be obtained. Plain films of the soft tissues of the neck or 
mandible may show involvement of soft tissues or bony structures. CT with contrast 
has become standard in delineating the extent of tumor and evaluating involvement 
of the mandible or extension into the base of the skull. MRI scans and positron emis-
sion tomography with their superior soft tissue contrast can be quite sensitive in 
detecting tumor extension and lymph node distributions 232. Criteria used for tumor 
involvement are abnormal contrast enhancement, soft tissue thickening, presence of 
a bulky mass, infiltration of lymphatic tissues (even without distortion of surrounding 
tissues), or a combination of these. Neck lymph nodes are considered pathologic 
when the smallest diameter is greater than 1 cm. In other studies, the presence of 
hypodense areas in more than 33% of the lymph nodes has been defined as nodal 
necrosis. Extracapsular extension is thought to be present when the nodal margin 
appears irregular, without clear distinction with the surrounding fat or when there is 
thickening of surrounding fibroadipose tissue or muscle. Chest x-ray films should 
be routine. Bone scans should be requested only if bone involvement is suspected. 
X-ray films of the skeleton may be required in patients with positive findings on bone 
scans or clinical suspicion of bony lesions.
Follow-Up
Patients with oropharyngeal cancer usually are followed up with careful physical and 
indirect laryngoscopic examination as well as thorough cervical lymph node evalua-
tion on a monthly basis for the first 6 months after therapy, every 3 months in years 2 
and 3, every 6 months from year 3 to 5, and yearly thereafter. A recent report on 46 
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patients treated with irradiation showed that postirradiation CT scans may not add 
incremental information to the clinical examination for predicting local tumor control. 
Diffuse and symmetric changes of the soft tissue or asymmetry without detectable 
mass or less than 10 mm was associated with primary tumor control 174.
Staging
In staging oropharyngeal tumors, it is extremely important to include both the ulce-
rated and infiltrating components of the tumor and all of its submucosal extensions. 
Because of a tendency to overestimate the size of oropharyngeal tumors, a ruler or 
caliper must be used to measure the diameter of the lesion 160. Visual, palpatory, and 
radiographic findings are critical in accurate staging. The usual staging classification 
for carcinoma of the oropharynx, including lymph node involvement, is that of the 
International Union Against Cancer or the American Joint Committee on Cancer 
(Table 1) 6. A criticism of this staging system is that it is largely two-dimensional and 
does not take into account the third dimension, which determines tumor bulk and 
morphology (e.g., endophytic or exophytic lesions of similar size, which respond dif-
ferently to similar treatment) 232.
Pathologic Classification
These tumors have characteristic features, including keratin in many cases, althou-
gh some are nonkeratinizing; the tumors are graded I to IV, depending on the degree 
of differentiation. Carcinomas that arise in the faucial arch, usually of the squamous 
cell type, tend to be keratinizing and more differentiated than tumors that arise from 
the TF. SCCs, often poorly differentiated, account for more than 90% of cancers of 
the BOT. Although it has been suggested that keratinizing, more differentiated tu-
mors have a somewhat better prognosis than others, no definite correlation between 
histologic type and pattern of behavior or response to therapy has been reported 232. 
Lymphoepithelioma is much rarer in the tonsil or BOT (less than 1.5%) than in the 
nasopharynx. Most pathologists agree that lymphoepithelioma represents a poorly 
differentiated, nonkeratinizing SCC with a profuse lymphoid infiltration 232. Other cell 
types include mucoepidermoid, adenocarcinoma, and adenoid cystic, which appear 
to behave more like salivary gland tumors of similar histology in other sites rather 
than like SCCs of similar size. Tumors of the salivary gland type are uncommon in 
the tonsil or faucial arch. Malignant melanomas of the TF are also rare 232. Primary 
small cell carcinoma of the tonsil, with neurosecretory granules demonstrated by 
electron microscopy, have been infrequently described. As in other locations, this 
tumor has a high propensity for regional, nodal, and distant metastatic spread with a 
very poor prognosis. Malignant lymphomas, usually non-Hodgkin's type, constitute 
10% to 15% of malignant tumors of the tonsil and 1% to 2% of the BOT. They tend to 
grow submucosally and may reach large size without significant mucosal ulceration. 
The surface of the tumor is covered by the same mucous membrane that covers the 
soft palate. Primary Hodgkin's disease in the tonsil is extremely rare. Metastatic car-
cinoma to the tonsil is rare, with only 92 cases reported in the world literature 232.
Prognostic Factors
Host and tumor factors have been correlated with survival but not consistently with 
primary, nodal, and distant relapses. Age and gender are host characteristics that 
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may have prognostic significance 232. In some reports, women have shown a bet-
ter prognosis than men, possibly because of earlier detection of tumors in women 
although other authors observed no significant survival difference between the gen-
ders. Significant differences in survival based on age (e.g., patients younger or older 
than 40 years) have not been established in sufficiently large and uniform patient 
cohorts and need to be stratified by disease stage and performance status 232. Tu-
mor characteristics that have prognostic significance include tumor size and exten-
sion (stage); presence of palpable lymph nodes; and location, number, and size 
of involved lymph nodes. Tumor regression during radiation therapy and histologic 
differentiation are additional prognostic factors reported. P53 and epidermal growth 
factor receptor overexpression has been associated with increased survival 232. A 
significant correlation has been found between the stage of the primary tumor, the 
presence of involved cervical lymph nodes, and 5-year survival 234. Tonsil tumor ex-
tension into the base of the tongue is associated with decreased survival 232. There 
is no definite correlation between histologic type or degree of tumor differentiation 
and patient survival. In patients treated surgically after irradiation, more than 90% 
with negative histologic specimens survived for 5 years compared with only 30% 
of patients with persistent tumor 232. Overall, BOT cancers have a worse prognosis 
than do their oral tongue or tonsil counterparts because of greater size at diagnosis, 
more frequent spread to adjacent structures, and higher rates of lymphatic spread. 
However, stage for stage, they may have similar prognoses as oral tongue cancers. 
Small exophytic tumors (i.e., superficial surface lesions) have higher rates of local 
tumor control by surgery or irradiation and a better prognosis than infiltrating or large 
tumors. Patients with tumors confined to the BOT survive longer than those with tu-
mors that extend to the faucial arch, oral cavity, or larynx and hypopharynx 232. The 
prognosis is better for patients without palpable lymph nodes (N0) and for those with 
small, ipsilateral, mobile lymph nodes rather than those with large, fixed, contralate-
ral, or bilateral nodes 234.
Management Strategies, Results, and Outcomes
Lymphoepithelioma, representing a poorly differentiated, nonkeratinizing SCC with 
a profuse lymphoid infiltration, is rare (less than 1.5%) in the TF/SP and BOT. Mu-
coepidermoid, adenocarcinoma, and adenocystic carcinomas behave more or less 
like “salivary gland type of tumors” of similar histology in other sites of the head and 
neck, rather than like SCC. Moreover, these salivary glandlike tumors are particu-
larly uncommon in the faucial arch and TF 287. Koss et al. 159 and Abedi and Sismanis 
1 found only a few cases of small cell carcinomas of the tonsil. Malignant lymphomas, 
mostly of the non-Hodgkin's type, constitute 10% to 15% of the TF and 1% to 2% of 
the BOT tumors. In contrast to non-Hodgkin's lymphoma, primary Hodgkin's disease 
in the oropharynx is extremely rare 14. Metastatic lesions to the TF/SP and BOT are 
exceptionally rare as well. Oreggia et al. 224 found women to have a better prognosis 
than men (at 5-year overall survival [OS], 40% vs. 9%). In contrast, Vallis et al. 301 
observed no significant difference between genders. Similarly, young age has not 
proven to be of prognostic significance 150. Tumor characteristics like tumor size, 
stage, lymph nodal status, and tumor regression during therapy have been found to 
be of some prognostic significance. No definite correlation has been observed bet-
ween histologic type, tumor differentiation, and patient survival 250,301. In contrast, p53 
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overexpression and targeting the epidermal growth factor receptor family do seem 
to be of prognostic value 267. For the more advanced tumors, there is a need for im-
provement, and the jury is still out on which treatment approach offers better tumor 
control and fewer side effects at the same time. One approach addressing the pro-
blem of improving the locoregional control in advanced tumors is reported by Hoog-
steen et al. 136. They tried to modify the response of malignant cells to radiation by 
overcoming tumor hypoxia. The Head and Neck Oncology group of the department 
of Radiotherapy of the St. Radbond University Hospital in Nijmegen argued that this 
can be done in several ways, including, for example, hyperbaric oxygen, carbogen 
breathing combined with nicotinamide, hypoxic cell sensitizers, and erythropoietin. 
There is now compelling evidence that shows that low hemoglobin levels before and 
during treatment are associated with reduced tumor control and decreased survival. 
The authors investigated the impact of low haemoglobin levels on locoregional con-
trol in patients who have been treated with accelerated radiotherapy with carbogen 
and nicotinamide. This is another example of good local tumor control and survival 
by modulating tumor cell biology (e.g., hypoxia) (Tables 7 and 8). For BOT tumors 
treated with accelerated radiotherapy with carbogen and nicotinamide, Kaanders 
et al. 153 showed an actuarial local control (LC) rate of 84% and actuarial OS rate 
of 50%. Similar findings were observed for TF/SP tumors at 5 years: LC rate of 
86% and OS rate of 33%. Hyperbaric oxygen as adjunctive therapy, although never 
proven in a randomized setting, is another effective way of modulating the oxygen 
status of normal tissues beneficially 92. In Erasmus MC, such a trial is currently on-
going. To measure the oxygen status of the tissues of these patients, a novel optical 
spectroscopic technique is used; this so called differential path-length spectroscopy 
allows for the in vivo measurement of hypoxia-related parameters such as blood 
oxygenation, blood content, and microvessel size in the most superficial layer of 
tissue 5. For the advanced oropharyngeal tumors, there are many more innovative 
approaches feasible. For example, Suntharalingam 292 reviewed the beneficial effect 
of systemic and/or intra-arterial CHT as organ-preservation therapy. The author ar-
gued that the real focus in the treatment approach of the tumor, however, should be 
on newer biologic agents targeting cellular protein receptors. For more details one 
is referred to XII.
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Therapy       T1# of pat (%)
      T2
# of pat (%)
     T3
# of pat (%)
    T4
# of pat (%)
MD Anderson 1
                TF/SP Concomitant Boost 5 29 (96%) 41 (78%) 4 (50%)
                BOT Concomitant Boost 4 27 (96%) 22 (67%) 1 (NE)
Erasmus MC 2
                TF/SP EBRT 6 fr./week + HDR/IRT 13 (100%) 65 (89%) 24 (91%) 1 (100%)
                TF/SP EBRT 6 fr./week + S+PORT 5 (100%) 22 (95%) 58 (85%) 8 (69%)
                BOT EBRT 6 fr./week + HDR/IRT 9 (100%) 13 (84%) 9 (56%) 10 (89%)
                BOT EBRT 6 fr./week + S+PORT 0 1 (100%) 10 (100%) 6 (100%)
KUN 3
               TF/SP ARCON 0 3 (100%) 17 (100%) 8 (53%)
                BOT ARCON 1 (100%) 4 (100%) 4 (100%) 15 (76%)
Table 7: Comparison of radiation therapy schedules for treatment of carcinoma of the tonsil-
lar fossa/soft palate and base of tongue: 5 years actuarial local control. Data obtained from 1 
Gwozdz et al. and Mak et al., 2 Levendag et al., 3 Kaanders et al. See also bibliography.
Therapy       T1# of pat (%)
      T2
# of pat (%)
     T3
# of pat (%)
    T4
# of pat (%)
MD Anderson 1
                TF/SP Concomitant Boost 5 (100%) 29 (64%) 41 (63%) 4 (58%)
                BOT Concomitant Boost 4 (100%) 27 (80%) 22 (57%) 1 (55%)
Erasmus MC 2
                TF/SP EBRT 6 fr./week + HDR/IRT 13 (77%) 65 (68%) 24 (66%) 1 (100%)
                TF/SP EBRT 6 fr./week + S+PORT 5 (67%) 22 (72%) 58 (50%) 8 (38%)
                BOT EBRT 6 fr./week + HDR/IRT 9 (67%) 13 (54%) 9 (53%) 10 (40%)
                BOT EBRT 6 fr./week + S+PORT 0 1 (0%) 10 (27%) 6 (67%)
KUN 3
               TF/SP ARCON 0 3 (33%) 17 (38%) 8 (25%)
                BOT ARCON 1 (100%) 4 (50%) 4 (50%) 15 (47%)
Table 8: Comparison of radiation therapy schedules for treatment of carcinoma of the tonsil-
lar fossa & soft palate and base of tongue: 5 years actuarial overall survival. Data obtained 
from references 1 Gwozdz et al. and Mak et al., 2 Levendag et al., 3 Kaanders et al. See also 
bibliography.
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Tumors of the Tonsillar Fossa and/or Soft Palate
For general reading on TF and/or SP tumors treated by external beam RT (EBRT) 
and/or surgery, one is referred to the literature search as referenced in this section 3
,7,14,15,18,51,66,70,87,96,97,101,102,138,145,164,170,175,189,190,193,196,203,209,225,226. The TF and/or SP tumors 
are also typically tumor sites very suitable for BT. For an overview on the techniques 
and results obtained with BT, see the following references for example 71,80,81,176,178,199,
200,201,202,230,236,237,246,327. Perez et al. 234 addressed the important issue of ipsilateral and/
or contralateral neck failure in a series of 384 patients treated in a single institution 
(Washington University, St. Louis, MO) (Fig. 17). A similar type of analysis was done 
for the 254 patients with TF and/or SP tumors treated at Erasmus MC, Rotterdam 
(Fig. 18). Interestingly, in the Erasmus MC series, 37 patients received no treatment 
to the contralateral clinically N0 neck; only 1 patient (3%) had a recurrence in the 
neck. Based on these findings, in recent years one has become more selective in 
treating the contralateral neck. That is, according to treatment protocol in Erasmus 
MC, the contralateral neck is only treated if the CTV is crossing the midline, or when 
dealing with N2c,3 disease, or if the TF tumor is infiltrating the glossopalatine sulcus 
and/or the BOT 175.
Figure 17: Carcinoma of the tonsil. Incidence of ipsilateral and contralateral neck recurrence 
in 384 patients treated with irradiation alone or combined with surgery at Mallinckrodt institute 
of Radiology, Washington University. Book: Principles and  Practice of Radiation Oncology 
2004. (Perez CA, Brady LW, Halperon EG, Schmidt-Ullrich RK. Lippincott Williams & Wilkins, 
chapter 38 page 1031). 
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Tumors of the  Tonsillar Fossa  & Soft Palate 
254  patients 
Erasmus MC 1991  – 2001 
Regional Relapse 
1/3 
No Tx RT - only ND - only Preop PORT No Tx RT - only ND - only Preop PORT 
Figure 18: No Tx: no treatment. RT-only: radiation therapy as a single modality.ND-only: neck 
was treated by neck dissection alone. Preop: neck treated by neck dissection and preopera-
tive irradiation 46 Gy. PORT: ND and postoperative radiation therapy.
Treatment Results
T1 lesions less than 1 cm can be treated with surgical resection or irradiation to the 
primary only to a dose of 65 to 70 Gy in 7 weeks. The majority of T1 or T2 tumors of 
the TF and/or SP are treated by irradiation, the ipsilateral neck inclusive, be it electi-
vely or because of N+ disease (see previous section). For T3 and T4 tumors, surgery 
of the primary is often advocated; it can require removal of the primary tumor, partial 
removal of the mandible in combination with an ipsilateral neck dissection (combined 
resection). Because of the high incidence of a recurrence with surgery as a single 
modality 86, surgery is to be followed by PORT 23. Recent insights have demonstrated 
the potential beneficial effect of PORT combined with CHT 56. Because of the parti-
cular location of some of these tumors (e.g., tumor growth in the midline of the SP), 
surgical resection of advanced tumors can lead to a permanent functional defect 
(e.g., in the SP). This then needs to be repaired by reconstructive surgery; otherwise 
the patient is left with open nasal speech. For reasons of organ preservation, T1-T3 
TF/SP tumors are therefore frequently treated by RT, albeit by EBRT alone (70 to 75 
Gy) to the neck and primary or EBRT (40 to 50 Gy) to the primary and neck, followed 
by a boost to the primary tumor by means of low-dose-rate (LDR; total dose, 20 to 
30 Gy) or high-doserate (fractionated HDR; total dose, 20 to 25 Gy) BT (for details 
on BT, see Clinical Section on Tonsillar Fossa and/or Soft Palate and Tumors of the 
Base of Tongue). For the advanced cases, EBRT is combined with concomitant CHT 
22. Data from the literature on the surgical, EBRT only, and EBRT plus IRT results 
with regard to LC and survival are summarized in Tables 9-11, respectively.
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First Author N T1/T2,%
T3/T4,
%
LC T1/T2,
5-Yrs % LC T3/T4, 5-Yrs % 
DFS,
5-Yrs %
OS,
5-Yrs 
%
Mizono, 1986 40 LRC: 73
Parsons, 2002 406 12 (T4) 76 CSS: 57 47
Perez, 1991 127 69 41 3-yrs 39
Perez, 1998 230 14 T1: 80, T2: 71 T3: 65, T4: 58
Foote, 1994 72 3 T1: 78, T2: 76 T3: 4, T4: 0/2
LRC Stage I: 73 LRC Stage III: 53
LRC Stage II: 69 LRC Stage IV: 56
Schuller, 1979 20 Stage IV: 20 CSS: 20
Rabuzzi, 1982 47 Stage IV: 45 CSS: 57
Givens, 1981 37 Stage IV: 51 CSS: 54
Gluckman, 1985 82 Stage IV: 39 CSS: 56
Table 9: Tonsillar fossa / soft palate: local control and survival according to stage, surgery and 
PORT. LC: local control. LRC: local regional control. CSS: cause specific survival.
Tumors of the Base of Tongue
SCCs, often poorly differentiated, account for more than 90% of cancers 
of the BOT. It is often difficult to estimate exact tumor extension by clinical 
examination. Fullness in the soft tissue around the hyoid bone may be a sign 
of inferior penetration through the valleculae (the transition zone between the
BOT and the epiglottis). Tumors in the valleculae tend to be exophytic; they fre-
quently encroach on the lingual aspect of the epiglottis. Rarely do these tumors 
infiltrate the palatine tonsils. Bilateral and contralateral lymphatic spread is common; 
retrograde spread to retropharyngeal lymph nodes has been reported in advanced 
cases. Overall, patients with BOT cancers present with lymphatic metastasis in 50% 
to 80%, with the jugulodigastric and parapharyngeal nodes most commonly involved. 
Bilateral spread is observed in 37% to 5 5% 179,227.
The incidence of pathologic lymph nodes (pN+) in the ipsilateral clinical N0 neck is 
estimated to be 22% to 33%. Contralateral lymphatic metastasis at presentation is 
observed in 37%, albeit by RT or surgery. These data testify to the fact that in BOT 
cancer, the neck should be treated electively bilaterally (N0; levels II-IV), or thera-
peutically (N+; levels I-V). An overview of the pertinent literature on BOT cancer can 
be obtained from references 15,44,66,87,101,119,123,124,127,128,129,135,136,141,143,148,155,163,168,169,184,189,1
92,193.
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First Author N T1/T2,%
T3/T4,
%
LC T1/T2,
5-Yrs %
LC T3/T4, 
5-Yrs % 
DFS,
5-Yrs %
OS,
5-Yrs %
Jackosn, 1999 170 63 DSS: 76.2 DSS: 61 55.7
Marcial, 1993 137 92 32 3-yrs 24
Horiot, 1992 325 56 47 35
O'Sullivan, 1997 229 76
Bataini, 1989 465 35 T1: 90, T2: 84 T3: 64, T4: 47
Selek, 2004 60 100 82.6 74.3
Mak-Kregar, 1993 68 76 75 3-yrs
Di Marco, 1990 183 75 28
Withers, 1995 676 75
Mendelhall, 2000 400 T1: 83, T2: 81 T3: 74, T4: 60 CSS: 70 49
Wong, 1989 150 5 T1: 94, T2: 81 T3: 67, t4: 47 CSS: 70
Perez, 1998 154 23 T1: 76, T2: 63 T3: 59, T4: 33 CSS: 70
Erkal, 2001 107 61 49 T1: 86, T2: 91 T3: 67, T4: 19 CSS: 70 42
Chao, 2004 56 TF: 85 4-Yrs TF: 79 4-Yrs
SP: 100 4-Yrs SP: 100 4-Yrs
Table 10: Tonsillar fossa /soft palate: local control and survival according to stage external 
beam radiotherapy. LC: local control. LRC: local regional control. CSS: cause specific survi-
val. DFS: disease free survival TF: tonsillar fossa. SP: soft palate.
 
First Author N T1/T2,%
T3/T4,
%
LC T1/T2,
5-Yrs %
LC T3/T4, 
5-Yrs % 
DFS,
5-Yrs %
OS,
5-Yrs %
Pernot, 1992 277 57 76 5-yrs 51
Puthawala, 1985 80 24 84
LRC Stage 
I:3/3
LRC Stage 
III:85
LRC Stage
II:100
LRC Stage 
IV:56
Pernot, 1994 361 1 T1:80, T2:71 T3:65, T4:58 CSS: 63 53
LRC: 75
Levendag, 2004 104 77 T1-T3: 88 57 67
Esche, 1988 43 T1: 34/43 92 CSS: 64 37
Mazeron, 1993 100 94 71 53
Peiffert, 1994 73 65/73 2/73 T1: 80, T2: 67 CSS: 64 30
Table 11: Tonsillar fossa / soft palate: local control and survival according to stage, brachythe-
rapy boost. LC: local control. LRC: local regional control. CSS: cause specific survival. DFS: 
disease free survival.
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Treatment Results
With regard to the management of BOT tumors, in short, the primary tumor in ear-
lystage oropharyngeal cancers can be treated by either EBRT or IRT or surgery, 
whereas more advanced lesions often are treated by surgery plus PORT. Also 
EBRT, followed by a boost by IRT or intraoral cone and/or concomitant CHT for the 
more advanced cases, is frequently used. In the majority of institutions, however, 
RT is the preferred definitive treatment mode for T1, T2, and some of the exophytic 
T3, N0, N1 cancers. In general, a neck dissection is warranted only in these early 
cancer stages in patients treated by RT and experiencing a residual regional mass 6 
weeks after completion of the therapy. In this respect, Doweck et al. 71 discussed the 
controversial role of selective neck dissection after definitive RT. For N1–3 disease, 
some protocols have successfully used routine neck dissections after preoperative 
RT (46 Gy), with excellent control rates. For the more advanced (endophytic) T3 
lesions, as well as for the T4 tumors with significant extension into normal surroun-
ding tissues, organ/normal tissue deformities are frequently the cause of clinical pro-
blems, for example, resulting in swallowing disability and trismus. For this category 
of patients, the treatment is frequently “tailor made” and surgery followed by PORT 
might sometimes be a more sensible option 299. Reviewing the literature, however, 
the implementation of concomitant CHT has also been shown to be a highly effec-
tive treatment combination. BOT tumors may be resected transorally or via mandi-
bulotomy; the last approach is frequently combined with reconstruction by tissue 
grafting 272. Patients with advanced tumors may require a glossectomy. In these 
cases, a tracheotomy (to avoid aspiration) with placement of a speech button and a 
percutaneous endoscopic gastrostomy to circumvent swallowing dysfunction (thus 
to secure adequate food intake during treatment and immediate follow-up) is often 
performed at the time of surgery. The relevant data taken from the literature with 
regard to locoregional tumor control and survival has been summarized in Table 12 
(for surgery), 13 (for EBRT), and 14 (for EBRT combined with a BT boost). Finally, 
two typical protocols, exemplified by Figures 19 and 20, illustrate different treatment 
approaches, but similar (good) LC and survival for oropharyngeal tumors. Figure 19 
represents the oropharynx protocol of Erasmus MC, with emphasis on organ func-
tion-preserving properties by using accelerated fractionation during the first series 
of IMRT (6 fractions per week) and HDR-BT, or Cyber Knife as a boost technique. 
Figure 20 illustrates the protocol of the M.D. Anderson Cancer Center, with the main 
focus on the concomitant boost (altered fractionation) technique.
Tumors of the Lateral and Posterior Pharyngeal Walls
These tumors are less frequently reported in the literature and generally do 
not do so well with either RT or surgery as opposed to the TF and/or SP tumors
or the tumors of the BOT. For a short bibliography see references 53,59,63,83,144,1
52,191,206,208,242,285,293,295,326. 
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First Author N T1/T2,%
T3/T4,
%
N0,
%
LC T1/T2,
5-Yrs %
LC T3/T4, 
5-Yrs % 
DFS,
5-Yrs %
OS,
5-Yrs 
%
Pol, 2004 58 26 (T4) 18 91 55
Foote, 1993 55 49 LRC: 48
Kraus, 1993 100 38 LRC: 72 DSS: 61 55
Malone, 2004 40 70 25 LRC: 100 2-Yrs DSS: 93.6 74.7
Parsons, 2002 390 13 (T4) 76 CSS: 62 49
Sessions, 2003 262 19 45 LRC: 74 CSS: 49.6 42.4
Table 12: Base of tongue: local control and survival according to stage, surgery and PORT. 
LC: local control. LRC: local regional control. CSS: cause specific survival.
First Author N T1/T2,%
T3/T4,
%
N0,
%
LC T1/T2,
5-Yrs %
LC T3/T4, 
5-Yrs % 
DFS,
5-Yrs %
OS,
5-Yrs %
Selek, 2004 40 100 100 76 83
Spanos, 1976 174 37 T1: 91,T2 : 71
T3: 78,
T4: 52
Jaulerry, 1991 166 59 30 69 32 27
Mendenhall, 
2000 217
19 
(T4)
T1: 96,
T2: 91
T3: 81,
T4: 38
CSS: 
50 64
Mak, 1995 54 17 LRC T1/T2:85 59
LRC T3: 67
Hinerman, 1994 47 qd 18 LRC: 70 44
90 bid
Marcial, 1983 141 25 LRC: 31 15
Housset, 1987 29 100 0 T1: 100, T2: 74 52
Wang, 1991 79 qd T1-T3 Conventional T1/T2: 79 T3: 24
T1/T2: 
65,
T3: 14
90 bid T1-T3 bid T1/T2: 85
T1/T2: 
76, 
T3: 53
Chao, 2004 18 LRC: 88 80 4-Yrs
Table 13: Base of tongue: local control and survival according to stage, external beam ra-
diotherapy. LC: local control. LRC: local regional control. CSS: cause specific survival. DFS: 
disease free survival. bid: twice daily. qd: one fraction per day.
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First Author N T1/T2,%
T3/T4,
%
N0,
%
LC T1/T2,
5-Yrs %
LC T3/
T4, 5-Yrs 
% 
DFS,
5-Yrs %
OS,
5-Yrs 
%
Harrison, 1997 68 3 (T4) T1: 87,T2: 93
T3: 82,
T4: 100
T1: 88,
T2: 93,
T3: 82
87
Puthawala, 1988 70 17 (T4) T1: 100, T2: 88
T3: 75, 
T4: 67 67 35
Barrett, 2004 20 35 10 2-Yrs 33
Takacsi-Nagy, 2004 37 81 19 100 60 52 46
Karakoyun-Celik, 
2005 40 54 30 LC: T1-4: 78 54 62
Pol, 2004 30 67 (T4) 30 63 45 40
Gibs, 2003 41 49 32 14 20 79 66
Brunin, 1999 216 61 30 T1: 93,T2: 66
T3: 45, 
T4: 18
CSS 
I-IV: 
63-23
27
Crook, 1988 48 100 T1: 85,T2: 71 50
Hoffstetter, 1996 136 55/136 N0/N1: 81
T1: 86,
T2: 69 T3: 64
Horwitz, 1996 20 11/20 9/20 10/11 T4: 8/9 72
Housset, 1987 29 100 T1: 6/6, T2: 74 30.5
Lusinchi, 1989 108 57/108 T3:51/108
T1: 85,
T2: 50 T3: 69 26
Table 14: Base of tongue: local control and survival according to stage, brachytherapy boost. 
LC: local control. CSS: cause specific survival. DFS: disease free survival.
Treatment Results
Guillamondequi et al. 112 found 28% recurrences after surgery, with salvage in less 
than one third of the patients. Fein et al. 81 at the University of Florida compared re-
trospectively once-daily versus twice-daily fractionation. The observed LC rates were 
100% versus 100% for the T1 category, 67% versus 92% for the T2 tumors, 43% 
versus 80% for T3 tumors, and 17% versus 50% for T4 tumors. Meoz-Mendez et al. 
207 reported on a mixed group of patients with hypopharyngeal and pharyngeal wall 
carcinomas treated in the M.D. Anderson Cancer Center: the LC for T1 was 91%; 
for T2, 73%; for T3, 61%; and for T4, 37%. Those treated with surgery and PORT 
or preoperative RT fared better (LC, 75%) as opposed to RT alone (LC, 51%). A 
study by Marks et al. 194,195 compared preoperative RT with definitive RT. There was 
no difference in LC, but significantly more grade III/IV complications in the surgery 
group. Spiro et al. 286, from Memorial Sloan Kettering Cancer Center in New York, 
reported on 78 patients with posterior wall carcinomas. The cumulative 5-year survi-
val was poor: 32%. Good results, albeit in a small selected series of patients, were 
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Patient Intake
RWHHT / Joint Clinic
N+?
Tonsillar Fossa /
Soft Palate / Base of Tongue
(Oropharynx)
no
Staging
Biopsy, PA report / revision, 
Examination under anesthesia, 
Ultra Sound Fine Needle Aspiration, 
CT, MRI, PET, Surgical report
yes
IRT / 
IMRT /
Surgery
ND
PORT 60 Gy
Brachytherapy/
IMRT
Protocol
Surgery
Protocol
Primary Tumor
Primary Tumor Neck
CURATIVE PROTOCOL
IMRT 46 Gy
T3,4, N2c, N3?
2 Courses 
Concomitant
Chemo-Radiation
no
yes
Ipsilateral Neck Bilateral Neck
Invasion BOT,
crossing midline SP
Cyberknife
3*5.5 Gy
IRT
20-22 Gy IMRT 70 Gy
High risk
Irradical resection,
lymfnode metastasis
with ECE,
two or more nodes
Close margins,
perineural growth, 
T3, T4-tumors 
Intermediate risk
PORT 66 Gy
Risk?
No risk
No PORT
BT
CKF?
yes
no
Erasmus MC
Figure 19: All curative cases are treated by 6 fractions per week.
obtained with an I125 or Ir192 implant; there was an LC rate of 82% at 5 years 284.
In general, the locoregional outcome and survival is significantly better for the early 
T1, T2, and T3N0,1 carcinomas as opposed to the (endophytic) T3,T4 and N2,3 
tumors. Although RT alone most likely confers less functional impairment than is the 
case with surgery, surgery followed by PORT remains a valuable treatment option for 
advanced tumors. Different surgical approaches have been proposed for the primary 
tumor (see Chapter 17 in Harrison et al. 126). A (bilateral) modified neck dissection 
is also included in the treatment approach of these difficult-to-manage malignant tu-
mors. Posterior pharyngeal wall tumors in particular pose a technical problem when 
one needs to deliver high doses of definitive radiation to the primary tumor because
of the proximity of the spinal cord. Grimard et al. 111 described an elegant technique 
for radiating these tumors without compromising the spinal cord tolerance by using 
two posterior arcs with closure of one jaw beyond the central axis. The initial target 
volume encompasses the primary tumor and the bilateral neck levels II-V, with the
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Tonsillar Fossa /
Soft Palate / Base of Tongue
(Oropharynx)
IMRT /
Surgery
PORT
56 Gy, 28 fx
IMRT / 3DCRT
Protocol
Surgery
Protocol
CURATIVE PROTOCOL
High risk
Close or microscopically 
positive margins
Perineural extension, 
Vascular invasion
Positive nodes
Extranodal extension
Surgical Bed
PORT 
60 Gy, 30 fx
Risk?
PORT
50 Gy, 25 fx
M.D. Anderson Cancer Center
TF: Large T2, 
T3, N0, N1
SP/BOT: T2,
exophytic T3,
N0/N1 
TF: T2, N0-N2
SP: T1,T2, N0-N1 
BOT: T1/T2, N0/N1
3DCRT Study
TF/SP/BOT:
Exophytic T3, 
T4 or N2/N3
Concomitant boost 
69-72 Gy
(40 to 42 fx)
66 Gy PTV  +
involved nodes
54 Gy PTV 
subclinical disease
50 Gy initial TV 
70 Gy boost  TV
Additional BT if
residual palpable
disease
Undissected
regions 
Elective 
irradiation
Figure 20: All curative cases are treated by 6 fractions per week.
parapharyngeal and retropharyngeal lymphatics inclusive. Finally, results in terms of 
tumor control, survival, and (severe) complications are summarized in Table 15.
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Recurrent Disease and Salvage
The management of a locoregional failure in the head and neck remains a formida-
ble challenge. Most recurrences (80%) manifest in the first 2 years following primary 
treatment. At least 50% of patients who die from uncontrolled disease have local 
and/or regional disease as their sole site of failure. Moreover, the majority (80%) 
of those who develop distant metastases also have local and /or regional failure. 
Another, related clinical entity is the management of second primary tumors (about 
3% per year 161,220) occurring in previously irradiated regions. Selected patients with 
locoregional recurrences can be successfully salvaged with surgery and/or RT. Tre-
atment options are more limited if initial treatment consists of surgery combined with 
RT or high-dose RT. The average cure rate of these patients has been reported to 
vary between 30% and 40%, and most failures are due to locoregional relapses. 
The use of surgery alone as a salvage procedure in case of recurrent BOT cancer 
was reported by Pradhan et al. 242. In approximately one third of the patients, LC was 
achieved for the duration of 1 year. Thirty-five patients required a total glossectomy. 
The role of RT is not widely appreciated as yet, mainly because of concerns about 
the tolerance of local tissues to reirradiation. In this regard, BT plays a crucial role 
(high-dose, small volume, rapid dose fall -off) 140,165,197. An equivalent EBRT dose 
of 60/2 Gy by five fractions per week is being applied mostly as the reirradiation 
dose schedule. An important prognostic factor favoring long-term LC is an interval 
of more than 1 year between the radiation courses. Langlois et al. 165, for example, 
report on 123 patients treated for recurrent cancer or a new cancer of the tongue or 
oropharynx, arising in previously irradiated volumes.The actuarial LC rate was 67% 
at 2 years and 59% at 5 years. Levendag et al. 176 analyzed a 13-year experience 
with reirradiation. An improvement in LC was observed (50% vs. 29%) for the EBRT 
plus IRT as opposed to the EBRTalone series. The improvement in LC was typically 
not reflected in a survival benefit; that is, an actuarial OS of 20% at 5 years was ob-
served in both series. Mazeron et al. 200 had similar results: actuarial LC was 72% at 
2 years and 69% at 4 years. Although LC of the tumor was achieved in the majority 
of these patients, only 14% remained alive at 5 years. Best results were achieved in 
lesions of the faucial arch and posterior pharyngeal wall (LC, 100%). Other ways of 
applying reirradiation is in an intraoperative setting for residual microscopic disease 
by means of a silicone flexible intraoperative template (Fig. 21). After the dose of 
10 Gy (prescribed mostly at 1 cm from the afterloading catheter in the flexible in-
traoperative template) has been delivered, the surgical defect can be closed by a 
reconstructive procedure using “fresh,” that is, donor tissue (e.g., deltopectoral flap) 
that has not been previously irradiated. The dose is mostly prescribed to a distance 
of 1 cm 157; subsequently, a course of fractionated EBRT is applied as an outpatient 
procedure (e.g., 26 × 1.8 Gy). As with any retreatment situation, the complication 
rate is substantially higher than with primary therapy.
Oropharynx
----------------
52
..........
First 
Author N Modality
T1/
T2,
%
T3/
T4,
%
N0,
%
LC
T1/T2,
5-Yrs
%
LC
T3/T4,
5-Yrs
%
DFS ,
5-Yrs
%
OS,
5-Yrs % SC
Pommier, 
1997 14 BT 37 21 None
Chenal,
1996 55
RT/
Surgery 55 67
38, 
mean
 23 
months
Fein,
1993 9 RT
T1:100, 
T2:92
T3:80,
T4:50
2 daily fx, 2-yrs
Mak-
Kregar, 
1994
8 RT/Surgery 100 50 38
Spiro,
1990 78
RT/
Surgery 32
Menden-
hall, 1988 75
RT/
BT
T1: 75, 
T2: 57
T3: 44,
T4: 20
II: 44,
III:19
I: 0/2,
 II:1/16, 
III:2/22,
IVA: 0, 
IVB: 8
 IVA: 
2/14,
IVB: 
3/20
Hull, 
2003 148
RT/
Surgery 40 59 36
T1:93
T2: 82
T3: 59,
T4: 50
I: 89, 
II:88,
I: 56,
II: 52 16
III: 44,
IV: 34
III: 24, 
IV: 22
Julieron, 
2001 77
Sur-
gery+
PORT
Local failure: 11 35 GPO: 22
Chang,
1996 74 RT
2-yrs;
 T1:100, 
T2: 55
2-yrs; 
T3:31, 
T4:29
2-yrs;
I: 100, 
II: 85,
2-yrs;
I: 75, II: 
67,
III: 58, 
IV: 40
III: 33, 
IV: 30
Cooper, 
2000 22 RT 3-yrs; 73 3-yrs: 5
Yoshida, 
2004 51
RT/
Surgery 56
CSS: 
48
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First 
Author N Modality
T1/
T2,
%
T3/
T4,
%
N0,
%
LC
T1/T2,
5-Yrs
%
LC
T3/
T4,
5-Yrs
%
DFS ,
5-Yrs
%
OS,
5-Yrs % SC
Meoz-
Mendez, 
1978
164 RT 13/56
53/
108
69/
164
1-yrs;
T1: 91,
 T2: 73
1-yrs;
T3: 
61,
T4: 37
I: 0, 
II:7,
III:15, 
IV:17
Table 15: Local control for posterior pharyngeal wall tumors after treatment by radiation the-
rapy and/or surgery. SC: Severe Complicatoins, GPO: General postoperative
Figure 21: A: flexible intra-operative template (FIT) positioned on the tumor bed and 
a delto-pectoral flap is used to close the skin defect. B: the simulation radiograph of 
the FIT in situ (neck).
Radiation Therapy Techniques
Conventional Radiation Therapy
Irradiation portals for oropharyngeal cancers should encompass the primary tumor 
and its local and regional “extensions,” with a margin for the CTV (approximately 
0.7 cm) and for the PTV (approximately 0.5 cm). The concept of regional coverage
has been eluded to before extensively. Patients are generally treated in the supine 
position with bite-block and thermoplastic mask immobilization, with daily treatment 
of all fields. Neck portals should extend superiorly until C1 for N0, and the base of 
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skull (retrostyloid space) in case of N+ disease. Patient examples (T2N2b BOT tu-
mor and T2N2b TF/SP tumor) with regard to the geometry of portals, treatment tech-
niques used, and dose distributions are shown in Figures 22-33. In the examples 
presented in Figures 22-26, the primary tumor and both sides of the upper neck 
are irradiated using a conventional lateral parallel -opposed technique for the upper 
neck in case of a T2N2b BOT tumor. Both sides of the lower neck are generally ir-
radiated through a single anteroposterior field, sometimes with a midline block. In 
order to p revent overdose at the junction line, a junction zone of 1 cm between the 
lateral fields and the anteroposterior portals is treated daily in Erasmus MC with 
maximum or minimum field sizes (the so called slip zone). If appropriate, the midline 
block shields the larynx and spinal cord. The spinal cord is shielded after admini-
stration of 46/2 to 50/2 Gy and if indicated, the posterior cervical triangles are boos-
ted with 10-MeV electrons, therewith sparing the spinal cord. Tissue compensators 
(wedges) are used to ensure dose homogeneity in the lateral portals and to prevent 
excessive dose to the supraglottic larynx. After 46/2 Gy with 4- to 6-MV photon 
beams has been applied, the remaining dose can be delivered with high-energy 
photons (15 to 18 MV) in order to reduce the dose to the parotids, the mandible, 
and/or the temporomandibular joints (buildup). The middle ear and inner ear should 
be carefully shielded posteriorly. Small tumors of the TF, anterior tonsillar pillar, and 
retromolar trigone can be treated by ipsilateral wedged anterior and posterior fields 
or with BT. With the wedge technique, the dose to the mandible is high, and a gre-
ater incidence of complications (e.g., soft tissue necrosis and osteonecrosis of the 
mandible) can be anticipated. Limiting irradiation to the ipsilateral neck reduces the 
probability of xerostomia 18. This approach was confirmed by O'Sullivan and Grice 
225, who reported a 3-year tumor control rate of 77% and cause-specific survival rate 
of 76% in 228 patients with carcinoma of the tonsillar region treated with ipsilateral 
-only RT techniques (oblique wedge pair arrangement). Contralateral neck failure 
was observed in only eight patients (3.5%). Levendag et al. had similar observations 
(Fig. 18). Contralateral failure in the untreated neck was only 3% 175. The intraoral 
cone technique, using orthovoltage or electrons, has been used selectively in the 
treatment of patients with small lesions. Adequate tumor coverage is aided by CT-
based treatment planning (with or without MRI fusion); moreover, at the present time 
it is reasonable to consider CT-based treatment planning for head and neck cancer 
more or less obligatory. Many of the previously described techniques have therefore 
substantially changed since the introduction of new and innovative technology, such 
as IMRT, three-dimensional conformal radiation therapy, and cone beam CT (see 
also dedicated section XIII on IMRT). Figures 27-33 represent a TF and SP tumor 
treated by IMRT techniques. The figures depict adequate target coverage and maxi-
mum effort to spare major salivary glands. We have compared, for bilateral irradia-
tion, bilateral sparing of parotid glands (Fig. 27), as opposed to maximum sparing of 
contralateral parotid glands (Fig. 28), or reducing CTV contralateral side (Fig. 29). 
The corresponding dose-volume histograms are depicted in Figures 30,31 and 32. 
Also, using this technology, new concepts can be incorporated in future treatment 
protocols. For example, Thorstad et al. 298 from M.D. Anderson Cancer Center, re-
port favorable results for SCC of the oropharynx treated with IMRT. Multivariate 
analysis showed that the GTV (primary tumor ± nodes) became an independent risk 
factor determining locoregional control (GTV <50 mL LC ± 90% vs. GTV >50 mL LC 
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± 20%; p <.0001). From this type of data, the authors concluded that selecting “high-
volume” patients for aggressive treatment protocls might be warranted. For more 
details, see IMRT section.
Figure 22: BOT tumor, staged T2N2b. Beams Eye View conventional parallel opposed fields 
upper neck. Red dotted line: PTV. Blue volume: CTV neck. Red volume: primary tumor. Ma-
genta volume: lymphnodal volume levels II and III. 
Figure 23: See legend figure 20. Dose (46/2 Gy) distribution axial CT slice upper 
neck and low anterior neck. Dose generally prescribed at 3cm depth or at a particu-
lar point of interest (e.g. in case of lymphnodes in lower neck). Note: no midline block 
because of potential shielding of tumor extensions.
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----------------
56
..........
Figure 24: See legend figure 20. Field configuration and doe distribution boost to primary 
tumor to total dose of 24/2 Gy using parallel-opposed fields. Note shielding posterior neck 
(cord); dose shielded area supplemented by abutted high energy electron fields (10 MeV).
Figure 25: See legend figure 20. Beams Eye View treatment primary tumor and neck node 
levels II and III (boost).
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Figure 26: Cumulative Dose Volume Histogram BOT tumor treated to a cumulative dose of 70 
/2 Gy. See also legend figure 20 and figure 23.
.
Figure 27: Dose distribution (color wash) TF and SP tumor, staged to T2N2b for first series of 
RT (46/2 Gy). Upper neck and primary tumor irradiated using a 5-field IMRT technique. CTV 
consists of primary tumor and neck levels I-V (ipsilateral, left) and neck levels II-IV (contrala-
teral, right). Dose prescribed  according ICRU 50 guidelines. Field configuration: Upper neck 
IMRT (this figure), lower neck A-P portal (figure 31). Equal sparing of both parotid glands  was 
achieved. For abutted low anterior neck portal, see figure 31.
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Figure 28: See legend figure 25. In order to better spare the contralateral parotid gland, re-
laxation of the ipsilateral parotid constraint is pursued and a asymmetric 4-field IMRT tech-
nique was implemented. Dose is prescribed to ICRU 50 guidelines. For abutted low anterior 
neck portal, see figure 31. 
Figure 29: See legend figure 25. In order to improve sparing of contralateral parotid gland, 
contralateral cranial border of upper neck (level II) is lowered by 1 cm. A 5-field IMRT techni-
que was used. For abutted low anterior neck portal, see figure 31.
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Figure 30: Dose Volume Histogram (DVH) corresponding to figure 25. Note:mean dose left 
parotid gland 23.2 Gy, mean dose right parotid gland 22.0 Gy.
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Figure 31: DVH corresponding to figure 26. Note: mean dose left parotid gland 34.8 Gy; howe-
ver, mean dose right (= contralateral) parotid gland (16.9 Gy) improved by about 5 Gy.
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Figure 32: DVH corresponding to figure 27. Note: mean dose left parotid gland 23.0 Gy, mean 
dose right (= contralateral) parotid gland 12.7 Gy. That is, a significant amount of sparing was 
obtained due to lowering the cranial border of the right neck.
Figure 33: Low anterior neck dose distribution; dose generally prescribed at 3cm depth or at a 
particular point of interest in the neck (e.g. in case of lymphnodes in lower neck). Note: midline 
block sparing e.g. larynx.
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Dose and Fractionation Primary Sites in Oropharynx
In general for T1–2 lesions, doses of 66 to 70 Gy in 6.5 to 7 weeks with conventional 
fractionation (1.8 to 2.0 Gy per fraction daily, six fractions per week) are recommen-
ded for definitive radiotherapy. However, for T3–4 oropharyngeal cancers, several 
studies have demonstrated better locoregional control when either accelerated or 
hyperfractionated regimens are used with concurrent CHT 41,88,91,155. (For details on 
altered fractionation, see section Chemotherapy, Targeted Therapy, and Altered 
Fractionation Regimens). For locally advanced lesions in the head and neck, in re-
cent years the addition of concurrent CHT to either conventional or altered fractiona-
ted radiation has shown to be beneficial compared to radiation therapy alone.
Side Effects of Conventional Treatment Techniques
Normal Tissue Toxicity Profile—Acute Effects
The major sequelae of RT can be divided into acute and chronic side effects. They 
are multifactorial. The potential acute effects on the oral cavity and pharynx after ap-
proximately 1 to 3 weeks of RT include mucositis (ulcer), sore throat, loss of taste, 
and xerostomia (if any of the major salivary glands are in the treatment portal). Ap-
proximately 5% of patients develop sialadenitis within 24 hours of the first irradiation 
treatment, but this usually resolves within 24 to 48 hours. The skin experiences ery-
thema, peeling, and pigmentation. If the capacity of the basal cell layer to repopulate 
the epidermis is overwhelmed, the result is moist desquamation. Likewise, epilation 
of hair-bearing areas with accompanying loss of sweat and sebaceous gland func-
tion occurs.
Normal Tissue Toxicity Profile— Late Effects
The late effects after definitive RT can include xerostomia, dental caries, altered 
sense of taste, swallowing problems, dysphagia, altered quality of voice, lymphe-
dema, hypothyroidism, epilation, trismus, cervical fibrosis, atrophy of the mucosa 
and skin, as well as soft tissue and bone necrosis. In a Rotterdam series on or-
opharyngeal tumors 25% grade III/IV mucositis (“pinpoint ulcer,” 47/190) and 10% 
trismus (19/190) were reported. In the process of osteoradionecrosis, radiation is 
believed to exert an avascular effect on tissues and epithelia that are thinner and 
more susceptible to injury. The process usually starts with ulceration of soft tissues, 
which can progress to bone exposure. For refractory cases, hyperbaric oxygen tre-
atment has been advocated. Factors that can influence osteoradionecrosis include 
elective dental extraction after RT and treatment of tumors near bone. In the modern 
era, osteonecrosis should be an uncommon event (<5%) 17. Technique could also 
play a role, the BT nonlooping technique being associated with a higher reported 
injury rate than the looping technique 124,191. Of these late side effects, xerostomia is 
the most prominent 317, and will be discussed in more detail in the next paragraph. 
Dysphagia and trismus, although clinically important to prevent, are still somewhat 
underscored. These are given a prominent place in the discussion involving quality 
of life (QOL) in the section Performance Status Scale, Socioeconomic Outcomes, 
and Quality of Life. Finally, clinical reports on late side effects are summarized data 
in Table 16 9,99,121,145,175,184,203,226,227,234,285,320.
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Xerostomia
Given the way most patients were treated in the (recent) past, frequently using 
nonsparing parallel -opposed techniques, xerostomia seems to be the overriding 
side effect. Roesink, et al. from the Utrecht Medical Center reported important ob-
servations on the dry mouth syndrome, in particular related to the dose-effect relati-
onship of the major salivary glands (Fig. 34). Irradiation of the salivary glands is ob-
viously associated with loss of function, quantitatively and qualitatively, thus among 
other things resulting in a reduction in salivary flow and consequently dryness of the 
mouth. Moderate-to-severe xerostomia occurs in more than 75% of patients treated 
with conventional lateral beam arrangements. The best definition for objective paro-
tid gland toxicity appeared to be reduction of stimulated output to <25% of the pre-
radiotherapy output 260. Two dose-response curves for stimulated parotid saliva flow 
rates obtained from relatively large patient groups are available 76,259 (Fig. 34). Both 
studies conclude that the mean dose to the parotid gland best predicts its function 
after radiotherapy. The steepness of the dose-response curve and the TD50 value 
at 1 year after irradiation differHowever, we can conclude from these studies that it 
is rather safe, in terms of preservation of stimulated parotid gland function, to have a 
mean parotid gland dose of less than 25 Gy.
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Figure 34: Dose effect relationship xerostomia from Roesink et al. (for explanation see text). 
NTCP: normal tissue control probability.
When a mean dose is reached above 50 Gy, nearly all patients will have a severe 
decrease in parotid flow rate. It is generally accepted that IMRT is a valuable tool 
for reducing the dose to the parotid gland. Several studies report on salivary flow 
after IMRT for oropharyngeal tumors. However, clinical studies that objectively de-
monstrate and quantify the advantages of IMRT compared with conventional beam 
arrangements are scarce. Chao et al. 49 found a correlation of the parotid flow ratio 
with the mean parotid dose, and a lower mean parotid dose in 27 IMRT patients 
compared with 14 patients treated conventionally. IMRT versus conventional treat-
ment, however, did not independently influence the functional outcome of the saliva-
ry glands in this study. Roesink 259,260 and Terhaard et al. 297 prospectively evaluated 
a total of 56 patients with oropharyngeal cancer. Of these, 26 received conventional 
radiotherapy and 30 patients were treated with IMRT. The mean dose to the parotid 
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N First Author Site Incidence % Incidence %
EBRT
2308 Parsons, 2002 TF Servere complicationsFatal complications 60.8
154 Perez, 1998 TF Fatal complicationsNonfatal complications
2/154
30/154
1
19
178 Jackson, 1999 TF Osteoradionecrosis 3.5
676 Withers, 1995 TF
Severe late complications, 
grade 3/4
(mucossa, bone and 
muscle)
217 Mendenhall,2000 BOT
Insufficient ability to 
swallow, osteonecrosis, 
chondronecrosis,
 fatal radiation-induced 
sarcoma
8/217 3.7
91 Spanos, 1976 BOT Bone Necrosis 15/91 16
842 Parsons, 2002 BOT Servere complicationsFatal complications
3.8
0.4
Surgery 
+ 
PORT
151 Ang et al, 2001 All
Ulcer/soft tissue necrosis
Fibrosis
Dysphagia
Fistula
Osteonecrosis requiring 
surgery
Chondritis
2/76
(63 Gy/5 wk)
19/76
(63 Gy/5 wk)
16/76
(63 Gy/5 wk), 
2/76
(63 Gy/5 wk)
1/76
(63 Gy/5 wk)
0/76
(63 Gy/5 wk)
3
25
21
3
1
0
2/75
 (63 Gy/7 wk)
13/75
(63 Gy/7 wk)
13/75
(63 Gy/7 wk)
5/75
(63 Gy/7 wk)
2/75
(63 Gy/7 wk)
1/75
(63 Gy/7 wk)
3
17
17
7
3
1
86 Levendag, 2004 All
Late effect: Mucosa
Late effect: Salivary glands
Late effect: Dysphagia
Late effect: Pain
Late effect: Trismus
6/86
2/86
14/86
9/86
18/86
7
2
16
10
21
616 Parsons, 2002 TF Servere complicationsFatal complications
23
3.2
86 Perez, 1998 TF Fatal complicationsNonfatal complications
2/86
46/86
2
53
17 Machtay, 1997 BOT
Gastrostomy and/or 
tracheostomy
Osteoradionerosis/soft-
tissue 
necrosis
Grade 3 trismus
Facial edema
5/17
0/17
1/17
1/17
29.4
0
5.9
5.9
407 Parsons, 2002 BOT Severe complicationsFatal complications
32
3.5
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N First Author Site Incidence % Incidence %
BT
104 Levendag, 2004 All
Late effect: Mucosa
Late effect: Salivary glands
Late effect: Dysphagia
Late effect: Pain
Late effect: Trismus
41/104
6/104
21/104
21/104
1/104
39
6
20
20
1
68 Harrison, 1998 BOT Fatal complications 3
41 Gibbs, 2003 BOT
Soft-tissue necrosis/
ulceration
Osteoradionecrosis
Gastrosstomy
Sarcoma
3/41
2/41
1/41
1/41
7.3
4.8
2.4
2.4
 
Table 16: Late complications after oropharyngeal cancer radiation treatment
glands was 48.1 Gy for the conventional treatment and 33.7 Gy for IMRT. As a re-
sult, 6 weeks after treatment the number of parotid complications was significantly 
lowerafter IMRT (55%) than after conventional radiotherapy (87%). There are several 
studies using toxicity scoring systems instead of saliva measurements. Eisbruch et 
al. report on parotid function after conformal radiotherapy and IMRT 76. In a matched 
case control study with a low number of patients treated with standard radiotherapy, 
the QOL scores of patients treated with IMRT improved over time after irradiation, 
and no improvement was seen in patients treated with standard radiotherapy 144. In 
the studies of Chao et al. 50, the dosimetric advantage of IMRT compared with con-
ventional techniques did translate into a significant reduction of late salivary toxicity 
in patients with oropharyngeal carcinoma. One has to keep in mind that the sub-
mandibular glands also play a major role in producing saliva: in resting state, 70% 
of the saliva production is believed to be generated by the submandibular glands. 
The submandibular glands as well as the minor salivary glands are given more at-
tention in clinical research at the present time, but much research on role of these 
structures still has to be performed. However, sparing of the submandibular gland in 
oropharyngeal cancer is extremely difficult in case of bilateral treatment of the neck. 
One possible future avenue is to routinely transfer the submandibular gland ventrally 
in the contralateral node-negative neck.
Performance Scale Status, Socioeconomic Outcomes, and Quality of 
Life
Performance Status Scale and Socioeconomic Outcome
A great deal of clinical interest and research is devoted at the present time to (func-
tional) QOL issues, in particular after treatment with interstitial RT 237,258. This seems 
relevant, in particular because of the great variation in treatment modalities and tre-
atment schemes used in head and neck cancer with otherwise similar tumor control 
and survival outcome 253. The acute toxicity of concurrent chemoradiation is signifi-
65
..........
cant. However, because of organ preservation, according to an article by Nguyen et 
al. 217, patients may achieve a better QOL after chemoradiation compared with con-
ventional use of surgery and PORT. Measurement instruments, such as validated 
questionnaires for QOL, are still evolving but are becoming a routine part of (clinical) 
research protocols. One such set of evaluation tools frequently used in head and 
neck cancer is the Performance Status Scale (PSS), as designed by List et al. 179,180. 
The system yields scores reflecting patients’ ability to eat in public, understandability 
of patient’s speech, and normalcy of diet. The scale has been validated; the best 
possible score is 100 (normal). Harrison et al. 125 retrospectively examined patients 
with SCC of the BOT who were treated with RT or surgery, comparing QOL and 
functional outcome using PSS. Patients treated with RT had consistently better per-
formance status and QOL scores and no difference was observed in all three functi-
onal PSS (eat in public, understandability of patient’s speech, and normalcy of diet) 
scores, for early and for the more locally advanced tumors (p = .84). For surgery, 
the PSS deteriorated significantly when comparing T1 and T2 versus T3 and T4 (p 
= 0.0014). Pol et al. 240 studied retrospectively similar type of patients; that is, locally 
advanced T3/T4 BOT cancer treated by surgery plus PORT or EBRT plus HDR-IRT. 
The authors concluded that for all PSS, the patients scored better in functional QOL 
when treated by RT as opposed to surgery (p = N.S.). The difference in functional 
outcome could help clinical investigators in the future as to which treatment is to be 
preferred per tumor site. In fact, the findings also illustrate the preference of patients 
for organ-preservation therapy in general. Harrison et al. 123 also reported that at 
a median follow-up of 5 years, patients’ annual incomes were similar to those at 
presentation, and the great majority of patients were still in full-time work. Nijdam 
and Levendag 218 studied the total hospital costs of TF and/or SP tumors treated by 
either IMRT plus BT boost with or without neck dissection versus surgery plus PORT 
(IMRT). Excellent locoregional tumor control (at 5 years, ±85%) was observed for 
either combined modality approach. Of particular interest is that the weighted mean 
cost for BT was significantly less as opposed to surgery: 18,001 versus 28,130. The 
main denominator in the excessive costs for surgery in this protocol is the number 
of days of clinical admission to the hospital. Table 17 summarizes the costs for the 
different treatment options in the current Erasmus MC protocol.
Mea costs BT
(weighted # patients)
Mean costs S
(weighted # patients)
Mean costs EBRT
(weighted # patients)
Treatment € 13.466 € 24.219 € 12.502
Folow-up € 649 € 607 € 482
(Treatment of) relapse € 2.848 € 1.897 € 4.577
   and/or metastases
Mean costs total group € 1.038 € 1.407 € 3.582*
Mean costs total group € 18.001 € 28.130 € 21.143
*Only two patients with significant late side-effects needing long lasting treatments
Table 17: Costs of different treatment modalities used according to Erasmus MC protocol for 
oropharyngeal cancer.
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Health-Related Quality of Life
Several questionnaires have been developed to assess health-related quality of 
life (HRQOL) for head and neck cancer patients 27,30,46,314. Each of the side effects 
can have a different impact on the HRQOL 28,29,105,106,115,116, varying from changes of 
speech and voice quality to impact on well-being and HRQOL in a broader sense. 
Interestingly, Nordgren et al. 220,221 evaluated the HRQOL of patients with pharyngeal 
carcinoma at diagnosis and after 1 and 5 years in a prospective multicenter study. 
Again, the HRQOL at diagnosis seems to be an important factor for the prognosis of 
both HRQOL over time and survival.
Trismus and Quality of Life
Trismus, severely restricted mouth opening, is a common problem in head and neck 
oncology. According to Dijkstra et al. 67,68, it is present at the time of diagnosis in 
approximately 2% of patients due to tumor growth; in tumors originating from or in 
the parapharyngeal space it is even more frequent (55%). Additionally, another 8% 
increase in trismus is due to treatment per se, be it surgery or RT 312. One of the 
reasons for this variation in reporting is the lack of uniform criteria. Dijkstra et al. 
proposed to use as a cut-off point for mouth opening 35 mm, irrespective of dental 
status, but they acknowledge that differences per subgroup may exist. The paired 
mastication apparatus facilitates opening of the mouth; it consists of the processes 
coronoideus and the condyle of the mandible, as well as the muscles responsible 
for jaw movement. The functionality of this muscular compartment 95 can be sum-
marized as follows: depression (lateral pterygoid, gravity), elevation (temporalis, 
masseter and medial pterygoid), protrusion (lateral pterygoid, masseter, temporalis), 
retraction (posterior fibers temporalis, deep fibers masseter), and lateral movement 
(contralateral lateral pterygoid, bilateral temporalis). Surgery and RT may induce 
trismus by causing fibrosis of one of the aforementioned muscles. Fibrosis might 
significantly impact QOL of the patient as it can affect the phonation, nutritional sta-
tus, and dental hygiene of the patient 248. The development of some of these late 
effects typically depend on factors like previous treatment, total dose, fractionation, 
irradiated volume, and treatment techniques. Dijkstra reported mandibular function 
impairments in 18% of 89 patients with cancers in the oral cavity and oropharynx. 
In the Rotterdam series, the incidence was only 1% for the treatment group EBRT 
plus BT; for the surgery plus PORT series it amounted to 21% 67. Ways to counteract 
this often long-lasting problem of trismus are mechanical appliances to reduce the 
severity of fibrosis 161, hyperbaric oxygen 156, pentoxifylline 54,312, surgical corrective 
measures 48, and IMRT. Figure 35 depicts an axial CT slice on which the relevant 
muscles for jaw movement are delineated, the processes coronoideus and condyle 
of the mandible inclusive. One may decrease the dose to the masseter muscle signi-
ficantly with IMRT by putting a constraint on the masseter muscle (Fig. 36).
Speech and Quality of Life
For technical treatment planning reasons, voice, and speech can be affected at the 
time of the actual treatment of cancers in the oropharynx and during the follow-up 
period. In a recent article by van Gogh et al. 104, the authors also concluded that 
deviant voice quality can also lead to limitations in social life 302,303. A robust, short, 
five-item questionnaire was suggested to be able to detect voice deterioration and 
differentiate this in a busy outward clinic from a cancer in the larynx 104,152.
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Figure 35: Paired mastication apparatus with structures of relevance depicted on axial CT 
slice. 
Figure 36: Dose volume histogram showing reduction in mean dose to masseter muscle with 
or without constraint (in masseter muscle) when using IMRT techniques.
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Dysphagia and Quality of Life
Swallowing function may be affected adversely by surgical and nonsurgical tre
atment of advanced oropharyngeal cancer 281. Gastrotomy tube (G-tube) 
dependence 6 to12 months after surgical management varies in the literature bet-
ween 6% and 39% 75,280. Rates of swallowing dysfunction after chemoradiation are 
less well defined; G-tube dependence varies between 13% and 64% at short-term 
follow-up and between 13% and 33% at long-term follow-up 94,107,185,215,216,221,265. 
In general, after long-term follow-up (>1 year), one third of patients were repor-
ted to be G-tube– dependent (BOT 67% vs. TF/SP 25%; p = .049). The swallo-
wing apparatus, being the wall of the pharynx (Fig. 37), is composed of two layers 
of muscles: the external three constrictor muscles (superior, middle, and inferior
constrictor [with its cricopharyngeal and thyropharyngeal part]), the circular fibers 
of esophagus inlet, and the internal longitudinal levator muscles (stylopharyngeus 
and palatopharyngeus muscles). Deglutition or swallowing is a complex act of these 
seven muscular structures. A study was recently initiated in Erasmus MC to get more 
insight in the problem of dysphagia. First, the components of the swallowing appa-
ratus were determined and delineated on CT. After delineation, dose-volume histo-
grams were constructed and mean doses calculated for every muscular structure. 
Fifty-five patients with cancer in the oropharynx who were treated between 2000 and 
2005 in Erasmus MC were used to study the problem of dysphagia in more detail. All 
patients were asked to respond to validated questionnaires PSS, EORTC H&N35, 
and the M.D. Anderson Dysphagia Inventory (Fig. 38). Using a univariate ordered 
logistic regression analysis technique, it was found that the probability for having 
serious complaints with swallowing increases significantly with dose (Fig. 39), but 
interestingly, this was significant for the superior and middle constrictor muscles. A 
multivariate analysis showed that the only significant factor was BT (dose). Howe-
ver, given the tight enveloping nature of the deglutition musculature, it needs very 
sophisticated three-dimensional treatment planning to spare the constrictor muscles 
without compromising on the dose to the primary tumor.
Figure 37: Anatomy swallowing apparatus; see for details text on dysphagia. Photograph from 
Moore KL, Dalley AF. Clinically Oriented Anatomy 4th Edition, 1999 p.1051, Lippincott Wil-
liams & Wilkins, Philadelphia.
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Figure 38: Examples of responses of patients to validated questionnaires HN 35, PSS and 
MDADI (for abbreviations, see text) the swallowing (HN35), eating in public (PSS) and dys-
phagia (MDADI) were studied for brachytherapy vs no brachytherapy as well as for BOT vs 
TF/SP.
Figure 39: Dose effect relationship for dysphagia. From the figure it seems apparent that with 
higher doses more dysphagia problems can be expected; moreover the problem of dysphagia 
seems less with the use of brachytherapy as a boost technique (less dose to the superior- 
and middle constrictor muscle). SCM: Superior constrictor muscle; MCM: Middle constrictor 
muscle. 
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Brachytherapy
The history of BT dates back to the beginning of the 20th century, when the first BT 
procedures were performed using Radium-226 needles. Brachytherapy (“brachy” 
= Greek for “short”) is a treatment modality in which the tumor is irradiated by po-
sitioning the radioactive sources very close to (mould or endocavitary techniques) 
or even inside the tumor volume (interstitial implant), either by permanent (seed) 
implant or by temporarily inserted applicators or afterloading catheters. In principle, 
BT is a conformal type of radiation therapy technique. In recent years, artificial ra-
dionuclides such as Cs137, Co60, I125, and Ir192 have become available. Manual 
afterloading of the sources into applicators or afterloading tubes replaced direct loa-
ding of sources into the patient. The French developed the so-called “Paris system” 
for low-dose-rate dosimetry purposes; that is, for parallel -equidistant sources, the 
system suggests specifying the dose of the implant as being 85% of the average 
dose in the basal dose points (local minima). A similar type of dose prescription is 
used for HDR BT (Figs. 40 and 41). 
Also, computer-controlled afterloading devices, supported by sophistica-
ted treatment planning software with optimization capabilities, became avai-
lable. The BOT implant consists of afterloading catheters after the percutane-
ous introduction of trocars in a submental or submandibular approach (Fig. 
42) 103. For patients with disease extension toward the pharyngoepiglottic
fold, lateral loops are added. The spacing between each end of the “looping” cathe-
Figure  40: Patient with BOT implant. Sagittal view X-ray film of catheters with dummy sources 
in situ (right panel). Yellow line depicts central calculation plane. Also shown is cross section 
of tumor in central plane (left panel). Blue dots are basal dose points (“centers of gravity”). 
White dots represent “sources”. Dose is prescribed to 85% of mean central dose (= average 
of doses calculated in centers of gravity of all triangles).
.
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Figure 41: TF and SP implant. Dose distribution central plane. Dose prescribed to 0.5 cm after 
geometrical optimization.
Figure 42: Patient with catheter configuration for BOT implant.
ters running over the dorsum of the tongue is ±1 cm. As a safety precaution, when 
removing the implant, a temporary tracheostomy is sometimes performed in patients 
immediately before the implantation. A typical case for fractionated HDR TF and SP 
implant is depicted in Figure 41. In the majority of cases, two to three catheters are 
implanted in TF and faucial arches (Fig. 41, inset). A temporary nasogastric feeding 
tube is placed at the completion of most of our BT procedures. The development of 
radiobiologic models enables one to predict to a certain extent the tumor control pro-
bability and normal tissue complication probability after the application of BT, much 
depending on factors such as fraction size, dose rate, the tumor, and the normal 
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tissues one is dealing with. Temporary BT has been used with several dose-rate 
categories. The French have published extensively on interstitial radiation therapy 
of TF and/or SP tumors, as well as on cancers of the BOT 32,60,69,79,86,98,139,175,201,229,23
5,236,249,274,327; most of these data regard LDR implants. For example, Mazeron et al. 
199 report on a subset of patients with early-stage (T1, T2) tumors of the TF and/or 
SP, with a LC rate of approximately 85%, that is, a regional control rate of 97% for 
N0, and 88% N1–3 disease. Patients were typically treated by 45 Gy EBRT and a 
30 Gy LDR Ir192 boost. Soft tissue ulceration occurred in 17 patients. Similar lo-
coregional control rates were reported by Pernot et al. 235,236 (LC LDR boost TF/SP 
T1, T2N0 tumors 90% vs. T1, T2N1–3 86%) and Levendag et al. 175,177 (TF and/or 
SP tumors LRC 87% at 5 years). The series of patients in Rotterdam were treated 
by fractionated HDR BT (daytime regimen) or PDR (24 hours regime) (Table 18). 
Esche et al. 79 described 43 patients with carcinoma of the SP and uvula with LC 
rate of 92%. Overall survival was 60% at 3 years and 37% at 5 years. The cause-
specific survivals were 81% and 64%, respectively. The leading cause of death was 
other aerodigestive cancers (these cancers occur with an actuarial rate of 3% per 
year posttreatment). The “BT school ” of Memorial Sloan Kettering Cancer Center 
in New York pioneered large-volume implants in particular for cancer of the BOT, a 
technique initially designed by Vikram and Hilaris 307 and Vikram et al. 308. Harrison et 
al. 120,121,125,127 elaborated on cancer of the BOT and also related outcomes to QOL. 
Some of the control rates with IRT can be taken from Table 42.11 (TF/SP) and Ta-
ble 42.14 (BOT). In skillful, well-trained, hands, BT remains an extremely gratifying 
technique for applying high doses of radiation for small –volume disease located in 
the midline (e.g., SP tumors) with (in case of fractionated HDR) highly conformal and 
accelerated properties. Finally, IRT can also be a very rewarding technique, given 
the high doses in smallvolume disease and the rapid dose falloff in the treatment of 
recurrent cancers and/or in case of reirradiation 58. 
For the future, image-guided BT will become routine; summation of dose distribu-
tions of BT and EBRT will become mandatory (Fig. 43). Moreover, by the develop-
ment of soft x-ray sources and afterloading machines that carry multiple sources and 
have multiple drives, the flexibility of intraoperative BT has increased. One of these 
sources that is currently being tested is ytterbium 169. 
Chemotherapy Targeted Therapy, and Altered Fractionation Regimes
Concurrent CHT and altered fractionated irradiation have shown indepen-
dently to improve the outcome for head and neck cancer patients. The combi-
nation maximizes the chance for preservation of organ function and has the po-
tential to improve the results even more by integration with new biologic agents 
10,36,187,206,261,264,288. Many of the hyperfractionated and/or accelerated schedules have 
resulted in improved locoregional control. Concomitant CHT appears to result in im-
proved LRC and OS, in contrast to neoadjuvant CHT and maintenance CHT 22,42,217. 
Not infrequently, these treatment regimes increase toxicity as well. Finally, the role 
of intra-arterial CHT 206,213,257 as well as the benefit of induction (neoadjuvant) and 
adjuvant CHT remains to be determined. In their concise review on randomized trials 
concerning multimoda lity treatment approaches, Bernier and Bentzen 22 empha-
sized that, to maximize outcome, each of the components of a particular treatment 
regime needs to be optimized separately. Importantly, Benasso et al. 20 and Taylor 
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Table of reference (Gy) for fractionated HDR (fr.HDR) and PDR brachytherapy as of 2001.
Tumor site fr.HDR PDR SRT
BT as full course:
Nasal vestibule, Skin, Lip 4+12x3+4
One-plane implant: microscopic disease 4+12x3+4 2.5+29x1.5+2.5
Any other site T1-4 4+16x3+4 2.5+38x1.5+2.5 6x6
Re-irradiation nasopharynx 15x3
Re-irradiation other tumors 4+15x3+4 2.5+35x1.5+2.5(preference)
BT as boost:
Nasopharynx
    After 60Gy EBRT 4+3x3+4
    After 70Gy EBRT 4+3+4 4x2.8
    Re-irradiation after 46 Gy EBRT 6x3
One-plane implant: microscopic disease
    After 46Gy EBRT 4+3+4 2+8x1+2
Any other site T1-4
    After 46Gy EBRT 4+4x3+4 2+18x1+2 3x5.5
Total number of brachytherapy fracionts. Full course: radiation is only given by means of bra-
chytherapy. In the case of booster doses, generally 46/2 Gy are given by means of external 
beam radiation therapy (EBRT). The booster dose for cancer in the nasopharynx is given after 
either 60/2 EBRT or 70/2 gy EBRT. SRT (stereotactic radiation therapy) means a booster 
dose by Cyberknife (as of 2005).
Table 18: Fractionation schedules for “fractionated HDR”, “PDR” and SRT (Cyberknife) used 
in the Erasmus MC-DDHCC. 
et al. 295 conducted multivariate analyses of patients treated in chemoradiotherapy 
head and neck trials, and pointed out that the second most important prognostic 
factor is the experience of the Center. Regarding the effects on OS and locoregional 
control by altered fractionation and/or concomitant CHT, in 2004 Rosenthal and Kian 
261 made some recommendations for treatment selection: conventional fractionation 
(and dose) for T1 and favorable T2N0,1 tumors, altered fractionation for unfavorable 
T2 or exophytic T3N0,1 (with or without neck dissection in case of N2,3 disease), 
and concurrent CHT for the more advanced cancers. Meanwhile, toxicity ameliora-
tion and identification of predictive biomarkers and effective molecularly targeted 
therapy should be pursued 261,292. Salama et al. 264 published on aggressive trimoda-
lity treatment for the subset of patients with recurrent and/or second primary cancers 
in the head and neck. They evaluated 115 patients treated with a median lifetime 
radiation dose of 131 Gy. The locoregional control, OS, and freedom from distant 
metastasis rate at 3 years were 22%,
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Figure 43: Treatment planning software is currently being developed in Erasmus MC to sum-
mate variable IMRT doses with BT doses, taking into account deformation of the target vo-
lume and normal tissues during treatment.  
51%, and 61%, respectively. However, of note is that 19 patients died of treatment-
related toxicity, 5 of these because of carotid blow-out. Suntharalingam 292 reviewed 
the early trials in 2003. Recognizing the mostly nonspecific nature of the toxicities 
of healthy tissues consequential to combined modality therapy, he argued that the 
real focus should be on researching newer biologic agents, targeting cellular protein 
receptors. Epidermal growth factor receptor is one of these receptors critical to cel-
lular proliferation, differentiation, and survival. As it has been shown to be widely 
expressed in SCC cells of the head and neck, it was suggested that anti–epidermal 
growth factor receptor therapy could become a powerful agent in combined modality 
therapy in the future.
Nonrandomized Studies
Some of the studies reviewed in this section are designed to treat advanced cancers 
in the head and neck in general and not focused solely on tumors in the oropharynx. 
As has been shown by the meta-analyses, concomitant CHT and/or altered fractio-
nation result in improved locoregional control and OS, but also a substantial amount 
of toxicity has been observed 35,238. In fact, with regard to concomitant CHT, Pignon 
and Bourhis 238 showed at 5 years an 8% increase in OS and a hazard ratio of 2.17 
for overall toxicity. Harrison 128 published the results of a phase II trial treating 82 
patients with unresectable head and neck cancer using the delayed concomitant 
boost technique with concurrent cisplatin. The 3-year LC for oropharynx cancers 
was 64%. Twenty-four percent of patients required a treatment break. Two deaths 
due to sepsis occurred during treatment. Severe chronic toxicity occurred in three 
patients: one osteoradionecrosis, one frontal lobe necrosis, and one case of lung 
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toxicity secondary to adjuvant CHT. Bieri 25 reported on delayed concomitant boost 
radiation in which a planned total dose of 69.6 Gy was given in 5.5 weeks; one third 
of the patients received concurrent cisplatin-based CHT. Among the 55 patients with 
oropharynx carcinoma, LRC at 3 years was 69.5%. Eighty-two percent experienced 
grade 3 and 4 mucositis. Patients receiving CHT had more grade 3 dysphagia (68% 
vs. 25%; p = .003), hospitalization (37% vs. 14%; p = .08), and a need for nasogas-
tric tube (68% vs. 22%; p = .001). Nathu 214 published the results of induction CHT 
followed by RT for patients with oropharyngeal carcinomas treated at the University 
of Florida. Neoadjuvant CHT consisted of cisplatinum (100 mg/m2) and 5-fluorouacil 
(1.0 mg/m2/day × 5 days) for three cycles, and was followed by definitive RT (83% 
received hyperfractionated RT from 74.4 to 81.75 Gy). Outcome was compared with 
oropharyngeal tumors treated with a similar radiation regimen, but without CHT. Mul-
tivariate analysis showed no difference in local failure or distant failure. However, 
disease-specific survival and OS were improved in those who received induction 
CHT (58% vs. 27% and 42% vs. 17%, respectively). Because of the nonrandomized 
nature of the study and the lack of statistically significant improvement in parame-
ters of tumor control, the authors cautioned against any conclusions regarding the 
benefit of induction chemotherapy. A phase II study on 61 patients with advanced 
oropharyngeal carcinoma using induction chemotherapy followed by concurrent 
chemoradiation was reported by Vokes 309. Neck dissections (n = 35) were perfor-
med for N2 to N3 disease. At a median follow-up of 39 months (68 months among 
survivors), LRC was 70%, distant metastasis-free survival was 89%, disease-free 
survival was 64%, and OS was 51%. Acute toxicity was substantial, with severe or 
life-threatening mucositis and leukopenia during the induction phase, whereas 81% 
had grade 3 or 4 mucositis during the concurrent chemoradiotherapy. The authors 
concluded that the treatment sequence of induction chemotherapy followed by con-
current chemoradiotherapy and optional organpreservation surgery is promising but 
that less toxic regimens need to be identified. Bensadoun 21 reported on 54 patients 
with unresectable oropharynx and hypopharynx carcinoma treated with concomitant 
hyperfractionated radiation (75.6 to 80.4 Gy) and three cycles of 5-FU/cisplatin in 
weeks 1, 4, and 7. Four percent mortality was observed from treatment related sep-
ticemia, 86% grade 3/4 mucositis but no patient required a treatment break greater 
than 4 days because of mucositis. Grade 2 xerostomia was observed in 70% of the 
patients and grade 2 cervical fibrosis in 45% of the patients. At a median follow-up 
of 16 months, diseasespecific survival was 72%. There are many other examples of 
chemoradiotherapy regimen for oropharyngeal carcinomas with encouraging LRC 
rates, but with short-term follow-up and/or too small patient numbers 10,100,187. A pro-
mising approach was presented by the Memorial Sloan Kettering Cancer Center. Ar-
ruda et al. 62 studied 50 patients treated by IMRT in conjunction with concurrent CHT 
(86%). At 2 years, local progression-free OS and distant metastases-free survival is 
98%, 98%, and 84%, respectively. Six of 42 patients remained with their percutane-
ous endoscopic gastrostomy until the time of analysis.
Randomized Trials
A prime example of a multinational, randomized trial of molecularly targeted the-
rapy is the study by Bonner et al. 33 that was recently published in the New England 
Journal of Medicine. It compares patients with advanced cancers in the head and 
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neck treated with high-dose RT alone (n = 213) or with RT plus weekly cetuximab, 
a monoclonal antibody against epidermal growth factor. The outcome of the study 
showed a significant improvement of locoregional control (hazard ratio locoregional 
progression or death 0.68; p = .005) and OS (49 months for combined therapy vs. 
29.3 months for RT alone [hazard ratio for death, 0.74; p = 0.03]). It reduced morta-
lity without increasing the common side effects of radiation. Studies for future targe-
ted therapies combining cetuximab with chemotherapeutic agents such as Taxotere, 
cisplatin, and 5FU are now underway. Concurrent CHT with hyperfractionated radi-
ation was explored by Brizel 36 in a phase III randomized trial. One hundred sixteen 
patients with advanced head and neck cancer were randomized to hyperfractionated 
radiation alone treated with 1.25 Gy twice daily 5 days per week to 75 Gy during a 
6-week period versus a concurrent CHT arm consisting of 5-FU/CDDP given on 
weeks 1 and 6 of splitcourse hyperfractionated radiation. Both groups received two 
adjuvant courses of 5-FU/CDDP after completion of radiation. At a median follow-up 
of 41 months, the concurrent CHT showed improved LRC (70% vs. 44%; p = .01) and 
a trend toward improved 3-year OS (55% vs. 34%; p = .07) and relapse-free survival 
(61% vs. 41%; p = .08). However, patients in the chemoradiotherapy arm developed 
more acute toxicity, including the requirement for more feeding tubes (44% vs. 29%) 
and worse hematologic suppression. Chronic toxicity was no different, with about a 
10% incidence of necrosis of the skin or bone in both arms. The trial has been critici-
zed, not only for the added toxicity, but also because of the imbalance in the propor-
tion of advanced neck disease (44% vs. 63%) treated in the concurrent chemoradio-
therapy, which may have accounted for the difference in LRC. Jeremic 148 reported 
a phase III randomized study testing whether daily low-dose cisplatin improved out-
come for patients undergoing hyperfractionation radiation compared with those tre-
ated with the same hyperfractionated radiation alone in locally advanced head and 
neck cancers (37% were oropharynx). One hundred thirty patients with stage III or IV 
disease were randomized to 1.1 Gy twice daily to 77 Gy per 7 weeks with or without 
cisplatin (6 mg/m2/day). At a median follow-up of 79 months, the investigational arm 
showed improved LRC (50% vs. 36% at 5 years; p = .041), progression-free survival 
(46% vs. 25% at 5 years; p = .0068), and OS (46% vs. 25% at 5 years; p = .0075), 
and fewer distant metastases (14% vs. 43% at 5 years; p = .0013). Daily concurrent 
CHT was well tolerated, with no increase in acute grade 3 mucositis and esophagitis. 
There were no increases in late skin or severe effects to bone or salivary gland. A 
multicenter randomized trial reported by Staar 288 tested whether the combination 
of hyperfractionated accelerated radiation (69.9 Gy/5 × 5.5 weeks) with carboplatin 
(70 mg/m2) and 5-FU (600 mg/m2/day × 5 days) on weeks 1 and 5 of RT improved 
outcome compared with the same radiation regimen alone. At a median follow-up 
of 22 months, the 1- and 2-year respective rates of LRC were 69% and 52% after 
chemotherapy/RT compared with 58% and 45% after RT alone (p = .14). Patients 
with oropharyngeal carcinomas had a trend toward improved 2-year LRC with che-
moradiotherapy compared with RT alone (51% vs. 42%; p = .07). Another German 
multicenter randomized trial compared hyperfractionated accelerated radiotherapy 
alone (77.6 Gy) with hyperfractionated accelerated radiochemotherapy (70.6 Gy) 
using mitomycin C and 5-FU (130). For patients treated inside the trial, no significant 
difference in survival was observed. A randomized phase II EORTC trial explored 
the feasibility of concomitant cisplatin and RT with conventional fractionation or mul-
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tiple fractions per day (MFD). The MFD schedule was designed to achieve higher 
tumor concentrations of cisplatin at the time of irradiation by reducing the number of 
radiation treatment weeks from 7 to 3. No difference in acute and late side effects 
in both treatment arms while better tumor response was obtained with MFD. It is ar-
gued that the better tumor response in the MFD might be due to a (67%) higher daily 
dose of cisplatin concomitant with RT being given in a 3-week period 13. Hao et al. 119 
updated the meta-analyses outcome of concomitant CHT trials to date in SCC of the 
head and neck. They confirmed an 8% benefit in 5-year absolute survival. Toxicity in 
general seems to be more pronounced with combined modality regimens using hy-
perfractionated RT or when the concomitant CHT regimen included carboplatin plus 
5-FU. Several other randomized studies (e.g., Horiot et al. 139 or Fu et al. 93) have 
demonstrated the beneficial effect of hyperfractionation and/or accelerated fractio-
nation over standard fractionation. Also, Calais 42,43 demonstrated better locoregional 
control when altered fractionation is used with concurrent CHT. According to Hao 
et al. 119, the current state of the evidence supports strongly to offer platinum-based 
concurrent CHT with conventional fractionated RT as a treatment option for patients 
with advanced head and neck cancers treated outside a clinical trial. 
Three-Dimensional Conformal RT/IMRT
The introduction of the multileaf collimator and three-dimensional treatment plan-
ning systems (TPS) in the 1990s has been instrumental for the development and 
application of three-dimensional conformal radiation therapy and IMRT. The major 
advantages of IMRT for irradiation of the complex head and neck anatomy are now 
generally recognized. The possibility of tightly shaping the higher isodose surfaces 
around the often concave target volumes allows for substantial sparing of critical 
structures. The use of electrons for irradiating the posterior neck, without exceeding 
the cord dose, has become almost obsolete. In this section, procedures are descri-
bed for a safe and beneficial application of this powerful tool with focus on the IMRT 
techniques as used in the Erasmus MC.
IMRT
Treatment Planning
In the Erasmus MC, in case of radical radiation therapy of oropharyngeal cancer, 
IMRT is used to deliver a total dose of 46 Gy, 2 Gy per fraction, 6 fractions per 
week, to the primary tumor and neck, generally followed by a BT- or CyberKnife 
boost (Fig. 19). In line with the International Commission on Radiation Units and 
Measurements criteria for dose homogeneity in the PTV, it is generally required that 
100% of the PTV must obtain more than 95% of the prescribed dose 143, although 
small underdosages (e.g., around the salivary glands) are acceptable in specific 
cases. Tolerating minor PTV underdosages has also been described by Fogliata 
et al. 83 and Wu et al. 325. Recently, we have studied this trade-off between full PTV 
coverage and sparing of the parotid glands, using a model for calculation of the sub-
clinical disease control probability 163. For the patients in the study, the mean parotid 
gland dose decreased by more than 10 Gy by allowing for a small underdosage in 
the PTV, corresponding with a reduction in the calculated subclinical disease control 
probability of typically 1% and a little higher. The applied planning constraints for the 
critical structures for IMRT as used in Erasmus MC are presented in Table 19 and 
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ERASMUS MC RTOG protocol H-0022
Spinal cord Dmax < 50 Gy Dmax < 45 Gy
Mandible Dmax < 70 Gy
Glottic Larynx # 2/3 below 50 Gy
Brainstem Dmax < 50 Gy Dmax < 54 Gy
Parotid gland Dmean < 26 Gy Dmean < 26 Gy *
Oral cavity Dmean < 26 Gy
# Sparing of the larynx is described in detail in section IMRT, Treatment planning
* At least 50% of either parotid gland receives < 30 Gy, or at least 20 cc of the combined vo-
lume of both parotid glands receives < 20 Gy.
Table 19: Dose constraints for the critical stuctures according to the Radiation   Therapy 
Oncology Group (RTOG) protocol H 0022, and as applied in IMRT techniques as used in the 
Erasmus MC. (1):2): At least 50 % of either parotid gland receives < 30 Gy, or at least 20 cc 
of the combined volume of both parotid glands receives < 20 Gy.
compared with the RTOG H-0022 protocol 247. For plan design, the constraints for 
the cord and the PTV are overriding, and the criteria for the parotids and oral cavity 
are planning objectives rather than hard constraints. To create a safety margin, the 
cord constraint is set for the spinal canal, rather than for the cord per se. Depending 
on the patient geometry, different planning strategies are used. The most favorable
 strategy is to spare both parotid glands. This is done using a nonequiangular, five-
field technique, with gantry angles of 0 degrees, ±60 degrees and ±140 degrees 
(optimized for each individual patient), using 6-MV beams. Especially when the 
boost is also delivered with IMRT, significant sparing of both parotids is frequently 
not feasible. It may then be decided to largely relax the constraint for the ipsilateral 
parotid gland and to focus on sparing of the contralateral gland. Generally, a non-
symmetrical fourfield technique is then applied, with two parallel -opposed beams 
at gantry angles of around 350 degrees and 160 degrees (or 10 degrees and 200 
degrees, depending on tumor position). With such an approach, that is, sparing of 
a single parotid gland structure Eisbruch et al. 73 observed a salivary flow increase 
after 2 years. In the absence of positive nodes, the lower neck region is treated 
with two non-IMRT anterior fields, positioned on either side of the cord with sparing 
of the larynx (midline block) (Fig. 33). The International Commission on Radiation 
Units and Measurements dose homogeneity criterion is then less strictly enforced. 
Another technique to cover the lower neck region is to extend the upper IMRT fields. 
Figures 27 and 30 show a five-field technique (0 to 46 Gy) for a patient with a TF 
tumor (T2N1) to be treated by RT to the primary and bilateral neck. For this bilateral 
parotid sparing treatment plan, mean doses to the parotids are 22 and 23 Gy, res-
pectively. For comparison purposes, Figures 28 and 31 show a treatment plan with 
focus on maximum sparing of the contralateral parotid, yielding mean doses of 17 
Gy (contralateral parotid gland) and 30 Gy (ipsilateral parotid gland).
Patient Setup Verification, Correction, and PTV-Margins
IMRT is most effective when used in combination with narrow PTV margins that have 
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to be in line with the geometrical uncertainties for the patient involved. This implies a 
proper knowledge of the setup variations. Each patient has a setup error that occurs 
during all fractions (the systematic or mean error) and day-to-day variations around 
this mean setup error (the random errors) 26,278. By its nature, the systematic error of 
an individual patient can be obtained only from measurements during each fraction, 
and is therefore not known at the time of treatment planning. The setup uncertain-
ties are generally quantified by three standard deviations Σx,Σy, and Σz, describing 
the distribution of systematic setup errors in the patient group, and the standard 
deviations σx, σy, and σz that represent the day-to-day variations. For head and neck 
cancer patients, these standard deviations are mostly derived from measurements 
with electronic portal imaging devices (EPIDs). Stroom et al. 289,290, from our institu-
tion, derived for each direction, i, the required PTV margin, Mi , given by: Mi = 0.7·σi 
+ 2·Σi. In this approach, the PTV margin of each new patient is fully based on setup 
measurements performed for previously treated patients. The formula reflects the 
idea that systematic errors, potentially leading to an underdosage of a specific part 
of the tumor in all fractions, are more severe than random errors. The equation was 
confirmed by the work of van Herk et al. 132. Setup errors can be minimized using 
EPID measurements and a correction protocol. Deviations in the patient setup are 
then quantified by comparison of the EPID images with digitally reconstructed radi-
ographs derived from the planning CT scan. It is essential that the demarcations on 
the patient’s skin or mask, used for setup at the linac, are in exact agreement with 
the isocenter of the planning CT scan. These demarcations should not be adjusted 
in a session at a conventional simulator, neither should verification be based on 
acquired simulator images 19. In an online protocol, the patient setup error is as-
sessed in each fraction using a few monitor units (MUs), followed by a subsequent 
correction and delivery of the remainder of the MUs. With such a protocol, both the 
systematic error and the random component can be substantially reduced. However, 
a disadvantage of online protocols is the involved workload at the treatment unit 
and the unavoidable increase of the fraction time. For this reason, so-called off-line 
protocols are more often applied than online protocols. In an off-line protocol, EPID 
images are only acquired in a limited number of fractions, and all image analyses 
are performed off-line, that is, not during the time of the delivery of the fractions. 
The latter excludes the possibility of reduction of random errors, which is of lesser 
relevance for the determination of the required margin (equation). Instead, the aim 
of an off-line protocol is to reduce the more important systematic patient setup errors 
by estimating the optimal a priori setup correction for subsequent fractions. In the 
Erasmus MC we have developed and implemented the no-action level (NAL) proto-
col for off-line corrections 63, which is now applied for most patient groups, including 
those with oropharyngeal cancer. For each patient, the protocol starts with acquisi-
tion of EPID images during the first Nm fractions (Erasmus MC Nm = 2 for head and 
neck sites), without applying any setup corrections. The involved systematic setup 
error for the complete fractionated treatment is then estimated by calculation of the 
mean setup error in these first Nm fractions. In the remainder of the fractions, the 
patient is first set up using the (original) marks on the patient mask. Then, prior to 
dose delivery, an a priori setup correction is performed as prescribed by minus the 
(estimated systematic error), followed by irradiation; no images are acquired. The 
first application of the NAL protocol for head and neck cancer was described by de 
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Boer et al. 65. The patients in this study were treated with parallel -opposed laterals, 
and the NAL protocol was therefore only applied in two directions. Table 20 shows 
the setup errors for IMRT patients, as derived in a recent analysis (not published). 
As previously outlined, for each patient, the setup correction is based on an estimate 
of the systematic setup error, derived from measurements in only two fractions. As a 
consequence, application of the NAL protocol will diminish the systematic errors, but 
not cancel them out. In Table 20, both the distribution of the residual systematic er-
rors, ΣNAL, and the distribution of (calculated) initial systematic errors, Σinit, that would 
have occurred without application of NAL, are presented. The presented margins 
are calculated with the equation provided. In clinical practice, margins of 5 mm are 
used for all directions, leaving some room for delineation uncertainty. Recently, the 
NAL protocol has been extended (eNAL) to systematically update setup corrections 
based on weekly follow-up measurements 64.
LR CC AP
σ 1.6 1.6 1.4
Σinit 2.3 1.6 2.1
Minit 6 5 6
ΣNAL 0.9 0.9 0.8
MNAL 3 3 3
Table 20: Set-up errors and calculated margins (in mm) for H&N cancer patients treated 
in the Erasmus MC with IMRT.  Left-right (LR), cranio-caudal (CC), anterior-posterior (AP) 
directions. Standard deviations σ (distributions of random errors), ΣNAL (residual systematic 
errors with the clinically applied NAL set-up correction protocol), Σinit (systematic errors that 
would have occurred without NAL), MNAL, and Minit are margins calculated with Equation (1) 
(see text).  
Dosimetric Quality Assurance
In our institution, IMRT is delivered with dynamic multileaf collimation (DMLC), 
using the sliding window technique. Because of the complexity, a dedicated quality 
assurance (QA) protocol is instituted, supplementing the QA procedures for non-
IMRT treatments. All involved dosimetric measurements for IMRT are performed 
with EPIDs (Fig. 44) 89,90,131. For daily linac QA, the sliding-gap method as propo-
sed by LoSasso et al. 181, measuring the leaf positioning accuracy with an ioniza-
tion chamber for a single leaf pair, has been extended to two-dimensional, using 
the EPID 305. The measurements take 3 minutes, including the analyses. Errors in 
leaf positioning as small as 0.1 to 0.2 mm can be detected. Apart from the daily 
verification of the leaf motions, QA procedures are performed for each individual 
IMRT patient 228,304,306,328,329. These procedures aim at (a) verification of the final TPS 
dose calculation for the optimized treatment parameters such as the leaf trajecto-
ries, and (b) verification of the correct execution of the plan at the linac. Currently, 
the TPS dose is only verified by an independent dose calculation for a single or 
few points in the center of the tumor. A fully three-dimensional procedure is being 
developed. For verification of the correct fluence delivery at the linac, EPID dose 
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measurements are performed both prior to the first treatment fraction (pretreatment 
verification 229,306, and during treatment (“in vivo” verification 305. For pretreatment 
verification, portal dose images (a two-dimensional dose distribution in the plane 
of the fluorescent screen of the EPID) measured with the EPID are compared with
predictions. Differences point at errors in leaf sequencing, data transfer from the 
TPS to the linac, or to dosimetric/mechanical linac performance problems. Presently, 
portal dose image comparison (Fig. 45) has been fully integrated in the applied EPID 
software (Theraview NT, Cablon Medical, Heusden, The Netherlands); a method for 
automated image analysis also has been implemented. 
Figure 44: Left panel: the Elekta Synergy system with an additional kV tube and 2D detector 
for acquisition of cone-beam CT-scans and the Theraview NT EPID for set-up verification and 
dosimetric QA; Right panel: sagittal cone beam CT-slice for a H&N patient.
Images are only reviewed by a physicist in case of a failure to pass the automa-
ted test. Because of the high spatial resolution, EPIDs are suited for detection of 
tongue-and-groove underdosage effects. For a group of 270 IMRT patients, the pre-
treatment procedure has revealed four serious errors prior to the start of treatment 
329. Recently, methods have been developed for back-projection of fluence profiles, 
measured with the EPID, in the planning CT scan or in an in-room acquired cone 
beam CT scan, allowing full three-dimensional analyses 328. Deviations in in vivo 
measured PDIs may be due to errors in fluence delivery, but may also be caused by 
changes in patient anatomy or variations in patient setup. To discriminate between 
the two, the split IMRT field technique 305 has been developed, which is now routinely 
applied for all head and neck cancer patients.
Alternative IMRT Approaches
Beam Orientations
Instead of dedicated orientations, often a relatively large number of equiangular be-
ams are used. Whereas some articles report techniques with seven equiangular 
beams for oropharynx tumors 62,239, others advocate nine beams 324. Generally, an 
odd number is used to avoid opposing beams.
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Simultaneous Integrated Boost
For oropharyngeal cancer patients treated in the Erasmus MC, the boost is generally 
delivered with BT or the CyberKnife after 46 Gy. When using IMRT for full –dose 
delivery, a simultaneous integrated boost technique may be applied 166,247,325. The 
involved simultaneous optimization of the large field and the boost technique does 
generally result in superior plans, compared with sequential optimization 211. With 
the simultaneous integrated boost technique, an enhanced fraction dose may be 
selected for the primary tumor, yielding two simultaneous opportunities for biologic 
dose escalation: a shortening of the total treatment duration and an increased LC 
as a result of the higher daily tumor dose. However, the possibilities for application 
of escalated fraction doses are limited by the risk of increased toxicity 166,325. Alter-
natively, to minimize complications, the fraction dose in the elective regions may be 
reduced. The current RTOG study H-0022 applies a simultaneous integrated boost 
technique, prescribing a GTV total dose of 66 Gy at 2.2 Gy / fraction, and a dose for 
the subclinical disease region of 54 Gy (1.8 Gy / fraction) 247.
Plan Optimization and Evaluation Using Radiobiologic Models
Instead of using dose- and dose-volume–based objectives and constraints, plan op- 
timization and evaluation can, in principle, also be done using radiobiologic criteria 
such as the tumor control probability, normal tissue control probabilities, and the 
equivalent uniform dose for the tumor and organs at risk. For the head and neck re- 
gion, several parameter sets for biologic models exist, derived from observed tumor
Figure 45: Screen-shot for dosimetric IMRT verification with an EPID. Portal dose images 
(PDI), measured prior to the start of the first treatment fraction,  compared to predictions. 
measured PDI, (b) predicted PDI, (c) PDI comparison using the y- index, (d) PDI difference 
image, (e) PDI difference image, excluding the tongue-and-groove areas, (f) profile compari-
son for the leaf pair marked with a yellow line in (a)-(e), (g) dose and y-index differences for 
this leaf pair, (h) result of the automated test for 2D image comparison (Pass in this case). 
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control and toxicity data 76,77,259,269 (also used in tumor control probability/normal tis-
sue control probabilities calculating modules 315). Unfortunately, the results vary con-
siderably with the applied parameter set: for a group of oropharynx cancer patients, 
van Vulpen et al. 310 reported predicted normal tissue control probabilities differences 
for the parotid glands ranging from -3% to +35% when applying different parameter 
sets. To our knowledge, articles describing a decisive role in clinical decision-making 
for the treatment of oropharyngeal cancer patients have not yet been published.
Step-and-Shoot or Segmental IMRT (SMLC)
Apart from the DMLC technique, intensity-modulated profiles can also be generated 
by sequential delivery of static field segments, with a variable shape and number of 
monitor units (SMLC). In the transition period from end of delivery of one segment 
to shaping of the next segment, the beam is switched off. DMLC allows for more 
precise realization of the optimized fluence profiles. However, some studies have 
concluded that the differences are of minor clinical importance 4,55,83. It has also been 
reported that DMLC treatments require more MUs and SMLC treatments take more 
time. A leaf-sequencing algorithm for DMLC has been developed that fully prevents 
the occurrence of tongue-and-groove underdosage reported by van Santvoort et al. 
266. Currently, we use the Cadplan TPS (Varian Medical Systems, Espoo, Finland) 
for inverse planning and leaf sequencing. It was demonstrated that for extreme pro-
files, tongue-and-groove underdosage of up to 30% may occur with this TPS 80. 
However, the protocol for pretreatment verification of the fluence profiles of each 
individual IMRT patient has never revealed a clinically relevant tongue-and-groove 
error. Also for SMLC, leaf-sequencing algorithms have been developed that reduce 
or prevent the occurrence of tongue-and-groove underdosage 61,182.
Study N
Me-
dian 
FU
LRC DFS DMFS OS
Acute Xe-
rostomia
 ≥ gr 2
Acute 
Mucositis 
≥ gr 3
Acute Xe-
rostomia ≥ 
gr 2 
Late 
Muco-
sitis
 ≥ gr 3 
(%) (%) (%) (%) (%) (%) (%) (%) (%)
Chao, 
2005 74 33 mo 78 66 84 87 41 12
Garden, 
2004 80 17 mo 94
Huang, 
2003 41 14 mo 89 91 89
De 
Arruda, 
2006
50 18 mo 86 84 98 60 38 33
Yao, 
2005 56 18 mo 98
Chao, 
2001 26 47 mo 88 80 42 30 10
Table 21: Overview of reported treatment results of oropharyngeal cancer using IMRT. Toxici-
ty scored according to RTOG criteria. LRC: local-regional control. DFS: disease free survival. 
DMFS: distant metastases free survival. OS: overall survival.
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Clinical Results
Some of the clinical results are presented in the section Xerostomia. Excellent re-
views are presented by Puri et al. 243 and Lee et al. 168. Table 21 summarizes the 
preliminary clinical results of several studies of IMRT treatment for oropharyngeal 
carcinoma. The studies confirm the high rates for (loco-) regional control, distant 
metastases-free survival, disease-free survival, and OS in combination with redu-
ced toxicity in comparison to conventional radiotherapy. Finally the multi-institutional 
RTOG study (H-0022) using IMRT for early-stage oropharyngeal cancer has com-
pleted accrual, and final results are to be expected shortly 247. IMRT allows dose to 
be concentrated in the tumor volume while sparing normal tissues. However, the 
downside to IMRT is the potential to increase the number of radiation-induced se-
cond cancers. The reasons for this potential are more MUs and, therefore, a larger 
total-body dose because of leakage radiation and, because IMRT involves more 
fields, a larger volume of normal tissue is exposed to lower radiation doses. In fact, 
Hall 114 calculated that IMRT may double the incidence of solid cancers in long-term 
survivals. In contrast to older patients, if balanced by an improvement of local tumor 
control, the use of IMRT might not be acceptable in children. An alternative might be 
to replace x-rays with protons in case of scanning pencil beams.
Alternative External Beam Approaches
Helical Tomotherapy
Apart from IMRT with linear accelerators, helical tomotherapy 186 (HiArt, TomoThe-
rapy Inc., Madison, WI) can also be used for highly conformal dose delivery. Several 
articles report on dose distributions for head and neck cancer patients that might be 
superior to those obtained with linacs, regarding sparing of critical structures 82,230,310. 
Long-term clinical evaluations are not available as yet. Compared to linac-based 
IMRT, tomotherapy requires more MUs to deliver the same target dose, because of 
the applied fan-beam 212. This increases the whole-body dose equivalent, which may 
increase the risk for radiation-induced secondary malignancies 84. The clinical im-
plications of irradiating larger volumes to lower doses with tomotherapy, compared 
with smaller volumes with intermediate doses in linac IMRT, are unknown.
CyberKnife
The robotic CyberKnife system (Accuray Inc., Sunnyvale, CA) is another means of 
applying high dose of radiation with high accuracy 2. Some preliminary experience 
with the CyberKnife is available from the Erasmus MC for cancer in the oropharynx 
(Fig. 19 shows the protocol). This regards the delivery of a boost treatment of three 
fractions of 5.5 Gy on each consecutive day, prescribed at the 80% isodose. Pa-
tients are immobilized with the regular thermoplastic mask with a three-point fixation. 
Highly conformal plans with steep dose gradients are generated using 100 to 200 
noncoplanar and nonisocentric coned beams. Figure 46 shows a typical dose dis-
tribution for a CyberKnife boost with the applied beam orientations. The CyberKnife 
image-guidance system and the patient skull are used for frequent measurement of 
the patient setup during treatment. Observed translations and rotations are used for 
immediate correction of the position and direction of the next beams. Because of 
these continuous adjustments, a PTV margin of only 2 mm was applied originally.
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Recently, the images obtained with the CyberKnife image-guidance system have 
been retrospectively analyzed, to quantify patient motion during delivery of a treat-
ment fraction 135. 
For head and neck cancer and brain cancer patients, the maximum observed dis-
placement in a 2-minute period was 2.8 mm in a single direction; a maximum rota
tion of 2.3 degrees was observed after 3 minutes. The overall systematic and random 
threedimensional errors after 15 minutes are 1.3 and 1.2 mm (2 SD), respectively. 
With the CyberKnife image-guidance system, these in-fraction patient movements 
are automatically compensated using the robotic manipulator.
Cone-Beam CT
An important next step in image-guided RT for head and neck tumors may be the 
use of the recently introduced cone-beam CT scanners, integrated in linacs (Fig. 44) 
146,172,202. In contrast to EPIDs, these systems allow for visualization of soft tissues. 
So far, the image quality is not as good as for modern diagnostic scanners. During 
the fractionated head and neck treatment, various processes may result in a gradual 
change of the patient anatomy, such as postoperative changes/edema, weight loss, 
and shrinking of the primary tumor and/or nodal masses 11,118. Large changes in the 
size of the GTV and the size and position of the parotid glands have been observed. 
These changes may result in suboptimal treatment as the dose delivery in all fracti-
ons is usually based on a treatment plan that is designed for the patient anatomy in 
the planning CT scan, which is acquired prior to the start of treatment. Studies have 
been performed to investigate the impact of replanning based on, or triggered by, 
anatomy changes observed in acquired cone beam CT scans 118,210. A major clinical 
question to be answered is the target definition in case of a shrunken gross target 
volume. As part of the IMRT QA protocol, cone-beam CT scans may also be used to 
assess the “dose of the day” 328.
Figure 46: Left Panel: CyberKnife boost dose distribution of a patient with a tonsillar fossa 
tumor. Right panel: The applied beam setup. The light blue rods represent the beam directi-
ons that were actually used for treatment, with lengths proportional to the beam weight. The 
beams marked with the dark blue rods were available for treatment planning, but not selected 
in the final plan.
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Future Technical Developments
Dose-Calculation Algorithms
It is well known that, especially in the presence of low-density inhomogeneities, sig-
nificant dose-calculation errors may occur for single beams, even when using a mo-
dern commercial TPS. Such errors have also been observed for clinical, multibeam 
head and neck treatment plans 34,251,270. Improved accuracies can be obtained with 
Monte Carlo dose-calculation algorithms, and vendors of TPSs have started to offer 
this tool 129,251. However, to obtain clinically acceptable calculation times, approxima-
tions and simplifications are often used that could jeopardize the potential advan-
tages of the full Monte Carlo technique. A comprehensive overview is provided by 
Reynaert et al. 252.
Paperless Electronic Records
In the previous section one is confronted with innovative, highly technological care, 
but also with clinical research regarding QOL issues. These processes will undoub-
tedly go on with virtually no limitations. From the organizational (data-retrieval) point 
of view, one could envisage that most departments of radiation oncology will even-
tually be structured as a “paperless office” (Fig. 47). Direct architecture changes the 
conventional workflow into a productive workspace environment; that is, with a click 
of a button it combines the ease of the use of Windows with access to all types of 
vendor applications, including record and verify, e-mail, IMRT-QA, and office ap-
plications. This server client architecture gives users the freedom to access their 
applications anywhere in the hospital or in the world for collaboration, consultation, 
or to access particular applications for personal use. Features like pen-enabled com-
puting, centralized storage, and secure remote access of the applications via broad-
band are not new in the information technology arena, but definitely are not routine 
to radiation therapy. It is setting a stage for any type of new application to fit into the 
existing  infrastructure without adding new workstations or PCs in the already fully 
taken workspace. The future generation of connectivity between radiotherapy appli-
cations is true flexibility at the physician’s desk, a solution without constraints.
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Figure 47: Various applications are consolidated in a vendor’s independent  workspace: flexi-
bility and freedom of access to any application with a click of a button in a truly paperless 
office. 
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AbstrAct
Purpose/Objective: To assess the relationship between the radiation therapy 
(RT) dose received by the muscular components of the swallowing (sw) apparatus 
and – dysphagia related - quality of life (QoL) in oropharyngeal cancer.
Materials/Methods: Between 2000-2005, 81 patients with SCC of the oropharynx 
were treated by 3DCRT or IMRT, with or without concomitant chemotherapy (CHT); 
43 out of these 81 patients were boosted by brachytherapy (BT). Charts of 81 pa-
tients were reviewed with regard to late dysphagia complaints; 23% experienced se-
vere dysphagia. Seventeen patients expired. Fifty-six out of 64 (88%) responded to 
Quality of Life (QoL) questionnaires; that is, the Performance Status Scales of List, 
EORTC H&N35, and the M.D. Anderson Dysphagia Inventory. The superior (scm), 
middle (mcm), and inferior constrictor muscle (icm), the cricopharyngeus muscle and 
the inlet of the esophagus, are considered of paramount importance for swallowing. 
The mean dose was calculated in the muscular structures. Univariate analyses and 
multivariate analysis were performed using the proportional odds model. 
Results: Mean follow-up was 18 months (range 2-34) for IMRT, and 46 months for 
3DCRT (range 2-72). At 3-years, a LRC of 84%, DFS of 78% and OS of 77% was 
observed. A significant correlation was observed between the mean dose in the scm 
and mcm, and severe dysphagia complaints (univariate analysis). A steep dose-
effect relationship, with an increase of the probability of dysphagia of 19% with every 
additional 10 Gy, was established. In the multivariate analysis, BT (Dose) was the 
only significant factor.
Conclusion: A dose-effect relationship between dose and swallowing complaints 
was observed. One way to improve the QoL is to constraint the dose to be received 
by the swallowing muscles.
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introduction
In organ preservation therapy of head and neck cancer, over the years a number of 
investigators have noted a significant increase in dysphagia; this most likely relates 
to more aggressive treatment used in order to obtain better tumor control rates. The 
aggressive nature of the treatment modalities is exemplified by high doses of radia-
tion, and/or (altered) fractionation regimen with or without (concomitant) chemothe-
rapy 9. Xerostomia has been well documented in patients treated with chemotherapy 
and / or radiation. It has been argued that the degree of xerostomia corresponds 
with dysphagia experienced by the patients 32,33. At the present time we embarked 
on a study that relates these two factors in a retrospective and prospective fashion. 
This data analysis will be presented in a next paper. It is important to investigate 
the anatomical structures and functionality of the swallowing apparatus, in order to 
define potential rehabilitation strategies. Examples of preventative measures are 
the pre- and post treatment exercises and/or the introduction of Therabite 34,35. Few 
studies have examined the association of dysphagia with the location of the primary 
tumor site 36,37.
This paper examines by chart review swallowing disorders in 81 patients with orop-
haryngeal cancers. All patients were treated by highly conformal radiation therapy 
techniques, which are 3D Conformal Radiotherapy (3DCRT) and Intensity Modu-
lated Radiotherapy (IMRT), with or without concomitant chemotherapy. First, the 
anatomical structures involved in swallowing were defined. Subsequently the dose 
was computed in each - swallowing related - individual muscular structure. Finally 
severe late dysphagia disorders (grade 3 and 4), measured by quality of life instru-
ments such as the performance status scale (PSS) 28, the EORTC Head and neck 
35 (H&N35) 30, and the M.D. Anderson dysphagia inventory (MDADI) 38, were related 
to tumor site, treatment technique and dose. For this purpose one has to establish 
first the anatomical substrate of the swallowing mechanism. After reviewing the li-
terature, five musculature structures were considered paramount in swallowing 39. 
These muscular structures are the superior constrictor muscle (scm), the middle 
constrictor muscle (mcm), the inferior constrictor muscle (icm), the cricopharyngeus 
muscle (cphm) and the 1 cm of the muscular compartment of the esophageal inlet 
(eim). A previous study by Eisbruch et al. 16 showed that elevation of the larynx and 
pharynx during swallowing appeared to be essential for protection of the airway and 
propulsion of the bolus. This elevation is facilitated by the contraction of longitudinal 
constrictor muscles which are interspersed with the circular fibers of the scm, inclu-
ding the stylopharyngeus-, salpingopharyngues- and palatopharyngeus muscles. In 
fact, when the larynx and pharynx are elevated and pulled forward, they are also 
pushed away from the lower posterior pharyngeal wall, facilitating opening the eso-
phageal inlet (cphm and eim).
Dysphagia in oropharyngeal cancer patients
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IMRT 3DCRT
Concomittant
Chemotherapy
Concomittant
Chemotherapy
TF / SP BOT TF / SP BOT TF / SP BOT TF / SP BOT
2000-2002 9 0 15 10
2002-2005 22 5 4 4 10 1 0 1
Total 35 46
 
Table 1: Eighty-one patients diagnosed with squamous cell carcinoma of the oropharynx and 
treated curatively between 2000-2005 by highly conformal radiation therapy techniques.
MAteriAl And Methods
This study is based on a cohort of 81 patients diagnosed with squamous cell carci-
noma (SCC) of the oropharynx, treated with curative intent between 2000-2005 in 
a single institution by highly conformal radiation therapy techniques (Table 1). That 
is, 46 patients by 3DCRT and 35 patients by IMRT. The treatment of preference for 
Tonsillar Fossa / Soft Palate tumors, T1-T3 disease, or Base of Tongue tumors (T1-4 
disease), consisted at the time of a first series of 46 Gy (2 Gy per fraction, 6 fractions 
per week) by IMRT or 3DCRT to the neck and primary tumor, followed by a boost of 
fractionated HDR or PDR BT (TD 20-22 Gy) to the primary tumor. In case of neck 
nodes, a neck dissection was executed. For those patients not eligible for BT (e.g. 
medically unfit, patient refusal, T4 tumors and advanced parapharyngeal extension), 
a combined resection, followed by IMRT or 3DCRT postoperative radiation therapy 
is performed. For details see Levendag et al. 9. 
Patients were staged according to the TNM classification (UICC /AJCC Classifica-
tion edition 2004) 11. Of the current series, 28 patients had T3 and 4 patients had 
T4 disease; 50 patients had N+ neck disease (table 2). For this patient category the 
local relapse free survival (LRFS), the disease free survival (DFS) and overall survi-
val (OS) were determined. During follow up 4 patients died because of intercurrent 
disease and 13 because of tumor relapse and/or regional metastases.Out of the 81 
patients, according to the charts, 19 (23 %) experienced late dysphagia grade 3 or 
4, that is dysphagia scored at the time-point more than 3 months after completion of 
the treatment. Dysphagia disorder grade 3 is defined as severe dysphagia or odyno-
phagia with dehydration or weight loss (>15% from pre-treatment baseline) requiring 
N-G feeding tube, I.V. fluids or hyper-alimentation. Dysphagia grade 4 is defined 
by complete obstruction, ulceration, perforation, and/or fistula. In order to evaluate 
dysphagia in more detail, the remaining 64 patients alive with no evidence of disease 
received in January 2006 four types of questionnaires: 1. The EORTC core Qua-
lity of Life (QoL) Questionnaire [QLQ]-C30 (30 items), 2. The EORTC QLQ-H&N35 
swallowing scale, including four items (problems with swallowing of liquid [q.35], pu-
reed food [q.36], solid food [q.37], or aspiration when swallowing [q.38]), 3. The Per-
formance Status Scale (PSS) of List, with the functions eating in public, normalcy of 
diet and understandability of speech, and 4. the M.D. Anderson Dysphagia Inventory 
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(MDADI), consisting of 20 questions with global, emotional, functional, and physical 
subscales. Also, after the follow up of the present series of patients was completed 
(January 2006), all patients alive NED were seen once again at the outpatient clinic, 
with their complaints / wellbeing profile  ultimately scored once again for the degree 
of xerostomia, pain, trismus, mucositis and swallowing. 
A schematic diagram and the delineation of the swallowing muscles on CT 
are shown in figures 1a and 1b. Every 3DCRT and IMRT treatment plan of the 
previously irradiated 56 patients was retrieved; subsequently the muscular structu-
res of the swallowing apparatus were delineated on the axial CT slices used at the 
time for the 3D treatment plan. Figure 2 typically shows a delineated muscle (scm) 
with the dose distribution of IMRT displayed on CT. The dose contribution by the 
3DCRT or IMRT technique to the muscular structures (mean dose, maximum dose 
and minimum dose) was computed using original treatment plans 13. In 14 out of 43 
patients boosted by BT, a 3D conformal treatment plan was used for applying the 
BT. From these CT-based 3D dose distributions of the 14 patients, a mean BT dose 
contribution to the muscular structures was calculated (Table 3). This mean BT dose 
N0 N1 N2a N2b N2c N3 Total
T1 1 3 2 5 1 1 13
T2 13 2 3 2 0 0 20
T3 9 4 3 4 1 0 21
T4a 1 1 0 0 0 0 2
Total 24 10 8 11 2 1 56
Table 2: TNM Classification UICC / AJCC, Geneva, 2004 edition.
Figure 1 (a): Delineation of muscular structures of the swallowing apparatus on axial- and 
sagittal CT-slices. (b): Schematic diagram of the delineated five muscular structures conside-
red of paramount importance in swallowing: the superior constrictor muscle (scm), the middle 
constrictor muscle (mcm), the inferior constrictor muscle (icm), the cricopharyngeal muscle 
(cphm) and the 1 cm of the muscular compartment of the esophagus inlet (eim). Also shown 
are the outlines of the projected Tonsillar Fossa / Soft Palate (red) as well as the Base of 
Tongue (cyan blue).
BOT
TF
Superior Constrictor M.
CricoPharyngeus Muscle Proximal 1 cm Esophagus
Middle Constrictor Muscle
Inferior Constrictor M.
C3-C4
Base of Skull-C3
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was also used for calculation of total dose for the remaining patients treated by a 
(non CT-based) BT boost. Finally, for the 43 patients treated by BT, the 3DCRT or 
IMRT dose and the BT dose were summated. 
Statistical analyses
Prevalence of dysphagia: For chart review, PSS, H&N35, and MDADI, a moderate 
and severe degree of dysphagia is established by clustering, that is, for example for 
chart review the RTOG grades 3 and 4 were combined. Similarly, for H&N35 (q35, 
q36, q37 and q38) ‘quite a bit’ and ‘very much’ dysphagia was scored as grade 3 and 
4, respectively. The PSS cut-off scores ≤ 50 and MDADI scores ≤ 50 were taken as 
the prevalence of a significant degree (equivalent to grade 3 or 4) of dysphagia. 
Univariate dose-response relationship: For the scm, mcm, icm, cphm and eim, the 
correlations of dose in these muscular structures and the absence or presence of 
dysphagia grade 3 and 4 combined (binair) were calculated by the proportional odds 
model.  
Dysphagia threshold values: A logistic model was used to calculate the probability of 
dysphagia complaints for a median dose in a particular muscular structure. This was 
done for every dysphagia related question of the different QoL questionnaires. 
Figure 2: Taken at the level of the mid-tonsillar fossa, an axial CT-slice is shown with the deli-
neated muscular structure involved in swallowing (i.e. at this level the scm). Also displayed is 
the dose distribution using an IMRT technique.
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Using this model (p= 1 / (1 + exp (-(a+ b * dose)))) one can calculate the dose for the 
different probabilities of grade 3 and 4. As the distribution of scores of the question-
naires is highly ‘non-normal’, ordinal regression (presently used model) is more valid 
and more informative than ordinary least-squares regression 40. 
Multivariate analysis
The following variables were used in the multivariate analysis: age, sex, site, T-
stage, N-stage, dose, technique, surgery, chemotherapy and brachytherapy.
results
Prevalence of dysphagia: Eighty one patients with SCC of the TF/SP and BOT 
were analyzed for dysphagia (table 1). Advanced staged disease is present in 75% 
(14/56) of patients (table 2). The IMRT series of patients investigated has a mean 
follow up of 18 months (range 2-34) for IMRT as opposed to 46 months (range 2-72) 
for 3DCRT. Overall, the LRFS, DFS and OS at 3 years were 84%, 78% and 77%, 
respectively (figure 3).
Mean dose by BT (Gy)
TF BOT
Superior constrictor muscle 5.72 8.82
Middle constrictor muscle 2.81 7.14
Inferior constrictor muscle 0.93 2.84
Cricopharyngeus muscle 0.45 0.63
Oesophagus inlet 0.45 0.49
Table 3: Dose contribution (mean doses) to the scm, mcm, icm, cphm and eim of brachythe-
rapy boost of Tonsillar Fossa / Soft Palate- or Base of Tongue. For abbreviations, see text.
IMRT 3DCRT
C o n c o m i t a n t 
Chemotherapy
C o n c o m i t a n t 
Chemotherapy
TF / SP BOT TF / SP BOT TF / SP BOT TF / SP BOT
2000-2002 0 0 0 0 6 0 10 7
2002-2005 16 4 3 4 6 0 0 0
Total 27 29
Table 4: Breakdown of 56 patients treated by highly conformal radiation techniques 
(IMRT/3DCRT) and concomitant chemotherapy, responding to QoL questionnaires. Exclu-
ded: deaths due to intercurrent disease (4), deaths due to tumor (13), non-responders to QoL 
questionnaires (8).
Dysphagia in oropharyngeal cancer patients
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Chart review revealed nineteen out of 81 patients (23 percent) experienced mode-
rate to severe (RTOG grade 3 and 4) dysphagia. Out of the 64 patients, 56 (88%) 
responded to the QoL questionnaires. The characteristics of the patient subsites of 
the oropharynx, 41 TF/SP patients and 15 patients with BOT tumors, are listed in 
tables 4 & 5. The prevalence of grade 3 and 4 dysphagia (score ≥ 50) for patients 
studied by using the response to H&N35 (q.35, q.36, q.37 and q.38), was 18%, 11%, 
20% and 7% respectively. With regard to PSS, a score ≤ 50 was seen in 19% of the 
patients eating in public, in 30% with respect to normalcy of diet and in 2% for dif-
ficulty in understandability of speech. Regarding the MDADI: a score ≤ 50 was found 
in 26% (total MDADI score) of the patients. Thus, 28% for the global subscale, 21% 
for the functional subscale, 21% for the emotional subscale and 32% for the physical 
subscale. For the analyses of this paper, all patients were seen in last follow-up at 
the outpatient clinic in January 2006. Relevant late side-effects were scored, such as 
VAS pain, VAS xerostomia, mucositis, trismus and dysphagia were observed in 16% 
(8/51), 59% (30/51), 24% (12/51), 6% (3/51) and 12% (6/51) respectively.  
Univariate dose-response relationship
The doses given in patients with cancer in the oropharynx was app-
lied by 3DCRT or IMRT or a combination of the previous with concomi-
tant chemotherapy, to a total dose of 46 Gy; fractionated HDR or PDR BT was 
used as a preferential boost technique (Dose range boost 20-22 Gy). From table 
3 one can appreciate the mean BT dose received by the different muscular swal-
lowing structures in TF/SP and BOT tumors of 14 patients treated by 3D conformal 
CT-based BT. It is evident from figure 4 that patients treated with fractionated HDR 
TF/SP BOT All oropharynx
Number of patients 41 15 56
Male gender 27 10 37
Mean age (range) years 57 (40-73) 55 (44-68) 56 (40-73)
BT boost 34 9 43
IMRT (full course) 19 8 27
3D CRT (full course) 12 0 12
3D CRT + concomitant CHT 10 7 17
N0 22 2 24
N+ 19 13 32
T1,2 vs. T3,3 28 vs. 13 5 vs. 0 33 vs. 23
IMRT / 3D CRT +CDDP 3 4 7
 +Neck dissection 15 9 24
Table 5: Table displays the characteristics of the 56 patients alive NED with cancer of the 
oropharynx responding to the quality of life questionnaires.
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Figure 3: LRFS and OS at 3-years of 81 patients with cancer of the oropharynx treated with 
3DCRT or IMRT between 2000-2005. For abbreviations see text.
Swallowing structure Median dose Range
Scm 51 Gy 22-73 Gy
Mcm 48 Gy 11-72 Gy
Icm 32 Gy 6-73 Gy
Cphm 23 Gy 4-73 Gy
Eim 18 Gy 3-64 Gy
Table 6: For the 5 muscular structures studied, the median dose and dose range are given.
Figure 4: Dose distribution in superior constrictor muscle. Patient with tonsillar fossa / soft 
palate implant. Patients treated with fractionated HDR / PDR BT receive a substantially lower 
physical dose (and to a smaller volume) to the superior constrictor muscle as opposed to tre-
atment with full course IMRT or 3DCRT.
Dysphagia in oropharyngeal cancer patients
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<< 50% < 50%
100% 100%
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/ PDR BT receive a substantially lower physical dose (Gy) and in a smaller volume 
of the scm / mcm, as opposed to when treated by IMRT or 3DCRT alone. Table 6 
shows for the 5 muscular structures patients studied, the median dose and dose 
range. 
The results of the dose-response relationships are exemplified by figures 5 and 
6 and depicted per muscular structure in table 7. The dose in particular muscular 
structures were significantly associated with some of the items of the questionnaires. 
With regard to the QoL questionnaire H&N35, the dose in the scm, mcm & eim was 
significantly correlated with the item q.35 (see also page 8; ‘liquid’). Similarly cor-
related is the dose in scm & mcm with item q.36, the dose in scm, mcm & icm with 
item q.37 (see also page 8; ‘solid’) and the dose in icm with item q.38 (see also page 
8; ‘aspiration’). Furthermore a significant effect was found for the dysphagia data 
obtained from the charts and the general MDADI score (see table 7). PSS scores 
were found not significant.
Dysphagia threshold values
 A mean dose of 51 Gy, 48 Gy and 32 Gy was found in the scm, mcm and icm, res-
pectively. With regard to the moderate and severe dysphagia complaints combined, 
an overall probability of 18%, 11%, 20% and 7% was observed for q35, q36, q37
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Dose in Superior Constrictor Muscle (Gy), n=81
No complaints
Quite a bit of complaints
A little bit of complaints
A lot of complaints
Figure 5:
Figure 5: Using the quality of life questionnaire of the EORTC H&N35 (item q35; 
swallowing liquids), this figure shows a dose-effect relationship for the probability of 
having no - dysphagia related - complaints and the dose (Gy) in the superior con-
strictor muscle. For ‘quite a bit, ‘ a little bit’ and ‘a lot of ‘ complaints, no significant 
relationship was found for dysphagia and dose to the scm.
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Figure 6: Significant dose-response relationship for dysphagia complaint category 
EORTC H&N35 item q.35 and dose in superior constrictor muscle. Patients can be 
subdivided in those treated by a brachytherapy boost (blue symbols) and those tre-
ated by 3DCRT or IMRT only (red symbols).
 
General 
MDADI
H&N35, 
q38, 
‘aspiration’
H&N35, 
q37, 
‘solids’
H&N35, 
q36, 
‘pureed’
H&N35, 
q35, 
‘liquids’
N=56
0.020.020.02
0.02
0.030.02
0.040.03
0.020.030.02
EIMCPHMICMMCMSCM
Table 7: Dose-response relationships are exemplified by figures 5 and 6. Table 7 shows the 
dose-response relationships in particular muscular structures relative to the items q.35-38 of 
the QoL questionnaire EORTC H&N35, “late dysphagia” (by chart review) and the general 
MDADI. In case of significance, p-values are given. For abbreviations, see text.
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and q38 respectively. Using the logistic model for an overall probability of 2%, 10%, 
20%, 30%, 40% and 50%, a dose in the scm of 22 Gy, 44 Gy, 55 Gy, 63 Gy, 69 Gy 
and 74 Gy was calculated. Same type of computations was done for the dysphagia 
disorders noted in the chart (see table 8).
In the multivariate analysis, if dose received by the scm and BT are entered simul-
taneously in the logistic regression analysis for H&N35 (q35-q38) and dysphagia 
established by chart review, only BT remains a significant factor (p=0.05; odds ratio 
0.06).
discussion
It is evident from the current literature that the intensification of therapy for head and 
neck cancer in general, either by altered fractionation RT schemes (e.g. in case of 
accelerated RT) and/or by the addition of concomitant chemotherapy, results in im-
proved local-regional tumor control 43. Unfortunately, as shown by meta-analysis, the 
late sequelae also increase. Dysphagia is obviously correlated with the functionality 
of the swallowing mechanism. The functionality is based on a number of muscular 
structures that determine the transport of the bolus. For example, elevation of the 
larynx and pharynx during the swallow procedure is essential for protection of the 
airway and propulsion of the bolus. This elevation is facilitated by the contraction of 
longitudinal constrictor muscles which are interspersed with the circular fibers of the 
scm. Because of the limited availability and lack of awareness of objective measures 
to assess swallowing disorders, the incidence of this dysfunction seems also to be 
underreported 44. Furthermore, swallowing related complaints have been shown to 
increase significantly in patients with reduced production of saliva after chemoradi-
ation 33,45. Swallowing disorders after surgery depend on the extent of the resection, 
the specific structures resected, and the nature of the reconstruction. 
Probability Dose q35 Dose q36 Dose q37 Dose q38 Chart review dysphagia
2% 22 10 22 23 6 21 10
10% 44 35 10 53 48 33 41 35 19 58 72 44 38 29 14
20% 55 51 37 62 61 47 52 47 33 69 69 50 50 43 30
30% 63 61 58 68 67 55 58 56 42 73 56 56 52 39
40% 69 69 72 73 73 64 65 62 50 62 58 47
50% 72 71 69 63 67 66
60% 72 63
Overall 18% 11% 20% 7% 23%
Median dose 51 48 32 51 48 32 51 48 32 51 48 32 51 48 32
Table 8: Numbers in table denote mean doses in Gy for the probabilities 2%, 10%, 20%, 30%, 
40%, 50%, or 60%, of dysphagia disorders administered to swallowing muscles scm, mcm 
and icm. The dysphagia problems are defined by the QoL EORTC H&N35 q.35-38 question-
naire and the “late dysphagia” data obtained by chart review. For explanation of details of 
table and abbreviations, see text. 
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Patients undergoing postoperative RT experience radiation induced fibrosis, edema 
and necrosis of a number of normal tissues, for example, the muscles responsible for 
oropharyngeal sphincter. Eisbruch et al. reported on the toxic effects of concomitant 
chemotherapy and RT: several months after treatment, aspiration was experienced 
by 62% of patients 46. Additionally, swallowing muscula ture weakness, pharyngeal 
residue, reduced hyoid/laryngeal movement, reduced epiglottic inversion, velopha-
ryngeal incompetence, and upper esophageal strictures were found. These disor-
ders are again likely the result of muscular fibrosis that causes incoordination of 
the swallowing process. It is thereby difficult to separate out the individual role of 
chemotherapy and RT in these swallowing disorders 17. Nguyen et al. report that the 
severity of dysphagia isfrequently associated with a compromised QoL, anxiety, and 
depression 19.
This paper analyzes the dose-volume effect relationships for dysphagia of pa-
 tients with oropharyngeal cancer treated by 3DCRT and IMRT. The majority of pa-
tients studied (78 % [63/81]), had stage 3 and 4 disease.  This is also reflected in the 
frequent use of chemoradiation (42%) and the intermediate prognosis of this group. 
According to literature, the prevalence of dysphagia in organ preservation therapy is 
high. In some papers on head and neck cancer survivors, swallowing dysfunction is 
reported to be as high as 50% 5,17,18,22. Chart review of the 81 patients showed that 
19 (23 percent) experienced moderate to severe dysphagia (RTOG grade 3 and 
4) during the course of their treatment. It is of importance to note that IMRT in our
Figure 7: Significant dose-response relationship for dysphagia disorders (“late dysphagia”; 
data taken from chart review) and dose in superior constrictor muscle. The probability of swal-
lowing problems increased significantly with dose (± 19% per 10 Gy after 55 Gy) for the scm 
(and mcm).
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institution was initiated only as of 2000. With a mean follow up of 18 months (range 
2-34) for IMRT, the prevalence of dysphagia might therefore be underreported and 
may be a confounding factor.
PSS and QoL instruments were used to objectivate the long-term effects of RT of 
the swallowing apparatus in oropharyngeal cancer patients in some detail. The pre-
valence of grade 3 and 4 dysphagia for the items of the H&N35 ranged from 7-18%; 
the RTOG grade 3 and 4 equivalent scores for the PSS varied from 2-30% and for 
the MDADI from 21-32%. So, dysphagia, as a late effect after radiation therapy, is 
indeed a significant problem in cancer of the oropharynx. When measured by the 
QoL questionnaires, dysphagia grade 3 and 4 was not very dissimilar to observa-
tions taken from chart review (23%). For the analyses of this paper, patients were 
additionally seen in last follow-up at the outpatient clinic in January 2006. The out-
come of this “last” follow up clinic showed that severe xerostomia (VAS) and grade 3 
and 4 dysphagia in long term follow-up were present in 59% (30/51) and 12% (6/51) 
respectively.  
For the late dysphagia grade 3 and 4 (data taken from chart review) significant rela-
tionships were found with scm (p=0.002), mcm (p=0.003) and icm (0.006). Using the 
EORTC QoL questionnaire H&N35, the probability of having no complaints versus 
dose in the scm was found to be significant (p=0.02; odds-ratio 1.08, 95% confiden-
ce interval 1.01-1.14) for item 35 (‘liquids’) as displayed in figure 5. The significant 
dose-effect relationships of QoL questionnaire H&N35 (q.35-q.38 (‘liquids, ‘pureed’, 
‘solids’ and ‘aspiration’)), and the general MDADI, are summarized in table 7. In ge-
neral, with lower doses to the muscular structures, which is particularly the case in 
patients treated with BT boost, less problems with dysphagia have been observed 
(figure 6). Again, using the H&N35 with the endpoint q.35 (‘liquids’), the difference 
between BT vs. no BT was significant (p=0.001; odds ratio 0.06, 95% confidence 
interval 0.01-0.32). From figure 7 (dose-response relationship of late dysphagia), the 
steepness of the curve after a dose of 55 Gy, can be expressed by 19% per 10 Gy.
From table 8 one can appreciate the probabilities of severe dysphagia when apply-
ing a particular dose to the scm, mcm and icm. These computations were done for 
swallowing items of H&N35 and late dysphagia (chart review). Again it is demonstra-
ted that severe dysphagia is not an uncommon co-morbidity. For example the proba-
bility is 40% for a median dose of about 70 Gy to the pharyngeal constrictors for item 
q.35 (‘liquids’). For a median dose of 50 Gy there is a 20% chance of dysphagia but 
only in the scm and mcm. Almost absence (2%) of severe dysphagia is encountered 
for mean doses of 22 Gy (q.35; ‘liquids’), 22 Gy (q.36: ‘pureed’) and 21 Gy (q.37: 
‘solids’) for the scm. Finally in the multivariate analysis, if dose (received by the swal-
lowing musculature) and BT are entered simultaneously in the logistic regression 
analysis for H&N35 (q.35-q.38), general MDADI and late dysphagia taken from chart 
review, only BT remains a significant factor (p=0.05). This can be explained by the 
high correlation of the dose in the swallowing musculature and BT: Brachytherapy 
patients got lower doses in smaller volumes in the swallowing musculature than no-
BT patients. Actually, dose is interchangeable for BT in four cases.
119
..........
conclusions
We identified a subset of patients with oropharyngeal cancers with inability to swal-
low normally. Patients had been treated with highly conformal RT techniques, that is 
3DCRT, IMRT and combinations of these with BT as a boost. Some of these patients 
were treated with concomitant chemotherapy as well. The dysphagia encountered 
in these patients is obviously multi-factorial. We were particularly interested in this 
paper whether the complaints were site and/or dose related. Patients were studied 
using QoL instruments. The responses of the QoL questionnaires, demonstrated that 
the probability of swallowing disorders increased significantly with dose (±19% per 
10 Gy after 55 Gy) for the scm and mcm. In contrast to what is commonly reported, 
concomitant chemotherapy was not a significant factor in the multivariate analysis. 
However, this might be due to the small numbers. It is mandatory to investigate new 
techniques /modalities that can better spare the swallowing musculature.
Dysphagia in oropharyngeal cancer patients
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AbstrAct
Purpose/Objective: To assess the relationship for oropharyngeal (OP) cancer 
and nasopharyngeal (NP) cancer, between the dose received by the swallowing 
structures and the dysphagia related quality of life (QoL).
Materials/Methods: Between 2000-2005, 85 OP- and 47 NP cancer patients 
were treated by radiation therapy. After 46 Gy, OP cancer is boosted by IMRT, bra-
chytherapy (BT) or frameless stereotactic radiation / Cyberknife (CBK). After 46 Gy, 
the NP cancer was boosted with parallel-opposed (P-O) fields or IMRT to a total 
dose of 70 Gy; subsequently, a 2nd boost was given by either BT (11 Gy) or SRT/
CBK (11.2 Gy). Sixty OP- and 21 NP cancer patients responded to functional and 
QoL questionnaires: i.e. the Performance Status Scales, EORTC H&N35, and M.D. 
Anderson Dysphagia Inventory. The swallowing muscles were delineated and the 
mean dose calculated using the original 3D CT-based treatment plans. Univariate 
analyses were performed using logistic regression analysis.
Results: Most dysphagia problems were observed in the BOT tumors. For OPC, 
boosting with IMRT resulted in more dysphagia as opposed to BT or SRT/CBK. For 
NPC patients in contrast to the first booster dose (46-70Gy), no additional increase 
of dysphagia by the 2nd boost was observed. 
Conclusion: The lowest mean doses of radiation to the swallowing muscles were 
achieved when using BT as opposed to  SRT/CBK or IMRT. For the 81 patients alive 
with no evidence of disease for at least one year, a dose-effect relationship was 
observed between the dose in the superior constrictor muscle and the ‘normalcy of 
diet’ (PSS) or ‘swallowing scale‘ (H&N35) scores (p<0.01).
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introduction
In recent years, aggressive nature of the treatment modalities is seen after the in-
troduction of high doses of radiation, and/or some of the (altered) fractionation regi-
men with or without (concomitant) chemotherapy (CHT). A frequently occurring but 
underreported serious late side-effect is dysphagia. Swallowing is a complex action 
requiring rapid and precise coordination between sensory input and motor function 
of the swallowing apparatus 1. Tongue strength may play a role as well in oropha-
ryngeal swallowing, particularly when related to the oral phase of the swallowing 
process 2,3. Co-morbid conditions, large tumors (T3-T4 vs. T2), and resections e.g. 
of the base of tongue and soft palate can be associated with profound swallowing 
problems 4. Several papers reported an aspiration rate of 21%-81% with chemoradi-
ation treatment 4-11. The types of impairments of the swallowing function after radio-
therapy are described in literature as follows: poor pharyngeal motility, with subse-
quent pharyngeal residue, epiglottic immobility, reduced laryngeal excursion, poor 
closure of the laryngeal vestibule and aspiration 12-16. Swallowing disorders are most 
likely caused by radiation-induced edema and neuromuscular fibrosis 17.  Impaired 
swallowing function may be dependent on both total dose and the treatment volume 
18-21. Patients are able to perceive decrements in their swallowing function and may 
have limited their oral intake in response to that perception 22. For patients treated by 
chemoradiation some authors claim slowly (partly) recovering of the dysphagia after 
6 to 12 months 4,23,24. Examples of preventative measures for these swallowing pro-
blems are the pre- and post-treatment exercises and/or the introduction of Therabite 
25-27. Furthermore, it has been argued that the experienced dysphagia corresponds 
significantly with the degree of xerostomia 28. This paper presents a detailed analysis 
of the relationship of the severity of dysphagia complaints and the dose delivered 
to the relevant muscular swallowing structures. The influence of the factors dose, 
treatment technique and site dependency will be assessed in some detail. 
MAteriAl And Methods
Between 2000-2005 a cohort of 132 patients diagnosed with squamous cell carci-
noma of the Tonsillar Fossa / Soft Palate (TF/SP) (n=63), Base of Tongue (BOT) 
(n=22) and Nasopharynx (NP) (n=47) were treated curatively in a single insti-
tution by various radiation therapy techniques (table 1). All patients were seen in 
joint consultation by the radiation-oncologist and H&N surgeon. Patients were as-
sessed by clinical examination, panendoscopy, CT and/or MRI of the head and 
neck. In order to properly stage the disease, a biopsy of the primary tumor, and
ultrasound-guided fine needle aspiration of suspicious regio nal lymph nodes, res-
pectively, was performed. Finally patients were staged according to the TNM clas-
sification 2004 edition 29.
With regard to the nasopharynx: patients are treated routinely by EBRT: that is 46/2 
Gy to the primary tumor and bilateral neck, and 24/2 Gy to the primary tumor (so-cal-
led 1st boost) and N+ neck (Figure 1). In case of T3-T4 tumors and/or N+ disease, 
the EBRT part of the treatment is preceded by 3 courses of neoadjuvant CHT. The 
external beam part of the treatment (up to a total dose of 70 Gy) is given by IMRT 
Dysphagia in  oropharyngeal and nasopharyngeal cancer patients
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Tonsillar Fossa / 
Soft Palate
Base of
 Tongue
Nasopha-
rynx
# patients 45 15 21
Male gender 30 10 15
Mean age 57 55 55
Brachytherapy 34 8 10
Stereotactic RT / 
 Cyberknife boost 5 1 7
IMRT / 3DCRT
 (full course) 6 6
No 2nd boost nasopharynx 4
Table 1: Characteristics of 81 patients with cancer of the tonsillar fossa / soft palate, base of 
tongue and nasopharynx and responding to the quality of life questionnaires.
techniques, if feasible; the daily fraction size is 2 Gy, a total of 6 fx/week is being ap-
plied. T1N0, and T2N0 nasopharyngeal cancers are given a so-called 2nd boost by 
fractionated endocavitary brachytherapy (ECBT; 11 Gy) 30. The 2nd boost in advan-
ced local disease (T3,T4) is given preferably by fractionated stereotactic radiation 
(SRT) or by frameless SRT (Cyberknife)(11.2 Gy). If BT was not feasible for whatever 
(medical) reason, or in case of T3,T4 N0,+ disease, the primary is boosted by means 
of stereotactic radiation or, currently, by the Cyberknife (4 times 2.8 Gy prescribed to 
the 80% iso-doseline to the residual GTV seen on an MRI scan taken at the 40-46 
Gy level). Over the years, the treatment of preference for T1-T3 TF and/or SP tumors 
and T1-4 cancer of the BOT, consisted of a first series of 46 Gy (2 Gy per fraction, 
6 fx/week by IMRT or 3DCRT to the neck and primary tumor, followed by a boost of 
fractionated High Dose Rate (Total Dose 20 Gy) / or Pulsed Dose Rate (Total Dose 
22 Gy) to the primary tumor. In case of neck nodes, a neck dissection (ND) was 
executed before BT was applied. For those patients not eligible for BT (e.g. patients 
with TF/SP tumor but medically unfit, patient refusal, T4 tumors and/or extensive pa-
rapharyngeal extension), a combined resection followed by post-operative radiation 
therapy (IMRT or 3DCRT) is performed. For details see Levendag et al. 31.
The results of chart review for swallowing disorders grade 3 and 4 in 132 patients 
with OPC and NPC is presented. Dysphagia grade 3 is defined as severe dysphagia 
or odynophagia with dehydration or weight loss (>15% from pre-treatment baseline) 
requiring nasogastric feeding tube, I.V. fluids or hyper-alimentation; dysphagia gra-
de 4 is defined by complete obstruction, ulceration, perforation, and/or fistula. From 
the 132 patients, 67 OPC and 28 NPC patients alive with no evidence of disease 
for at least one year received 4 types of questionnaires: 1. The EORTC core Quality 
of Life (QoL) Questionnaire [QLQ]-C30, 2. The EORTC QLQ-H&N35 32, 3. The Per-
formance Status Scale (PSS) of List et al. 33 and 4. the M.D. Anderson Dysphagia 
Inventory (MDADI) 34.
With regard to the swallowing mechanism, the following anatomical structures were
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Staging
Biopsy, PA report / revision, 
Examination under anesthesia, EBV 
Ultra Sound Fine Needle Aspiration, 
CT, MRI, PET, Surgical report
Patient Intake
RWHHT / Joint Clinic
Favorable
(T2/N0)
MRI after ≥ 40 Gy
yes
Primary Tumor
<=T2a?
no
Favorable
(T1/N0)
Cyberknife boost 4 * 2.8 Gy
(81.2 Gy  dose)
fr. HDR  4 + 3x3 + 4 
BT Boost  (77 Gy  total dose)
fr. HDR  4 + 3x3 + 4 
BT Boost  (77 Gy  total dose)
PT + Bilateral Neck
IMRT 46 Gy
PT + Bilateral Neck
IMRT 46 Gy
PT 
IMRT 60 Gy
PT 
IMRT 60 Gy
PT 
IMRT 70 Gy
Unfavorable
(T3,4/N0, T1-4/N+)
3 courses neo-adjuvant
Cisplatin + 5-FU
N?
N0 N+
PT and Neck (N+) 
70 Gy
PT 70 Gy
+ Neck 46 Gy
Cyberknife 4 * 2.8 Gy
(81.2 Gy total dose)
fr. HDR 4+3+4 Gy
BT Boost (81 Gy total dose) 
Primary Tumor
<=T2a?no yes
PT + Bilateral Neck
IMRT 46 Gy
Figure 1: Flowchart of nasopharyngeal cancer treatment.
Figure 2: Schematic diagram of the delineated five muscular structures considered of para-
mount importance in swallowing.
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Figure 3: Definitions and delineations of the swallowing muscles of the swallowing apparatus 
on a sagital CT-slice. 
identified: the superior constrictor muscle (scm), the middle constrictor muscle 
(mcm), the inferior constrictor muscle (icm), the cricopharyngeal muscle (cphm) and 
the 1st cm of the muscular compartment of the esophagus inlet (eim) (Figure 2 & 
3) 18,35. Subsequently, every treatment plan of the previously irradiated patients was 
retrieved, now with the muscular structures of the swallowing apparatus being deli-
neated on the axial CT slices. The mean dose contribution by the 3DCRT or IMRT 
technique to the muscular structures was computed using the original treatment 
plan. For the patients treated by parallel-opposed fields and from whom a CT-scan 
was available that was used at the time for treatment planning purposes, also the 
dose contribution to the swallowing muscles was calculated 36. The mean  BT dose 
was computed from the available CT-based 3D dose distributions. For those patients 
boosted by BT, SRT or Cyberknife, the 3DCRT, IMRT or parallel-opposed dose and 
the boost doses, respectively, were physically summated. Finally the relationship of 
the mean total dose received by each of the 5 swallowing muscles to the respon-
ses of the three - dysphagia related - QoL questionnaires (EORTC H&N35, PSS & 
MDADI), is established per tumor site and treatment technique. Also the possible 
relationship of dysphagia with xerostomia is assessed in some detail.
Prevalence of dysphagia: From chart review, EORTC H&N35 (swallowing scale), 
PSS (normalcy of diet) and the MDADI questionnaires, prevalence of dysphagia was 
scored. Also, a moderate and severe degree of dysphagia is established by cluste-
ring, that is, e.g. for chart review RTOG grade 3 and 4 were combined. Similarly, for 
H&N35 (swallowing) ‘quite a bit’ and ‘very much’ dysphagia was scored as grade 3 
and 4, respectively. The PSS (normalcy diet) score ≤ 50 and total MDADI score ≤ 
50 were taken as the prevalence of a significant degree (equivalent to grade 3 or 4) 
of dysphagia. 
1: Nasopharynx
2: Tonsillar Fossa / Soft Palate
3: Base of Tongue
Constrictor Muscles:
Superior: BOS - upper C3
Middle: Upper C3 - Hyoid (upper C4)
Inferior: Hyoid - Caudal Cricoid (upper C6)
Cricopharyngeal Muscle:
Caudal Cricoid (upper C6) - 1st Treacheal Ring
1 cm Esophageal Inlet:
Uppre part 2nd Tracheal Ring - Caudal part 3rd 
Tracheal Ring
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Univariate dose-response relationship: For the scm, mcm, icm, cphm and eim, the 
correlations of an independent continuous variable (dose) in these muscular structu-
res and a dependent binary variable (that is the absence or presence of dysphagia 
grade 3 and 4 combined) were calculated using logistic regressions.  For example: 
Pr{Normalcy of Diet ≤ 50 | Dose in SCM} 
   = 1 / (1 + exp (- (α + β * Dose SCM )))
The unknown parameters alpha and beta are estimated with the maximum likelihood 
method. A test is also performed whether the hypthesis β =0 can be rejected. A p-
value of < 0.05 is interpreted as beta being statistically significant from zero. Thus, 
in the case p < 0.05 there is a significant relationship between probability P and 
dose in the muscles. Low dose means low probability and high dose means high 
probability.
results
Between 2000-2005, 132 OPC and NPC patients were treated by RT. The majority 
of these patients had advanced staged tumors (table 2a-c). The localregional control 
(LRC) for TF & SP, BOT and NPC patients at 5 years and the overall survival are 
shown in figures 4a-c. Sixty seven OPC patients and 28 NPC patients are included 
in this report (table 3). Sixty patients responded to all given Quality of life question-
naires in case of OPC (response rate: 60/67=90%) and 21 out of 28 in case of NPC 
(response rate: 75%).
According to the charts, 24 (18 %) patients experienced dysphagia grade 3 or 4 with 
a tumor located in the TF and/or SP in 22%, in the BOT in 32% and in the NP in 6% 
The prevalence of grade 3 and 4 dysphagia was also studied using the response to 
the PSS (ND), H&N35 (swallowing)  and MDADI (table 4). The OPC patients were 
also grouped according to the boost techniques used, that is BT, CBK or IMRT / 
3DCRT. Results for PSS (Normalcy 
of Diet), H&N35 (swallowing) and, MDADI are shown in table 5. For the NPC group, 
the reported number of patients with severe dysphagia was high
(Table 6). The results of the dose-response relationships are presented by table 
7 and figure 5. Taken from the QoL questionnaire H&N35, the dose in the scm, 
mcm was significantly correlated with the swallowing scale. Similarly correlated is 
the dose in scm & mcm with PSS, (normalcy of diet). 
Dysphagia and xerostomia related responses to questionnaires were also strongly 
associated. As can be seen in table 8, quite a number of these associations were 
highly significant. There was no significant influence of age, sex, nodal status, che-
motherapy, brachytherapy, site, T-category and N-category found with univariate 
logistic regressions analysis.
Dysphagia in  oropharyngeal and nasopharyngeal cancer patients
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(a) T1 T2 T3 T4
N0 2 16 10 0
N1 4 5 4 0
N2a 2 4 0 0
N2b 4 5 1 0
N2c 0 1 3 0
N3 1 0 0 1
(b) T1 T2 T3 T4
N0 0 0 1 2
N1 0 2 2 1
N2a 0 1 4 0
N2b 2 1 3 0
N2c 2 0 1 0
(c) T1 T2a T2b T3 T4
N0 1 3 1 2 4
N1 2 2 2 1 3
N2 3 0 0 4 10
N3a 4 1 1 0 2
N3b 1 0 0 0 0
Table 2: TNM Classification UICC / AJCC, 2004 edition. (a): Tonsillar fossa / soft palate (b): 
Base of tongue (c): Nasopharynx .
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Figure 4a-c: Localregional control and overall survival at 5-years of  patients with cancer of 
the tonsillar fossa / soft palate (a), the base of tongue (b) and the nasopharynx (c) treated 
between 2000-2005.
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Oropharynx Nasopharynx
# patients 85 47
Deaths 17 8
Deaths of disease 8 7
Metastasis - 3
2nd primary 1 1
Lost to Follow-up - 7
Eligible questionnaires 67 28
No responses 7 6
No CT-scan - 1
60 21
Table 3: Breakdown of the exclusion criteria of the 132 oropharyngeal- and nasopharyngeal 
cancer patients. In total 81 patients remained eligible, that is patients without evidence of 
disease responding to the questionnaires.
Dysphagia-related questionnaires
H&N35
 (Swallowing)
PSS 
(Normalcy of Diet)
MDADI 
(Total)
TF / SP (n=45) 11% 27% 20%
BOT (n=15) 27% 27% 33%
NP (n=21) 20% 48% 5%
Table 4: Poor scores (%) of dysphagia for the questionnaires EORTC H&N35, PSS, and 
MDADI in the tonsillar fossa / soft palate (TF/SP), base of tongue (BOT) and nasopharynx 
(NP). 
Dysphagia-related questionnaires
H&N35
 (Swallowing)
PSS 
(Normalcy of Diet)
MDADI 
(Total)
Brachytherapy (n=42) 7% 21% 14%
Cyberknife (n=6) 17% 33% 17%
Intensity-modulated radia-
tion therapy / three-dimen-
sional conformal radiation 
therapy n=12)
42% 58% 58%
Table 5: Poor scores (%) of dysphagia according to the questionnaires EORTC H&N35, PSS, 
and MDADI in oropharyngeal cancer patients when grouped by boost technique.
Dysphagia in  oropharyngeal and nasopharyngeal cancer patients
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discussion
From the current literature we know that the intensification of therapy for head and 
neck cancer in general results in improved localregional tumor control 37-39. However, 
late sequelae also increase, including swallowing disorder 40.  
Limited data on swallowing problems is reported before 2005 28. Recently 
increased attention is given to the swallowing problem because of the ongoing 
randomized clinical trials in dysphagia 41. The prevalence of dysphagia in or-
gan preservation therapy is reported to be as high as 50% 7,17,42,43. A study by 
Eisbruch et al. 35 showed that elevation of the larynx and pharynx during swal
lowing are essential for protection of the airway and propulsion of the bolus. Af
ter chemoradiation there is decreased base of tongue and/or posterior pharyngeal 
contraction and reduced pharyngeal contraction, resulting in impaired bolus trans-
port through the pharynx 9. Logemann et al. concludes that there is only little if any 
difference in frequency of swallowing problems across different disease sites af-
 
Dysphagia-related questionnaires
Boost Technique H&N35 (Swallowing) MDADI
(Total)
No boost (n=4) 0% 0%
Brachytherapy (n=10) 10% 10%
SRT, CBK (n=7) 14% 0%
Table 6: Poor scores (%) regarding dysphagia according to the questionnaires EORTC H&N35 
and MDADI in nasopharyngeal cancer patients when grouped by boost technique.
Figure 5: Dose-effect relationship for the probability of having dysphagia (PSS, normalcy of 
diet) and the dose (Gy) in the superior constrictor muscle. Curve of the estimated logistic re-
gression is shown together with the estimated probabilities for each data point. 
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ter treatment and according to the same authors that the effects of the different
chemotherapy agents were seemingly small 3. Pre-treatment swallowing therapy 
may improve dysphagia and reduce the need for tube feedings 44. Feng et al. demon-
strated significant relationships between dose-volume parameters of structures and 
objective and subjective measurements of swallowing dysfunction45. Other groups 
also showed significant correlations of various dysphagia endpoints with dose; for 
the supraglottic lesions 46 and glottic cancers 20,46. 
This paper analyzes the dose-volume relationships for dysphagia (and xerostomia). 
It particularly relates the side-effects (QoL) to different treatment techniques and to 
widely separated anatomical locations; that is the base of tongue, the tonsillar fossa 
and/or soft palate, and the nasopharynx. The treatment results for these intermedia-
te prognostic groups are shown in figure 4a-c. From our series of 132 patients, chart 
review showed that 24 (18%) patients experienced moderate to severe dysphagia 
(RTOG grade 3 and 4) with more problems in patients with BOT (32%) cancer as 
opposed to patients with cancer of the TF/SP (22%) and NP (6%). As the prevention 
of dysphagia is of paramount importance in clinic and given the substantial amount 
of dysphagia in the present series, it was felt of interest to study this subject in detail 
by QoL instruments. Out of the 95 patients alive with no evidence of disease, 81 
Coefficients H&N35 
(Swallo-
wing)
PSS
(Nomralcy 
of Diet)
MDADI 
(Total)
Global 
Dysphagia
Emotional 
Dysphagia
Physical 
Dysphagia
Functional 
Dysphagia
Dose scm 0.320* 0.310* 0.273† 0.252† 0.275† 0.247† 0.214†
Dose mcm 0.344* 0.258† 0.278† 0.266† 0.286† 0.247† 0.235†
Dose icm 0.198 0.007 0.105 0.202 0.105 0.066 0.095
Dose cphm 0.039 0.234 0.095 0.007 0.150 0.121 0.115
Dose eim 0.031 0.187 0.015 0.055 0.047 0.035 0.025
Table 7: Correlation coefficients for EORTC H&N35, PSS and MDADI and the dose in swallo-
wing muscles. Swallowing muscles: the superior constrictor muscle (scm), the middle constric-
tor muscle (mcm), the inferior constrictor muscle (icm), the cricopharyngeus muscle (cphm) 
and the 1st cm of the muscular compartment of the esophagus inlet (eim). Note: With Bon-
ferroni’s correction only dose in scm and mcm vs. H&N35 (Swallowing) remain significance. 
Global, emotional, physical and functional dysphagia are distinct domains of the MDADI.
* Significant at the 0.01 level (2-tailed).
† Significant at the 0.05 level (2-tailed).
Dysphagia-related items Xerostomia-related items
p-values (Rho, 95% CI) H&N35, dry mouth H&N35, sticky saliva VAS xerostomia
H&N35, swallowing <0.001 (0.64, 0.49-0.76) <0.001 (0.56, 0.38-0.70) <0.001 (0.49, 0.30-0.64)
PSS, normalcy of diet <0.001 (0.47, 0.27-0.63) <0.001 (0.33, 011-0,52) <0.001 (0.50, 0.31-0.65)
Total MDADI <0.001 (0.58, 0.40-0.72) <0.001 (0.47, 0.27-0.64) <0.001 (0.60, 0.42-0.73)
Pain with swallowing <0.01 (0.35, 0.14-0.54) - <0.01 (0.34, 0.12-0.53)
Table 8: Dysphagia related items correlated with xerostomia related items using Spearman’s 
rank correlation. P-values are given when significant.
Dysphagia in  oropharyngeal and nasopharyngeal cancer patients
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(85%) responded to the QoL questionnaires. According to the responses to the QoL 
questionnaires, swallowing problems are also most frequently encountered in pa-
tients with tumors of the BOT. Although correlations between the questionnaires 
were poor, almost a third of the patients’ complain of swallowing disorders (table 4). 
Moreover, patients seem to experience more complaints of dysphagia with longer 
follow up (this finding is part of a separate paper in preparation). If grouped by treat-
ment technique, most severe dysphagia was found in IMRT / 3DCRT, compared to 
BT group and SRT/CBK group (table 5). One explanation could be the cumulative 
dose in the swallowing structures. For example, if treated by EBRT techniques, the 
mean dose in the scm was 70 Gy in case of BOT tumors, 64 Gy in TF/SP and 67 
Gy in NPC. If the booster is given by BT, the highest mean dose in scm is 52 Gy for 
BOT and 42 Gy for TF/SP (table 9). However, comparing dose distributions in TF/
SP, BOT and NP, from tables 9 and figure 6 it can be seen that in the scm and mcm 
the highest dose was found in patients with NPC.
The NPC patient category is always treated (per protocol) by a large volume 
boost dose (so called first boost) of 24 Gy by EBRT techniques to a cumula-
tive dose of 70 Gy to the primary tumor and positive neck nodes. It is at present 
unclear to us why the patients with NPC treated by a high dose to the upper swal-
lowing muscles do not complain of dysphagia to the same extent compared to e.g. 
BOT cancer patients. One possible explanation could be the infiltrating nature of the 
disease itself in the case of BOT cancers. The BT or SRT / CBK booster dose in 
NPC is, however, of no relevance to the scm and other muscles given the very small 
volume and rapid dose fall-off.
Several dose-effect relationships between dysphagia problems and the dose re-
ceived by the swallowing muscles were found to be significant (table 7). Most   sig-
nificant were the relationships between EORTC H&N35 and the dose in the scm / 
mcm and the association of the PSS (normalcy of diet) and the dose in the scm (p-
values lower than 0.01). Figure 5 shows an example of the dose-effect relationship 
between PSS (normalcy of diet) and the dose in scm for all (81) patients. The higher 
the dose, the more chance of complaints of dysphagia. Xerostomia and dysphagia 
are strongly associated as depicted in table 8. Particularly highly correlated were the 
questions of the EORTC H&N35 questionnaire regarding swallowing, dry mouth and 
sticky saliva. 
The previous findings suggest that BT dose distributions are more sparing  to the 
swallowing musculature and salivary glands as opposed to the CBK/SRT and IMRT 
techniques. In order to differentiate between the intrinsic values of the irradiation 
techniques used, and whether it is simply due to margins, we computed for the 6 
GTV’s of clinical patients irradiated by CBK, the dose in the scm, mcm, left and right 
parotid, cord and CTV for PTV margins of 0, 2 and 5 mm, respectively. For each 
margin there is, approximately,little difference in dose if one compares the dose dis-
tribution in the various normal tissue structures. If one takes the clinical situation into 
account, that is com paring a PTV margin of 0 mm in case of BT vs. CBK  with 2 mm 
margin and a 5 mm margin for IMRT an advantage can be observed for the BT and 
CBK with respect to the dose contributed to the normal tissues (table 10). 
Moreover a higher dose is obtained in the CTV treated by the CBK compared to 
IMRT (18.3 Gy vs. 16.6 Gy). Margins do seem to have an substantial effect on the 
dose received by the swallowing muscles. 
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 Tonsillar Fossa /      Base of Tongue            Nasopharynx
                                            Soft Palate 
Figure 6: Plot of individual mean dose distribution of the superior constrictor muscle in the 
tonsillar fossa / soft palate, base of tongue and nasopharynx.
conclusions
Patients treated with a variety of disease sites (TF / BOT / NPC) and treated by va-
rious RT techniques (IMRT / 3DCRT / BT / SRT / CBK) vary in their prevalence of 
severe dysphagia. Responses to QoL questionnaires in relation to the dose received 
by scm and mcm, demonstrated a dose-effect relationship. Dysphagia is also site 
(geographical position) dependant; most dysphagia problems are seen in BOT can-
cer patients. Although NPC patients receive the highest dose due to the treatment 
techniques used, dysphagia is still less as opposed to patients with cancer of the 
BOT. The explanation of this phenomenon remains somewhat unclear; it is specu-
lated that this might have to do with the infiltrative (muscles) nature of the BOT can-
cers. Dysphagia is obviously multi-factorial. In particular, dysphagia is strongly cor-
related withxerostomia. From the findings of the present research, we would like to 
emphasize for the future to focus more on treatment planning research (constraints), 
especially for issues like this frequently underreported dysphagia problem. 
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Tonsillar Fossa / Soft 
Palate
IMRT / 3DCRT
 n=6
BT
n=34
CBK
n=5
(Gy)
Scm 64 42 53
Mcm 61 36 47
Icm 45 24 29
Cphm 29 21 23
Eim 27 20 18
Base of Tongue IMRT / 3DCRTn=6
BT
n=34
CBK
n=5
(Gy)
Scm 70 52 (34)
Mcm 68 50 (39)
Icm 51 36 (35)
Cphm 38 26 (42)
Eim 36 20 (40)
All oropharynx IMRT / 3DCRTn=12
BT
n=34
CBK
n=5
(Gy)
Scm 67 44 50
Mcm 65 38 45
Icm 48 27 32
Cphm 34 22 25
Eim 32 20 23
Table 9: Mean dose to the superior-, middle- and inferior constrictor muscle, the cricopharyn-
geus muscle and the 1st cm of the muscular compartment of the esophagus inlet. Patients are 
grouped according to the boost-treatment technique used, that is IMRT / 3DCRT, brachythe-
rapy (BT) and Cyberknife (CBK).
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IMRT
N=6 PTV_5mm PTV_2mm PTV_0mm
(Gy)
Scm 13.3 12.0 11.1
Mcm 9.6 8.2 7.5
Left parotid 4.1 3.8 3.1
Right parotid 3.2 2.8 2.5
Cord 7.4 7.4 6.7
GTV 16.6 16.5 16.6
Cyberknife
N=6 PTV_5mm PTV_2mm PTV_0mm
(Gy)
Scm 14.3 12.7 10.8
Mcm 11.0 9.0 8.3
Left parotid 2.4 1.8 1.7
Right parotid 2.7 2.2 1.7
Cord 8.7 6.8 6.3
GTV 18.0 18.3 18.3
Table 10: Mean dose to the superior constrictor muscle (scm), middle constrictor muscle 
(mcm), left parotid, right parotid, cord and GTV with 0, 2 and 5 mm margins applied for the 
GTV, planned with IMRT 3D treatment planning system (XiO 4.3.3, CMS, USA) and 
Cyberknife plannings software (Multiplan 1.4.0, Accuray Inc., USA), respectively.
Dysphagia in  oropharyngeal and nasopharyngeal cancer patients
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AbstrAct
Purpose/Objective: Dysphagia is a major late complication of intensive chemora-
diotherapy of head and neck cancer. The initial clinical results of intensity-modulated 
radiotherapy (IMRT), or brachytherapy, planned specifically to reduce dysphagia are 
presented.
Patients and Methods: Previous research at Michigan University has suggested 
that the pharyngeal constrictors and glottic and supraglottic larynx are likely structu-
res whose damage by chemo-RT causes dysphagia and aspiration. In a prospective 
Michigan trial, 36 patients with oropharyngeal (n = 31) or nasopharyngeal (n = 5) 
cancer underwent chemo-IMRT. IMRT cost functions included sparing noninvolved 
pharyngeal constrictors and the glottic and supraglottic larynx. After a review of pu-
blished studies, the retropharyngeal nodes at risk were defined as the lateral, but not 
the medial, retropharyngeal nodes, which facilitated sparing of the swallowing struc-
tures. In Rotterdam, 77 patients with oropharyngeal cancer were treated with IMRT, 
three dimensional RT, or conventional RT; also one-half received brachytherapy. 
The dysphagia endpoints included videofluoroscopy and observer-assessed scores 
at Michigan and patient-reported quality-of-life instruments in both studies.
Results: In both studies, the doses to the upper and middle constrictors correlated 
highly with the dysphagia endpoints. In addition, doses to the glottic and supraglottic 
larynx were significant in the Michigan series. In the Rotterdam series, brachythe-
rapy (which reduced the doses to the swallowing structures) was the only significant 
factor on multivariate analysis. 
Conclusion:The dose–response relationships for the swallowing structures found 
in these studies suggest that reducing their doses, using either IMRT aimed at their 
sparing, or brachytherapy, might achieve clinical gains in dysphagia.
143
..........
introduction
Intensification of the therapy for head and neck cancer, by altered fractionated radio-
therapy (RT) or the addition of concurrent chemotherapy, has resulted in improved 
tumor control rates. The main late sequela after treatment intensification has been 
increasing rates and severity of long-term dysphagia 1. Dysphagia after chemo-RT of 
head-and-neck cancer is associated with aspiration, an underreported complication 
of therapy 2.
A previous study at the University of Michigan found that the pharyngeal constrictors 
(PCs) and the glottic and supraglottic larynx (GSL) changed anatomically after inten-
sive chemo-RT, and their malfunction explained the post-therapy abnormalities ob-
served in the objective assessments of swallowing 3. Intensity-modulated RT (IMRT) 
plans whose cost function included sparing these structures without compromising 
target irradiation achieved significantly reduced doses to the swallowing structures 
compared with “standard” IMRT 3. A prospective trial aiming to assess the clinical 
benefits gained by these strategies was subsequently initiated at Michigan.
At Erasmus MC in Rotterdam, brachytherapy (BT) has been used for many years as 
a tool to facilitate the delivery of a high tumor dose 4 and 5. BT substantially reduces 
the doses delivered to neighboring tissues, specifically the neighboring swallowing 
structures, compared with conventional RT. Both IMRT aimed at the sparing of the 
swallowing structures at Michigan and BT at Rotterdam produced a wide dose range 
in these structures. This has allowed studies of dose–response relationships, whose 
initial results are summarized in this report.
pAtients And Methods
Patients and therapy
At Michigan, all 36 patients with oropharyngeal (n = 31) or nasopharyngeal (n = 
5) cancer received IMRT, which included cost functions for sparing the PCs, GSL, 
and esophagus, without underdosing the targets, according to previously detailed 
methods 3. Treatment was delivered in 35 fractions, with the gross disease (clinical 
target volume [CTV]1), high-risk (CTV2), and low-risk (CTV3) targets receiving 70, 
63, and 59 Gy at 2.0, 1.8, and 1.7 Gy/fraction, respectively, concurrent with weekly 
carboplatin and Taxotere (oropharynx) or cisplatin (nasopharynx). At Rotterdam, 77 
patients were treated with IMRT (n = 37), three-dimensional conformal RT (n = 22), 
or computed tomography-based parallel-opposed beam techniques. In 52% of the 
patients, BT was used according to previously detailed methods 4,5. Additional details 
regarding the treatment methods used in Rotterdam have been previously published 
6.
Target and structure delineation
Of particular importance to target delineation for IMRT at Michigan was the delinea-
tion of the retropharyngeal (RP) nodes. These nodes were defined as targets for all 
nasopharyngeal and almost all oropharyngeal cancers, particularly in patients with 
other clinically involved nodes. The RP nodes are divided into the lateral and medial 
RP nodal chains. The lateral RP nodes (“nodes of Rouviere”) lie medial to the carotid 
Michigan and Rotterdam dysphagia experiences
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arteries and lateral to the longus coli and capitis muscles, and the medial RP nodes 
are intercalated along the lymphatics near the midline. Only the lateral RP nodes 
were defined as targets, and their CTVs were contoured in the spaces medial to the 
carotid arteries. The medial RP nodes were not defined as targets (unless radiologic 
evidence was present for gross lateral RP involvement), because they have been 
reported to be very rarely involved as metastatic sites 7,8. Additional details regarding 
RP target delineation for this study, and its rationale, have been previously published 
9. The inclusion in the CTVs of only the lateral RP nodes, and the exclusion of the 
medial ones, facilitated the sparing of the swallowing structures.
Contouring of the swallowing structures, including the PCs and GSL, has been pre-
viously detailed 3. In brief, the three parts of the PCs (upper, middle, and lower) 
were outlined as a single structure for which the cranial-most extent was the caudal 
tips of the pterygoid plates and the caudal-most extent was the inferior border of 
the cricoid cartilage. For the purposes of analysis, the PCs were considered as one 
structure and were also schematically divided into three parts: the superior PC was 
defined from the cranial-most extent through the upper edge of the hyoid bone, the 
middle PC was defined from the upper through the lower edge of the hyoid, and the 
inferior PC was defined from below the hyoid through the inferior edge of the cricoid 
cartilage. Caudal to the inferior border of the cricoid, the esophagus was contoured, 
and its caudal-most extent corresponded to the caudal-most extent of the low neck 
targets. The GSL was contoured as a single structure.
Evaluation of dysphagia
At Michigan, dysphagia was evaluated before and periodically after therapy with 
videofluoroscopy, quality-of life (QOL) instruments, including the HN-QOL questi-
onnaire and the University of Washington HN-QOL Questionnaire, and the obser-
ver-rated Radiation Therapy Oncology Group late toxicity, scored by the treating 
physicians. At Rotterdam, dysphagia was assessed by three QOL instruments: the 
performance status questionnaire assessing “eating in public” and “normalcy of diet,” 
the European Organization for Research and Treatment of Cancer head-and-neck 
35-item “swallowing” and “aspiration” questionnaire, and the M.D. Anderson dyspha-
gia inventory–dysphagia-specific QOL questionnaire for head-and-neck cancer.
results
In the Michigan study, at 3 months after therapy, videofluoroscopy-based strictures 
were observed in 3 patients (8%) and aspirations (passage of barium past the vocal 
cords) in 16 (44%). The mean ± SD dose to the PC, GSL, and esophagus was 64 ± 
5, 56 ± 10, and 41 ± 13 Gy, respectively. Significant correlations were observed bet-
ween videofluoroscopy-based aspirations and the mean doses to the PC and GSL, 
as well as the partial volumes of these structures receiving 50–65 Gy. The greatest 
correlations were associated with doses to the superior PC (p = 0.005). All patients 
with aspirations had received a mean PC dose of >60 Gy or PC V65 >50%, and 
GSL V50 >50%. Reduced laryngeal elevation and epiglottic inversion correlated with 
the mean PC and GSL doses (p <0.01). All 3 patients with strictures had received 
a PC V70 >50%. Worsening patient-reported liquid swallowing was correlated with 
the mean PC (p = 0.05) and esophageal (p = 0.02) doses. Only the mean PC doses 
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correlated with worsening patient-reported solid swallowing (p = 0.04) and observer-
rated swallowing scores (p = 0.04). Of the individual PCs, the mean dose to the su-
perior PC had the greatest correlation with the observer-rated and patient-reported 
dysphagia scores. Additional details of the results at Michigan have been previously 
published 9.
In the Rotterdam study, of 77 patients, 60 were alive and without evidence of di-
sease. The locoregional relapse-free survival rate was 92% at a mean follow-up 
of 41 months (range 4–72). On univariate analysis, a significant correlation was 
observed between the doses delivered to the superior or middle PC, and the perfor-
mance status scores, dysphagia scores of the European Organization for Research 
and Treatment of Cancer Head-and-Neck 35-item questionnaire, and M.D. Ander-
son dysphagia inventory–dysphagia-specific QOL questionnaire for head-and-neck 
cancer. In each QOL instrument, BT was associated with better outcome (p = 0.01). 
On multivariate analysis, BT was the predominant factor associated with reduced 
symptoms, because its use significantly reduced the doses to the superior and mid-
dle PCs. Additional details of the results at Rotterdam have been previously publis-
hed 6.
discussion
In the Michigan and Rotterdam studies, statistically significant correlations were 
found between the dysphagia endpoints, including aspiration, and the dose–volume 
parameters for the superior and middle PCs. These relationships can be explained 
by several important details of the swallowing mechanism. Elevation of the larynx and 
pharynx during swallowing is essential for airway protection and bolus propulsion. 
This elevation is facilitated by contraction of the longitudinal muscles, which blend 
with the circular fibers of the superior PC, including the stylopharyngeus, salpingop-
haryngeus, and palatopharyngeus. As the larynx and pharynx are pulled up and 
forward by these muscles, they are pulled away from the lower posterior pharyngeal 
wall and facilitate opening of the upper esophageal sphincter at the cricopharyngeal 
level 3,10. These mechanisms of swallowing and protection from aspiration, as well as 
our results, suggest that the benefits from efforts to spare the swallowing structures 
are likely to be maximized if they include the superior PCs, rather than being con-
fined to the esophagus and its upper inlet (i.e., the caudal part of the inferior PCs).
The dose–effect relationships we have reported can now serve to define the optimi-
zation goals for IMRT. They should motivate efforts to reduce these doses as much 
as possible using either IMRT or BT, or both. Most importantly, care in the outlining 
of targets in the vicinity of these structures, avoiding target underdosing, and de-
termining and reporting the locations of locoregional recurrences, are essential to 
ensure that the rates of local recurrences do not increase compared with the rates 
observed previously after IMRT or BT.
Michigan and Rotterdam dysphagia experiences
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AbstrAct
Background and purpose: Dysphagia is a serious complaint but frequently un-
derreported. This paper assesses for oropharyngeal cancer (OPC) the relationship 
between the dose received by the swallowing structures, and the findings of a fi-
beroptic endoscopic evaluation of the swallowing process (FEES).
Materials and methods:  Between 2000 and 2005, 60 out of 67 OPC patients 
local-regionally NED for at least one year following treatment responded to three 
types of QoL questionnaires; i.e. Performance Status Scales, EORTC H&N35, and 
M.D. Anderson Dysphagia Inventory. Twenty-four patients agreed to the FEES pro-
cedure. The main swallowing muscles were delineated, with the mean dose per 
muscle calculated using the original 3D CT-based treatment plans. Regression ana-
lysis was performed between FEES variables and the doses in the different swal-
lowing muscles and the dysphagia related questionnaires. 
Results: A significant relationship was found between the results of FEES and the 
mean dose in the superior constrictor muscle (SCM). Some of the subjective dys-
phagia complaints were significantly correlated with the FEES variables in this re-
trospectively study.
Conclusion: A higher dose in the SCM generally results in worsening of the fin-
dings obtained by the FEES examination.
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introduction
In recent years, chemoradiation protocols are becoming standard in the more ad-
vanced head and neck cancer patients because of their organ preservation proper-
ties. However a significant increase in side-effects, such as dysphagia, is also seen 
due to the use of more aggressive treatment modalities. Patients with complaints 
of dysphagia demonstrate significantly worse swallowing functions as indicated by 
lower oropharyngeal swallow efficiency (OPSE), increased pharyngeal transit times, 
larger residues, more swallows with aspiration 1, epiglottic immotility, pharyngeal 
dysmotility, limited laryngeal elevation and limited movement of the base of ton-
gue 2. Less tongue strength may play a role as well in oropharyngeal swallowing, 
particularly when related to the oral phase of the swallowing process 3,4. Impaired 
swallowing function may be dependent on both the total dose received by the swal-
lowing muscles and the treatment volume 5-8. Furthermore, it has been argued that 
the experienced dysphagia corresponds significantly with the degree of xerostomia 
9,10. It is important to diagnose dysphagia early as it negatively affects the quality of 
life of head and neck cancer patients; moreover, nutritional surveillance needs to be 
provided to prevent malnutrion 11. Examples of preventative measures for dysphagia 
are pre- and post-treatment exercises and/or the introduction of Therabite 12-16. Pre-
treatment swallowing therapy may improve dysphagia 17,18 and reduce the need for 
tube feedings. This paper will present regression analysis of fiberoptic endoscopic 
evaluation of swallowing (FEES) on the dose received by the swallowing structures. 
Also correlations will be calculated between the FEES variables and the swallowing 
related quality of life (QoL) questionnaires. 
MAteriAls And Methods
Sixty-seven patients with oropharyngeal cancer were treated curatively in a single 
institution by radiation therapy (RT) techniques between 2000 and 2005, of the pa-
tients 60 NED oropharyngeal cancer patients responded to QoL questionnaires, i.e. 
Performance Status Scales, EORTC H&N35, and M.D. Anderson Dysphagia Inven-
tory. Of these patients. The patients were seen in joint consultation by the radiation 
oncologist and H&N surgeon. Diagnosis was established by clinical examination, 
panendoscopy, CT and/or MRI of the head and neck. Biopsy of the primary tumor, 
and ultrasound-guided fine needle aspiration of suspicious regional lymph nodes 
were performed. Patients were staged according to the TNM classification 2002 
edition 19, and patients staged before 2002 were restaged. Treatment protocol of the 
oropharyngeal patients had been detailed before 5. In summary, as of 2000, a total 
dose of 46 Gy is given by IMRT. By an accelerated fractionation schedule (in our 
institution routinely used since 2000), six fractions of 2 Gy are delivered 5 days per 
week (once a week two fractions per day, administered with a minimum interval of 6 
hours between fractions, the other 4 days one fraction of 2 Gy per day). For advan-
ced T3/T4 tumors, in recent years the IMRT 0-46 Gy is frequently combined with two 
courses of chemotherapy (cisplatin 100 mg/m2). The IMRT is followed preferentially 
by a BT booster dose using a pulsed-dose-rate (PDR) or fractionated high-dose-rate 
fr. HDR BT schema, in conjunction with a neck dissection (ND) in case of positive 
neck nodes. If BT of the primary tumor is (technically) not feasible (e.g. in case of 
FEES outcome in oropharyngeal cancer
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parapharyngeal extension) or in case of patient refusal for whatever reason, from 
2005, it is optional to use the Cyberknife to deliver the booster dose (3 x 5.5 Gy). For 
tumors of the tonsillar fossa and/or soft palate (TF/SP) to be boosted by brachythe-
rapy (BT), fractionation schedules are similar. In case of fractionated HDR, after 
an initial fraction of 4 Gy, four additional fractions of 3 Gy, and a final fraction of 4 
Gy  (20 Gy total, two fractions per day, minimum 6 hour interval between fractions) 
is applied (“day-time” regimen). For PDR (pulsed-dose- rate): an initial fraction of 2 
Gy followed by 18 x 1 Gy and a final fraction of 2 Gy (22 Gy total, 8 fraction per day, 
minimum 3 hours interval between fractions) are given (“day-and-night” schedule). 
These schedules are in accordance with our previously published BT protocol for the 
head and neck.
The 67 OPC patients alive and with no evidence of disease (NED) received four 
types of quality of life (QoL) questionnaires in 2007: 1. The EORTC core QoL Ques-
tionnaire [QLQ]-C30, 2. The EORTC QLQ-H&N35 with the swallowing scale, in-
cluding four items (problems with swallowing of liquid, pureed food, or solid food, 
and aspiration when swallowing) and aspiration 20,3. The Performance Status Scale 
(PSS) of List et al. with the item normalcy of diet 21,4. The M.D. Anderson Dysphagia 
Inventory (MDADI), 22 consisting of 20 questions with global, emotional, functional, 
and physical subscales. 
One objective of this paper is to analyze dysphagia measured according to the sco-
ring parameter of the FEES procedure in relation to the dose received by the swallo-
wing muscles. The muscular structures involved are the superior constrictor muscle 
(scm), the middle constrictor muscle (mcm), the inferior constrictor muscle (icm), 
the cricopharyngeal muscle (cphm) and the 1st cm of the muscular compartment of 
the esophagus inlet (eim) 5,23. Subsequently, every treatment plan of the previously 
irradiated patients was retrieved, now with the muscular structures of the swallo-
wing apparatus newly delineated on the axial CT slices. The mean dose contribution 
to the muscular components of the swallowing mechanism using parallel-opposed, 
3DCRT or IMRT treatment plans was computed using the original treatment plan 
with the newly delineated swallowing muscles. From the available CT-based 3D 
dose distribution of patients boosted by means of BT, the mean BT dose was cal-
culated. For those patients boosted by BT, SRT or Cyberknife, the 3DCRT, IMRT or 
parallel-opposed dose and the boost doses, respectively, were physically summa-
ted. Also dose-volume dependencies are calculated.
FEES was done according to the technique described by Langmore et al. 24. The 
patient eats and drinks while the hypopharyngeal and laryngeal structures were kept 
in view with the fiberscope. Liquid (colored water), pureed food (yoghurt), and che-
wable food (cracker) were ingested. While one examiner passed the endoscope, 
another observed the patients’ swallowing. Ten variables were scored: mucus sta-
ses and residue, penetration and aspiration of water, yoghurt and crackers, respecti-
vely (table 1). Prevalence of dysphagia: A moderate / severe degree of dysphagia is 
established by clustering the answers ‘quite a bit’ and ‘very much’ dysphagia of the 
EORTC H&N35 (swallowing and aspiration) 5. The PSS (normalcy of diet) score ≤ 
50 and total MDADI score ≤ 50 were taken as the prevalence of a significant degree 
(equivalent to grade 3 or 4) of Dysphagia. Also for the variables of the FEES, residue 
of water, yoghurt and crackers, respectively, were dichotomized, adding together 
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answers ‘absent’ and ‘little’ vs. ‘moderate’ and ‘severe’. Patients who cannott eat 
the cracker were dichotomized as severe. Mucus stases, aspiration and penetration 
of water, yoghurt and crackers score are already dichotomized during the scoring 
itself. Using the 10 dichotomized variables of the FEES procedure, a single score 
was calculated by summing up the individual scores of mucus stases and residu-
es and twice the scores of aspiration and penetration of water, yoghurt and crac-
kers, respectively. The aspiration and penetration scoring were doubled as these 
variables of the FEES do weigh more in the case of dysphagia.
Statistical considerations
Univariate logistic regression analysis was performed for the individual binary FEES 
variables on dose in five muscular structures: scm, mcm, icm, cphm and eim. 
Correlations between FEES variables and QoL variables were assessed using 
Spearman rank correlation analysis. P-values ≤ 0.05 will be considered significant.
# patients No Yes Little Moderate Severe NA
Mucus Stases 17 7 0
Water residue 13 8 3 0 0
Water penetration 22 2 0
Water aspiration 24 0
Yoghurt residue 3 8 6 7 0
Yoghurt penetration 22 2 0
Yoghurt aspiration 23 1 0
Cracker residue 3 7 2 7 5
Cracker penetration 18 1 5
Cracker aspiration 19 0 5
Table 1: Fiberoptic endoscopic evaluation of swallowing (n = 24); Mucus stases/residue: no, 
little, moderate, severe, NA. Aspiration/penetration: no, yes, NA. 
results
Twenty-four NED oropharyngeal cancer patients responded to QoL questionnaires, 
i.e. Performance Status Scales, EORTC H&N35, and M.D. Anderson Dysphagia In-
ventory and agreed to the FEES procedure. The FEES procedures were done after 
a minimal follow up of 1 year with no evidence of disease between November 2006 
and March 2007. Mean follow up for FEES was three and half years (range 0,08-6,6 
years). Patient characteristics are shown in table 2.
The prevalence of grade 3 and 4 dysphagia according to the H&N35 questionnaire 
(swallowing scale with a score ≥ 50), was 15% (9/60) for OPC. For PSS (Normalcy 
of diet) and total MDADI, values of 23% (14/60) and 27% (16/60), respectively, were 
obtained. These three questionnaires were used for analysis only as the EORTC-
C30 did not contain swallowing related questions. The mean doses and the partial 
FEES outcome in oropharyngeal cancer
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# patients
Tumor site 24
    Tonsillar Fossa 16
    Base of Tongue 8
Male 19
Age (mean/median) 58 / 60
Stage
    T1 3
    T2 12
    T3 8
    T4a 1
    N0 8
    N1 4
    N2a 6
    N2b 3
    N2c 2
    N3 1
Chemotherapy 13
3DCRT 11
IMRT 13
Boost
    No 4
    Brachytherapy 16
    Cyberknife 4
Table 2: Patient characteristics.
volumes of the swallowing muscles received dose (VD) are summarized in table 3.
Results of the FEES variables investigated are shown in table 1. With regard to 
the dose-effect relationship of the individual FEES variables (mucus stases and 
residual, penetration and aspiration with water, yoghurt and crackers), there is 
no significant relationship seen with the doses in the swallowing muscles (scm, 
mcm, icm, cphm and eim). However, a significant linear regression between the 
total FEES score (summation of the FEES variables) and the superior constrictor
muscle was observed (figure 1); this was not the case for the other lower situated 
swallowing muscles. Significant correlations between FEES variables and answers 
to the swallowing related quality of life questionnaires were as seen in table 4. Mostly 
‘cracker penetration’ and ‘yoghurt’ residue showed a relationship with the - dyspha-
gia related - questionnaires. No relationships were found for the QoL question regar-
ding ‘pureed food’ and ‘aspiration’ with the FEES variables. Also no correlati-
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Median Range
SCM Mean Dose (Gy) 53 (20-73)
V20 (%) 100 (36-100)
V40 (%) 100 (0-100)
V50 (%) 0 (0-100)
V60 (%) 0 (0-100)
MCM Mean Dose (Gy) 50 (21-72)
V20 (%) 100 (17-100)
V40 (%) 93 (0-100)
V50 (%) 0 (0-100)
V60 (%) 0 (0-100)
ICM Mean Dose (Gy) 34 (8-69)
V20 (%) 73 (7-100)
V40 (%) 45 (0-100)
V50 (%) 0 (0-100)
V60 (%) 0 (0-100)
CphM Mean Dose (Gy) 23 (3-57)
V20 (%) 43 (2-100)
V40 (%) 13 (0-100)
V50 (%) 0 (0-67)
V60 (%) 0 (0-57)
EIM Mean Dose (Gy) 17 (3-46)
V20 (%) 32 (0-100)
V40 (%) 2 (0-100)
V50 (%) 0 (0-4)
V60 (%) 0 (0)
Table 3: Mean doses of the swallowing structures and partial volumes receiving specified 
doses (VD).
ons were found for the FEES variables mucus stases, water penetration, water aspi-
ration, yoghurt penetration and yoghurt aspiration with quality of life questionnaires.
The total FEES score showed a significant relationship with QoL question regarding 
swallowing ‘pureed food’ (p≤0.01) and ‘solid food’ (p≤0.05) of the EORTC H&N35, 
and also with the ‘normalcy of diet’ (p≤0.05) question of the PSS and the total MDADI 
questionnaire (p≤0.05) No significant correlation was found regarding swallowing 
‘liquids’ and aspiration questionnaires.
FEES outcome in oropharyngeal cancer
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discussion
Swallowing is a complex action requiring rapid and precise coordination between 
sensory input and motor function of the swallowing apparatus 25. Recently there is 
increased focus on dysphagia given the ongoing randomized clinical trials in dys-
phagia 26. Reflexive cough while eating and drinking is important for the detection of 
oral pharyngeal dysphagia 27. Swallowing is generally divided into phases that are 
modified during normal development due to anatomic and physiologic maturation 28. 
The prevalence of dysphagia in organ preservation therapy is reported to be as high 
as 50% according to some papers on head and neck cancers 29-32 and an aspiration 
rate of 21-81% with chemoradiation 29,33-39 has been observed. However, its preva-
lence is probably being underreported because of its clinically silent nature. The 
following phases are identified in swallowing, i.e. an oral, oral propulsive, pharyn-
geal and esophageal phase. Swallowing disorders affect both oral and pharyngeal 
phases; they are most likely caused by radiation-induced edema and neuromuscular 
fibrosis 30. The types of impairments of the swallowing function after radiotherapy 
are described in the literature as follows: poor pharyngeal motility, with subsequent 
pharyngeal residue, epiglottic immobility, reduced laryngeal excursion, poor closure 
of the laryngeal vestibule and aspiration 40-46. A study by Eisbruch et al. 23 showed 
that elevation of the larynx and pharynx during swallowing is essential for protection 
of the airway and propulsion of the bolus. After chemoradiation there is decreased 
base of tongue and/or posterior pharyngeal contraction, resulting in impaired bolus 
transport through the pharynx 36. Co-morbid conditions, T3-4 tumors (vs. T2), and 
resections of the base of tongue and soft palate (vs. defects of other dynamic struc-
tures) were associated with the most profound swallowing problems 39. For patients 
treated by concomitant chemoradiation, some authors claim slow recovering of the 
dysphagia after 6-12 months 39,47,48, and patients have fewer functional swallows, 
i.e. swallows with longer pharyngeal delay, greater oral, and /or pharyngeal residue 
than normal swallows in patients with the same age and sex, than patients treated 
by radiation alone at 12 months post-treatment completion 49. Logemann et al. con-
clude that there is only little if any difference in frequency of swallowing problems 
across different disease sites after treatment. Several groups showed significant 
relationships between dose-volume parameters of structures and mostly subjective 
measurements of swallowing dysfunction 5,50-52.
FEES and videofluoroscopy (modified barium swallow) for examining swallowing 
has some subjective nature. Kelly et al. investigated whether these types of dyspha-
gia examinations influence the scoring of penetration and aspiration. Indeed pene-
tration aspiration is perceived to be greater (more severe) from FEES than for the 
videofluoroscopy recordings 53. This has to be taken into account when looking at 
the data. Whether patients have their dietary and behavioral management guided by 
the results of videofluoroscopy and / or FEES, their outcomes with respect to pneu-
monia incidence and pneumonia-free interval are essentially the same 54. Although 
comparison of cost-effectiveness of videofluoroscopy via videofluoroscopy and vi-
deoendoscopy via FEES with sensory testing resulted in that FEES appears to be 
more cost-effective than videofluoroscopy 55.
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In this paper, the severity of dysphagia was measured by the FEES procedure in 
tumors originating from the tonsillar fossa and / or soft palate or base of tongue. 
Subsequently, a relationship between dose and the outcome of the FEES procedure 
was established. It also describes the correlation of QoL (dysphagia) and the FEES 
outcome in patients for at least one year with no evidence of disease after treatment 
by radiation. In recent years intensification of therapy for head and neck cancers in 
general, either by altered fractionation RT schemes and/or by the addition of con-
comitant chemotherapy, results in improved local-regional tumor control 56-58. It is of 
interest to note that in the analyzed patient subset of this paper, in 54% of the cases 
radiation was combined with concomitant cisplatin based chemotherapy. However, 
late sequelae have also increased 59, thereby modifying the quality of life of the pa-
tients in a negative fashion 33. Given the significant impact of dysphagia on the QoL, 
prevention of this serious late side-effect is of paramount importance. We therefore 
studied this subject in more detail by performing the FEES procedure in patients 
radiated for the primary cancer located in the oropharynx. Placement of the flexible 
endoscope for FEES traverses partly the same path as a food bolus in the pharynx, 
and could therefore negatively influence safe and efficient swallowing. Suiter et al. 
determined if the presence of a flexible fiberoptic endoscope in the pharynx affects 
swallow physiology; this effect could not be established 60.
The QoL instruments used in our study were the questionnaires of the EORTC 
H&N35 (swallowing scale, aspiration), the MDADI and the PSS (normalcy of diet). 
Of the 67 patients alive with NED, 60 responded to the QoL questionnaires and 24 
agreed to the FEES procedure. The BT dose was added to the EBRT by physical 
summation. BED was not calculated as it is of low relevance as the dose fall-off is 
very steep for BT. Even the BT dose contributing to the target is only maximally 
one-third of the total dose, so the contribution of the BT is even less. Moreover the 
dose rate is lower for the swallowing muscles than estimated compared to the target. 
Overall treatment for patients treated by external beam radiation only and external 
beam radiation + brachytherapy is the same: more or less 6 weeks. Calculating the 
BED is “technically” possible, however questionable as what the relevance is, also 
which  values should be included in some of the parameters are still debatable. 
Of the five swallowing muscles studied, only for the superior constrictor muscle a 
dose-effect relationship for the total FEES score was found (figure 1). In line with 
our previous findings, indeed it is suggested that radiation to the superior constrictor 
muscles is extremely important for swallowing; dose in scm also correlates well with 
the answers to swallowing related QoL questionnaires 5. Individual variables scored 
for FEES did not correlate significantly; this may be due to the small subgroups of 
patients investigated. In our previous paper we described a multivariate analysis on 
a greater group with the following variables used: age, sex, site, T-stage, N-stage, 
dose, technique, surgery, chemotherapy and brachytherapy. Brachytherapy see-
med to be a significant factor, but chemotherapy and the other factors did not reach 
significance. The mean doses and the partial volumes of the swallowing muscles 
received dose (VD) are correlated very well as reported also by Feng et al, therefore 
no correlation analysis between (VD) with questionnaires was done 6.
Also is found that the total FEES score is correlated well with the capability of swallo-
wing of pureed and solid foods, as formulated in the EORTC H&N35 questionnaire, 
and with the normalcy of diet item from the Performance Status scale and total mean 
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score of the MDADI. These findings show that the total FEES score of the variables 
is more sensitive to the patient findings than the individual FEES variables; this pro-
bably can be explained by the small number of patients who underwent the FEES 
procedure.
conclusions
Oropharyngeal cancer patients frequently suffer from a significant degree of severe 
dysphagia. Total FEES score showed a dose-effect relationship for the dose re-
ceived by the superior constrictor muscle, and correlates well with the responses to 
the QoL questionnaires. From the findings of the present clinical research, we would 
like to emphasize for the future to focus even more on constraints for the superior 
constrictor muscles and the dysphagia problem.
Figure 1: Dose vs. total FEES score relationship.
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AbstrAct
Background: To assess the correlation between the radiation therapy (RT) dose 
to the mastication apparatus and trismus of oropharyngeal cancer patients.
Methods: 81 patients treated by RT were analyzed. The masseter, pterygoid and 
temporalis muscles and the coronoid and condyl were delineated on axial CT-slices. 
The mean dose in these structures was correlated with outcome of quality of life 
questionnaires. 
Results:  56 (88%) patients responded; 16% of the patients scored grade 3/4 on 
the Head&Neck35 ‘opening mouth’ question. A significant correlation was observed 
between dose in masseter and pterygoid muscles and trismus (p = 0.02). 
Conclusion: Patients treated with brachytherapy received a lower dose in masti-
catory muscles. A steep dose-effect relationship between mean dose in masseter 
muscle and pterygoid muscles and the probability of having trismus complaints was 
observed; with every additional 10 Gy to the pterygoid muscle, an increase of the 
probability of trismus of 24% was observed.
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introduction
The wording ‘trismus’ has been coined in relation to a complication of the movement 
of the mandible following surgery and /or radiotherapy (RT) in head and neck can-
cer. It has been described as any type of restriction in opening of the mouth including 
radiation and conditions after trauma, surgery or tetanus 1-4. The functionality of the 
‘trismus related’ muscular compartment can be summarized as follows: Depression 
(lateral pterygoid muscles, gravity), Elevation (temporalis-, masseter- and medial 
pterygoid muscles), Protrusion (lateral pterygoid-, masseter-, temporalis muscles), 
Retraction (posterior fibers temporalis- and deep fibers masseter muscles), and La-
teral movement (contralateral lateral pterygoid- and bilateral temporalis muscles). In 
radiation-induced fibrosis, there is presence of infiltrating inflammatory cells, atypi-
cal fibroblasts, and large amount of various extra-cellular matrix components. The 
result of this fibrosis limits the mouth opening, with major effects on nutrition, dental 
hygiene, swallowing and phonation. To alleviate the symptoms of trismus, an active 
mobilizing treatment is worth considering 5. Usually trismus is investigated as a se-
condary outcome variable. Effects of therapeutic interventions are scarcely investi-
gated 6. Few publications yet discuss the prevention of trismus in the era of modern 
conformal radiation therapy techniques. Even more so, the definition and delineation 
of the normal tissue structures involved in trismus is to the great extent lacking. This 
paper was set out to define the precise location and role of the structures of the mas-
tication apparatus. After identification of the structures, each of them was delineated 
on axial CT-slices of a consecutive series of patients with cancer of the Oropharynx, 
radiated by, highly conformal, Intensity Modulated Radiotherapy (IMRT)/3D Confor-
mal Radiotherapy (3DCRT). In order to investigate a dose-effect relationship, the 
mean dose was computed for every structure and related to the responses to the 
Quality of Life (QoL) questionnaires.
MAteriAl And Methods
This study is based on a cohort of 81 patients diagnosed with scc of the oropharynx 
and treated curatively between 1999-2005 in a single institution by highly conformal 
radiation therapy techniques. That is, 46 patients by 3DCRT and 35 patients by 
IMRT. At the time, treatment of preference for T1-T3 disease consisted of 46/2 Gy 
external beam radiation therapy (EBRT) to the neck and primary tumor, followed 
by a boost by means of fractionated HDR (High Dose Rate) or PDR (Pulse Dose 
Rate) brachytherapy (BT) to the primary tumor. In case of neck nodes, a neck dis-
section was performed. For those patients not eligible for BT (e.g. medical unfit, 
patient refusal, T4 tumors and extensive parapharyngeal extension), a combined 
resection, followed by EBRT is performed. The clinical target volume for the N0, 
N+ neck is delineated according to the rulings of the international consensus 7,8. 
External beam RT is prescribed according to International Commission on Radiation 
Units and Measurements 50 and 62 recommendations and generally delivered by 
a linear accelerator with a 6-10 MV (photon) beam. By an accelerated fractionation 
schedule, six fractions of 2 Gy are delivered 5 days per week (once a week two frac-
tions per day, administered with a minimum interval of 6 hours between fractions) 9. 
Trismus in oropharyngeal cancer patients
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This accelerated conformal RT technique has been used routinely since 2000. For 
brachytherapy of the tonsillar fossa and / or soft palate, a split period of 1-2 weeks 
is allowed before implanting 2-3 catheters (single plane) in the CTV of the primary 
tumor. After optimization, the dose is prescribed at 0.5 – 0.75 cm of the central plane 
of implanted catheters. In case of a primary cancer in the base of tongue, a volume 
implant with afterloading catheters is performed, usually by implanting 3 sagital pla-
nes covering the whole of the BOT. Dose prescription for BOT implant is according 
to the Paris System rules; dose is prescribed at 85% of the mean basal dose. Frac-
tionation schedules for tonsillar fossa and / or soft palate and BOT are similar. In 
case of fractionated HDR, after an initial fraction of 4 Gy, four additional fractions of 
3 Gy, and a final fraction of 4 Gy  (20 Gy total, two fractions per day, minimum 6 hour 
interval between fractions) is applied. For PDR (Pulsed Dose Rate): an initial fraction 
of 2 Gy followed by 18 x 1 Gy and a final fraction of 2 Gy (22 Gy total, 8 fraction per 
day, minimum 3 hours interval between fractions) are given. These schedules are in 
accordance with our previously published BT protocol for the head and neck 9. Using 
this protocol, excellent loco-regional control has been obtained in T1-T3 tonsillar 
fossa and/or soft palate tumors and T1-4 tumors originating from the BOT. At 10 
years the local control rate was approximately 80% 10. 
Patients were staged according to the TNM classification (UICC /AJCC 2004)11. 
Thirty-two patients had T3/T4 disease, 50 patients had N+ disease. For this patient 
category the local relapse free survival (LRFS), the disease free survival (DFS) and 
overall survival (OS) were calculated. During follow up, 4 patients died because of 
intercurrent disease, 13 died because of tumor relapse and/or regional metastases. 
In order to evaluate trismus in more detail, the remaining 64 patients alive with no 
evidence of disease received 3 types of quality of life questionnaires: 1. The EORTC 
(European Organisation for Research and Treatment of Cancer) Core Quality-of-Life 
Questionnaire [QLQ]-C30 (30 items) 2. the EORTC Head and Neck cancer module 
QLQ-H&N35 with the items ‘opening mouth’ and ‘pain in jaw’ and scales ‘speech’ 
and ‘social eating’, the Performance Status Scale (PSS) of List with the functions: 
eating in public, normalcy of diet and understandability of speech. Given these items, 
albeit somewhat arbitrary, we thought it reasonable to define severe trismus (grade 
3/4) to correspond with a PSS score ≤ 50, QLQ-C30 and H&N35 ≥ 50.
Questionnaires
The QLQ-C30 and QLQ-H&N35 QoL instruments, were developed and translated by 
the European Organization for Research and Treatment of Cancer (EORTC). The 
questionnaire has 2 parts. The core questionnaire (Quality-of-Life Questionnaire 
[QLQ]-C30) applies to all patients with cancers, and the disease-specific questionnaire 
(QLQ-H&N35) is designed for patients with cancer of the head and neck region. The 
raw scores obtained from the EORTC questionnaires were converted to scores ran-
ging from 0 to 100 using linear transformation according to the scoring procedures 12.
The QLQ-C30 includes 30 questions comprising both multi-item scales and single-
item measures. The 5 functional scales are physical functioning, role functioning, 
emotional functioning, cognitive functioning, and social functioning. The 3 symptom 
scales are fatigue, nausea and vomiting, and pain. 
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Figure 1: Schematic diagram of the delineated structures of the mastication apparatus.
There is also a global QOL scale. The 6 single-item measures are dyspnoe, insom-
nia, appetite loss, constipation, diarrhea, and financial difficulties. A high score for a 
scale represents a higher response level. Thus, a high score for a functional scale 
represents a high or healthy level of functioning, a high score for the global QOL 
scale represents a high QOL, but a high score for a symptom scale or item repre-
sents a high level of symptoms (problems). 
The comprises 35 questions incorporating 7 multi-item scales and 11 single items. 
The multi-item scales are pain, swallowing, senses, speech, social eating, social 
contact, and sexuality. The single items are teeth, opening mouth, dry mouth, sticky 
saliva, coughing, felt ill, pain killers, nutritional supplements, feeding tube, weight 
loss, and weight gain. For all items and scales, high scores indicate more problems. 
An important issue of this paper is to correlate dose with the trismus complaints. For 
this purpose we defined the relevant structures of the mastication apparatus. The 
relevant muscles for jaw movement (masseter-, temporalis- and pterygoid muscles) 
Trismus in oropharyngeal cancer patients
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are delineated, the processes coronoideus and condyl of the mandible inclusive. On 
the axial CT-slices of the treatment plans of every patient, the 5 bilateral structures 
of interest were delineated (figure 1). 
Regarding the temporalis and pterygoid muscles, the most cranial slice was con-
toured 5 mm cranial to the coronoid process. The most caudal slice of the co-
ronoid process and the condyl of the mandible are contoured at the level where
the coronoid process and condyl of the mandible are not separately visible anymore. 
Both masseter muscles are contoured in all axial slices. The external beam dose 
contribution of the external beam part to the muscular structures was computed 
(mean doses) using the original treatment plan 13. From a 3D dataset of 14 patients 
boosted by means of BT, the mean BT dose was calculated. For those patients tre-
ated by BT, the external beam dose and the BT dose were summated. 
Statistical Analysis
Prevalence of trismus: As endpoints for trismus, data obtained by chart review for 
trismus related complaints and the QoL scores taken from the EORTC H&N35 and 
PSS of List questionnaires were obtained. For the H&N35 ‘opening mouth’ item the 
gradings ‘quite a bit’ and ‘very much’ trismus were taken as grade 3 and 4, respec-
tively. The PSS score ≤ 50 was taken as a significant degree (equivalent to grade 3 
and 4) of trismus. 
Univariate dose-response relationship: For the masseter-, pterygoid-, temporalis 
muscles and coronoid and condyl bony processus of the mandible, the correlations 
of dose in these structures and the absence or presence of trismus grade 3 and 4 
combined were calculated by the proportional odds model. 
Multivariate analysis: For the multivariate analysis the following variables were used: 
age, sex, site, T-classification, N-classification, dose, technique, unilateral /bilateral 
irradiation surgery, chemotherapy and brachytherapy.
results
At 5-years, for the 81 patients analyzed, a local regional control rate of 84% and an 
overall survival of 77% was observed. Sixty-four patients were alive with no eviden-
ce of disease at the censor date; 56 / 64 (88%) responded to the – trismus related 
– questions of the QoL questionnaires. The patient characteristics of the subsites 
of the oropharynx, being 41 patients with the tonsillar fossa /soft palate tumors and 
15 patients with base of tongue (BOT) tumors, are lis ted in table 1. In 77% (43/56) 
brachytherapy (BT) was used; in 20% radiation was combined with concomitant 
chemotherapy (cCHT). Follow-up varied from 18 months (range 2-34) for IMRT to 
46 months for 3DCRT (range 2-72). 
According to the notes in the charts, 3 (4 %) patients experienced trismus. In con-
trast, in 15% of the IMRT group and in 20% of the 3DCRT group, the - trismus rela-
ted - question of H&N35 (‘opening mouth’) was scored in category 3 or 4. Similarly, 
for tonsillar fossa and / or soft palate tumors categories 3 or 4 were observed in 12% 
vs. 27 % in BOT tumors. The cCHT group scored 25% vs. 9% in the non-cCHT pa-
tients. In the BT group in 12% of the cases category 3 and 4 was found vs. 31% in 
the non-BT patients (table 2).
Figure 2 shows the boxplot of the H&N35 question ‘opening mouth’ by BT vs. non-
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BT. With regard to the PSS, 19% had difficulty with eating in public, 30% problems 
with normalcy of diet and in 2% difficulty with understandability of speech. Table 3
TF / SP,
no. of patients
BOT,
no. of patients
All Oropharynx, 
no. of patients
Number of patients 41 15 56
Male gender 27 10 37
Mean age (range) 
years 57 (40-73) 55 (44-68) 56 (40-73)
BT Boost 34 9 43
IMRT + cCHT 3 4 7
IMRT - cCHT 16 4 20
3DCRT + cCHT 10 7 17
3DCRT - cCHT 12 0 12
+ Neck Dissection 15 9 24
Table 1: Patient characteristics of 56 patients with squamous cell carcinoma of the oropha-
rynx. Abbreviations: TF: Tonsillar Fossa; BOT: Base of Tongue, cCHT: concurrent Chemo-
therapy; BT: Brachytherapy; IMRT: Intensity Modulated Radiotherapy; 3DCRT: 3D Conformal 
Radiotherapy.
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Figure 2: Boxplot of the EORTC H&N35 (European Organisation for Research and Treatment 
of Cancer Head & Neck cancer module ) question ‘opening mouth’ grouped by Brachytherapy 
vs. No Brachytherapy cases.
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Poor scores - trismus related - QoL TF, No. of patients BOT, %, No. of patients
H&N35* Opening Mouth 12% (5/41) 27% (4/15)
H&N35* Pain in Jaw 5% (2/41) 14% (2/14)
H&N35* Speech 2% (1/41) 13% (2/15)
H&N35* Social Eating 10% (4/40) 21% (3/14)
PSS† Understandability of Speech 2% (1/42) 0% (0/15)
Outpatient Clinic 5% (2/42) 7% (1/14)
IMRT, %, No. of patients 3DCRT, %, No. of patients
H&N35* Opening Mouth 15% (4/27) 17% (5/29)
H&N35* Pain in Jaw 8% (2/26) 7% (2/29)
H&N35* Speech 7% (2/27) 3% (1/29)
H&N35 Social Eating 16% (4/25) 10% (3/29)
PSS† Understandability of Speech 0% (0/28) 3% (1/29)
Outpatient Clinic 4% (1/28) 18% (5/28)
Non-CHT, %, No. of patients CHT, %, No. of patients
H&N35* Opening Mouth 9% (3/32) 25% (6/24)
H&N35* Pain in Jaw 3% (1/31) 13% (3/24)
H&N35* Speech 6% (2/32) 4% (1/24)
H&N35* Social Eating 13% (4/31) 13% (3/23)
PSS† Understandability of Speech 0% (0/33) 4% (1/24)
Outpatient Clinic 3% (1/32) 8% (2/24)
BT, %, No. of patients Non-BT, %, No. of patients
H&N35* Opening Mouth 12% (5/43) 31% (4/13)
H&N35* Pain in Jaw 2% (3/13) 23% (1/42)
H&N35* Speech 2% (1/43) 15% (2/13)
H&N35* Social Eating 2% (1/43) 55% (6/11)
PSS† Understandability of Speech 2% (1/43) 0% (0/14)
Outpatient Clinic 5% (2/42) 7% (1/14)
Table 2: Percentage of patients scoring poor scores in Trismus related QoL questions bet-
ween TF vs. BOT, non-CHT    vs. CHT, BT vs. non-BT and IMRT vs. 3DCRT.
*EORTC (European Organisation for Research and Treatment of Cancer) Head & Neck can-
cer module. 
†Performance Status Scale. Abbreviations: QoL: Quality of Life; TF: Tonsillar Fossa; BOT: 
Base of Tongue, CHT: Chemotherapy; BT: Brachytherapy; IMRT: Intensity Modulated Radio-
therapy; 3DCRT: 3D Conformal Radiotherapy.
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shows the distribution of poor scores for the H&N35 “opening mouth” and “pain 
in jaw” question. The percentages poor scores increased with T classification. All 
patients were ultimately seen at the outpatient clinic in December 2005 and catego-
rized having limitations in opening mouth (6/56: 11%) or functionality within normal 
limits (89%: 50/56). The mean inter-incisal (id) distance measured approximately 39 
mm (range 10 mm to 65 mm); the id of the patients scored as trismus (chart review) 
were 27 and 28 mm with 1 missing. Table 4 illustrates the id’s for patients scored 
having limitations ‘opening mouth’ at the time last follow-up, for patients with trismus 
according chart review and for those cases scoring category 3 or 4 of the - trismus 
related - QoL questionnaires vs. no limitations in mouth opening.
Univariate dose-response relationship: The results of the dose-response relation-
ship stratified per muscular structure and complaint category of the different quality 
of life questionnaire are shown in table 5. In the univariate analysis a significant 
correlation was observed between the dose in the masseter-, pterygoid muscles, 
the coronoid and the trismus related question of the H&N 35 questionnaire. Further 
more a significant effect was found for trismus observed at the last follow-up visit of 
outpatient clinic correlating with dose in the masseter -, pterygoid muscles and the 
coronoid bone. In the multivariate analysis, BT was the only significant factor. 
An overall probability of 5% and 10%, was observed for ‘opening mouth’ 
(H&N35) and speech (H&N35) respectively. Figure 3 shows the relation-
ship between the probability of having complaints by increasing dose divi-
ded for BT and non-BT treatment. For every 10 Gy in the pterygoid muscle, af-
ter a dose of 40 Gy, an increase of probability of trismus of 24% was observed. 
For those patients of whom the trismus related muscles were irradiated bilaterally, a 
significant increase of the chance for trismus was observed with regard to the item 
‘opening mouth’ (H&N35) (p=0,02)  (table 6). All other items of the QoL were found 
not to differ significantly unilaterally and bilaterally.
discussion
In order to obtain better tumor control rates, in recent years more aggressive re-
gimes have been implemented in the treatment of cancer of the head and neck. 
The aggressive nature of the treatment modalities is exemplified by using high 
doses of radiation per se, and /or (altered) fractionation regimen 9. For example, 
Bourhis et al. showed in a meta-analyses an increase in local control of 6.4%, 
and an increase in OS of 3.4%, by using hyperfractionated or accelerated RT 
in the cancer of the head and neck 14. At present, in organ preservation the-
rapy, concomitant chemotherapy is also frequently used. The more recent data 
of Bonner et al. showed benefit of combining EGFR-targeted antibody cetuxi
mab with radiation 15. Future studies will focus on combining targeted antibody the-
rapy with cCHT and radiation. However, one has to keep in mind that clinical inves-
tigators have frequently reported that combined treatment can be more expensive 
and /or results in excess of side-effects. Frequently encountered late side-effects are 
for example xerostomia, dysphagia and trismus 16. Xerostomia has been well docu-
mented in patients treated with chemotherapy and / or RT 17. Some studies have
Trismus in oropharyngeal cancer patients
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Poor scores of trismus related QoL T1 T2 T3 T4
H&N35* opening mouth 8% (1/13)
15% 
(3/20)
14% 
(3/21)
100% 
(2/2)
H&N35* pain in jaw 0% (0/12)
5% 
(1/19)
5% 
(1/21)
100% 
(2/2)
Table 3: Percentage of patients scoring poor scores in trismus related QoL questions between 
T classification. *EORTC (European Organisation for Research and Treatment of Cancer) 
Head & Neck cancer module.
reported on trismus 4,6,9,18; however few studies examined trismus in relation to the 
location of the primary tumor site and dose, which is the purpose of the present 
analysis. 
Traditionally, radiation-induced trismus is treated with mobilization exercises using 
mechanical appliances and/or by hyperbaric oxygen, or oral medications, such as 
pentoxifylline 1,19,20. Sometimes fibrotic tissue is released by surgical excision to ease 
symptoms 21. Buchbinder et al. compared three techniques of intervention on trismus 
22,23. The authors claim that TheraBite® (Atos Medical AB, Sweden) increases the
 
Poor 50% Good 50%
Trismus related Qol P-value N Mean id (mm) Range N
Mean id 
(mm) Range
H&N35, opening mouth 7 32 10-45 35 40,6 25-65
H&N35, speech 3 40 35-45 39 39,1 10-65
H&N35, pain in jaw 0.03 2 26.5 25-28 39 39,8 10-65
H&N35, social eating 5 28.4 10-44 35 40,7 25-65
PSS, eating in public 10 33.3 10-45 33 41,0 25-65
PSS, understandability 
of speech 1 42 42 42 39,2 10-65
PSS, normalcy of diet 13 34.5 10-50 30 41,3 29-65
Chart 0.0001 2 27.5 27-28 41 39,8 10-65
Last follow-up 6 30.2 10-45 37 40,7 25-65
Total, mean 32.7 40,2
Table 4: Inter-incisal distances (id) for patients having limitations ‘opening mouth’ at the time 
of last follow-up. This was measured in patients having trismus according chart review and 
for those patients scoring poor scores in trismus related QoL questions vs. good scores in 
‘opening mouth’.
Abbreviations: H&N35, EORTC (European Organisation for Research and Treatment of Can-
cer) Head & Neck cancer module; PSS, Performance Status Scale. 
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P-Values Left 
mas-
seter
Right 
mas-
seter
Left 
ptery-
goid
Right 
ptery-
goid
Left co-
ronoid
Right 
coro-
noid
Left 
man-
dibular 
condyl
Right 
man-
dibular 
condyl
Inter-incisal  distance
Follow-up clinic 0.04 0.02 0.03 0.03
H&N35, opening mouth 0.02 0.02 0.03 0.03
H&N35, pain in jaw
H&N35, speech 0.01 0.049
H&N35, social eating
PSS, Understandability 
of speech
Table 5: P-values of dose-response relationships stratified per muscular sructure and com-
plaint category of the different trismus related QoL questionnaires. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 3: Relationship between the probability of having complaints of ‘opening mouth’ (Eu-
ropean Organisation for Research and Treatment of Cancer Head & Neck cancer module ) 
by increasing the dose, for Brachytherapy (BT) and No Brachytherapy (No BT) treatment, 
respectively.
‘opening mouth’ substantially more than exercises with wooden tongue blade or 
manual stretching. Trismus has a significant impact on the quality of life of head 
and neck cancer patients 1. The incidence of radiation-induced trismus like other 
radiation-induced late complications, depends on factors such as the total dose 
of radiation, fractionation, overall treatment time and treatment techniques. By the 
group of Dijkstra et al., a reduced opening mouth of 18% (sd: 17%) was found in 
patients treated by RT involving the structures of the temporomandibular joint and /
or pterygoid muscles 6. The authors found a cut-off point of ≤ 35 mm for the inter-
Right pterygoid muscle dose (Gy)
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incisal distance 24. They concluded that the increase in opening mouth by exercise 
is substantially more in non-cancer patients as opposed to patients with trismus 
related to cancer of the head and neck. 25. Kent et al. showed a high prevalence of 
trismus (47%) in cancer patients following > 55 Gy to the masseter and/or pterygoid 
muscles 26. In a previously reported Rotterdam series, the incidence was only 1% 
for the treatment group EBRT + BT, but for the surgery + post-operative RT series 
it amounted to 21%, demonstrating substantial the interplay between surgery and 
radiation dose 9. Finally, Jen et al. reported in nasopharyngeal carcinoma patients 
a trismus incidence of 14%-17% 27. The population studied is based on 81 patients 
diagnosed with scc of the oropharynx and treated curatively between 1999-2005, 
in a single institution, by highly conformal radiation therapy techniques (3DCRT or 
IMRT). According to the notes in the charts, 3 (4%) patients experienced trismus. 
Anatomical structures involved in swallowing were defined (masseter-, temporalis-, 
pterygoid muscle, condyl- and coronoid processus), and the mean dose in each 
individual structure computed. Finally the probability of trismus measured by quality 
of life instruments, being performance status scale (PSS) scores according to List 28 
and the EORTC Head and Neck 35 (H&N35) 29-31, was related to the mean dose in 
the masticatory structures. Based on the - trismus related - QoL questions, a num-
ber of parameters seemed to be more often associated with trismus. For example, 
the less favorable parameters in this regard were tumors located in the BOT, and 
treatment by 3DCRT, cCHT, non-BT and high dose raditaion. None of these factors, 
however, were found to be significant (table 3). 
The mean measured inter-incisal distance was 39 mm (range 10 mm to 65 mm). In 
the group of patients with a poor - trismus related - QoL, being defined as having 
Poor scores - trismus
related - QoL
Unilateral,
No. of patients, (%)
Bilateral, 
No. of patients, (%)
p-
value
H&N35, Opening Mouth 0/18 (0%) 9/37 (24%) 0.02
H&N35, Pain in Jaw 0/18 (0%) 4/36 (11%)
H&N35, Speech 0/18 (0%) 3/37 (8%)
H&N35, Social Eating 0/18 (0%) 7/35 (20%)
PSS, Eating in Public 1/18 (6%) 10/38 (26%)
PSS, Understandability of 
Speech 0/18 (0%) 1/38 (3%)
PSS, Normalcy of Diet 3/18 (17%) 14/38 (37%)
Chart 1/26 (4%) 2/54 (4%)
Last Follow-up 0/18 (0%) 6/37 (16%)
 
Table 6: Percentages of poor score regarding trismus related QoL questionnaires between 
unilateral and bilateral irradiation. 
Abbreviations: H&N35, EORTC (European Organisation for Research and Treatment of Can-
cer) Head & Neck cancer module; PSS, Performance Status Scale. 
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a score of less or equal than 50%, the mean id’s were less (33 mm) as opposed to 
those patients with a good QoL score (40 mm) (table 4). However, only the H&N35 
question ‘pain in jaw’ was significant. Similar conclusions about the id can be drawn 
from the chart review (and last follow-up clinic), with chart review showing a signifi-
cant difference in id (28 vs. 40 mm) between patients having trismus or no trismus 
(p=0,0001) (table 4). Obviously the data set (including subgroups) contains only 
small numbers of patients and one therefore has to be prudent with drawing any 
conclusions. Table 5 illustrates for some of the structures of the mastication ap-
paratus a significant relationship with a particular QoL question and dose. In this 
respect, by univariate analysis, a significant relationship was found between dose 
in the masseter muscles as well as the pterygoid muscles and coronoid bone and 
trismus complaints (table 5). In the multivariate analysis, BT was the only remaining 
significant factor. For those patients of whom the trismus related muscles were ir-
radiated bilaterally, a significant increase of the probability of trismus was observed 
but only with regard to the item ‘opening mouth’ of the EORTC H&N35 questionnaire 
(p=0.02) (table 6). 
conclusions
This paper focuses on dose-effect relationships for trismus related structures of the 
mastication apparatus. Figure 3 shows the relationship between the probability of 
having complaints of trismus with dose for BT and non-BT treated patients, res-
pectively. For example, for every additional 10 Gy in the pterygoid muscle, after a 
dose of 40 Gy, an increase of probability of trismus of 24% was observed. Given the 
retrospective nature of this study, we recognize the limitations of its findings. The 
small sample represents however a carefully selected group of patients with base 
of tongue and tonsillar fossa tumors treated by highly conformal RT techniques. 
Currently having the availability of IMRT techniques, one may decrease the dose 
received by putting constraints on masseter and pterygoid muscles. This is shown, 
for example, by figure 4 for the masseter muscle. Future studies should be designed 
in a prospective manner and focused on larger patient populations. 
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Figure 4: Dose volume histogram for the left masseter muscle with and  without a constraint 
in the left masseter muscle.
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AbstrAct
Background: Interstitial brachytherapy (IBT) is a highly conformal radiation the-
rapy technique when treating cancer of the Head and Neck; it is used as a boost 
technique integrated in an organ function preservation protocol, with the oropharynx 
being a site of preference. 
Material & Methods: The dose of radiation can be accurately delivered to the 
target by a radioactive source, dwelling in the implanted afterloading catheters con-
nected to an afterloading machine. The prescribed dose (dwell times and source 
positions) is delivered after 3D dose calculation, using computerized (optimization) 
algorithms. Characteristics as steep dose fall-off and small margins make the dose 
distribution highly conformal and confine to the irradiated volume. Thus it allows for 
delivering high doses of radiation to the target (with intrinsic dose escalation), while 
at the same time sparing the critical surrounding normal tissues. Moreover, being 
able at present to sum the dose of the external beam (46/2 Gy) to the dose of the 
IBT, biological treatment planning is within reach. 
Results & Conclusions:  For oropharyngeal cancer boosted by IBT, at 10-years 
an excellent local control rate of 90% was observed. However, lack of training & clini-
cal experience, only suitable for relatively small volume disease, invasiveness of the 
procedure and difficult logistics (operating room) can be, albeit rarely, conditionally 
limiting. Late side effects (e.g. soft tissue necrosis) are not totally negligible either, 
but if present in the great majority of cases spontaneously healing will occur. When 
comparing IBT to other forms of conformal radiation, such as stereotactic radiation 
therapy, Cyberknife and IMRT, the quality of life, as scored by the patient responses 
to the EORTC H&N35 questionnaires, in general speak in favor of IBT.
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introduction
Major improvements in surgical- and radiation therapy (RT) techniques have come 
about; overall survival (OS), however, showed little change. That is, typically pa-
tients with tumors of the head and neck present in more than 50% with locally advan-
ced disease at the time of diagnosis, have local control rates of about 60-80% and 
a 5-years OS of approximately 30-50%, due to high incidence of secondary tumors 
originating from the aerodigestive tract (2nd tumors actuarial increase 3% annually). 
Substantially enhanced morbidity during and immediately after treatment, in particu-
lar in the fragile elderly, and less compliance due to excessive co-morbidity because 
of alcohol and tobacco abuse, might be reasons why some of these patients do not 
benefit (in terms of improvement of overall survival) from some of the proposed and 
promising new treatment approaches 1. Also the late occurring side-effects, such as 
xerostomia, dysphagia, pain and fibrosis (e.g. trismus) give rise for concern. That is, 
some of these (interrelated) side effects can have a significant impact on the quality 
of life (QoL) 2. This again might be a reason for being somewhat reluctant in enrolling 
patients in aggressive but promising protocols. In trying to improve one’s result, that 
is in order to investigate new treatment strategies, a proper balance must exist bet-
ween tumor response and treatment related acute- and late morbidity as opposed to 
the associated risk of non compliance. 
We have opted over many years for IMRT with moderate acceleration, a treatment 
strategy which, according to a large meta-analysis, is very beneficial. In fact, it can 
be given without any enhancement of (late) side effects, and with only a minimally in-
creased acute reaction 3. For the external beam radiotherapy (EBRT) part (46/2 Gy) 
of the protocol, we have used as of the year 2000, IMRT as the treatment technique 
of preference. Boost doses to the primary tumor were given, if technically feasible, 
by means of high-dose-rate interstitial brachytherapy (IBT), thus like the EBRT in 
an accelerated fashion. As with IBT in general, only limited sized tumors (T1-3) are 
eligible for an IBT boost. If IBT is not feasible, IMRT and (in case of T3,T4 disease) 
concomitant chemotherapy is applied. In conclusion, this chapter is on dose accele-
ration (majority of patients receiving 6 fractions of IMRT / week; first series to a total 
dose of 46 Gy/2); dose escalation (majority treated by HDR-IBT), and on sparing 
(IMRT; HDR-IBT). It will focus on issues such as local & regional control, survival, 
early- and late side effects, and quality of life (QoL) after primary radiation therapy by 
EBRT and IRT (boost) treatment. To note is the significant role BT can play in case 
of persistent disease 4 with regard to local control and overall survival (80% complete 
response to brachytherapy) after previous definitive external beam radiotherapy or 
in case of a recurrence after previous RT 5,6,7. Results are frequently reported depen-
dent on volume of the (persistent, recurrent) disease, previously applied dose fracti-
onation, interval between both treatment and site. For example, the most rewarding 
site seems to be cancer of the nasopharynx. Although it has been shown that BT can 
play substantial role in these cases, we will not discuss the literature on this subject 
in detail. Suffice to summarize in general variable response rates were observed 
(20-80%) with only limited or no survival benefit 5-7.
Interstitial radiation therapy in cancer of the oropharynx and oral cavity
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Historical Perspective Brachytherapy 
In many of the classical handbooks on radiation therapy, as well as in the current 
literature, one can find excellent reviews on low- and high dose rate brachytherapy 
8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24. The history of BT dates back to the beginning of the 
20th century, with the first BT procedures being performed using radium-226 need-
les. Alexander Graham Bell, the inventor of the telephone, suggested in 1901 to 
destroy a tumor “by inserting radioactive needles in the heart of the cancer”, a first 
example of interstitial radiation therapy. Brachytherapy (brachy = Greek for short) is 
a treatment modality in which the tumor is irradiated by positioning the radioactive 
sources very close to the target surface (surface mould type), in naturally existing 
cavities of the body (endocavitary type) or in afterloading catheters implanted in the 
to be irradiated tissue (interstitial type). In recent times many artificial radionuclides 
such as I-125 and Ir-192 have become available and are used for example in the 
treatment of cancer of the head and neck. The French developed the so-called Pa-
ris system for LDR dosimetry purposes, that is, for parallel-equidistant sources the 
system recommends specifying the dose of the implant at 85% of the average dose 
in the basal dose points (local minima). Currently a similar type of dose prescrip-
tion is used for high-dose rate (HDR) volume implants, such as the implant of the 
base of tongue (BOT), even though the sources may not be totally equidistant. Also 
computerized afterloading devices, supported by sophisticated 3D treatment-plan-
ning software with optimization capabilities became available. Finally, the concept 
of HDR versus pulsed-dose rate (PDR; in principle mimicking LDR by using many 
small fractions at small intervals) was launched (table 1). More recently a renewed 
interest has emerged in being able to sum the doses delivered by EBRT and BT (in 
this chapter an example will be presented). This way biological treatment planning 
comes within reach. 
Dose Rate Specifications
LDR 0.4 – 2 Gy / hour
MDR 2-12 Gy / hour
HDR > 12 Gy / hour
Fractionated HDR Erasmus MC day-time schedule. First and last fraction 4 
Gy, in between 4 fractions of 3 Gy, maximum 2 fractions 
per day, interval 6 hours. No radiation in weekend.
Pulsed-Dose-Rate Erasmus MC 24 hour schedule. First and last fraction 2 
Gy, in between 18 fractions of 1 Gy, maximum 8 fracti-
ons of 1 Gy, interval 3 hours. Continuation of BT over the 
weekend.
Table 1:  ose rate categories, taken from the literature and from the Erasmus MC proto-
cols (PDR, fr.HDR). Fr.HDR: Fractionated HDR is given in fraction sizes of 3-4 Gy by con-
necting the afterloading tubes to microSelectron HDR (source strength 370 MBq). In case of 
PDR, fraction sizes of 1-2 Gy are being delivered by microSelectron PDR (source strength 
37 MBq).
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Brachytherapy Protocol Evolution
From the beginning it was realized that BT can be used routinely as a very con-
formal type of treatment, particularly for cancer located in the midline. Ob-
vious examples are endocavitary boosts in cancers in the nasopharynx, 
IBT as a boost for cancer in the oropharynx, oral cavity, and in general for 
small volume disease in case of re-irradiation or in postoperative irradiation
of the neck. In the Erasmus MC we initiated a treatment protocol implementing the 
use of IBT in 1991; Over the years a few changes were introduced because of impor-
tant biological- and/or technical developments at the time, such as the introduction 
of IMRT, accelerated RT (6 fractions per week), and concomitant chemotherapy (for 
advanced T3,T4 tumors only) 25.
In the course of time, in the Erasmus MC, the preferred treatment for oral cavity tu-
mors was argued to be surgery rather than IMRT 20,26. This is partly due to the ease 
of surgical access and/or feasibility of reconstruction after resection of these tumors. 
Also in favor of surgery are the facts that this treatment is frequently a one-time type 
of treatment procedure (surgery) and the notion that IBT in the oral cavity is being 
associated a relatively high risk of serious complications (osteoradionecrosis) 27. 
For oropharyngeal tumors, the principle therapy in the Erasmus MC is primary RT by 
IMRT to the neck and primary cancer to a dose of 46 Gy followed by a neck dissec-
tion in case of the neck containing positive lymph nodes and a boost to the primary 
by HDR-IBT. Finally, the principles underlying the BT protocol as designed in 1991 
have been strictly adhered to in general.
However, at the time a number of patients were found to be non-eligible for IBT, due 
to e.g. medical reasons (medically unfit to undergo invasive procedures), or because 
of tumors with deep parapharyngeal extension, or (albeit rare) simply because of 
patient refusal. These patients would be offered surgery to the primary (and neck), 
or a boost to the primary tumor by IMRT. Currently, however, if brachytherapy is not 
feasible, they are offered as a second-line of boost treatment a Cyberknife (CBK) 
boost. The CBK, a non-invasive stereotactic - robotic - linear accelerator, was instal-
led in 2005 in the department of RT in the Erasmus MC. The dose fractionation of the 
CBK boost protocol is 3 times 5.5 Gy, with the dose prescribed to the 80% isodose 
line. The boost volume is based on the original tumor mass, only with a PTV margin 
of 3 mm. Treatment policy regarding the neck remained the same, except that in N+ 
cases the proposed ND was planned after completion of the CBK boost (in order not 
to have too large a split between the IMRT series and the CBK boost) (figure 1). 
Brachytherapy Techniques 
All oropharyngeal tumors are jointly seen by the H&N surgeon and radiation onco-
logist with the patient under general anaesthesia. Using clinical information, pan-
endoscopy, CT/MRI of the primary and neck, biopsy from the primary tumor and 
FNAC (fine needle aspiration cytology) of the node(s) and placing the radiopaque 
markers, patients are staged 28,29. That is, at the time of the examination, markers 
are placed at the boundaries of what we believe to be the microscopic extensions 
(CTV) of the primary tumor. With the clinical information of the marker positions and 
on the images of the tumor (CT/MRI) combined, the primary tumor is delineated on a 
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treatment planning-CT. The BT techniques that are eluded to in this section in great 
detail, are the typical implants of primary cancers in the oropharynx, that is the single 
plane tonsillar fossa (TF) and/or soft palate (SP) implant, and the volume implant of 
the base of tongue (BOT) or combinations of these. IBT of oral cavity tumors (e.g. 
mouth, cheek, oral tongue etc.) are certainly feasible but in our institution (Erasmus 
MC) are in “competition” with surgery, and as a consequence less often executed.
Figure 1: In the course of time changes have been introduced: First around 1996 accelerated 
fractionation to a total dose of 46 Gy was introduced (for details see legend of figure 2). As of 
2000 all primary cancers were treated by IMRT. In later years, for some of the very advanced 
T3/T4 cancers, concomitant chemotherapy was added. Treatment policy regarding neck dis-
section and implant primary tumor remained the same. In 2008 the Cyberknife was used for 
boosting the primary tumor in case IBT was not feasible (see text).
Patient Intake
RWHHT / Joint Clinic
N+?
Tonsillar Fossa /
Soft Palate / Base of Tongue
(Oropharynx)
no
Staging
Biopsy, PA report / revision, 
Examination under anesthesia, 
Ultra Sound Fine Needle Aspiration, 
CT, MRI, PET, Surgical report
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CURATIVE PROTOCOL
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Cyberknife
3 * 5.5 Gy
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Brachytherapy Techniques Oral Cavity
For IBT of cancer of the oral cavity, in general, one is introducing Ir-192 source 
“lines” in parallel-opposed looping catheters covering the CTV of the primary tu-
mor. Besides this arching technique, single plane in practice are frequently used. 
Basically simple - straightforward - techniques. The preferred spacing between the 
source “lines” is approximately 0.5-0.7cm. Care should be taken to maintain strict 
parallelism of the sources and lead protection at the inner side mandible of at least 
one HVL (half value layer) should be provided at the time of the irradiation in order 
to prevent osteoradionecrosis (ORN) to occur. Because of easy access to surgery of 
these small oral cavity tumors, and still a relatively high risk of ORN when using IBT, 
implanting these cancers is not routinely being performed in Erasmus MC (anymore). 
Moreover, the necessary lead protection of the mandible per se leaves sometimes 
just too limited a space for the afterloading catheters (sources) to be implanted. With 
regard to the oral cavity, section V of this chapter will mainly focus on and illustrate 
some of the results as reported in the literature. 
Brachytherapy Technique TF and/or SP
With regard to the TF and/or SP tumors: these sites are often difficult to accurately 
depict on CT or MRI images. At the time of the brachytherapy procedure, the (resi-
dual) tumor, as well as the boundaries of CTV can be clearly seen and thus accura-
tely delineated. In general the implant, as opposed to IMRT, is thus more “on target”, 
has smaller margins (no PTV margin) and as a consequence the irradiated volume 
is thus smaller and more conformal (see also figure 2)16,29. With regard to the proto-
col; first, an IMRT treatment plan of the primary tumor and neck is generated (CTV 
margin 5 mm, PTV margin 5 mm) and applied using an accelerated fractionation 
scheme to a total dose of 46/2 Gy. Afterloading tubes (2-3) are then implanted in the 
TF and SP approximately 1 (-2) week(s) after completion of the IMRT. Markers are 
implanted at the boundary of the CTV (CTV can sometimes be determined by the 
demarcating mucositis (after the first series of IMRT [46 Gy] has been applied). No 
PTV margin is needed in case of IBT, since the tumor is moving with the catheters in 
situ. The dose is prescribed at a distance of 5mm or 7.5mm of the central plane. The 
3D dose distribution plan is generated using also dose point optimization. A neck 
dissection (ND) is performed in case of a N+ neck. Whether the contralateral neck is 
to be irradiated electively is still subject to debate. Our data suggest that this should 
only be done in case of infiltration of the primary tumor in the BOT or in case the SP 
tumor-infiltration extends over the midline 29 (figures 3-6).
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Figure 2: The treated volume of a tonsillar fossa and soft palate tumor with a delineated PTV 
using a margin of 3 mm in case of a Cyberknife treatment. For a similar tumor treated by bra-
chytherapy or the IMRT, the margin for PTV is 0 mm or 5 mm, respectively. Using the different 
margins as discussed in the text, the right panel of this figure displays the consequences for 
the irradiated volume of a tonsillar fossa tumor radiated either by brachytherapy (CTV), Cy-
berknife (PTV) or IMRT (PTV).
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Figure 3: Schematic diagram of implant techniques (routes for the afterloading catheters to 
cover the target) in case of tumors sitting in the TF, SP, or both.
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Figure 4: Home made instruments to inject marker seeds to demarcate the clinical target 
volume.
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Dose prescription 0.5-0.75 cm
Figure 5: Afterloading catheters running submucosally after having been implanted according 
to one of the techniques shown in figure 4.
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Uvula
MS
Virtual demarcation line (based on ms)
Figure 6: Dose distribution TF tumor with extension into the SP. Note marker seed position 
demarcating the boundary of the CTV. 
Brachytherapy Technique BOT
Another frequently performed implant technique is the volume implant of the BOT 
originally described and pioneered as a LDR technique by Vikram in 1981 30,31,15,13. 
In general 3 afterloading catheters are implanted by introducing the afterloading 
(slightly curved) needles just above or beneath the hyoid bone (depending on the 
location of the primary tumor), therewith entering the oropharyngeal air cavity just 
posteriorly /caudal to the primary BOT tumor. These catheters run over the dorsum 
of the tongue and exit through the cheek (figures 7 & 8). Another 6 catheters are in-
troduced somewhat more ventrally; each dorsum running catheter is then connected 
with specially designed sliding buttons to 2 of these vertical /ventral catheters, with 
1 cm spacing between the sliding buttons. This way, three planes are constructed, 
each consisting of 3 catheters; that is, one central plane and two lateral sagital pla-
nes. After geometrical optimization a 3D dose plan is generated. The dose of the 
implant is specified at 85% of the average dose in the basal dose points (local mi-
nima), quite similar to the Paris system. For safety precautions (e.g. bleed at the time 
of removal of the implant), a tracheotomy is sometimes performed. In case of small, 
lateralized tumors in the BOT, we sometimes refrain from implant the whole of the 
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BOT (as was routinely done in the past), but in stead (boost) the residual or primary 
tumor mass only (CTV margin inclusive). Both necks are irradiated to 46/2 Gy in an 
accelerated fashion by means of IMRT. In case of N+ disease, a ND and an implant 
of the primary tumor is performed in the same session (figures 9&10).
Figure 7: View of patient with BOT implant. 
 
results
Results Cancer in the Oral Cavity 
Many papers have been published on interstitial brachytherapy of primary can
cers in the head and neck, the majority being classical papers from the LDR 
era on cancers in the oral cavity and oropharynx 32,33,34,35,19,26,36,37,38,39. Some 
of the outcome data on local control have been summarized in table 2 (oral ca-
vity tumors) and table 3 (oropharyngeal tumors). Furthermore, the references 
provided in this chapter enables one to get an in-depth view on the good results with 
IBT in terms of local- and regional control, disease free survival and overall survival. 
Given the reasons presented before (see section IV), the oral cavity experience 
as presented in the literature can summarized as follows: At 5-years the LC varies 
between 36% - 93%, and the OS from 8 - 69% (Table 2). Importantly, one of the few 
randomized studies in brachytherapy is on mobile tongue cancer and was published 
by the Japanese36; showed no significant difference for mobile tongue cancer treated 
with LDR versus fractionated HDR. This was true for LC (84% vs. 87%) and cause 
specific survival (CSS) (86% vs. 88%) 36. 
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Marker seed deepest point
Figure 8: Dorsum of the tongue running afterloading catheter connected to two more ventrally 
positioned afterloading catheters in same sagital plane. Note specially constructed sliding 
(connecting) button.
  
Figure 9: Dose distribution of BOT implant after geometrical optimization. Note marker 
seeds.
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Figure 10: Tumor in BOT with extensions into TF and partially in SP. Basically it is a complex 
implant combining the dose distributions as shown in figure 6 & figure 9. This type of implant 
is preferably done under direct vision and would be difficult to perform by CT guidance.
Results Cancer in the Oropharynx
To investigate the results of using a combination of EBRT or IMRT (46/2 Gy) and 
LDR- or HDR-IBT (boost), we first analyzed the data of our institution. From 1991 
to 2005, 336 oropharyngeal cancer patients were treated non-surgically for the 
primary cancer at the Erasmus MC, Rotterdam); at 5-years an actuarial LC rate 
for BT vs. non-BT was 84% vs. 60% (P< 0.05), DFS of 59% vs. 43% (P<0.05), 
and OS of 64% vs. 39% (P<0.05) was found. Apparently, the use of IBT seems 
to be of benefit, when considering LC, RC, DFS and OS 16. From a multivariate 
analysis, it was found that BT and the time period (i.e. before or after the year 
2000), are of significant influence on local control. 
Piccirillo and Vlahiotis 40 reported on the co-morbidity being of significant influence 
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in outcome of treatment and prognosis. Similar experiences have been reported by 
others. Mazeron e.g. reported in 1988 and 1989 his LDR experience with IBT for 
T1,T2 cancers in the TF and/or SF; at 5 years a local control of 85%, regional con-
trol of 97% (88% for N1-3 disease) 41.  Also, Pernot et al. (1996) obtained 90% LC 
with T1T2N0 TF/SP tumors and 86% in case of T1T2N1-3 using an LDR-IBT boost 
20. Esche9 reported on 43 patients with tumors in SP and uvula. LC was again high 
(92%) with OS of only 64% at 5-years, emphasizing in his paper the force of mortality 
of aerodigestive secondary tumors. Harrison reported excellent LC rates using HDR-
IBT volume implants, a technique first pioneered by Vikram 30,31. A 5-year LC, DFS 
and OS of 89%, 80% and 86% was published. Similar observations were made by
van de Pol et al 21; data were published in 2004 describing the Rotterdam results of 
T3/T4 BOT cancer treated by IBT as opposed to BOT cancer treated with surgery 
and PORT (VUmc, Amsterdam). The local failure at 5-years were 37% and 9%, for 
the IBT-series as opposed to the surgical series. The BT cases were non-selected; 
in fact some of these patients we would now even consider palliation. Thus, not 
unexpectedly, a lesser control for the IBT was found considering Rotterdam. 
However, analyzing the data in more detail, the overall survival was not significantly 
different (median 2.5 years vs. 2.9 years, respectively [p = 0.47]. Moreover, the 
quality of life was significantly better for the IBT patients (see next paragraph) treated 
in Rotterdam.
First Author N Primary, Boost or  PO BT
LC 
5-yrs %
DFS  
5-yrs %
OS
5-yrs %
Lefebvre, 1994 429 53-91
Wadsley, 2003 24 Primary BT 76 91 2-yrs 81 2-yrs
Mazeron, 1990 117 Primary BT 50-86 8.-52
Chu, 1973 83-94
Wendt, 1995 103 Primary BT & Boost 65-92 2-yrs
Mendenhall, 
1989 31 Primary BT & Boost 40-75
Inoue, 2001 51 Primary BT 84-87
Benk, 1990 110 Primary BT & Boost 36-88 24-42
Bailet,1982 966 53-91
Decroix, 1981 602 Primary BT & Boost 76 48 36
Pernot, 1994 448 Primary BT & Boost 49-93 25-69
Table 2: Overview of some of the published data on local control (LC), disease free survival 
(DFS) and overall survival (OS) for cancer in the oral cavity.
A: Tonsillar Fossa / Soft Palate
First Author N T1/T2,%
T3/T4,
%
LC T1/T2,
5-Yrs %
LC T3/T4, 
5-Yrs % 
DFS,
5-Yrs %
OS,
5-Yrs %
Pernot, 1992 277 57 76 5-yrs 51
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Puthawala, 1985 80 24 84
LRC Stage 
I: 3/3
LRC Stage 
III: 85
LRC Stage II: 
100
LRC Stage 
IV: 56
Pernot, 1994 361 1 T1: 80,T2: 71
T3: 65,
T4: 58 CSS: 63 53
LRC: 75
Levendag, 2004 104 77 T1-T3: 88 57 67
Esche, 1988 43 T1: 34/43 92 CSS: 64 37
Mazeron, 1993 100 94 71 53
Peiffert, 1994 73 65/73 2/73 T1: 80,T2: 67 CSS: 64 30
B: Base of Tongue
First Author N T1/T2,%
T3/T4,
%
N0,
%
LC T1/T2,
5-Yrs %
LC T3/T4, 
5-Yrs % 
DFS,
5-Yrs %
OS,
5-Yrs %
Harrison, 1997 68 3 (T4) T1: 87, T2: 93 T3: 82, T4: 100
T1: 88, T2: 
93, T3: 82 87
Puthawala, 
1988 70 17 (T4)
T1: 100, T2: 
88
T3: 75, T4: 
67 67 35
Barrett, 2004 20 35 10 2-Yrs 33
Takacsi-Nagy, 
2004 37 81 19 100 60 52 46
Karakoyun-
Celik, 2005 40 54 30 LC: T1-4: 78 54 62
Pol, 2004 30 67 (T4) 30 LC 63 45 40
Gibs, 2003 41 49 32 14 20 79 66
Brunin, 1999 216 61 30 T1: 93, T2: 66 T3: 45. T4: 18
CSS I-IV: 
63-23 27
Crook, 1988 48 100 T1: 85, T2: 71 50
Hoffstetter, 
1996 136 55/136
N0/
N1:81 T1: 86, T2: 69 T3: 64
Horwitz, 1996 20 11/20 9/20 10/11 T4: 8/9 72
Housset, 1987 29 100 T1: 6/6, T2: 74 30.5
Lusinchi, 1989 108 57/108 T3:51/108 T1: 85, T2: 50 T3: 69 26
Table 3: Overview of some of the published data on local control (LC), disease free survival 
(DFS) and overall survival (OS) for cancer in the Tonsillar Fossa and Soft Palate (SP and/or 
SP), and cancer in the Base of Tongue (BOT). 
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Side Effects and Quality of Life
Acute side-effects
It has been argued that many studies insufficiently address the enhanced toxicity 
and the compliance of patients during and immediately after treatment for some of 
the currently used aggressive treatment regimes. Although acute side-effects in can-
cer of the oral cavity are certainly not negligible, it appears hard to produce reliable 
data on this issue with respect to this type of cancer if solely based on the literature. 
This section therefore deals only with the acute side effects of patients with cancer in 
the oropharynx based on our own (peer reviewed) experience. It is evident from the 
charts that acute morbidity, leading to non-compliance, is extremely low. Obviously, 
this is due to the fact that the large irradiated volume is treated by a slightly acce-
lerated fractionation schedule, and only taken to a dose of 46/2 Gy. Moreover, the 
implant is done after 1-2 weeks at the time when the side effects, experienced from 
the external beam irradiation (IMRT) part of the treatment, are already partly sub-
dued. The acute side-effects typically seen in IBT patients are mucositis grade 3 (- 
4), maximally at the site of the implant during the time of irradiation, and xerostomia; 
soft tissue necrosis (“ulceration”, grade 3 and 4) and pain, leading to swallowing 
problems, are typically in case of IBT experienced maximally between 3-6 months 
post treatment. Most frequently there is a good healing tendency, with spontaneous 
healing. If soft tissue necrosis and/or pain is persistent, patients are subjected to a 
course of hyperbaric oxygen (6 weeks; 30 sessions) with often good results 42.
Late side-effects
From the charts of 336 oropharyngeal cancer patients we found that patients 
treated according to our IBT-protocol, do experience late side-effects such as 
mucositis (32%), xerostomia (15%*), dysphagia (31%), pain (22%) and osteo-
radionecrosis (3%). Table 4 43,13,16 summarizes some results published in the li-
terature. Most of these typically radiation induced late side-effects, in particular 
the soft tissue necrosis or ulceration, are self-limiting, that is heal spontaneously 
over a period of a few months. As is suggested by the literature, several of the-
se late occurring side-effects might not only be dose-related, but also asso-
ciated with the quality of the implant 44,45,46,47,48. For that purpose a number of 
physical parameters were analyzed in patients with large implants of the BOT; 
that is, 43 LDR- and 32 optimized fr.HDR/PDR volume implants. These 75 
patients were considered to be a representative sample taken from the database of 
the “oropharyngeal cancer patients” (see section before). The physical pa rameters, 
being defined in table 5, were studied in these rather irregular large volume implants. 
Albeit may be somewhat preliminary, some conclusions can be drawn: 1. It seems 
relevant to study the maximum and minimum doses in the basal dose points. 2. 
The UI and QI are strongly correlated. 3. Probably due to the optimization of the 32
*: Unfortunately, not systemically scored/reported in charts
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First Author N Site Incidence %
Levendag, 2004 104 All Late effect: mucosa
Late effect: salivary glands
Late effect: dysphagia
Late effect: pain
Late effect: trismus
41/104
6/104
21/104
21/104
1/104
30
6
20
20
1
Harrison, 1998 68 BOT Fatal complicatons 3
Gibbs, 2003 41 BOT Soft-tissue necrosis/ulceeraton
Osteoradionecrosi
Gastrostomy
3/41
2/41
1/41
7.3
4.8
2.4
Table 4: Late complications after oropharyngeal cancer radiation treatment, BT Boost.
Definitions of physical parameters in the base-of-tongue study
 Parameter    Definition
Dbase85 85% of the average dose in all basal dose points 45
Db_min Lowest dose in any of the basal dose points
Db_max Highest dose in any of the basal dose points
Sd_dbas
Standard deviation in the doses over all basal dose points; a measu-
re of the (in)homogeneity of the dose over all basal dose points (and 
thus the implant)
Vdis100 
Total volume (distributed, so not necessarily contiguous) receiving 
at least the prescribed dose; also called treated volume according 
to ICRU 58 45
Vdis150 Total volume (distributed, so not necessarily contiguous) receiving at least 150% of the prescribed dose 
The ratio Vdis150/ Vdis100 is a measure of the dose inhomogeneity 
(= DNR)  45.
UI
Uniformity index derived from natural DVH (according to Anderson 
44); a measure of the dose homogeneity taking into account the 
choice of reference isodose in relation to the relatively homogene-
ously irradiated volume
QI
Quality index derived from natural DVH (according to Anderson 44 
and modified by R. van der Laarse);  a measure of the dose homo-
geneity only, without taking into account the choice of the reference 
isodose in relation to the relatively homogeneously irradiated vo-
lume 48
DNR—dose nonuniformity ratio; DVH—dose–volume histogram; ICRU—International Commission on 
Radiation Units and Measurements; QI—quality index.
Table 5: Physical parameters studied in 32 LDR- and 43 fr.HDR/PDR volume implants in 
sample of patients with cancer in the oropharynx. 
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fr.HDR/PDR implants, only relatively small differences between the UI, QI, DNR, 
and the sd of the basal dose of the LDR- as opposed to the same parameters of the 
fr.HDR/PDR base of tongue implants. 
Most striking, no correlation was observed between the responses to the QoL ques-
tionnaires and any of the physical parameters (see next section). In conclusion, 
quality indices are not very useful in daily practice.
Quality of Life
Harrison et al.49 published one of the first reports on QoL for IBT treatment of the 
BOT. It was stated that “most patients achieved excellent functional status and QoL”. 
Moreover, patients in general had no problem with maintaining their employment 
status after primary radiation (fr.HDR boost) for advanced BOT cancer. According 
to Babin et al.50, the “sociability” of individual patients has never been evaluated 
properly. He advocates studying QoL with emphasis in 3 domains: phsycial, psycho-
logical and social symptom domains.
On the other hand, Pourel et al.,51 stated that although health-related QoL is signi-
ficantly impaired in long-term survivors, the focus in treatment option comparisons 
should still be “survival” as being the most relevant endpoint. The group of Pourel 
et al., found no patient-, disease-, or treatment- related factors correlating with the 
swallowing scale and dry mouth items of the European Organization for Research 
and Treatment of Cancer EORTC - H&N35 questionnaire. Hammerlid et al. 52 repor-
ted on a prospective QoL study using the EORTC QLQ-C30 and EORTC H&N35 
questionnaires for patients with oral and pharyngeal carcinoma treated with external 
beam irradiation with or without BT. Most symptoms were at their peak 2 or 3 months 
after the start of treatment. Nutrition and pain were found to be the major problems, 
and, of special interest, as many as 19% to 40% reported psychiatric distress. 
Quality of life - Dysphagia
Dysphagia-related complaints have been the subject of a number of recent publica-
tions 53,54,55,56,57,58,59,60. Poulsen et al. 58 found that a field length greater than 82 mm 
for the second phase of irradiation increased the probability of requiring intervention 
with percutaneous endoscopic gastrostomy or nasogastric tube feeding, that is, 36% 
(> 82 mm) versus 16% (< 82 mm). Manger et al.57 showed that prophylactic enteral 
feeding during RT minimizes average weight loss compared with reactive feeding. 
Caudell et al.53 found a prevalence of 38% for dysphagia; by univariate analysis, the 
primary site, concurrent chemotherapy, RT schedule, and increasing age were signi-
ficantly associated with development of long-term dysphagia. The use of concurrent 
chemotherapy, the primary site, and increasing age remained significant factors on 
multivariate analysis. The authors concluded that adding concurrent chemotherapy 
to RT for locally advanced head and neck cancer resulted in increased and long-time 
present dysphagia. Feng et al.55, Jensen et al.56, Teguh et al.60,59 and Levendag et 
al.2, all were able to demonstrate the presence of significant relationships between 
the dose-volume parameters of structures and objective and subjective measure-
ments of swallowing function and/or aspiration. 
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Rotterdam database patients with cancer of the oropharynx.
Between 1991 and 2005, 458  oropharyngeal cancer patients were treated in a single 
institution by RT (boost), 336 were available for analysis of side-effects. Chart review 
revealed 31% (103 of 336) of patient with ‘severe’ dysphagia (Research Therapy 
Oncology Group grade III and IV). Out of the 336 patients, 188 were treated with 
IBT as a boost.  All patients alive and at least one year NED received three types of 
questionnaires: 1) the EORTC QLQ-C30 and EORTC QLQ-H&N35, which include 
a swallowing scale with four items (problems with swallowing liquid, pureed food, or 
solid food, and aspiration when swallowing) 61; 2) the Performance Status Scale of 
List et al.62, which includes a Normalcy of Diet item; and 3) the M.D. Anderson Dys-
phagia Inventory 63, which consists of 20 questions with global, emotional, functional, 
and physical subscales. By the censor date (January 1, 2006), 155 patients had res-
ponded to the QoL questionnaires. Of these 155 patients, 91 were male and 64 were 
female, and the mean age was 56 years (range, 35-78 years). Primary treatment 
sites were TF/SP (n = 108) and BOT (n = 47). Seventy-seven percent (119 of 155) 
had stage III or IV disease. Of the 155 patients, 107 received a BT boost (TF/SP, 
83; BOT, 24) and 48 received a boost by non-BT techniques (TF/SP, 25; BOT, 23) 
and 59 of 155 (38%) received chemotherapy in a concomitant fashion. We focused 
the data analysis in this review on the late side effects: “swallowing problems” and 
“xerostomia.” 
QoL Responses
(mean scores)
C30
QoL*
H&N35 
Swallowing‡
Brachytherapy (n=111) Boost
IMRT / 3DCRT  (n=52) first series 75 14
Par-Opp (n=59) first series 72 25
Ccyberknife (n=12) Boost
IMRT / 3DCRT (n=12) first series 73 15
Non-BT (n=49) Boost
IMRT / 3DCRT (n=23) first series 71 32
Par-Opp (n=26) first series 60 46
Selected Groups C30QoL
H&N35
Swallowing
MDADI
Physical
MDADI
Functional
MDADI
Emotional
All Patients, CBK excl. (n=160)
BT  (n=111) 74 20 68 78 77
vs. non-BT (n=49) 66 40 50 60 60
p-values n.s. < 0.001 < 0.001 < 0.001 < 0.001
Table 6: Quality of Life and Dysphagia (mean) scores compared byTechnique & Boost-Type.
‡ Problem scale: high score = severe problems.
*  Function scale: high score = good functions.
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Percentages of severe QoL scores for swallowing and dry mouth were lower for IBT 
patients than for non-BT patients (14-25% vs. 32-46% for H&N35 [swallowing] and 
52% vs. 67% for H&N35 [xerostomia]); the outcome of the other questionnaires on
“swallowing problems” (i.e. MDADI, List) are consistent for EORTC H&N 35 QoL 
questionnaires. For more detailed analyses see also table 6. From the univariate 
analysis, one can conclude that the following factors are significant for swallowing-
related problems: IBT, T stage, boost treatment, neck surgery, and neck irradiation. 
In the multivariate analysis, IBT and the dose in the superior constrictor muscle 
remained the only two significant variables. Finally, xerostomia and dysphagia are 
strongly correlated (P < 0.001), as well as the mean dose in the superior and middle 
constrictor muscle with the dry mouth syndrome 60. A steep dose-effect relationship 
was established (figure 11) 64; for the way the calculation was performed in order to 
arrive at this D-E curve, the reader is referred to previous publications by Levendag 
2 and Teguh 60. A 20% increase in complaints per 10 Gy was found after 60 Gy in 
the superior constrictor muscle. 
The tolerance of the swallowing muscles depends to some extent on the treat
ment modality used. In patients who receive BT as boost therapy, dysphagia is 
seen in 14% treated with an average dose of 53 Gy. In contrast, dysphagia was 
seen in 40% of patients treated with EBRT to a mean dose of 68 Gy (figure
11). We speculate that the increase in dysphagia is related to the increase in ir-
radiated volume and radiation dose. Apparently, the IBT side-effects are not totally 
negligible; this could be due the high cumulative dose of radiation, that is the dose of 
IBT plus the dose of the first series of EBRT (IMRT) (46/2 Gy) being delivered to (a 
part of) the swallowing muscle and/or the combination with chemotherapy. However, 
from our data, it seems that patients treated with an IBT-boost still have a better 
Figure 11: Dose-effect relationship swallowing problems measured by the scores obtained 
through responses to QoL questionnaires and the dose received by the swallowing muscles 
(as an example, this is dataset is relevant for the superior constrictor muscle).
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swallowing-related QoL than those receiving IMRT only. This is probably because of 
the steep dose fall-off in case of IBT in part of the swallowing related structure(s). It 
would be of interest to do the same type of analysis in the future in a more precise
way; that is, in stead of roughly summing physically “numbers of Grays”, it would be 
more appropriate to add real dose distributions in the total volume of interest (bio-
logical treatment planning). Because of the work on this issue at our department by 
Vásquez Osorio 65, it will now possible soon to do so in clinic. We expect this type of 
dose summing in combination with a process called  auto-contouring 66, will further 
increase the accuracy of the treatment planning process and therewith hopefully al-
lows for a further improvement of the QoL of our patients. 
conclusion
In conclusion, for oropharyngeal cancer boosted by IBT, at 10-years an excellent 
local control rate of 90% was observed. However lack of training, experience, small 
volume disease, invasiveness and logistics (operating room) can all be, albeit rarely, 
conditionally limiting. (Late) side effects (e.g. soft tissue necrosis) are not totally 
negligible, but if present, are in the great majority of cases spontaneously healing. 
When comparing IBT to other forms of conformal radiation, such as stereotactic ra-
diation therapy, Cyberknife and IMRT, the quality of life, in particular regarding the 
clinically significant problem of dysphagia, speaks in favour of IBT.
Interstitial radiation therapy in cancer of the oropharynx and oral cavity
----------------------------------------------------------------------------------------------
198
..........
References
1.  Overgaard, J. Chemoradiotherapy of head and neck cancer--can the bumble bee fly? 
Radiother.Oncol.  2009 92: 1-3.
2.  Levendag, P. C., Teguh, D. N., Voet, P., Van der, Est H., Noever, I., de Kruijf, W. J., 
Kolkman-Deurloo, I. K., Prevost, J. B., Poll, J., Schmitz, P. I., and Heijmen, B. J. Dys-
phagia disorders in patients with cancer of the oropharynx are significantly affected by 
the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect 
relationship. Radiother.Oncol.  2007 85: 64-73.
3.  Bourhis, J., Overgaard, J., Audry, H., Ang, K. K., Saunders, M., Bernier, J., Horiot, J. 
C., Le Maitre, A., Pajak, T. F., Poulsen, M. G., O'Sullivan, B., Dobrowsky, W., Hliniak, 
A., Skladowski, K., Hay, J. H., Pinto, L. H., Fallai, C., Fu, K. K., Sylvester, R., and Pig-
non, J. P. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a 
meta-analysis. Lancet  2-9-2006 368: 843-854.
4.  Grimard, L., Esche, B., Lamothe, A., and Spaans, J. N. Interstitial brachytherapy in 
the management of persistent head and neck disease after definitive external beam 
radiation therapy. Brachytherapy.  2009 8: 284-289.
5.  Glatzel, M., Buntzel, J., Schroder, D., Kuttner, K., and Frohlich, D. High-dose-rate bra-
chytherapy in the treatment of recurrent and residual head and neck cancer. Laryngos-
cope  2002 112: 1366-1371.
6.  Grimard, L., Esche, B., Lamothe, A., Cygler, J., and Spaans, J. Interstitial low-dose-
rate brachytherapy in the treatment of recurrent head and neck malignancies. Head 
Neck  2006 28: 888-895.
7.  Narayana, A., Cohen, G. N., Zaider, M., Chan, K., Lee, N., Wong, R. J., Boyle, J., 
Shaha, A., Kraus, D., Shah, J., and Zelefsky, M. J. High-dose-rate interstitial bra-
chytherapy in recurrent and previously irradiated head and neck cancers--preliminary 
results. Brachytherapy.  2007 6: 157-163.
8.  Crook, J., Mazeron, J. J., and Marinello, G. Combined external and interstitial implan-
tation for T1 and T2 epidermoid carcinoma of base of tongue: the Creteil experience. 
Int J Radiat Oncol Biol Phys 1988  2006 15: 105-114.
9.  Esche, B. A., Haie, C. M., Gerbaulet, A. P., Eschwege, F., Richard, J. M., and Chassa-
gne, D. Interstitial and external radiotherapy in carcinoma of the soft palate and uvula. 
Int.J.Radiat.Oncol.Biol.Phys.  1988 15: 619-625.
10.  Foote, R. L., Parsons, J. T., Mendenhall, W. M., Million, R. R., Cassisi, N. J., and Strin-
ger, S. P. Is interstitial implantation essential for successful radiotherapeutic treatment 
of base of tongue carcinoma? Int.J.Radiat.Oncol.Biol.Phys.  1990 18: 1293-1298.
11.  Gerbaulet, A., Poetter, R., and Mazeron, J. J. The GEC ESTRO Handbook of bra-
chytherapy 2002; ISBN 90-804532-6. The GEC ESTRO Handbook of brachytherapy 
2002; ISBN 90-804532-6 .
12.  Goffinet, D. R., Fee, W. E., Jr., Wells, J., Austin-Seymour, M., Clarke, D., Mariscal, J. 
M., and Goode, R. L. 192Ir pharyngoepiglottic fold interstitial implants. The key to suc-
cessful treatment of base tongue carcinoma by radiation therapy. Cancer  1-3-1985 
55: 941-948.
13.  Harrison, L. B., Lee, H. J., Pfister, D. G., Kraus, D. H., White, C., Raben, A., Zelefsky, 
M. J., Strong, E. W., and Shah, J. P. Long term results of primary radiotherapy with/
without neck dissection for squamous cell cancer of the base of tongue. Head Neck 
1998 20: 668-673.
14.  Horwitz, E. M., Frazier, A. J., Martinez, A. A., Keidan, R. D., Clarke, D. H., Lacerna, M. 
D., Gustafson, G. S., Heil, E., Dmuchowski, C. F., and Vicini, F. A. Excellent functional 
outcome in patients with squamous cell carcinoma of the base of tongue treated with 
external irradiation and interstitial iodine 125 boost. Cancer  1-9-1996 78: 948-957.
15.  Housset, M., Baillet, F., Dessard-Diana, B., Martin, D., and Miglianico, L. A retrospec-
199
..........
tive study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus 
postoperative radiation, external radiation plus interstitial implantation and external ra-
diation alone. Int.J.Radiat.Oncol.Biol.Phys.  1987 13: 511-516.
16.  Levendag, P., Nijdam, W., Noever, I., Schmitz, P., van de, Pol M., Sipkema, D., Braat, 
C., de Boer, M., and Jansen, P. Brachytherapy versus surgery in carcinoma of tonsillar 
fossa and/or soft palate: late adverse sequelae and performance status: can we be 
more selective and obtain better tissue sparing? Int.J.Radiat.Oncol.Biol.Phys.  1-7-
2004 59: 713-724.
17.  Levendag, P. C., Schmitz, P. I., Jansen, P. P., Senan, S., Eijkenboom, W. M., Sip-
kema, D., Meeuwis, C. A., Kolkman-Deurloo, I. K., and Visser, A. G. Fractionated high-
dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous 
cell carcinoma of the tonsillar fossa and soft palate. Int.J.Radiat.Oncol.Biol.Phys.  1-6-
1997 38: 497-506.
18.  Mazeron, J. J., Marinello, G., Crook, J., Marin, L., Mahot, P., Raynal, M., Calitchi, E., 
Peynegre, R., Ganem, G., Faraldi, M., and . Definitive radiation treatment for early 
stage carcinoma of the soft palate and uvula: the indications for iridium 192 implanta-
tion. Int.J.Radiat.Oncol.Biol.Phys.  1987 13: 1829-1837.
19.  Mazeron, J. J., Crook, J. M., Benck, V., Marinello, G., Martin, M., Raynal, M., Haddad, 
E., Peynegre, R., Le Bourgeois, J. P., Walop, W., and . Iridium 192 implantation of T1 
and T2 carcinomas of the mobile tongue. Int.J.Radiat.Oncol.Biol.Phys.  1990 19: 1369-
1376.
20.  Pernot, M., Hoffstetter, S., Peiffert, D., Aletti, P., Lapeyre, M., Marchal, C., Luporsi, E., 
Bey, P., and Nancy, V. L. Role of interstitial brachytherapy in oral and oropharyngeal 
carcinoma: reflection of a series of 1344 patients treated at the time of initial presenta-
tion. Otolaryngol.Head Neck Surg.  1996 115: 519-526.
21.  van de, Pol M., Levendag, P. C., de Bree, R. R., Franssen, J. H., Smeele, L. E., Nij-
dam, W. M., Jansen, P. P., Meeuwis, C. A., and Leemans, C. R. Radical radiotherapy 
compared with surgery for advanced squamous cell carcinoma of the base of tongue. 
Brachytherapy.  2004 3: 78-86.
22.  Vikram, B. and Hilaris, B. S. A non-looping afterloading technique for interstitial im-
plants of the base of the tongue. Int.J.Radiat.Oncol.Biol.Phys.  1981 7: 419-422.
23.  Vikram, B., Strong, E., Shah, J., Spiro, R., Gerold, F., Sessions, R., and Hilaris, B. A 
non-looping afterloading technique for base of tongue implants: results in the first 20 
patients. Int.J.Radiat.Oncol.Biol.Phys.  1985 11: 1853-1855.
24.  halperin, EC, Perez, CA, and Brady, LW. Perez and Brady's Principles and Practice of 
Radiation Oncology. 2009.
25.  Pignon, J. P., Bourhis, J., Domenge, C., and Designe, L. Chemotherapy added to loco-
regional treatment for head and neck squamous-cell carcinoma: three meta-analyses 
of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemo-
therapy on Head and Neck Cancer. Lancet  18-3-2000 355: 949-955.
26.  Lefebvre, J. L., Coche-Dequeant, B., Buisset, E., Mirabel, X., Van, J. T., and Pre-
vost, B. Management of early oral cavity cancer. Experience of Centre Oscar Lambret. 
Eur.J.Cancer B Oral Oncol.  1994 30B: 216-220.
27.  Lee, I. J., Koom, W. S., Lee, C. G., Kim, Y. B., Yoo, S. W., Chang, Keum K., Kim, G. 
E., Chang, Choi E., and Cha, I. H. Risk Factors and Dose-Effect Relationship for Man-
dibular Osteoradionecrosis in Oral and Oropharyngeal Cancer Patients. Int.J.Radiat.
Oncol.Biol.Phys.  25-3-2009 .
28.  Greene, F. L., Page, D. L., Fleming, I. D., and et al.  AJCC cancer staging manual, 6th 
edition. New York: Springer. 2006 .
29.  Levendag, PC, Al-Mamgani, A, and Teguh, DN. Contouring in Head & Neck Can-
cer.2009. Elsevier Professional Education. ISBN 978-3-437-59904-0.
30.  Vikram, B., Strong, E., Shah, J., Spiro, R., Gerold, F., Sessions, R., and Hilaris, B. A 
Interstitial radiation therapy in cancer of the oropharynx and oral cavity
----------------------------------------------------------------------------------------------
200
..........
non-looping afterloading technique for base of tongue implants: results in the first 20 
patients. Int J Radiat Oncol Biol Phys.1985 Oct  2006 11(10): 1853-1855.
31.  Vikram, B. and Hilaris, B. S. A non-looping afterloading technique for interstitial im-
plants of the base of the tongue. Int J Radiat Oncol Biol Phys.1981 Mar  2006 7(3): 
419-422.
32.  Wendt, C. D., Peters, L. J., Delclos, L., Ang, K. K., Morrison, W. H., Maor, M. H., Rob-
bins, K. T., Byers, R. M., Carlson, L. S., and Oswald, M. J. Primary radiotherapy in the 
treatment of stage I and II oral tongue cancers: importance of the proportion of therapy 
delivered with interstitial therapy. Int.J.Radiat.Oncol.Biol.Phys.  1990 18: 1287-1292.
33.  Wadsley, J. C., Patel, M., Tomlins, C. D., and Gildersleve, J. Q. Iridium-192 implan-
tation for T1 and T2a carcinoma of the tongue and floor of mouth: retrospective study 
of the results of treatment at the Royal Berkshire Hospital. Br.J.Radiol.  2003 76: 414-
417.
34.  Pernot, M., Malissard, L., Hoffstetter, S., Luporsi, E., Peiffert, D., Aletti, P., Kozminski, 
P., and Bey, P. The study of tumoral, radiobiological, and general health factors that 
influence results and complications in a series of 448 oral tongue carcinomas treated 
exclusively by irradiation. Int.J.Radiat.Oncol.Biol.Phys.  1-7-1994 29: 673-679.
35.  Mendenhall, W. M., Parsons, J. T., Stringer, S. P., Cassisi, N. J., and Million, R. R. T2 
oral tongue carcinoma treated with radiotherapy: analysis of local control and compli-
cations. Radiother.Oncol.  1989 16: 275-281.
36.  Inoue, T., Inoue, T., Yoshida, K., Yoshioka, Y., Shimamoto, S., Tanaka, E., Yamazaki, 
H., Shimizutani, K., Teshima, T., and Furukawa, S. Phase III trial of high- vs. low-dose-
rate interstitial radiotherapy for early mobile tongue cancer. Int.J.Radiat.Oncol.Biol.
Phys.  1-9-2001 51: 171-175.
37.  Decroix, Y. and Ghossein, N. A. Experience of the Curie Institute in treatment of can-
cer of the mobile tongue: I. Treatment policies and result. Cancer 1-2-1981 47: 496-
502.
38.  Benk, V., Mazeron, J. J., Grimard, L., Crook, J., Haddad, E., Piedbois, P., Calitchi, E., 
Raynal, M., Martin, M., Le Bourgeois, J. P., and . Comparison of curietherapy versus 
external irradiation combined with curietherapy in stage II squamous cell carcinomas 
of the mobile tongue. Radiother.Oncol.  1990 18: 339-347.
39.  Baillet, F, Delouche, G, and Bachelot, F. Epithelioma of the floor of mouth: multicentre 
retrospective study of 908 cases. J.Eur.Radiother 1982  2009 3: 147-52.
40.  Piccirillo, J. F. and Vlahiotis, A. Comorbidity in patients with cancer of the head and 
neck: prevalence and impact on treatment and prognosis. Curr.Oncol.Rep.  2006 8: 
123-129.
41.  Mazeron, J. J., Crook, J., Martin, M., Peynegre, R., and Pierquin, B. Iridium 192 im-
plantation of squamous cell carcinomas of the oropharynx. Am.J.Otolaryngol.  1989 
10: 317-321.
42.  Teguh, D. N., Levendag, P. C., Noever, I., Voet, P., Van der, Est H., van Rooij, P., 
Dumans, A. G., de Boer, M. F., van der Huls, M. P., Sterk, W., and Schmitz, P. I. Early 
Hyperbaric Oxygen Therapy for Reducing Radiotherapy Side Effects: Early Results 
of a Randomized Trial in Oropharyngeal and Nasopharyngeal Cancer. Int.J.Radiat.
Oncol.Biol.Phys.  20-4-2009 .
43.  Gibbs, I. C., Le, Q. T., Shah, R. D., Terris, D. J., Fee, W. E., and Goffinet, D. R. Long-
term outcomes after external beam irradiation and brachytherapy boost for base-of-
tongue cancers. Int.J.Radiat.Oncol.Biol.Phys.  1-10-2003 57: 489-494.
44.  Anderson, L. L. A "natural" volume-dose histogram for brachytherapy. Med.Phys. 
1986 13: 898-903.
45.  Das, RK. ICRU 58 (Dose and Volume Specification for Reporting Interstitial Therapy), 
by International Commission on Radiation Units and Measurements. Medical Physics, 
July 1998, Volume 25, Issue 7, p.1225  2008 .
201
..........
46.  Kolkman-Deurloo, I. K., Visser, A. G., Niel, C. G., Driver, N., and Levendag, P. C. Op-
timization of interstitial volume implants. Radiother.Oncol.  1994 31: 229-239.
47.  Saw, C. B. and Suntharalingam, N. Quantitative assessment of interstitial implants. 
Int.J.Radiat.Oncol.Biol.Phys.  1991 20: 135-139.
48.  Thomadsen, BR, Houdek, PV, van der Laarse, R, Edmunson, G, Kolkman-Deurloo, 
IKK, and Visser, AG. Treatment planning and optimization. In: S.Nag, Editor, HDR 
brachytherapy: a textbook, Futura, Armonk, NY (1994), pp.79-145.  2008 .
49.  Harrison, L. B., Zelefsky, M. J., Pfister, D. G., Carper, E., Raben, A., Kraus, D. H., 
Strong, E. W., Rao, A., Thaler, H., Polyak, T., and Portenoy, R. Detailed quality of life 
assessment in patients treated with primary radiotherapy for squamous cell cancer of 
the base of the tongue. Head Neck  1997 19: 169-175.
50.  Babin, E., Sigston, E., Hitier, M., Dehesdin, D., Marie, J. P., and Choussy, O. Quality of 
life in head and neck cancers patients: predictive factors, functional and psychosocial 
outcome. Eur.Arch.Otorhinolaryngol.  2008 265: 265-270.
51.  Pourel, N., Peiffert, D., Lartigau, E., Desandes, E., Luporsi, E., and Conroy, T. Quality 
of life in long-term survivors of oropharynx carcinoma. Int.J.Radiat.Oncol.Biol.Phys. 
1-11-2002 54: 742-751.
52.  Hammerlid, E., Mercke, C., Sullivan, M., and Westin, T. A prospective quality of life 
study of patients with oral or pharyngeal carcinoma treated with external beam irradia-
tion with or without brachytherapy. Oral Oncol.  1997 33: 189-196.
53.  Caudell, J. J., Schaner, P. E., Meredith, R. F., Locher, J. L., Nabell, L. M., Carroll, W. 
R., Magnuson, J. S., Spencer, S. A., and Bonner, J. A. Factors Associated with Long-
Term Dysphagia After Definitive Radiotherapy for Locally Advanced Head-and-Neck 
Cancer. Int.J.Radiat.Oncol.Biol.Phys.  15-7-2008.
54.  Dornfeld, K., Simmons, J. R., Karnell, L., Karnell, M., Funk, G., Yao, M., Wacha, J., 
Zimmerman, B., and Buatti, J. M. Radiation Doses to Structures Within and Adjacent 
to the Larynx are Correlated With Long-Term Diet- and Speech-Related Quality of Life. 
Int.J.Radiat.Oncol.Biol.Phys.  1-7-2007 68: 750-757.
55.  Feng, F. Y., Kim, H. M., Lyden, T. H., Haxer, M. J., Feng, M., Worden, F. P., Chepeha, 
D. B., and Eisbruch, A. Intensity-Modulated Radiotherapy of Head and Neck Can-
cer aiming to Reduce Dysphagia: Early Dose-Effect Relationships for the Swallowing 
Structures. Int.J.Radiat.Oncol.Biol.Phys.  6-6-2007 .
56.  Jensen, K., Lambertsen, K., and Grau, C. Late swallowing dysfunction and dysphagia 
after radiotherapy for pharynx cancer: Frequency, intensity and correlation with dose 
and volume parameters. Radiother.Oncol.  2007 85: 74-82.
57.  Mangar, S., Slevin, N., Mais, K., and Sykes, A. Evaluating predictive factors for deter-
mining enteral nutrition in patients receiving radical radiotherapy for head and neck 
cancer: a retrospective review. Radiother.Oncol.  2006 78: 152-158.
58.  Poulsen, M. G., Riddle, B., Keller, J., Porceddu, S. V., and Tripcony, L. Predictors of 
acute grade 4 swallowing toxicity in patients with stages III and IV squamous carci-
noma of the head and neck treated with radiotherapy alone. Radiother.Oncol.  2008 
87: 253-259.
59.  Teguh, D. N., Levendag, P. C., Sewnaik, A., Hakkesteegt, M. M., Noever, I., Voet, P., 
Van der, Est H., Sipkema, D., van Rooij, P., Baatenburg de Jong, R. J., and Schmitz, 
P. I. Results of fiberoptic endoscopic evaluation of swallowing vs. radiation dose in the 
swallowing muscles after radiotherapy of cancer in the oropharynx. Radiother.Oncol. 
2008 89: 57-63.
60.  Teguh, D. N., Levendag, P. C., Noever, I., van Rooij, P., Voet, P., Van der, Est H., 
Sipkema, D., Sewnaik, A., de Jong, R. J., de la, Bije D., and Schmitz, P. I. Treatment 
techniques and site considerations regarding dysphagia-related quality of life in can-
cer of the oropharynx and nasopharynx. Int.J.Radiat.Oncol.Biol.Phys.  15-11-2008 72: 
1119-1127.
Interstitial radiation therapy in cancer of the oropharynx and oral cavity
----------------------------------------------------------------------------------------------
202
..........
61.  Bjordal, K., de Graeff, A., Fayers, P. M., Hammerlid, E., van Pottelsberghe, C., Cur-
ran, D., Ahlner-Elmqvist, M., Maher, E. J., Meyza, J. W., Bredart, A., Soderholm, A. 
L., Arraras, J. J., Feine, J. S., Abendstein, H., Morton, R. P., Pignon, T., Huguenin, P., 
Bottomly, A., and Kaasa, S. A 12 country field study of the EORTC QLQ-C30 (version 
3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head 
and neck patients. EORTC Quality of Life Group. Eur.J.Cancer  2000 36: 1796-1807.
62.  List, M. A., DAntonio, L. L., Cella, D. F., Siston, A., Mumby, P., Haraf, D., and Vokes, 
E. The performance status scale for head and neck cancer patients and the functional 
assessment of cancer therapy head and neck scale - A study of utility and validity. 
Cancer  1-6-1996 77: 2294-2301.
63.  Chen, A. Y., Frankowski, R., Bishop-Leone, J., Hebert, T., Leyk, S., Lewin, J., and 
Goepfert, H. The development and validation of a dysphagia-specific quality-of-life 
questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia 
inventory. Arch.Otolaryngol.Head Neck Surg.  2001 127: 870-876.
64.  Teguh, D. N., Levendag, P. C., Kolkman-Deurloo, I. K., van Rooij, P., and Schmitz, 
P. I. Quality of life of oropharyngeal cancer patients treated with brachytherapy. Curr.
Oncol.Rep.  2009 11: 143-150.
65.  Vasquez Osorio, E. M., Hoogeman, M. S., Bondar, L., Levendag, P. C., and Heijmen, 
B. J. A novel flexible framework with automatic feature correspondence optimization 
for nonrigid registration in radiotherapy. Med.Phys.  2009 36: 2848-2859.
66.  Han, X., Hoogeman, M. S., Levendag, P. C., Hibbard, L. S., Teguh, D. N., Voet, P., 
Cowen, A. C., and Wolf, T. K. Atlas-based auto-segmentation of head and neck CT 
images. Med.Image Comput.Comput.Assist.Interv.Int.Conf.Med.Image Comput.Com-
put.Assist.Interv.  2008 11: 434-441.
203
..........
11
Quality of Life of Oropharyngeal Cancer Patients 
Treated with Brachytherapy - A Review 
David N. Teguh, M.D.,1
Peter C. Levendag, M.D., Ph.D.,1
Inger-Karine Kolkman-Deurloo, Ph.D.,1
Peter van Rooij, M.Sc.,1 
Paul I.M. Schmitz, Ph.D.,2 
1
 Radiation Oncology, Erasmus MC - Daniel den Hoed Cancer Center,
Rotterdam, The Netherlands. 
2
 Biostatistics, Erasmus MC - Daniel den Hoed Cancer Center,
Rotterdam, The Netherlands. 
Current Oncology  Reports. 2009 Mar;11(2):143-50
9
204
..........
AbstrAct
Brachytherapy (BT) is a highly conformal (accurate clinical target volume deline-
ation, no planning target volume margin) radiotherapy technique; the radioactive 
source, guided by afterloading catheters, is implanted into the heart of the tumor. 
The localized high dose of radiation enables high tumor control rates and, because 
of rapid dose fall-off, sparing of the adjacent normal tissues. At the Erasmus Medi-
cal Center, excellent results were observed: 5-year local regional control of 84%, 
5-year disease-free survival of 59%, and 5-year overall survival of 64%. Therefore, 
in the case of moderately sized tumors, for well-trained, skillful physicians, BT is the 
therapy of choice (if technically feasible). However, side effects are not totally ne-
gligible, partly because of the cumulative dose of BT and the first series of 46/2 Gy. 
However, patients treated with BT still have a better swallowing-related quality of life, 
which might improve further if summation of BT and the first series of 46/2 Gy, as 
well as auto-contouring of the neck levels, are realized. So far, there is no significant 
relationship between the quality index of the BT implants and local control/overall 
survival and/or quality of life.
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introduction
Although major improvements in surgical and radiation therapy (RT) techniques have 
come about, overall survival (OS) has not changed significantly in the past decade 1. 
Locally advanced disease in head and neck tumors is present in more than 50% of 
patients at diagnosis, with a 5-year survival rate of approximately 40% to 50% 1. Side 
effects of RT for tumors of the head and neck are well known and extensively descri-
bed in the literature. Moreover, in recent years, the late occurrence of dysphagia has 
been added to the list of side effects having a significant impact on patients’ quality 
of life (QoL) 2. Several papers on dose–effect (D-E) relationships for dysphagia and 
aspiration have been published recently 3–7. From these papers, it has become evi-
dent that among the several causes of dysphagia, the dose delivered to the swallo-
wing muscles is a key factor in its development. Therefore, it was thought of interest 
to study the role of brachytherapy (BT), which, given its conformality, may favorably 
influence the D-E relationship. Furthermore, prognostic factors for local control and 
side effects in association with BT also are detailed in this review.
brAchytherApy techniQues
The history of BT dates back to the beginning of the 20th century, with the first BT 
procedures being performed using radium-226 needles. Brachytherapy (brachy- = 
Greek for “short”) is a treatment modality in which the tumor is irradiated by posi-
tioning the radioactive sources very close to the mold (endocavitary techniques) or 
even inside the tumor volume (interstitial implant) by permanent (seed) implant or 
by temporarily inserted seeds, applicators, or radioactive sources using afterloading 
catheters. In principle, BT is a conformal type of RT technique. In recent years, 
artificial radionuclides such as cesium-137, cobalt-60, iodine-125, and iridium-192 
(IR-192) became available. Manual afterloading of the sources into applicators or 
afterloading tubes replaced direct loading of sources into the patient. The French 
developed the so-called Paris system for low–dose rate (LDR) dosimetry purposes; 
that is, for parallel-equidistant sources, the system recommends specifying the dose 
of the implant as 85% of the average dose in the basal dose points (local minima). 
A similar type of dose prescription is used for current high–dose rate (HDR) BT, 
even though the implanted sources (afterloading catheters) may not be totally equi-
distant. Also, computer-controlled afterloading devices, supported by sophisticated 
treatment-planning software with optimization capabilities, became available. The 
base-of-tongue (BOT) implant consists of afterloading catheters introduced in and 
surrounding the tumor volume after the percutaneous introduction of trocars in a 
submental or submandibular region is realized 8. For patients with disease extension 
toward the pharyngo-epiglottic fold, lateral catheters are sometimes added. Mostly, 
however, the BOT implant consists of three planes of afterloading catheters (with 
three catheters per plane). The spacing between each end of the “looping” catheters 
running over the dorsum of the tongue is ± 0.75 to 1 cm. As a safety precaution, a 
temporary tracheotomy is sometimes indicated for implant removal and is executed 
immediately before the implantation per se and/or at the time of neck dissection. In 
most cases, two or three catheters are implanted in the tonsillar fossa (TF) and fau-
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cial arches and/or soft palate (SP) tumors. A temporary nasogastric feeding tube is 
placed at the completion of most BT procedures. The development of radiobiologic 
models has enabled us to predict, to a certain extent, the tumor control probability 
and normal tissue complication probability after the application of BT, depending on 
factors such as fraction size, dose rate, the tumor, and the normal tissues one is 
dealing with. In general, BT can be divided into several dose rate categories:
LDR: dose rate varies between 0.4 and 2 Gy/h•	
Medium dose rate (MDR): dose rate varies between 2 and 12 Gy/h•	
HDR: dose is delivered at a rate higher than 12 Gy/h•	
Fractionated HDR (given at the Erasmus Medical Center [MC]): over many •	
years, a fraction size of 3 to 4 Gy with a minimum fraction interval of 6 hours and 
a total fraction number of 6 to 7, for boost doses varying between 18 and 21 Gy 
after 46/2 Gy external beam irradiation has been applied.During the weekend, 
no BT is delivered by this “daytime” fractionating schedule.
Pulsed–dose rate (PDR), LDR BT: regime simulates LDR by using many small •	
fractions. At the Erasmus MC, time intervals of (less than) a few hours between 
fractions are used. This so-called PDR regime is defined as a booster dose of 
HDR-type radiation with a fraction size of 1 to 2 Gy and an interfraction time in-
terval of 3 hours, with a total dose of 20 to 22 Gy. This PDR type of fractionation 
can be delivered over the weekend (automation: 24-hour regime).
In skillful, well-trained hands, BT remains an extremely gratifying technique for ap-
plying high doses of radiation for small-volume disease with highly conformal and 
accelerated properties. Through the development of soft x-ray sources and after-
loading machines that carry multiple sources and have multiple drives, increases in 
dose rate flexibility and radiation protection have been obtained. One of these sour-
ces, ytterbium-169, currently is being tested. Finally, unless the tumor is very small, 
interstitial BT usually is used in conjunction with external beam irradiation.
locAl control And survivAl
The French school has published extensively on interstitial RT (IRT) of TF and/or SP 
tumors, as well as of BOT cancers 9–15; most of these data regard LDR implants. For 
example, Mazeron et al. 16 reported on a subset of patients with early-stage (T1, T2) 
tumors of the TF and/or SP, with a local control rate (LCR) of approximately 85% 
and a regional control rate of 97% for N0 and 88% for N1-3 disease. Patients were 
typically treated with 45-Gy external beam RT (EBRT), conventional fractionation, 
followed by a 30-Gy LDR Ir-192 boost. Soft tissue ulceration occurred in 17 of the 
127 patients (13%). Similar LRCs were reported by Pernot et al. 17 (90% in TF/SP 
T1,T2N0 tumors vs 86% in T1,T2N1-3 tumors, with LDR boost) and Levendag et 
al. 18,19 (87% in TF and/or SP tumors at 5 years).The series of patients in Rotterdam 
were treated by fractionated HDR BT (daytime regimen) or PDR (24-hour regime). 
Esche et al. 10 described 43 patients with carcinoma of the SP and uvula with an 
LCR of 92%. An overall- and cause-specific survival of 60% and 81% at 3 years and 
37% and 64% at 5 years, respectively, was reported. The leading cause of death 
was other aerodigestive cancers; these cancers occur at an actuarial rate of 3% per 
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year post treatment. The “brachytherapy school” of Memorial Sloan-Kettering Can-
cer Center (MSKCC) in New York pioneered large-volume implants—a technique 
initially designed by Vikram 20,21—particularly for cancer of the BOT. Harrison et al. 22 
published extensively on the MSKCC experience with volume implants of the BOT. 
Five-year local control, disease-free survival (DFS), and OS rates of 89%, 80%, 
and 86%, respectively, were obtained. A classic paper published by Housset et al. 
23 reported on local control for EBRT versus surgery plus postoperative RT (PORT) 
versus EBRT alone in patients with BOT cancer. In essence, the results were sig-
nificantly worse for the EBRT-alone group, with local failure rates of 20.5% (EBRT 
+ IRT), 18.5% (surgery + PORT), and 43% (EBRT alone). Most data in the litera-
ture concern the observation that BT with or without EBRT is associated with good 
LCRs, but the morbidity may be significant; therefore, these implantations should be 
performed at centers with adequate experience in three-dimensional planning and 
adequate management of complications. Regarding the complications, it is impor-
tant to realize that in this day and age, advanced local disease frequently is treated 
with EBRT and concomitant chemotherapy, ultimately combined with BT. It is known 
from meta-analysis that concomitant chemotherapy does lead to better tumor control 
but is associated with greater morbidity 24.
From 1991 to 2005, 336 oropharyngeal cancer patients were treated nonsurgically 
at our institution, and the following results were observed with regard to actuarial 
local control, DFS, and OS rates when stratified by type of booster technique used, 
that is, BT versus no BT: the 5-year LCR was 84% versus 60% (P < 0.05), 5-year 
DFS was 59% versus 43% (P < 0.05), and 5-year OS was 64% versus 39% (P 
< 0.05). Outcomes for patients with cancer of the oropharynx depend on several 
well-known prognostic factors, such as weight loss, performance status, hemoglobin 
level, tumor (T) and nodal (N) stage, tumor sites, tumor differentiation, involvement 
of resection margins, extracapsular spread, perineural invasion, epidermal growth 
factor receptor inhibitors, presence of human papillomavirus, and previously used 
treatment modality 25.
From our multivariate analysis, we observed that BT and time period (< year 2000) 
are significant influences on local control. With regard to DFS and OS, BT’s influence 
disappears in multivariate analysis; sex, age, N stage, and head and neck surgery 
are prognostic factors instead. Piccirillo and Vlahiotis 26  described the prevalence 
of co-morbidity and its impact on treatment and prognosis in patients with cancer 
of the head and neck. The authors concluded that other diseases or conditions can 
affect treatment selection and prognosis. Failure to include an accurate description 
of comorbidities in hospital- and population-based registries may lead to misleading 
conclusions about treatment effectiveness, outcomes, and quality of cancer care.
QuAlity oF liFe
Harrison et al. 27 published one of the earliest reports on QoL data for BT treatment. 
They stated that most patients achieved excellent functional status and QoL and 
could maintain their pre-diagnosis earning potential and employment status after 
primary radiation for advanced BOT cancer. Babin et al. 28 conducted a brief review 
of patient-reported outcome measures in head and neck cancer and differentiated 
the following symptom domains: physical symptoms linked to diet and feeding pat-
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terns, communication disorders, pain, and the general state of health; psychologi-
cal symptoms including depression, irritability, and loss of self-esteem; and social 
symptoms including relationship difficulties with a partner or other family members, 
loss of work, reduction in salary, and a sense of uselessness, resulting in a negative 
impact on daily life. According to Babin et al. 28, the “sociability” of individual patients 
was evaluated rarely until now. According to Pourel et al. 29, although health-related 
QoL is significantly impaired in long-term survivors of T1-T3 oropharyngeal carci-
noma, the focus in treatment option comparisons should still be on survival as the 
most relevant end point; that is, QoL should be regarded as a secondary end point. 
This group found no patient-, disease-, or treatment-related factors related to the 
swallowing scale and dry mouth items on the European Organisation for Research 
and Treatment of Cancer (EORTC) H&N35 questionnaire, which is not in agreement 
with our findings (see next paragraph). Petruson et al. 30 reported that 80% of pa-
tients with tonsil and BOT cancer had problems with dry mouth and half the patients 
with tonsil and BOT cancer reported problems with swallowing solid food at 3-year 
follow-up. However, Pourel et al. 29 suggested that coping processes tend to “delete” 
any differences in symptom and functional scales among patients, regardless of 
the initial treatment. Hammerlid et al. 31 reported a prospective QoL study (EORTC 
QLQ-C30 and EORTC H&N35 questionnaires) of patients with oral and pharyngeal 
carcinoma treated with external beam irradiation with or without BT. Most symptoms 
were at their peak 2 or 3 months after the start of treatment. Nutrition and pain were 
found to be the major problems, and as many as 19% to 40% reported psychiatric 
distress. Patients who received additional BT did not report any increase in QoL pro-
blems (except for pain) compared with those who had external radiation only. QoL 
does not seem to be affected by the increased local radiation dose given when BT 
is included in the treatment regimen. In addition to better local control and sparing, 
Nijdam et al. 32 reported on the cost-effectiveness of this type of treatment; the mean 
total cost for patients treated with BT is lower compared with those treated with 
EBRT only or surgery.
dysphAgiA
Dysphagia-related complaints have been the subject of recent publications. Poulsen 
et al. 33 found that a field length greater than 82 mm for the second phase of irradi-
ation increased the probability of requiring intervention with percutaneous endosco-
pic gastrostomy or nasogastric tube feeding, that is, 36% (> 82 mm) versus 16%. 
Mangar et al. showed that prophylactic enteral feeding during RT minimizes aver-
age weight loss compared with reactive feeding. Important clinical parameters as-
sociated with enteral nutrition include tumor site, World Health Organization (WHO) 
performance status of 2 to 3, increasing age, low body mass index, and serum al-
bumin level. Patients with advanced-stage disease (III/IV) and a WHO performance 
status of 2 to 3 who smoke more than 20 cigarettes a day have a greater than 75% 
chance of needing enteral support during their treatment. Caudell et al. 35 found a 
prevalence of 38.5% for dysphagia; by univariate analysis, the primary site, concur-
rent chemotherapy, RT schedule, and increasing age were significantly associated 
with development of long-term dysphagia. The use of concurrent chemotherapy, the 
primary site, and increasing age remained significant factors on multivariate analy-
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sis. The authors concluded that adding concurrent chemotherapy to RT for locally 
advanced head and neck cancer resulted in increased long-term dysphagia. Feng et 
al. 36 demonstrated significant relationships between the dose–volume parameters 
of structures and objective and subjective measurements of swallowing function. 
Other groups also showed significant correlations of various dysphagia end points 
with dose in supraglottic lesions 3 and glottic cancers 3,37.
erAsMus Mc eXperience
Between 1991 and 2005, 458 oropharyngeal cancer patients were treated with cura-
tive intent in a single institution by RT techniques. One hundred twenty-two patients 
were excluded from the present analysis because they had tumors of the non–squa-
mous cell carcinoma type (n = 11), second primaries (n = 30), metastasis (n = 4), 
EBRT in a remote hospital (n = 12), LDR treatment (n = 2), death during treatment (n 
= 2), synchronous primary tumors (n = 16), or tumors treated with palliative intent (n 
= 39), or because of a protocol violation (n = 6). The remaining 336 patients form the 
basis of the analysis; of these, BT was used to treat 188 patients. Patients were seen 
in joint consultation by a radiation oncologist and head and neck surgeon. Diagnosis 
was established by clinical examination, panendoscopy, CT, and/or MRI of the head 
and neck. Biopsy of the primary tumor and ultrasound-guided fine-needle aspiration 
of the suspicious regional lymph nodes were performed 19. Patients were classified 
according to the 2004 edition of the American Joint Committee on Cancer’s staging 
manual 38. A detailed treatment protocol was described in earlier papers 6,7,18,32,39. 
The 336 patients with no evidence of disease (NED) received three types of question-
naires: 1) the EORTC core QoL (QLQ)-C30 and EORTC QLQ-H&N35, which include 
a swallowing scale with four items (problems with swallowing liquid, pureed food, or 
solid food, and aspiration when swallowing) 40; 2) the Performance Status Scale of 
List et al. 41, which includes a Normalcy of Diet item 40,3 the M.D. Anderson Dyspha-
gia Inventory 42, which consists of 20 questions with global, emotional, functional, 
and physical subscales. By the censor date (January 1, 2006), 155 patients had res-
ponded to the QoL questionnaires. Reviewing the charts of all the patients, we found 
that 31% (103 of 336) had dysphagia (Research Therapy Oncology Group grades III 
and IV). Thus, a cohort of 155 patients alive with NED after a minimum follow-1 year 
was available for analysis. Of these patients, 91 were male and 64 were female, and 
the mean age was 56 years (range, 35-78 years). Primary treatment sites were TF/
SP (n=108) and BOT (n=47). Seventy-seven percent of the patients (119 of 155) had 
stage III or IV disease. Of these 155 patients, 107 received a BT boost (TF/SP, 83; 
BOT, 24) and 48 received a boost from non-BT techniques (TF/SP, 25; BOT, 23). 
We focused the data analysis in this review on late side effects: 'swallowing' and 
'xerostomia'. Percentages of severe QoL scores for swallowing and dry mouth were 
lower for BT patients than for non-BT patients (14% vs. 34% for H&N35 [swallowing] 
and 52% vs. 67% for H&N35 [xerostomia]); the outcome data are consistent for all 
three QoL questionnaires. From the univariate analysis, one may conclude that the 
following factors are significant for swallowing-related questions: use of BT, T stage, 
boost treatment, neck surgery, and neck irradiation. In the multivariate analysis, BT 
and dose in the superior constrictor muscle remained significant. From Figure 1, one 
can appreciate a significant D-E relationship between the EORTC H&N35 swallo-
wing scale and dose in the superior constrictor muscle (P < 0.01). 
Review quality of life in oropharyngeal cancer patients treated with brachytherapy
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Figure 1: Correlation between the dose in constrictor superior muscle versus the swallowing 
item on the European Organisation for Research and Treatment of Cancer (EORTC) H&N35 
questionnaire, 1991 to 2005. 
A 20% increase in complaints per 10 Gy was found after 60 Gy in the superior con-
strictor muscle. We speculate that the increase in dysphagia is related to the incre-
ase in irradiated volume and radiation dose. Although the dose–volume data may 
prove a cause–effect relationship, clinical validation is needed to determine whether 
reducing the doses to the swallowing structures as much as possible is beneficial. 
Finally, xerostomia and dysphagia related structures also are strongly correlated (P 
< 0.001): for the mean dose in the superior and middle constrictor muscle versus dry 
mouth 7.
In conclusion, BT side effects are not totally negligible; this is partly the result of the 
cumulative dose of BT and the first series of EBRT (46/2 Gy). However, patients 
treated with BT still have a better swallowing-related QoL than those receiving EBRT 
only. Their QoL may improve even further if summation of BT and the first series of 
46/2 Gy, as well as auto-contouring of the neck levels, are realized.
Brachytherapy quality indices for LDR and HDR/PDR interstitial vo-
lume implants
Various evaluation parameters are used to describe the quality of interstitial volume 
implants 43–45. We analyzed these parameters for 75 representative volume BOT 
implants. Forty-three patients were treated with LDR BT using Ir-192 wires, and 32 
were treated with fractionated HDR or PDR BT using a single stepping Ir-192 sour-
ce. The main differences between LDR and HDR/PDR BT are the dose rate and the 
ability to optimize the dose distribution in HDR/PDR BT using dwell-time optimiza-
tion, which results in nonuniform loading along the catheter 46. Therefore, one would 
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Definitions of physical parameters in the base-of-tongue study
Parameter    Definition
Dbase85 85% of the average dose in all basal dose points 46
Db_min Lowest dose in any of the basal dose points
Db_max Highest dose in any of the basal dose points
Sd_dbas
Standard deviation in the doses over all basal dose points; a measure 
of the (in)homogeneity of the dose over all basal dose points (and 
thus the implant)
Vdis100 
Total volume (distributed, so not necessarily contiguous) receiving 
at least the prescribed dose; also called treated volume according to 
ICRU 58 46
Vdis150 Total volume (distributed, so not necessarily contiguous) receiving at least 150% of the prescribed dose 
The ratio Vdis150/ Vdis100 is a measure of the dose inhomogeneity 
(= DNR)  46.
UI
Uniformity index derived from natural DVH (according to Anderson 44); 
a measure of the dose homogeneity taking into account the choice of 
reference isodose in relation to the relatively homogeneously irradia-
ted volume
QI
Quality index derived from natural DVH (according to Anderson 44 and 
modified by R. van der Laarse);  a measure of the dose homogeneity 
only, without taking into account the choice of the reference isodose 
in relation to the relatively homogeneously irradiated volume 42
DNR—dose nonuniformity ratio; DVH—dose–volume histogram; ICRU—International Commission on 
Radiation Units and Measurements; QI—quality index.
Table 1: Definitions of physical parameters in the base of tongue study.
expect significant differences in the BT quality indices when comparing LDR with 
HDR/PDR implants. For these 75 patients, we have studied the standard deviation 
of the dose in the basal dose points as a measure of dose homogeneity. From a 
“natural” dose–volume histogram, the uniformity index (UI) was derived 45. The UI 
depends not only on the uniformity of the dose distribution, but also on the choice 
of reference isodose. Therefore, a quality index (QI) similar to the UI but indepen-
dent of the choice of reference isodose also has been evaluated 43. Other physical 
parameters investigated are Dbase85, Db_min, Db_max, Sd_dbas, Vdis100, and 
Vdis150. Definitions of these parameter are given in Table 1. We found that instead 
of evaluating the standard deviation of the dose in all basal dose points, it suffices 
to evaluate the maximum and minimum doses in these points for these rather ir-
regular implants, as the standard deviation of the dose in all basal dose points was 
strongly correlated to the maximum and minimum dose in the basal dose points were 
strongly correlated. A correlation between UI and QI was found, probably because 
of the uniform method of defining the reference isodose, that is, at 85% of the dose 
(rate) in the basal dose points. However, a relationship between UI or QI and the 
Review quality of life in oropharyngeal cancer patients treated with brachytherapy
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standard deviation of the dose in all basal points was not seen. The LDR and HDR/
PDR implants differ with regard to the treatment volume and the fact that the dose 
distribution of the HDR/PDR implants was optimized. Therefore, it is surprising that 
the differences in UI, QI, dose nonuniformity ratio (DNR), and the standard deviation 
of the basal dose between LDR and  HDR/PDR were relatively small (Table 2). A set 
of independent evaluation parameters can be defined with which the 
quality of interstitial volume implants can be characterized; this should include the 
maximum and minimum doses in the basal dose points and either the UI or DNR. 
These physical parameters were correlated with QoL questionnaire answers from 
the patients; however, no significant correlation could be established. Petruson et al. 
30 also reported that there are no correlations between BT QIs and QoL scores.
 
BOT implant 
dose rate
Treatment 
volume 
(cm3)
Standard devia-
tion basal dose 
(%)
UI QI DNR
LDR 89.7 ± 48.5 16.5 ± 7.7 1.43 ± 0.14 1.35 ± 0.11 0.33 ± 0.06
HDR/PDR 58.2 ± 21.7 11.3 ± 7.1 1.49 ± 0.11 1.42 ± 0.11 0.28 ± 0.04
Table2: Treatment volume and standard deviation of the dose in all basal dose points.
BOT: Base of tongue, DNR: dose nonuniformity ratio, HDR: high dose rate, LDR: low dose 
rate, PDR: pulsed dose rate, QI: quality index, UI: uniformity index.
conclusions
BT is a specialized technique for applying high doses of radiation to small-volume 
disease with highly conformal and accelerated properties. Patients treated with BT 
have better local control, DFS, and OS than those treated with EBRT. At Erasmus 
MC, excellent results were observed: 5-year LRC of 84%, 5-year DFS of 59%, and 
5-year OS of 64%. Selecting the right patients for BT, however, remains important. 
Using data from the Erasmus MC, we elected to report on a frequently underre-
ported side effect: dysphagia. Swallowing problems were measured by three 
validated QoL questionnaires; the BT patients were found to have fewer swallo-
wing problems compared with the non-BT group. Univariate analysis also de-
monstrated an advantage (ie, less dysphagia) related to T stage, boost treat-
ment, neck surgery, and neck irradiation. The multivariate analysis showed a signi-
ficant effect for BT (implicating fewer swallowing complaints because of the lower 
doses of radiation received by the superior swallowing constrictor muscles). To im-
prove dysphagia-related QoL, the dose distribution should be optimized further. The 
tolerance of the swallowing muscles depends to some extent on the treatment mo-
dality used. In patients who receive BT as boost therapy, dysphagia is seen in 14% 
treated with an average dose of 53 Gy. In contrast, dysphagia was seen in 40% of 
patients treated with EBRT to a mean dose of 68 Gy (Fig. 2). So far, no significant 
relationship has been seen between the QI of the BT implants and local control/OS 
and / or QoL.
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Figure 2. Probability for European Organisation for Research and Treatment of Cancer H&N35 
questionnaire swallowing scale versus dose in superior constrictor muscle.
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Key points
Results of conventional head and neck radiotherapy by external beam radio-•	
therapy, including a boost of external beam radiation, with or without concurrent 
chemotherapy, include a number of side effects among which are dysphagia 
and xerostomia.
In addition to side effects, the quality of life is also negatively affected.•	
In brachytherapy (BT), high doses are used in a short overall treatment time in •	
relatively small volume disease (accelerated conformal treatment),with excel-
lent tumor control rates.
The current chapter describes the outcome in 155 patients with tonsillar fossa •	
and/or soft palate tumors (n = 108) or cancers of the base of tongue (n = 47). 
Overall, according to chart review, a severe degree of dysphagia (RTOG gra-
des III and IV) was experienced in 31% of the patients. Similarly, according to 
responses to the EORTC H&N35 QOL questionnaires, severe dysphagia was 
observed in about 20% of the BT group and about 38% in the non-BT group.
Univariate analysis demonstrated less dysphagia for the following conditions: •	
lower mean doses applied to swallowing muscles, BT treatment, single neck ir-
radiation, and in case a neck dissection is performed. The multivariate analysis 
shows a signifi cant effect for BT (~ implicating less swallowing complaints due 
to the lower doses of radiation received by the swallowing muscles).
For improvement of the dysphagia-related QOL, it is suggested to try and •	
further optimize the dose distribution.
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introduction
In organ preservation therapy, for cancer in the head and neck, over the years a 
number of investigators have noted a signifi cant increase in dysphagia, defi ned 
as swallowing problems that most likely relate to more aggressive treatment regi-
mes used in order to obtain better tumor control rates. The aggressive nature of 
the treatment modalities is exemplifi ed by high doses of radiation and/or (accele-
rated) fractionation regimens, with or without (concomitant) chemotherapy 12. Xe-
rostomia has been well documented in patients treated with chemotherapy (CHT) 
and/or radiation. It has been argued that the degree of xerostomia corresponds with 
the amount of dysphagia experienced by the patient 16,17. To define potential reha-
bilitation strategies, it is important to investigate fi rst the anatomical structures and 
functionality of the swallowing apparatus. Examples of preventative measures are 
the pre- and posttreatment exercises and/or the introduction of Therabite 2,9. Few 
studies have examined the association of dysphagia with the location of the primary 
tumor site 20,21. This chapter analyses the response to validated QOL questionnaires 
in search of (severe) late side effects, such as swallowing disorders and xerostomia, 
in patients with oropharyngeal cancers treated between 1991 and 2005 in a single 
institution (Erasmus MC). The patient retrieval for the current analysis consisted 
of patients with tonsillar fossa and/or soft palate (TF and/or SP) or base-of-tongue 
(BOT) tumors treated by radiation therapy (RT). Over time the primary tumor was 
boosted by various RT techniques, that is, by either a parallel-opposed (P-O) fi eld 
confi guration, or by 3D conformal radiotherapy (3DCRT), intensity-modulated radio-
therapy (IMRT), or brachytherapy (BT). A treatment regime using conventional 2 Gy/
day fractionation, combined with a BT boost, has been applied in our institute by far 
the most over a great number of years (1991–2008) for various reasons: With regard 
to tumor control, HDR/PDR fractionation is given in an accelerated fashion with in-
trinsic dose escalation. A high conformality is obtained because of an accurate CTV 
delineation, no PTV margin (because catheters move with movement of target area), 
and rapid dose fall-off. The invasiveness of the procedure, the need for albeit some 
dexterity, the logistics in the OR, and patients being medically unfit for any type of 
surgical procedure are some of the disadvantages of BT. This chapter reports in 
particular those patients treated with BT. 
pAtients And Methods
All patients with squamous cell carcinoma of the oropharynx were treated by RT in 
the Erasmus MC. Patients were seen in joint consultation by the radiation-oncologist 
and HN surgeon. Diagnosis was established by clinical examination, and preferenti-
ally by panendoscopy, CT, and/or MRI of the head and neck. Biopsy of the primary 
tumor and, in the majority of cases, ultrasound-guided fi ne-needle aspiration of 
the suspicious regional lymph nodes were performed. Staging was done according 
to the TNM classifi cation, 2002 edition 6. The actuarial loco-regional control rate, 
diseasefree survival, and overall survival of the 336 patients, stratifi ed for type of 
booster technique (BT vs. non-BT), are depicted in Fig. 1 (LRC; 5 years 84 vs.60%), 
Fig. 2 (DFS; 5 years 59 vs. 43%), and Fig. 3, (OS;5 years 64 vs. 39%). Of the 336 
patients treated, 155 were disease free with a minimum follow-up of 1 year and were 
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selected for the purpose of the present QOL analysis.
Ninety-one patients were male, and 64 female; mean age was 56 years (range, 35–
78). Primary tumor sites were TF or SP (n = 108), or BOT (n = 47); 119/155 (77%) of 
patients were stages III and IV; for stage grouping, see also Tables 1 and 2. Over the 
years, the treatment of preference for T1–T3 TF and/or SP tumors and T1–T4 cancer 
of the BOT consisted of a first series of 46 Gy (2 Gy/fraction, five fractions/week; as of 
2000, six fractions/week) by a P-O technique, 3DCRT, or IMRT to the neck and prima-
ry tumor, followed by a boost of fractionated high dose rate/or pulsed dose rate BT to 
the primary tumor. The doses of the external beam radiotherapy techniques are pres-
cribed according to the International Commission on Radiation Units and Measure-
ment 50 and 62 recommendations. In case of BT, the dose was prescribed to 0.5–
0.75 cm of the catheter plane (TF and/or SP tumors; single plane implant), or to 85% 
of the mean central dose (BOT volume implant). The total dose of fractionated HDR 
was 20 Gy (4 Gy, 4 × 3 Gy, 4 Gy; two fractions/day 8-h interval minimum); in case 
of PDR, 22 Gy (2 Gy, 18 × 1 Gy, 2 Gy; interval 3 h) was given. In case of neck no-
des, a neck dissection (ND) was executed in the same surgical session as BT was 
applied. All patients were treated preferably by a BT boost (BT group; n = 107; 83 
TF/SP, 24 BOT); in case BT was not feasible, non-BT boost techniques were used 
(non-BT group; n = 48; 25 TF/SP, 23 BOT). The non-BT techniques used consisted 
of P-O techniques (P-O; n = 24), 3DCRT (n = 9), or IMRT (n = 15). For more details 
regarding the protocol, see 12,26. All 155 patients without evidence of disease for a 
minimum of 1 year received three types of questionnaires: (1) The EORTC H&N35
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Figure 1: Loco-regional control of tumors in the oropharynx, treated between 1991 and 2005 
in the Erasmus Medical Center – Daniel den Hoed Cancer Center. (BT, non-BT): primary 
tumors (tonsillar fossa and soft palate, base of tongue) were boosted by BT or by non-BT 
techniques. 
221
..........
0 2 4 6 8 10
0%
20%
40%
60%
80%
100%
years
pr
ob
ab
ili
ty
 o
f d
is
ea
se
 F
re
e 
su
rv
iv
al
bt n=188
non-bt n=148
p=0,0004
dFs
Figure 2: Disease-free survival of patients with tumors in the oropharynx, treated between 
1991 and 2005 in the Erasmus Medical Center – Daniel den Hoed Cancer Center.
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Figure 3: Overall survival of patients with tumors in the oropharynx, treated between 1991 and 
2005 in the Erasmus Medical Center – Daniel den Hoed Cancer Center.
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swallowing scale, including four items (problems with swallowing of liquid, pureed-
food, or solid food, and aspiration when swallowing) 1, (2) The performance status 
scale (PSS) of List et al. (1996) with item normalcy of diet, and (3) The MD Anderson 
Dysphagia Inventory (MDADI) 3, consisting of 20 questions with global, emotional, 
functional, and physical subscales. Treatment plans of previously irradiated patients 
were retrieved, with the previously defi ned fi ve muscular structures of the swallo-
wing apparatus delineated on the axial CT slices 13.Thus the mean dose contribution 
by the 3DCRT or IMRT technique to the muscular structures could be computed 
using the original treatment plan. From the patients treated by P-O fields and if a 
CT scan for treatment planning purposes was available, also the dose contribution 
to the swallowing muscles was calculated 7. From the available CT-based 3D dose 
distributions of patients boosted by means of BT, the mean BT dose was calculated. 
For the patients boosted by BT, the 3DCRT, IMRT, or P-O dose and the boost doses 
were physically summated. Finally, the relationship of the mean total dose received 
by the five swallowing muscles to the responses of the three–dysphagia-related–
QOL questionnaires (mean QOL scores; H&N35, PSS, and MDADI) is reported per 
tumor site (i.e., the TF and/or SP or BOT) and per treatment technique (BT vs. non-
BT). 
Dysphagia
From responses to the H&N35 (swallowing scale), PSS (normalcy diet), and to the 
MDADI questionnaires, prevalence of dysphagia was computed. Also, a moderate 
and severe degree of dysphagia is established by clustering, that is, e.g., regarding 
the charts, the RTOG grade 3 and 4 scores were combined. Similarly, for H&N35 
(swallowing) “quite a bit” and “very much” dysphagia (score ≥ 50) was scored as 
grade 3 and 4, respectively, and clustered as “severe.” The PSS (normalcy diet) 
score ≤ 50 and total MDADI score ≤ 50 were taken as the prevalence of a significant 
degree (equivalent to RTOG grade 3 or 4) of dysphagia. 
Xerostomia
Patients were also asked to respond to the dry mouth scale in the QOL question-
naire H&N35. The outcome was correlated to the dysphagia-related scale of the 
EORTC H&N35. A univariate and a multivariate analysis were performed for the 
parameters T-stage, N-stage, sex, age, dose in superior constrictor muscle (scm), 
dose in medial constrictor muscle (mcm), dose in inferior constrictor muscle (icm), 
dose in cricopharyngeal muscle (cphm), dose in fi rst centimeter of esophageal inlet 
(eim), site, neck irradiation unilateral, neck irradiation bilateral, neck irradiation plus 
ND, treatment before or after 2000 in relation to the QOL questionnaires.
Univariate Dose-Response Relationship
For the scm, mcm, icm, cphm and eim, the correlationsof dose in these muscular
structures and the absence or presence of dysphagia grade 3 and 4 combined 
(dataset dichotomized) were calculated using logistic regressions. For example:
Pr{H&N35 swallowing ≥ 50|Dose in scm} =1/(1 + exp (– (a + b *Dose scm))).We 
calculated coeffi cients for a and b and p-values for testing if b = 0.
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Tonsillara Fossa / Soft Palate (n=108)
Brachytherapy (n=83) Non-brachytherapy (n=25)
N0 N1 N2a N2b N2c N3 To-tal N0 N1 N2a N2b N2c N3
To-
tal
T1 2 4 3 5 0 2 16 0 0 0 1 0 0 1
T2 28 9 6 4 4 0 1 3 1 1 1 1 3 10
T3 9 1 3 2 0 0 15 3 5 0 0 2 0 10
T4a 0 0 0 0 0 0 0 2 1 0 0 0 0 3
T4b 1 0 0 0 0 0 1 1 0 0 0 0 0 1
Total 40 14 12 11 4 2 83 9 7 1 2 3 3 25
Table 1: UICC /AJCC 2002 edition TNM stage distribution for TF/SP tumors boosted by BT 
or non-BT techniques Tonsillar fossa/soft palate (n = 108) Brachytherapy (n = 83) Non-bra-
chytherapy (n = 25). 
Base of Tongue (n=47)
Brachytherapy (n=24) Non-brachytherapy (n=23)
N0 N1 N2a N2b N2c N3 To-tal N0 N1 N2a N2b N2c N3
To-
tal
T1 1 0 3 3 2 0 9 0 0 0 0 0 1 1
T2 1 0 1 2 1 0 5 1 2 0 0 2 1 6
T3 1 1 3 1 0 1 7 2 0 0 2 1 0 5
T4a 3 0 0 0 0 0 3 4 1 0 4 1 0 10
T4b 0 0 0 0 0 0 0 0 0 0 0 1 0 1
Total 6 1 7 6 3 1 24 7 3 0 6 5 2 23
Table 2:  UICC /AJCC 2002 edition TNM stage distribution for BOT tumors boosted by BT or 
non-BT techniques. 
results
Between 1991 and 2005, 155 oropharyngeal cancer patients were treated by RT; 
107 were boosted by BT, and 48 boosted by non-BT techniques. At the censor date 
1 January 2006, every patient without evidence of disease after a follow-up period 
of at least 1 year was asked to respond to three validated questionnaires, that is, the 
EORTC H&N35, PSS, and MDADI. Out of the patients alive NED, 93% responded. 
We have focused the data analysis in this chapter on calculating the mean number 
of patients with late side effects “dysphagia” (and “xerostomia”). Table 3 presents an 
overview of the boost techniques with the respective follow-up times.Tables 4 and 5 
summarize the QOL scores of the EORTC H&N35 for the BT group and the non-BT 
group with regard to the scales “swallowing” and “dry mouth,” respectively. Table 6 
presents QOL data with respect to the PSS scores, item “normalcy of diet.” Table 7 
shows the QOL mean scores of the MDADI. From the Tables 4–7 one can apprecia-
te differences in QOL outcome per validated questionnaire, per boost technique, and 
per tumor site. In short, the mean QOL scores for swallowing and dry mouth were 
Dysphagia in oropharyngeal cancer patients: adavantage for brachytherapy?
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better for BT patients as opposed to non-BT patients, for TF and/or SP tumors as 
opposed to BOT tumors and for those patients treated with BT and CHT vs. patients 
treated with CHT in combination with non-BT boost techniques. Better QOL scores 
were also observed in patients radiated to a single neck as opposed to bilateral neck. 
The outcome data are consistent for all three QOL questionnaires and summarized 
in Table 8. From the univariate and multivariate analyses one can conclude that BT 
and boost treatment are signifi cant parameters (p < 0.001) (Table 9). Also from Fig. 
4 one can appreciate a significant dose–effect relationship regarding swallowing; i.e., 
20% increase points per 10 Gy was found (Fig. 4).
Boost Technique # of Patients Mean FU years Range FU years
Brachytherapy 107 6.7 1.3-14.7
Non-Brachytherapy 48 3.7 1.0-10.5
IMRT 15 1.8 1.0-2.4
3DCRT 9 4.2 1.1-5.7
Parallel-Opposed 24 4.7 1.5-10.5
Table 3. Mean follow-up times for patients treated with different boost techniques: BT, IMRT, 
3DCRT, P-O.
discussion
This chapter analyzes the dose–volume relationships for swallowing problems (dys-
phagia) in oropharyngeal cancer. It particularly focuses on the relationship of swal-
lowing disorders caused by BT as opposed to other treatment techniques that have 
been used over the years to boost the primary tumor. Swallowing is a complex action 
requiring coordination between sensory input and motor function of the swallowing 
apparatus 24. Intensifi cation of therapy for head and neck cancer in general, either 
by altered fractionation RT schemes and/or by the addition of concomitant chemo-
EORTC H&N35: Swallowing scale (mean scores)
Quality of Life Categories Brachytherapy Non-Brachytherapy
TF/SP BOT Total TF/SP BOT Total
All patients 19 22 19 30 47 38
Ipsilateral Neck RT 9 No data 9 17 No data 17
Bilateral Neck RT 24 22 23 31 47 39
Ipsilateral RT + ND 10 No data 10 0 No data 0
Bilateral Neck RT + ND 21 12 22 28 40 32
Chemotherapy 12 14 13 33 42 38
Table 4. Outcome QOL for oropharyngeal cancer patients treated between 1991 and 
2005 in the Erasmus Medical Center-Daniel den Hoed Cancer Center: H&N35 swal-
lowing scale: high scores, more problems. 
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EORTC H&N35: Dry mouth scale (mean scores)
Quality of Life Categories Brachytherapy Non-Brachytherapy
TF/SP BOT Total TF/SP BOT Total
All patients 49 54 50 71 71 71
Ipsilateral Neck RT 35 33 35 78 No data 78
Bilateral Neck RT 56 55 56 33 71 71
Ipsilateral RT + ND 35 No data 35 56 No data 33
Bilateral Neck RT + ND 49 50 49 49 58 57
Chemotherapy 40 41 40 72 70 71
Table 5: Outcome QOL for oropharyngeal cancer patients treated between 1991 and 2005 in 
the Erasmus Medical Center- Daniel den Hoed Cancer Center: H&N35, dry mouth scale. 
therapy, results in improved loco-regional tumor control 5,11,23, and increase of late 
sequelae, such as dysphagia 22. In general, the prevalence of dysphagia is probably 
being underreported because of its (sometimes) clinically silent nature, but can be as 
high as 50% according to some papers on head and neck cancer survivors 4,18,19,27. 
Swallowing disorders are most likely caused by radiation induced edema and neu-
romuscular fibrosis 18. Consequentially, a reduced pharyngeal contraction results in 
an impaired bolus transport through the pharynx 8. Some controversy exists whether 
the various primary disease sites have a different impact on the severity and/or fre-
quency of dysphagia. Pretreatment swallowing therapy may improve dysphagia and 
reduce the need for tube feedings 10,15. The majority of our patients had stage III and 
IV disease (77%). After 2000, stage III and IV patients were offered more routinely 
concomitant CHT. In fact, before 2000 concomitant CHT was given to 11% of the 
advanced-staged patients, as opposed to 48% in advanced cases after 2000. Also, 
as of 2000, according to protocol, RT allowed for six fractions/week as opposed to 
(conventionally) five fractions. Between 1991 and 2005, 336 oropharyngeal cancers 
were treated. The LRC, DFS, and OS of the TF and/or SP and BOT tumors, boosted 
by BT or by non-BT techniques, are shown in Figs. 11.1–11.3. From this series of 
patients, chart review revealed that roughly 31% of patients experienced moderate 
to severe dysphagia (RTOG grade 3 and 4). Moreover, dysphagia was more of a 
problem in patients with BOT (40%) cancer as opposed to patients with cancer of 
the TF and/or SP (26%).
When grouped by the boost technique BT vs. non-BT, severe dysphagia (pro-
blem score of QOL H&N35 with swallowingitem ≥ 50) was observed in patients
with TF and/or SP tumors in 19% and for BOT tumors in 22%. For the non-
BT group, severe dysphagia was found in 30% of the TF/SP tumors and 
in 47% for the BOT tumors (see also Tables 4 and 5). A further break
down of the non-BT group with respect to the booster technique used showed se-
vere dysphagia in 42% for P-O, 25% for 3DCRT, and 25% for IMRT (data not shown 
in Tables 4 and 5). Also, more complaints were reported with higher doses, in parti-
cular with regard to the superior-and medial constrictor muscles. 
Figure 11.4 shows an example of the dose–effect relationship computed by logistic
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PSS: Normalcy of diet
Quality of Life Categories Brachytherapy Non-Brachytherapy
TF/SP BOT Total TF/SP BOT Total
All patients 75 78 75 64 51 58
Ipsilateral Neck RT 84 No data 84 75 No data 75
Bilateral Neck RT 70 78 73 63 51 57
Ipsilateral RT + ND 81 No data 81 100 No data 100
Bilateral Neck RT + ND 72 78 74 75 67 72
Chemotherapy 85 98 92 58 52 54
Table 11.6. Outcome QOL for oropharyngeal cancer patients treated between 1991 and 2005 
in the Erasmus Medical Center-Daniel den Hoed Cancer Center: PSS (performance status 
scale), item “normalcy of diet”.
MDADI (Mean scres)
Quality of Life Categories Brachytherapy Non-Brachytherapy
TF/SP BOT Total TF/SP BOT Total
All patients 75 74 75 59 52 55
Ipsilateral Neck RT 80 No data 80 55 No data 55
Bilateral Neck RT 71 74 72 60 52 55
Ipsilateral RT + ND 82 No data 82 81 No data 81
Bilateral Neck RT + ND 66 78 69 63 52 58
Chemotherapy 78 80 79 61 50 54
Table 7: Outcome QOL for Oropharyngeal cancer patients treated between 1991 and 2005 
in the Erasmus Medical Center: MDADI (MD Anderson Dysphagia Inventory), function scale. 
High scores better functions;
regression. The steepness of the curve from 60 Gy, can be expressed by 20% 
increase/10 Gy. Furthermore, next to dose being a significant factor, other variables 
of importance with respect to dysphagia are treatment of the unilateral (vs. bilateral 
neck), and ND (see also Table 8). We speculate that this increase in dysphagia 
(high dose, no BT, bilateral neck irradiation, no ND) has to do with the increase in 
irradiated volume and radiation dose. Finally, for the same reason, xerostomia and 
dysphagia are also strongly correlated; that is, p≤  0.001 for the parameter dose in 
the scm/mcm vs. the parameter dry mouth 25. 
conclusions
Overall, according to chart review, a severe degree of dysphagia (RTOG grade III 
and IV) was experienced in 31% of the patients. Similarly, according to respon-
ses to the EORTC H&N35 QOL questionnaires, severe dysphagia was observed in 
about 20% of the BT group and about 38% in the non-BT group. Univariate analysis
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Quality of Life Categories H&N35Swallowing
PSS
Normalcy of diet
MDADI
Dysphagia
BT all patients vs. non-BT all patients BT > BT > No data
Ipsilateral Neck RT vs. Bilateral Neck RT Ipsilateral > Ipsilateral > No data
Ipsilateral Neck RT + ND vs. Bilateral Neck RT Ipsilateral > Ipsilateral > No data
Chemotherapy BT vs. Chemotherapy non-BT CHT BT > CHT BT > No data
TF/SP BT vs. BOT BT TF = BOT TF = BOT No data
TF/SP non-BT vs. BOT non-BT TF > BOT TF > BOT TF > BOT
Table 8: For some of the relevant patient/tumor characteristics, comparison between the out-
come of three QOL questionnaires used in the present chapter (i.e., EORTC H&N35, PSS, 
MDADI).
The compared outcome data were taken from Tables 4–7. That is, the differences in sparing 
capacity (e.g., less problems with swallowing, better functioning in general) is based on res-
ponses to the validated QOL questionnaires EORTC H&N35 (see Table 4 item “swallowing” 
and see Table 5 item “dry mouth”), PSS (see Table 11.6 item “normalcy of diet”), and MDADI 
(see Table 11.7 item “dysphagia”).
>: better; =: equivalent; ND: neck dissection; RT: radiation therapy.
Univariate/MultivariateAnalysis
T-stage Brachy 
therapy
Boost 
Treat-
ment
Surgery 
Neck
Neck 
Irradia-
tion
Dose 
scm
Dose 
mcm
H&N 35 Swallowing 0,005 0,006 0,012 0,012 - <0,001 <0,001
H&N 35 Dry mouth - - 0,003 0,01 0,006 <0,001 <0,001
MDADI 0,018 0,002 0,026 - - <0,001 0,001
PSS Normalcy of Diet - - <0,001 - 0,02 <0,001 <0,001
Table 9: Univariate analysis: parameters found to be signifi cant in relation to outcome of QOL 
questionnaires H&N35 (swallowing, dry mouth), MDADI (dysphagia) and PSS (normalcy of 
diet). 
Multivariate analysis: the parameters of the univariate analysis found to be significant for 
H&N35 (swallowing), H&N35 (dry mouth), MDADI (swallowing) and PSS (normalcy of diet). 
scm: superior constrictor muscle; mcm: medial constrictor muscle.
demonstrated less dysphagia for the following conditions: lower mean doses applied 
to swallowing muscles, BT treatment, single neck irradiation, and in case a ND is 
performed. The multivariate analysis shows a signifi cant effect for BT (~implicating 
less swallowing complaints due to the lower doses of radiation received by the swal-
lowing muscles). For improvement of the dysphagia-related QOL, it is suggested to 
try and further optimize the dose distribution.
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Fig. 4: Univariate dose–response relationship: for the scm, mcm, icm, cphm, and eim. The 
correlations of dose in these muscular structures and the absence or presence of dysphagia 
grade 3 and 4 combined (data set dichotomized) were calculated using logistic regressions. 
For example: Pr{H&N35 swallowing ≥ 50|Dose in scm} =1/(1+exp (– (a + b * Dose scm))). We 
calculated coefficients for a and b and p-values for testing if b = 0. This graph exemplifi es the 
D–E curve for the superior constrictor muscle (scm).
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AbstrAct
Purpose: Comparison of quality of life (QoL) and side effects in a randomized trial 
for early hyperbaric oxygen therapy (HBOT) after radiotherapy (RT).
Methods and Materials: From 2006, 19 patients with tumor originating from the 
tonsillar fossa and/or soft palate (15), base of tongue (1), and nasopharynx (3) were 
randomized to receive HBOT or not. HBOT consisted of 30 sessions at 2.5 ATA (15 
msw) with oxygen breathing for 90 min daily, 5 days per week, applied shortly after 
the RT treatment was completed. As of 2005, all patients received validated ques-
tionnaires (i.e., the European Organization for Research and Treatment of Cancer 
[EORTC] QLQ-C30, EORTC QLQ Head and Neck Cancer Module (H&N35), Perfor-
mance Status Scale): before treatment; at the start of RT treatment; after 46 Gy; at 
the end of RT treatment; and 2, 4, and 6 weeks and 3, 6, 12, and 18 months after 
follow-up.
Results: On all QoL items, better scores were obtained in patients treated with hy-
perbaric oxygen. The difference between HBOT vs. non-HBOT was significant for all 
parameters: EORTC H&N35 Swallowing (p = 0.011), EORTC H&N35 Dry Mouth (p 
= 0.009), EORTC H&N35, Sticky Saliva (p = 0.01), PSS Eating in Public (p = 0.027), 
and Pain in Mouth (visual analogue scale; p < 0.0001).
Conclusions: Patients randomized for receiving hyperbaric oxygen after the RT 
had better QoL scores for swallowing, sticky saliva, xerostomia, and pain in mouth.
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introduction
The goal of treating head and neck cancer patients with radiotherapy (RT) is to de-
liver high doses of ionizing radiation to the cancer (target) aiming for control of the 
disease and to maximally spare the surrounding normal tissues. The parotid glands 
are frequently protected from radiation by applying intensity-modulated radiation 
therapy (IMRT) techniques. The quality of life (QoL) of oropharyngeal or nasopha-
ryngeal cancer patients treated with such high doses of RT is influenced by acute 
side effects, such as painful mucositis (e.g., leading to compromised food intake) 
and late sequelae, such as xerostomia, Grade 3/4 mucositis, trismus, and dyspha-
gia. These non-life-threatening side effects frequently affect QoL. Recently, we have 
reported a dose–effect relationship for swallowing problems. Using the European 
Organization for Research and Treatment of Cancer (EORTC) Head and Neck 
Cancer Module (H&N35) QoL questionnaire and fiberoptic endoscopic evaluation 
of swallowing (FEES), a significant increase in swallowing problems was reported 
with increasing dose 1. Xerostomia or dry mouth syndrome results in medical and 
psychological problems and social distress. For example, the disorder can cause dif-
ficulties in speech, chewing, and swallowing, leading to social problems, nutritional 
problems, and potentially severe dental decay. Dry mouth syndrome is caused by a 
lack of saliva and a change in the quality of saliva by radiation damage to the major 
and minor salivary glands. Saliva is produced in both resting and under salivary 
glands stimulatory conditions. Eisbruch et al. 2, for example, have shown that limiting 
the mean parotid gland dose to approximately 26 Gy can preserve the parotid gland 
function. Although the parotid glands contribute significantly to the saliva production 
under stimulatory conditions, they contribute only 20% of the total volume of saliva 
under resting conditions, whereas submandibular salivary glands contribute 65% 3. 
However, protecting the submandibular glands is far more difficult than protecting 
the parotid glands. Hyperbaric oxygen therapy (HBOT) is being used for treatment 
of late radiation tissue injury 4, but little is known whether HBOT shortly after radio-
therapy can reduce radiation side effects. Recently Williamson 5 published an expe-
rimental study of the use of hyperbaric oxygen immediately after radiation treatment 
for malignant disease in a rat model. He reported that, in contrast to the non-HBOT 
rats, HBO-treated rats showed continued growth of teeth and maintenance of spe-
cialized tissues, such as salivary gland and bone in the histological sections. The 
potential benefit of HBOT in preventing and reducing side effects of RT or chemo-
therapy in oropharyngeal or nasopharyngeal cancers of the head and neck was the 
subject of this study. It focused on reduction of radiotherapy toxicity in treatment of 
oropharyngeal cancer patients with or without administration of HBOT after comple-
tion of a radiotherapy treatment schedule (table 1). Our primary study objective was 
to determine whether adjuvant hyperbaric oxygen would reduced RT-related side 
effects in primary oropharyngeal and nasopharyngeal cancer of the head and neck 
treated by radiation therapy. The primary endpoint was toxicity: xerostomia, dyspha-
gia, trismus, and QoL.
Hyperbaric oxygen for reducing radiotherapy side effects
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Methods And MAteriAls
Patients
Patients presenting at the Erasmus Medical Center (Rotterdam, The Netherlands) 
with oropharyngeal or nasopharyngeal cancer were eligible for the trial. Patients 
aged > 18 with histological proof of squamous cell carcinoma of mucous membranes 
of the oropharynx and nasopharynx who were to be treated with curative intent and 
who had Karnofsky Performance Status score of ≥ 70 were included. All patients 
underwent dental examination before radiotherapy. The total prescribed dose of RT 
to the planning target volume ranged from 46 to 70 Gy. Prescribed brachythe rapy 
boost dose to the primary tumor ranged from 11 to 22 Gy, and prescribed Cyberknife 
boost dose ranged from 11.2 to 16.5 Gy. More detailed institutional treatment sche-
dule has been described elsewhere 6,7. The parotids received a mean dose of 6–67 
Gy (median dose, 37 Gy). Written informed consent was obtained before the start 
of the treatment. The study was approved by the Erasmus Medical Center medical 
ethics board.
Table 1: Trial schema of the hyperbaric oxygen trial of oropharyngeal and nasopharyngeal 
cancer patients.
Abbreviations: IMRT = intensity-modulated radiotherapy; BT = brachytherapy; CBK = Cyber-
knife; HBO = hyperbaric oxygen; PORT = postoperative radiotherapy.
235
..........
Hyperbaric treatment procedure
In patients randomized for HBOT, HBOT was started within 2 days after completion 
of radiotherapy (and chemotherapy if applicable). HBOT was given at the speciali-
zed Institute for Hyperbaric Medicine in Rotterdam in a multiplace hyperbaric cham-
ber. The chamber was pressurized with air over 10 min to a treatment pressure of 
2.5 atmospheres absolute (ATA). At this pressure, 100% oxygen was delivered by 
oronasal mask in three episodes of 25 min, interrupted by 5 min of air breathing, 
followed by a final 15-min block of oxygen. Depressurization was done on air over 
10 min, resulting in an overall treatment duration of 125 min with a total of 90 min of 
hyperbaric oxygen breathing. This treatment schedule was followed 5 working days 
per week for the duration of 6 weeks, adding up to 30 total sessions. During pressure 
changes, great care was taken to avoid barotraumas, particularly of the middle ear, 
which is the most common side effect of hyperbaric treatment.
Randomization
Patients were randomized by the trial office. This randomization took place directly 
after inclusion of the patients in the study by use of a block of several randomized 
sizes. Patients were stratified by tumor site (i.e., oropharynx or nasopharynx) and 
treatment modality (i.e., IMRT or Cyberknife/Brachytherapy or postoperative radio-
therapy).
Quality of life
For QoL investigation, all patients were given the following questionnaires: (1) The 
EORTC core QoL Questionnaire (QLQ)-C30, (2) The EORTC QLQ-H&N35 8, and 
(3) the Performance Status Scale (PSS) of List et al. 9 with the normalcy of diet item. 
Patients also used a visual analogue scale (VAS; 0–10) to rate their dry mouth and 
pain. At the time points 0 (before treatment), 1 (start of treatment), 2 (46 Gy), 3 (end 
of treatment), 4 (2 weeks posttreatment, 5 (4 weeks posttreatment), 6 (6 weeks post-
treatment), 7 (3 months posttreatment), 8 (6 months posttreatment), 9 (12 months 
posttreatment), and 10 (18 months posttreatment), questionnaires were sent to the 
patients by mail. After scoring, the questionnaires were returned to the data mana-
ger (table 2).
Statistical analysis
The sample size of this trial was based on a reduction of xerostomia of 50% to 25% 
at 1 year after starting treatment if HBOT was used, which meant that 2 × 66 pa-
tients (alpha = 0.05, two-sided; beta = 0.80) were needed to be included. A robust 
regression analysis was performed with the responses to the QoL questionnaires at 
the various time points (Table 2). Further, differences (p values) for the hyperbaric 
oxygen vs. control group were computed at time cohorts before radiotherapy (t = 0), 
at the end of radiotherapy and until 13 weeks posttreatment (t = 3 through t = 7), and 
during the time periods of 13 weeks until 78 weeks post treatment (t = 7 until t = 10). 
At t = 0, a Mann-Whitney U test was used. For the other two time cohorts, regres-
sion analysis for each complaint variable vs. time (coded with dummy variables) and 
treatment factor (yes/no hyperbaric oxygen) were performed with the program xtreg 
in Stata. This was a regression analysis based on maximum likelihood estimation 
Hyperbaric oxygen for reducing radiotherapy side effects
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List number Time point
0 Before treatment
1 Start treatment
2 Mid treatment (46 Gy)
3 End treatment
4 2 weeks post-treatment
5 4 weeks post-treatment
6 6 weeks post-treatment
7 3 months post-treatment
8 6 months post-treatment
9 12 months post-treatment
10 18 months post-treatment
Table 2: Time points corresponding to the quality of life list numbers.
and incorporating the longitudinal character of the data. Stata 9 software was used 
for the statistical analysis (Stata Statistical Software, Release 9; StataCorp, Col-
lege Station, TX).
results
Because of slow accrual and lack of financial support, the trial was stopped at a 
premature time point, with only 19 patients eligible to be studied for the effect of 
hyperbaric oxygen. All patients included in the tri al were analyzed to this effect. 
Patient characteristics are shown in table 3. At the censor date of March 1, 2008, 
with first patient included at the beginning of 2006, maximum follow-up time was 78 
weeks. Results regarding xerostomia-related questionnaires are shown in figure 1, 
figure 2 and figure 3. A significant difference in the HBOT group compared with the 
non-HBOT-treated control group was found for the sticky
saliva and dry mouth items of the EORTC H&N35 questionnaires and the VAS dry 
mouth item. The mean scores for the VAS dry mouth item per time point are given in 
Table 4. The p values were calculated by dividing the sequence of toxic events in an 
acute phase (end of radiation until 13 weeks posttreatment) and a late side effects 
phase (from 13 weeks until 78 weeks posttreatment). The differences in QoL scoring 
were not significant in the acute phase; however, late side effects were significantly 
reduced for the HBOT group (figure 1). For dysphagia-related questionnaires, there 
was also a significant difference in QoL between patients treated vs. not treated with 
hyperbaric oxygen (figure 4 and figure 5). The mean QoL scores for the EORTC 
H&N 35 swallowing item, per time point, are shown in table 5. The VAS score for 
pain in mouth between the with- and without-HBOT groups was also significantly 
different, as shown in figure 6. The following p values were established for EORTC
237
..........
HBO + HBO -
Number 8 11
Tumor site
    Tonsillar Fossa 6 9
    Base of Tongue 1 0
    Nasopharynx 1 2
Male / Female 6 / 2 6 / 5
TNM stage
     T1 2 2
     T2 5 3
     T3 1 4
     T4a 0 2
     N0 3 3
     N1 0 2
     N2a 0 1
     N2b 4 2
     N2c 0 2
     N3 1 1
Stage grouping
I 0 1
II 3 2
III 4 6
IV 1 2
Chemotherapy 3 5
Boost
    No 3 6
    Brachytherapy 4 2
    Cyberknife 1 3
Bilateral Neck 1 1
Table 3: Patient characteristics tableAbbreviation: HBO = hyperbaric oxygen.
H&N35 sticky saliva (p = 0.01), EORTC H&N35 dry mouth (p = 0.009), EORTC 
H&N35 swallowing (p = 0.011), PSS eating in public (p = 0.027), and VAS Pain in 
mouth (p < 0.0001). HBOT side effects were limited in our patients. HBOT was well 
tolerated in this group of patients. 
discussion
When radiation is used to treat cancer, it also (partly) affects a variety of critical 
Hyperbaric oxygen for reducing radiotherapy side effects
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surrounding normal tissues, which can become hypocellular, hypovascular, and 
hypoxic, frequently eluded to as “3 H tissue.” The hypoxic status of tissues can 
be counteracted to some extent by oxygenation of normal cells with HBOT. The 
effects of hyperbaric oxygen can be briefly summarized as follows: short-term ef-
fects are enhanced by oxygen delivery, reduction of edema, and phagocytosis 
activation, as well as anti-inflammatory effects. Long-term effects are neovascula-
rization, osteoneogenesis, and stimulation of collagen formation by fibroblasts 10.
It was recently found that a significant increase in mobilization of stem cells from 
the bone marrow occurs in the course of HBOT 4,11. Wound healing and recovery of 
normal-tissue radiation injury are the end result 12-14. It has been demonstrated that 
hyperbaric oxygen administration reaches its optimal effect after 24–30 sessions 
for neo-angiogenesis, and stem cell mobilization is particularly prominent after 20 
treatments 11. Therefore, in our study, we applied 30 sessions. It could be that 20 
sessions are sufficient to reduce side effects. This remains to be elucidated in future 
studies.
Clinically, hyperbaric oxygen has shown beneficial effects, for example, in hypoxic 
ulcers that result in severe wound-healing problems and in osteoradionecrosis 4. 
HBOT has been used for 40 years in combination with conservative treatment and 
radical surgery for necrotic soft tissues and bone that fail to heal.
Although there are some conflicting experimental results 15, it is now believed that 
HBOT does not promote cancer growth (primary or metastasis). Moreover, accor-
ding to Feldmeier et al. 16, no evidence indicates that hyperbaric oxygen is an initi-
ator or promotor of cancer de novo. According to Schonmeyr et al. 17, no difference 
of cellular proliferation of squamous cell cancer in vitro was observed comparing 
hyperbaric oxygen–treated cells with controls. In a study by Marx et al.  18, HBO in-
duced significantly angiogenesis, measurable after eight HBOT sessions. Recently, 
Gerlach et al. 19 published a retrospective study on the use of HBOT in clinic; they 
described 21 patients who received radiotherapy for oral or oropharyngeal carci-
noma in which swallowing-related problems significantly decreased with time. They 
also observed a subjective increase in saliva and an improvement in sense of taste. 
In a review by Bennett et al. 4, the authors concluded that there is some evidence 
that hyperbaric oxygen improves outcomes in late radiation tissue injury affecting 
bone and soft tissues of the head and neck, for proctitis, and to prevent the develop-
ment of osteoradionecrosis following tooth extraction in an irradiated field. A large 
double-blind randomized study has shown the substantial benefit of HBOT on QoL 
in chronic refractory radiation proctitis 20. In contrast to our study, these publications 
are concerned with the use of HBOT in late radiation tissue damage. The possible 
preventive action of HBOT immediately after radiotherapy has not been addressed, 
which was the purpose for our study.
We found a significant difference in several QoL aspects between patients in whom 
early hyperbaric oxygen was administered vs. a non-HBOT group. Five to 18 pa-
tients responded to the questionnaires at each time point. Although there was varia-
tion in response to the questionnaires at each time point, comparison of the groups 
at the various time points appeared to be nonsignificant (Mann-Whitney U test; p 
= 0.84). Clearly, the QoL of patients is similar until the end of radiation or in the 2 
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Figure 1: European Organization for Research and Treatment of Cancer (EORTC) Head and 
Neck Cancer Module (H&N35) sticky saliva item scores between the hyperbaric oxygen–
administered group of patients and the group that was not administered hyperbaric oxygen 
over an 18-month period. QoL = quality of life. 
Figure 2: European Organization for Research and Treatment of Cancer (EORTC) Head and 
Neck Cancer Module (H&N35) dry mouth item scores between the hyperbaric oxygen–admi-
nistered group of patients and the group that was not administered hyperbaric oxygen over an 
18-month period. QoL = quality of life. 
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Figure 3: Visual analog scale of the dry mouth between the hyperbaric oxygen–administered 
group of patients and the group that was not administered hyperbaric oxygen over an 18-
month period. QoL = quality of life. 
Figure 4: Performance status scale (PSS) eating in public item scores between the hyperbaric 
oxygen–administered group of patients and the group that was not administered hyperbaric 
oxygen over an 18-month period. QoL = quality of life. 
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Figure 5: European Organization for Research and Treatment of Cancer (EORTC) Head and 
Neck Cancer Module (H&N35) swallowing item scores between the hyperbaric oxygen–admi-
nistered group of patients and the group that was not administered hyperbaric oxygen over an 
18-month period. QoL = quality of life. 
Figure 6: Visual analog scale of the pain in mouth question between the hyperbaric oxygen–
administered group of patients and the group that was not administered hyperbaric oxygen 
over an 18-month period. QoL = quality of life. 
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List number HBO No HBO Total group
0 0 3 2
1 0 3 2
2 5 6 6
3 6 7 6
4 6 6 5
5 5 6 6
6 4 7 5
7 4 6 5
8 4 6 5
9 4 7 4
10 3 7 5
Table 4: Mean quality of life score for visual analog scale dry mouth at the different time 
points. Abbreviation: HBO = hyperbaric oxygen.
List number HBO No HBO Total group
0 7 25 17
1 6 28 18
2 45 59 53
3 42 56 48
4 42 52 48
5 19 19 19
6 15 33 27
7 10 30 21
8 12 33 24
9 7 40 20
10 0 54 22
Table 5: Mean quality of life score for EORTC H&N35 swallowing item at the various time 
points. Abbreviations: EORTC = European Organization for Research and Treatment of Can-
cer; H&N35 = Head and Neck Cancer Module; HBO = hyperbaric oxygen.
period within 2 weeks after radiation. The worst scores on the QoL items (patient 
complaints) were found at the end of radiation or in the period within 2 weeks af-
ter completion of radiation. A significant difference was observed for the EORTC 
H&N35 dry mouth question (figure 2), that is, baseline values for the patients treated 
with HBO and those not treated. However, we could not identify confounding factors 
to explain this difference. One possible reason for this is that some patients who 
knew they were not going to receive HBOT after radiation could argue that they must 
have a dry mouth to some extent because the purpose of the investigation was to 
investigate potential successful treatment of xerostomia with HBOT. Increased QoL 
in patients treated with hyperbaric oxygen showed a steep improvement beginning 2
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weeks after finishing RT. This was found to be particularly true for the data in our 
study regarding xerostomia and dysphagia. Pain (VAS score) was also almost totally 
eliminated (no pain 6 weeks posttreatment). Of interest is the fact that no significant 
effect of hyperbaric oxygen was shown for early side effects (see figure 1, figure 4 
and figure 5; time cohort 3 until 7 (≤ 13 weeks) as opposed to the late side effects 
(≥ 13 weeks posttreatment). Patients undergoing HBOT are probably aware that the 
treatment under study consisted of hyperbaric oxygen, with the reverse being true 
for those not receiving HBOT; however, we do not believe that patients filling in the 
questionnaires after 18 months maximum follow-up are biased by the treatment. 
Nevertheless, a placebo effect could not totally be disproved.
conclusions
A significant difference was observed between the non-HBOT vs. HBOT groups in 
almost every QoL issue studied. Although this study is limited by the small numbers 
of patients, we feel that the data are of interest because they emphasize the potenti-
al beneficial effect of early hyperbaric oxygen. Several issues remain to be explored. 
It is of interest to determine the optimal commencement of HBOT after radiation the-
rapy as well as the necessary number of treatments. Also, the mechanisms through 
which HBOT shortly after radiotherapy cause the demonstrated beneficial effects on 
QoL should be further explored. Because questions remain regarding HBOT after 
radiotherapy, a bigger randomized trial should be conducted to answer the remai-
ning questions.
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AbstrAct
Purpose: To quantify the anatomic changes caused by external beam radiothe-
rapy in head-and-neck cancer patients in full three dimensions and to relate the local 
anatomic changes to the planned mean dose.
Methods and Materials: A nonrigid registration method was adapted for RT ima-
ge registration. The method was applied in 10 head-and-neck cancer patients, who 
each underwent a planning and a repeat computed tomography scan. Contoured 
structures (parotid, submandibular glands, and tumor) were registered in a nonrigid 
manner. The accuracy of the transformation was determined. The transformation 
results were used to summarize the anatomic changes on a local scale for the ir-
radiated and spared glands. The volume reduction of the glands was related to the 
planned mean dose.
Results: Transformation was accurate with a mean error of 0.6 ± 0.5 mm. The 
volume of all glands and the primary tumor decreased. The lateral regions of the ir-
radiated parotid glands moved inward (average, 3 mm), and the medial regions ten-
ded to remain in the same position. The irradiated submandibular glands shrank and 
moved upward. The spared glands showed only a small deformation (not, vert, simi-
lar1 mm in most regions). Overall, the primary tumors shrank. The volume loss of the 
parotid glands correlated significantly with the planned mean dose (p <0.001).
Conclusion: General shrinkage and deformation of irradiated glands was seen. 
The spared glands showed few changes. These changes were assessed by a non-
rigid registration method, which effectively described the local changes occurring in 
the head-and-neck region after external beam radiotherapy.
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introduction
Technical improvements in dose delivery and verification of patient positioning have 
widened the therapeutic window for radiotherapy (RT) of head and neck cancer 1-6. 
For example, intensity-modulated RT makes it possible to escalate the dose by con-
forming the high-dose region tightly to the target volume, thereby sparing adjacent 
normal tissue. In-room imaging devices, such as cone beam computed tomography 
(CT) scanners or CT on rails, allow for the assessment of nonrigid setup errors in 
head-and-neck cancer patients 7-10. Currently, computer-aided dose optimization is 
determined from a single CT scan acquired before the start of treatment. During tre-
atment, significant anatomic changes, including shrinkage of the primary tumor and 
nodal masses and changes in overall body habitus, have been observed 11-13. These 
changes can cause deviations between the planned and delivered dose and might 
partly undo the benefits of intensity-modulated RT 14-16.
To date, mostly global measures, such as volume and position changes, have been 
used to quantify the anatomic changes 11,14. Using a repeat CT study, Robar et al. 17 
reported the systematic medial translation of the lateral regions of the parotid glands. 
This analysis was based on two selected points, one on the lateral and one on 
the medial border of the gland. In our study, a nonrigid registration method 18 was 
adapted and used to quantify local soft-tissue changes in 10 head-and-neck cancer 
patients using two CT scans: the planning CT scan and a repeat CT scan after 46 Gy 
of external beam radiotherapy (EBRT). This method allows for soft-tissue changes 
to be assessed in full three dimensions (3D). The shape and position changes of 
the primary tumor and the parotid and submandibular glands were quantified. After 
nonrigid registration, the glands were divided into irradiated glands, belonging to a 
treated neck, and spared glands, belonging to a nontreated neck. On the basis of 
these registrations, in both groups, the changes in shape and position during EBRT 
were summarized on a local scale by dividing each organ into six regions. Further-
more, the volume changes in the parotid and submandibular glands were related to 
the planned mean doses.
Methods And MAteriAls
Patient data
A total of 10 consecutive oropharyngeal patients, 5 men and 5 women, aged 48–83 
years (mean, 60 years), who were treated between November 2004 and December 
2005, were included in this study. The patient characteristic are listed in Table 1. 
The patients first underwent EBRT to a total dose of 46 Gy in 23 fractions (dynamic 
intensity-modulated RT), followed by a brachytherapy boost (20–22 Gy) 19-21. Two in-
travenous contrast-enhanced CT scans were available for each patient, the planning 
CT scan and a repeat CT scan taken with the patient in the treatment setup position 
2 weeks after the end of the EBRT (post-EBRT CT scan). A Posicast mask was used 
for immobilization during all CT scanning and treatment fractions. The slice spacing 
was 3 mm for the planning scan and 1.5 mm for the post-EBRT scan. Before the 
nonrigid registration, the CT scans were first rigidly matched using the bony anatomy 
Local anatomic changes studied with nonrigid registration
-----------------------------------------------------------------------------
250
..........
in the region of interest. The primary tumor and parotid and submandibular glands 
were manually contoured in both CT scans. For consistency, the post-EBRT CT 
scan was delineated, using the planning CT scan as a reference. All delineations 
were checked by a second observer. The delineated contours were used to create 
surfaces. These surfaces were defined by a set of triangles joining contours in the 
consecutive slices.
Bilateral neck treatment incded both necks; unilateral neck treatment included only 
ipsilateral neck, which was always located on right side; Patient 6 received concur-
rent chemotherapy. 
Pt. no. TNM classification Neck treatment Site
1 T1N2cM0 Bilateral Base of tongue
2 T3N2aM0 Bilateral Base of tongue
3 T2N1M0 Unilateral Tonsillar fossa
4 T2N0M0 Unilateral Tonsillar fossa
5 T2N0M0 Unilateral Soft palate
6 T3N2aM0 Bilateral Base of tongue
7 T2N0M0 Unilateral Tonsillar fossa
8 T1N1M0 Unilateral Tonsillar fossa
9 T3N3M0 Bilateral Base of tongue
10 T1N2cM0 Bilateral Base of tongue
Table 1: Patient characteristics. Abbreviation: Pt. no. = patient number.
Nonrigid registration method
A point-based method for nonrigid registration, known as Thin Plate Splines–Robust 
Point Matching or TPS-RPM, was modified 18,22. This method handles the nonrigid 
registration as a nonrigid point matching problem on which the correspondence and 
the transformation between two points sets, called in this report the “reference” and 
“deforming” point sets, are optimized iteratively. We generated sets of points based 
on the 3D surface of each delineated structure (Fig. 1, Step 1, and Fig. 2a,b). These 
points defined the boundaries of the structures in the method, and they were distri-
buted nearly homogeneously over the surface using a mean distance of 3 mm. The 
points were placed within the triangles that described the 3D surfaces. The distance 
was chosen so that the accuracy of the transformation was adequate to quantify 
the observed shape and position changes without exceeding the computational re-
sources. Note, the generated points were not restricted to the axial planes of the CT 
scans.
The iterative process for generating the transformation function is driven by determi-
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nistic annealing (Fig. 1, Step 2). This results first in a global and rough approximation 
and, later, in a local and detailed deformation. 
Each cycle of the process consists of two steps: (1) fuzzy corresponden-
ce estimation based on the position of the points, and (2) transformation up-
date based on the correspondence. At the end of each cycle, the positions 
of the deforming points are transformed by the newly found transformation. 
The annealing process controls the search range allowed to create the correspon-
dence between the reference and the transformed deforming point sets (global-to-lo-
cal strategy). At first, every deforming point is allowed to correspond to all reference 
points (global fuzzy correspondence). Gradually, the search range is decreased; 
as a consequence, only deforming and reference points in close proximity were 
allowed to correspond. Because the number and precise distribution of the points 
of the reference and deforming sets are, in general, different, no binary one-to-one 
correspondence is expected to exist between the points of both sets. The correspon-
dence between points is therefore not forced to reach a one-to-one state but is limi-
ted by the mean distance between the nearest neighbors of the deforming points. A 
pseudoclustering was implemented to, up front, avoid the correspondence of points 
between different organs. The final transformation T transforms the deforming point 
set to resemble the shape of the reference point set (Fig. 1, Step 3). When the roles 
of the reference and deforming point sets are switched in the process, a back-trans-
formation, BT, is generated.
Fig. 1. Process workflow. Step 1: Generation of points based on input structures' surfaces. 
Step 2: Nonrigid registration for generating the transformation function. Step 3: Application of 
generated transformation T to align deforming and reference structures.
Local anatomic changes studied with nonrigid registration
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Fig. 2: Illustration of steps of transformation process for 1 patient (bilateral neck treatment). 
(a,b) Structures and control points. (c,d) Overlapping structures before and after transfor-
mation. Transparent colors, planning; solid colors, post-EBRT. (e) Transformed points (as 
vectors), organs are separated for visualization. Par R/L = parotid right/left; Smg R/L = sub-
mandibular right/left. 
For the final analyses, we created refined surfaces based on the original surfaces. 
The triangles defining the surfaces were subdivided in smaller triangles, such that 
their edge length was, on average, 1.3 mm. Note, the refined surfaces were identical 
in shape to the original surfaces, but they contained more vertices, and these verti-
ces distributed nearly homogeneously.
Patient data analyses
The parotid and submandibular glands were divided into two groups defined by the 
neck treatment: irradiated glands, belonging to treated neck, and spared glands, 
belonging to the nontreated neck. Note, for each gland type, the irradiated glands 
included five left and five right glands from the bilateral neck treatment and five right 
glands from the ipsilateral neck in the unilateral neck treatment. The spared glands 
included five left glands from the contralateral neck in the unilateral neck treatment. 
The volume changes after treatment were measured. In addition, the volume chan-
ges of the glands were related to the planned mean dose in the organs.
A transformation T (Fig. 2d,e), and back-transformation BT were generated for each 
patient. Note, T and BT were determined for the glands and tumor of each patient simul-
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taneously, and not for each organ separately. To report the shape and position changes 
on a local scale, the refined surfaces of each organ were divided into six regions (Fig. 3).
The vertices of the refined surfaces were transformed and back-transformed using 
the transformations obtained per patient. To compare and process the results of the 
transformation and back-transformation in the same frame of reference, the direc-
tion of the resulting displacements of one of the transformations must be inverted 
(back-transformation in this study). For each of the six regions of an organ surface, 
all displacements resulting from T and BT were collected, and for each directional 
component (right–left, anterior-posterior, and inferior-superior), the average dis-
placement was calculated for each organ region per patient. The displacements 
per region were then averaged for the patient group, and standard deviations were 
calculated. Next, results of T and BT were averaged per region. Finally the length of 
the mean 3D displacement vector was calculated for each region on the basis of the 
average values of the directional components. These lengths and their correspon-
ding standard deviations, describing interpatient variations, are reported. Note, the 
changes determined from the nonrigid registration account for the deformation and 
shifts of the glands.
Fig. 3: Division in six regions for simple ellipsoid. Right, left, anterior, posterior, superior, 
and inferior subvolumes shown. Superior and inferior boxes contain 20% of total volume of 
bounding box. Four wedges define remaining (central) volumes. Each subvolume gathers ap-
proximately 17% of total number of organ surface vertices.
Accuracy of nonrigid registration
The transformation accuracy measures the misalignments between the transformed 
deforming surface and the reference surface (Fig. 2d). To quantify the transforma-
tion accuracy, the distance from each vertex of the transformed refined deforming 
surface to the closest triangle on the reference surface was measured, and its mean 
value is reported. There is no explicit drive in the method that makes the back-trans-
formation BT to be the inverse of the original transformation T; however, because 
the input points are the same, this behavior can be expected. Equivalence, or near 
equivalence, of the back-projection and the inverse of the original transformation is 
a minimal condition for application. This equivalence was expressed by the distance 
between a point and the same point after it was transformed and back-transformed 
Local anatomic changes studied with nonrigid registration
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(Fig. 4). In detail, a point P (on the surface) is transformed by the original transfor-
mation T(P) = PT. The transformed point PT is then back-transformed BT(PT) = P'. 
The distance equivalence d between P and P' was measured and reported. Note, 
the distance d also accounts for surface misalignments (because of transformation 
inaccuracy). When T and BT are inverse functions of each other and the misalign-
ment is zero between the transformed and reference surface, P' and P are mapped 
to the same position, and d is zero.
Fig. 4: Schematic drawing of transformation and back-transformation of point P. PT = T(P) is 
transformed P using transformation T; P' = BT(PT) is the back-transformed PT using back-
transformation BT. d is distance between P and P'. Distance d is zero when T and BT are 
inverse function of each other, with no misalignment between transformed and reference 
surfaces. Solid line represents deforming surface and dashed line, reference surface.
results
Figure 5 shows the anatomic changes for one of the patients who underwent 
bilateral neck treatment after EBRT. The space between the skin and mask in 
Fig. 5b clearly shows anatomic changes possibly caused by weight loss. Also 
visible  is the shrinkage and displacement of the contoured organs and tumor (Fig. 
5b) compared with the planning CT scan (Fig. 5a). Fig. 5c shows the transformed 
contoured structures of the planning CT scan together with the post-EBRT structu-
res. The transformed planning structures (red shadow) and the post-EBRT structu-
res (yellow contours) overlapped accurately.
In all patients, the transformation accuracy (surface misalignment between the refe-
rence and transformed deforming surfaces) was small, with an average mean dis-
tance of 0.6 ± 0.5 mm. These values were independent of organ or direction of the 
transformation (planning as reference and post-EBRT as deforming surfaces or vice 
versa). The average equivalence distance d (Fig. 4) was also small (1.5 ± 0.7 mm).
Volume reduction
All glands and primary tumors showed a significant reduction in volume. In the 
primary tumors, the volume reduction was 25% ± 15% compared with its origi-
nal volume (p <0.001, t test). Volume reductions, as well as the average planned 
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Fig. 5: Example of observed shape and position changes for head-and-neck patient (bilate-
ral neck treatment). (Upper) Parotid glands and (Lower) submandibular glands and primary 
tumor. (a) Planning computed tomography (CT) scan and delineated structures in red. (b) 
Post-external beam radiotherapy (EBRT) CT scan with planning (red) and post-EBRT CT 
scan (yellow) delineations. (c) Post-EBRT CT scan with delineated structures (yellow) and 
transformed planning structures (red shadow). 
mean doses, of the parotid and submandibular glands are summarized in Table 2.
The volume reduction for irradiated glands was significantly larger than the volume 
reduction of the spared glands (p <0.001 for the parotid and p = 0.05 for submandi-
bular glands, t test). Also, in the unilateral patients only, the volume reduction of the 
irradiated, or ipsilateral, glands was significantly larger than the volume reduction of 
the spared, or contralateral, glands (p = 0.02 for parotid and p = 0.001 for subman-
dibular glands, paired t test). No statistical difference was found in the volume re-
duction of the irradiated glands in patients with unilateral or bilateral neck treatment 
(p = 0.6, t test).
When correlating the volume changes with the planned mean doses, a significant 
relation was found for the parotid glands (p <0.001, r = 0.68, linear regression ana-
Gland Volume loss (%) p-value Planned mean dose (Gy)
Parotid glands
 Irradiated 17 ± 7 <0.001 25.15 ± 6.45
 Spared 5 ± 4 0.04 6.97 ± 3.49
Submandibular glands
 Irradiated 20 ± 10 < 0.001 45.62 ± 1.87
 Spared 11 ± 7 0.03 4.65 ± 2.49
Table 2: Volume reduction with respect to original volume and planned mean dose for irradi-
ated and spared glands. Data presented as mean ± standard deviation.
Local anatomic changes studied with nonrigid registration
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Fig. 6. Volume changes vs. planned mean dose for parotid glands. Solid line indicates linear 
regression (p <0.001, r = 0.68).
lysis; Fig. 6). No significant relation was found for the submandibular glands  (p = 
0.14, r = 0.35).
Local shape and position changes
The measured average deformations and standard deviation for all 10 patients are 
shown schematically in Fig. 7. The left side of Fig. 7, the solid line, represents the 
irradiated glands; the contralateral glands belonging to the irradiated group were 
mapped on the left side of Fig. 7. The spared glands are represented on the right 
side with the dashed line. The front view (Fig. 7b) shows the four glands and the 
displacement of each visible region after EBRT. Figure 7a shows the right view 
(posterior-anterior and inferior-superior projection) of the irradiated glands. Figure 7c 
shows the left view (anteroposterior–inferosuperior projection) of the spared glands. 
The arrows represent the direction of the displacement of each region in each pro-
Fig. 7: Three-dimensional (3D) lengths of average 3D vectors and standard deviations for 
each region in millimeters. Arrows show projection of average 3D deformation vectors in (a) 
right, (b) frontal, and (c) left views. Solid lines represent irradiated glands (15 parotid and 
submandibular glands); dashed lines represent spared glands (5 parotid and submandibular 
glands). External lateral walls of glands represented with gray shadows.
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jection. The values are the average 3D displacements in millimeters with standard 
deviations, when the average was taken for the patient group. The gray areas repre-
sent the external lateral walls of the glands.
Shape and position changes of parotid glands
The shape and position changes in all six regions of the irradiated parotids were 
significantly larger than the changes in the spared parotids group (maximal p = 0.02, 
t test per region; Fig. 7). Within the unilateral group, the shape and position changes 
between the ipsilateral parotid glands were, on average, larger than the shape and 
position changes of the contralateral glands, but the differences were not statistically 
significant. In the irradiated group, the parotid glands shrank, keeping the regions 
nearby to bony anatomy as an anchor. All regions showed a tendency to move in-
ward (right parotid leftward and left parotid rightward). The largest displacements 
were in the lateral and inferior regions. The region that moved the least was the 
medial region (partially adjacent to the bony structure). Spared parotid glands sho-
wed translations of about 1 mm for the superior, lateral, and anterior regions, all in a 
similar direction (inward and upward). The posterior region showed zero mean dis-
placement, and the inferior region showed the largest displacement. Figure 8 shows 
the scans of a patient who underwent unilateral EBRT, on which the asymmetric 
shrinkage of the parotids is visible (Fig. 8b). The nonsymmetric change in the space 
between the skin and mask is clear.
Fig. 8. Patient with unilateral irradiation (right neck). (a) Planning computed tomography scan. 
Red contours indicate parotid glands. (b) Computed tomography scan after external beam 
radiotherapy. Yellow contours indicate parotid glands after treament; red contours, parotid 
glands before treatment.
Local anatomic changes studied with nonrigid registration
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Shape and position changes of submandibular glands
The shape and position changes in most regions of the irradiated submandibular 
glands were significantly larger than the changes in the spared submandibular group 
(border line significance, p = 0.06 for the medial region, maximal p = 0.05, t test for 
other regions; Fig. 7). In the unilateral group, the shape and position changes bet-
ween the ipsilateral and contralateral glands were not significantly different. In the 
irradiated group, the submandibular glands shrank and moved upward. The regional 
displacements in these structures were directed mostly superiorly and posteriorly. 
The superior and medial regions moved the least. The rest of the regions presented 
a displacement of between 3 and 4 mm. All regions of spared submandibular glands 
displaced approximately in the same direction as the irradiated glands. The magni-
tude, however, was much smaller: 1–2 mm.
Shape and position changes of primary tumor
The results for the clinical target volume should be interpreted with care owing to the 
uncertainty related to its localization and the variability of the tumor sites included 
in the study. The clinical target volume presented a general shrinkage with a pro-
nounced reduction in the posterior region (4 ± 4 mm), mostly in the anterior direction. 
The displacements in the left region were 3 ± 4 mm rightward. The region that moved 
the least was the right region (1 ± 3 mm). The other regions moved about 2 mm.
discussion
The presented nonrigid registration method is a powerful tool to accurately assess 
local shape and position changes in head-and-neck patients. The measurement ac-
curacy of such changes was determined by the inherent accuracy of the method, as 
well as the accuracy and precision of the contouring by the physician. The inherent 
accuracy was investigated by assessing the transformation accuracy, and the equi-
valence of the inverse transformation T-1, with its corresponding back-transformation 
BT (expressed as the equivalence distance d). The transformation accuracy, defined 
as the mean distance between the reference surfaces and corresponding transfor-
med deforming surfaces, was 0.6 ± 0.5 mm. The observed small values for d (1.5 ± 
0.7 mm) confirmed that T-1 and BT are nearly equivalent, which is a minimal requi-
rement for clinical application. The displacements found for the spared glands had 
magnitudes in the order of the error of the method.
In an attempt to keep the systematic component of the delineation error small, in 
this study, the same person delineated both CT scans. Moreover, the planning CT 
scan was always used as a reference for post-EBRT CT scan delineation. However, 
some random variations in the contouring of both CT scans were still present. The 
uncertainty related to contouring mainly affects the clinical target volume, because 
the contrast between the tumor and its surrounding tissues is very low.
When the found transformation was applied to CT scans, a good alignment between 
the transformed structures and original contours was found. One should note that the 
nonrigid registration was controlled by the point sets on the surfaces of the organs. 
Therefore, the accuracy of the transformation is decreased outside the region of 
interest, because the contribution of the nonrigid components of the transformation 
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decreases further away from the region of interest. Inside the structures only a small 
misalignment is expected, because the organs are totally enclosed by control points, 
and the volume is relatively small. Kaus et al. 23 showed that for liver, lung, and pros-
tate cases, millimeter or even submillimeter accuracy was achieved, measured as 
the distance between the anatomic landmarks. Kaus et al. 23 tested three models, 
based on thin-plate splines (used in our method), Wendland function, and elastic 
body spline. None of the methods performed consistently better or worse.
The method aligns two sets of structures accurately. When larger areas outside the 
region of the structure set need to be aligned, more structures should be added to 
the nonrigid process. In theory, the method allows for the inclusion of more points, 
both for defining other organs (such as skin, bony anatomy) or including landmarks. 
However, the present method is limited by computational resources, such as memo-
ry and time, which now requires about 1.5 h/patient on a Pentium IV (2.8 GHz, with 2 
GB RAM). Chui et al. 24 introduced a cluster strategy to increase the amount of infor-
mation included in the registration without increasing computational requirements.
The local anatomic changes observed in this study were consistent with the global 
measurements reported in published studies 11,14,17,25. Hansen et al. 14 reported a 
mean change in the volume of 21.5% and 15.6% for left and right parotid, respec-
tively, between the planning and second CT scan used for replanning. Volumetric 
and positional changes for gross tumor volumes and normal tissues in relation to the 
C2 vertebra center of mass were reported by Barker et al. 11, who also found time 
trends in volume and position of parotid glands. When using the volume decrease 
rate found by Barker et al. 11 for 23 treatment days, a volume decrease of 13.8% is 
obtained. The average volume reduction for both parotids in our study was 14%. 
Barker et al. 11 found a median medial shift of 3.1 mm for the center of mass of the 
parotid glands. This medial shift of the center of mass might partly be explained by 
our observed asymmetric shifts in parotid gland surfaces, with average displace-
ments of 1 ± 3 mm and 3 ± 3 mm for the medial and lateral regions of the irradiated 
glands, respectively (Fig. 7). The changes in the lateral regions of the parotid were 
also reported by Robar et al. 17, who found a systematic displacement of a selected 
point in the lateral region of the parotid glands in the medial direction of 2.6 ± 0.3 
mm and −1.9 ± 0.2 mm, for the left and right parotid, respectively. A selected point 
in the medial region of the parotid did not show a systematic translation. However, 
the selection of the same lateral and medial point in a series of CT scans, relying 
on bony anatomy not fully in contact with the parotid gland, might include errors in 
the measured displacements. In addition, this approach assumes no changes in 
the inferior-superior or posterior-anterior direction of the parotid glands, which were 
observed in our patient group (Fig. 7). The full 3D approach used in our study is a 
more reliable strategy.
Barker et al. 11 found a significant correlation between weight loss and volume change 
in the parotid glands. Information about weight loss was not collected for our study. 
However, it is well known that, in general, patients lose weight during treatment. We 
also observed a significant volume loss for the spared glands. Our data showed that 
the planned mean dose is significantly related to the observed parotid gland volume 
Local anatomic changes studied with nonrigid registration
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reduction (p <0.001, r = 0.68; Fig. 6). Additional studies are needed to identify all 
variables leading to volume reduction.
As suggested by Barker et al. 11 and demonstrated by Hansen et al. 14 and Ro-
bar et al. 17, the observed anatomic changes might have a dosimetric effect when 
highly conformal treatment techniques are used. When comparing replanning with 
no-replanning treatments, Hansen et al. 14 found that the doses to target volumes de-
creased and the doses to normal structures increased. In the particular case of the 
parotid glands, all dosimetric endpoints (mean dose, dose to 50% of the volume, and 
volume receiving ≥26 Gy) to the right parotid gland significantly increased without 
repeat planning, although the changes for the left parotid gland were not significant. 
Robar et al. 17 reported an increase in the mean dose of 2.6% ± 4.3% and 0.2% ± 
4.0% for the left and right parotid. The asymmetry in the results between the left 
and right parotid presented by Hansen et al. 14 and Robar et al. 17 show the need to 
classify the parotid in a manner other than left or right; it is possible that the patient 
groups (14 patients for Hansen et al. 14 and 15 patients for Robar et al. 17 were not 
balanced with respect to whether the left and right neck was treated. In our study, 
a different classification, determined by the treated or nontreated neck, was used. 
We have demonstrated that for irradiated parotid glands, the lateral regions (with the 
lower planning doses) displace inward (i.e., toward the higher doses, with the spared 
parotid glands presenting little and near homogeneous deformation).
conclusion
The nonrigid registration method accurately described local changes occurring in 
the head-and-neck region after EBRT in full 3D. The classification of the glands 
into irradiated and spared groups revealed a significant difference in the volume 
reduction and shape and position changes between the groups. Glands belonging to 
nontreated necks showed few changes. Glands belonging to treated necks showed 
a general shrinkage and deformation. Nonrigid registration is an ideal tool with which 
to perform additional studies in larger patient series to investigate the relationship 
between the local dose and local shape and position changes in more detail.
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AbstrAct
Purpose: To develop and evaluate a method for adding dose distributions of com-
bined external beam radiotherapy (EBRT) and brachytherapy (BT) for oropharyn-
geal patients.
Materials and Methods: Two CT scans were used for 5 patients: the EBRT CT, 
used for EBRT planning, and the BT CT, acquired after catheter implantation. For 
each scan, the salivary glands, chewing and swallowing muscles were contoured, 
and a dose distribution was calculated. A non-rigid transformation was obtained by 
registering the organs’ surfaces. The transformation was then applied to the BT 
dose distribution, to map it onto the EBRT dose distribution. To account for dif-
ferences in fractionation, the physical doses were converted to equivalent dose in 
2Gy, and the total dose was found by adding dose voxel by voxel. The robustness 
of the method was investigated by varying delineations and input parameters of 
the registration method. The effect of the perturbations was quantified using Dose-
Volume Histograms (DVH) and gamma analyses (Distance-To-Agreement=1mm/
Dose-Difference=2Gy).
Results: The variations in input parameters and delineations caused only small 
perturbations in the DVH of the added dose distributions. The gamma index was low 
(median gamma index λ 0.4 for salivary glands and chewing muscles), and mode-
rately elevated for organs lying in areas with a steep gradient (median gamma index 
λ 1.5 for constrictor muscles).
Conclusions: The presented method allows adding dose distributions of combined 
EBRT and BT for oropharyngeal patients. The method is reliable and robust with res-
pect to uncertainty in organ delineation and perturbations in input parameters of the 
method.
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introduction
Combination of external beam radiotherapy (EBRT) and bra¬chy¬the¬ra¬py (BT) 
is commonly used in the treatment of head and neck cancer, cervical cancer and 
prostate cancer 1-3. EBRT aims at treating the primary tumor and areas at risk for mi-
croscopic disease, while BT is used to boost the primary tumor. However, in current 
clinical practice, BT boost are optimized independently, without taking into account 
the dose already delivered. The reason is that addition of 3-dimensional (3D) dose 
distributions is challenging due to anatomical changes of the patient, e.g. caused 
by weight loss, tumor shrinkage, different patient set-ups, implantation of catheters, 
insertion of applicators or other surgical procedures (see figure 1). Furthermore, to 
establish dose-effect relationships for tumor control and side effects in combined 
modality treatments, simple approximations are often used 4-7. Some studies use 
only part of the treatment to establish dose-effect relationships 6,7. In other studies, 
the accumulated dose was approximated without taking patient deformations into 
account. For example, Levendag et al. 4 and Teguh et al. 5 related the probability of 
experiencing dysphagia to the dose to the swallowing muscles for oropharyngeal 
and nasopharyngeal patients. To account for the total dose received by the organs, 
the physical EBRT and BT mean doses were simply summated.
Rigid registration, including rotation and translation, followed by the linear addition 
of the dose matrices is not accurate to add dose. A rigid transformation does not 
align deforming anatomy adequately (see figure 1). Non-rigid registration, on the 
other hand, allows to better align the anatomy, enabling different dose distributions 
to be mapped to a common frame of reference. Another aspect is the dose addition 
itself. Different modalities often use different fractionation schemes. Therefore, dose 
distributions require a conversion to biological equivalent doses before adding the 
dose in each voxel 8.
In this paper we propose a method for adding 3D EBRT and BT dose distributions, 
using a non-rigid registration framework developed in-house based on Chui et. al. 
9-11. The method was tested for organs at risk (salivary glands, swallowing and che-
wing muscles) of 5 oropharyngeal patients treated with EBRT, followed by BT boost. 
Three of the patients underwent neck dissection before catheter insertion 1, 4, 5. The 
biological effects of the different fractionation schemes were taken into account by 
converting the physical EBRT and BT dose to biologically equivalent dose for 2Gy 
fractions (EQD2, 8) before adding each dose voxel. The robustness of the method 
was investigated by variations in input parameters of the registration method and 
simulating variations in organ delineations around the clinical contours (delineation 
uncertainty).
3D dose addition of EBRT and BT using nonrigid registration
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Figure 1: Anatomical changes between EBRT and BT for patient 1 and 3. The first row shows 
the sagittal planes of patient 1. Notice the large anatomical changes between the EBRT and 
BT CT scan, mostly caused by the neck dissection, catheter insertion and different patient 
positioning. The second row presents the axial planes of patient 3. The first column shows 
the CT scans used for EBRT planning, the second column the repeat CT scans taken after 
catheter implantation and just before BT and the last rigid registrations based on bone. Notice 
that rigid registration is not adequate to align both CT scans.
MAteriAl And Methods
Patient data
Five oropharyngeal cancer patients were included in this study (see table 1). These 
patients belonged to a larger group previously used for quantifying anatomical chan-
ges using non-rigid registration 12. According to the protocol 1, 4, 5, 13, the patients first 
underwent EBRT to a total dose of 46Gy in 23 fractions (dynamic intensity-modula-
ted RT), followed by a brachytherapy boost two weeks after the end of EBRT (PDR 
scheme 2Gy-18x1Gy-2Gy, biologically equivalent to HDR scheme 4Gy-4x3Gy-4Gy) 
14. Patients 2 and 3 received unilateral EBRT to the ipsilateral neck, while patients 1, 
4 and 5 received bilateral EBRT. Just before catheter implantation, patients 1, 4 and 
5 (node-positive) underwent neck dissection in which the neck lymph nodes and the 
submandibular glands, among other soft tissue, were removed.
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Id. Sex Age Site TNM staging
1 m 57 Base of tongue T3 N2a M0
2 m 48 Tonsillar fossa T2 N0 M0
3 f 59 Soft palate T2 N0 M0
4 m 58 Base of tongue T3 N2a M0
5 f 52 Base of tongue T1 N2c M0
Table 1:  Patient characteristics. 
Two intravenous contrast-enhanced CT scans were used for each patient: the CT 
scan used for planning EBRT (EBRT CT scan), and a repeat CT scan taken two 
weeks after the end of EBRT, after catheter implantation and just before BT dose 
delivery (BT CT scan). The slice spacing was 3mm for the EBRT scans and 1.5mm 
for the BT scans. The catheters were clearly visible in the BT CT since copper wires 
were inserted for the CT acquisition. The body contour, chewing muscles (masseter, 
pterygoid and temporalis muscles), swallowing muscles (superior, middle and infe-
rior constrictor, cricopharyngeus, and esophagus inlet muscles) and major salivary 
glands (parotid and submandibular glands) were contoured in both CT scans. For 
consistency, the BT CT scan was delineated, using the EBRT CT scan as a refe-
rence. All delineations were checked by a second observer. Surfaces, defined by 
a set of triangles joining contours in the consecutive slices, were created from the 
delineated structures.
Dose distributions for the EBRT and BT treatments were calculated using the tre-
atment planning system used clinically at the time: CadPlan version 6.4.7 (Varian 
Medical Systems, USA) and Plato BPS version 14.2 (Nucletron, The Netherlands) 
respectively. The BT dose distribution was originally calculated based on implant 
reconstruction from orthogonal X-rays. For this study, we reconstructed the BT dose 
distribution on the BT CT scan. The catheters were made visible on the BT CT scan 
using copper wires enabling reconstruction of the implant geometry and definition of 
active dwell positions. The corresponding dwell times were copied from the original 
plan. Finally the BT dose was calculated and the dose grid was exported. Both dose 
distributions were interpolated to a regular grid with resolution with resolution 1x1x1 
mm3.
  
Dose addition
Figure 2 illustrates the steps to add the EBRT and BT dose distributions ta-
king into account anatomical changes. First, the triangulated surfaces genera-
ted from the delineated structures (above) were used to compute a non-rigid 
transformation using a non-rigid registration method developed in-house 10, 11. The 
non-rigid registration framework was previously validated using anatomical land-
marks 10 and was improved to reinforce inverse consistency 11. The non-rigid trans-
formation, modeled by a regularized thin plate spline 9, 15, implicitly comprises the 
changes between the two structures sets. Second, using the transformation ob-
3D dose addition of EBRT and BT using nonrigid registration
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Figure 2: Schematic showing the steps for dose addition. In step 3 we used the linear 
quadratic model with α/β = 3Gy for healthy tissues to convert doses to biologically 
equivalent doses for 2Gy fractions. 
tained, we computed the transformed BT dose by inverse mapping using the Insight 
Toolkit (ITK, 16). Inverse mapping finds the transformed BT dose on the EBRT grid 
dose by transforming each EBRT grid position into the BT dose grid. Then the dose 
is interpolated at the mapped location using the doses of the closest neighboring grid 
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points. This procedure avoids the creation of empty areas in the transformed dose. 
Third, both physical doses, i.e. EBRT dose and transformed BT dose, were sepa-
rately converted into biologically equivalent doses for 2Gy fractions (EQD2) using 
the linear quadratic model (α/β = 3Gy). Finally, the 3D total dose distribution was 
calculated by adding the converted EBRT doses and the transformed and converted 
BT dose voxel by voxel.
Robustness of dose addition
As in previous studies 10, each non-rigid registration produced a satisfactory non-
rigid transformation in terms of the transformation error (below 1mm), defined as 
the mean distance between surfaces, and checked by visual inspection. Previously, 
we validated the anatomical correspondence of the non-rigid registration framework 
using identifiable landmarks in CT data sets 10. However, the image sets currently 
used do not contain sufficient information to indistinguishably identify corresponding 
tissue elements on a functional subunit level. Alternatively, in this study we investi-
gated the robustness of the dose addition method with respect to changes in 1) the 
parameters of the non-rigid registration framework, 2) control point distribution and 
3) variations in organ delineation around the clinical contours. To assess the influen-
ce of each of these perturbations, we compared each total dose distribution resulting 
from a perturbation to the unperturbed reference total dose distribution using dose-
volume histograms (DVH) and the gamma index method 17. The gamma index com-
bines the dose-difference (DD) and distance-to-agreement (DTA), to compare two 
dose distributions. Gamma index was evaluated in each voxel within the delineated 
structures using DD=2Gy and DTA=1mm. Perfect agreement between two voxels is 
represented by a gamma index equal to zero (same dose in the same spatial posi-
tion). Two voxels that have the same dose and are separated by a distance of DTA, 
or that are in the same spatial position and which dose difference is DD, would score 
a gamma index equal to one. Figure 3 shows the gamma index between two voxels. 
We report distributions of gamma indices of all voxels inside the organs using box 
and whisker diagrams.
Figure 3: Gamma index as a function of distance and dose difference between two voxels 
using Dose-Difference=2Gy and Distance-To-Agreement=1mm.
Perturbations of framework parameters
The non-rigid registration framework uses points to represent the structures to be 
registered. The framework includes a procedure to generate points from surfaces 
which is controlled by the parameter r or density radius. The parameter r determines 
the density of control points, which affects the computational time and accuracy. 
3D dose addition of EBRT and BT using nonrigid registration
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Small r means large number of points, longer computational time and, theoretically, 
more accurate results. Conversely, large r produces few points, shorter computatio-
nal time and less accurate results. Based on previous experience, we tested r=5, 6 
and 8mm (reference r=5mm).
The second framework parameter is λ. This weight parameter controls the degree of 
deformation of the transformation function by regulating the thin-plate spline used as 
transformation. Large λ restricts the transformation to be mostly affine, opposite to a 
small λ, which relaxes the restriction. We tested λ=0.5 and 5, which in combination 
with the chosen r produced transformation errors below 1mm in 10. We used λ = 5 
as reference in this study.
Perturbations in control point distribution
We investigated the influence of using different control point distributions on the 
dose addition. As mentioned, the framework includes a procedure to gene-
rate control points, which spread pseudo-homogeneously on the surfaces of the 
delineated structures 10, 11. In this procedure, a refined surface of the structures is 
generated by dividing iteratively the triangles that join contours of consecutive sli-
ces. The vertices of the triangles already spread pseudo-homogeneously, however 
registering such a large number of points is beyond the computational resources 
available. Then, the vertices of the refined triangles are grouped in spheres whose 
radius is the density radius (r), and the centroid is calculated. Last, the points are 
replaced by the closest point on the surface to the calculated centroid. We used 
this procedure to create four control point distributions with the same density radius 
(r=6mm). By randomly varying the position of the grouping spheres, different point 
distributions were generated.
Perturbations in structures delineations
To determine the influence of delineation variations on the non-rigid registra-
tion, and consequently on the dose addition, we simulated observer variations 
of 1, 3 and 5mm in the delineation of structures. To simulate the variations, ran-
dom deformations were applied to the surfaces of the EBRT and BT structu-
res. Figure 4 explains the procedure to create random deformations. First, one 
third of the contour points that constitute the surface of the structures was ran-
domly selected. Only points that were not in close proximity to other organs 
were considered, in order to avoid overlapping of perturbed contours of neigh-
boring organs. Second, random deformation vectors were generated. In order to 
simulate the real situation, the deformation vectors were limited to the axial planes 
where the contours were drawn, and their direction and length was random, to a 
maximum of the variation simulated (1, 3 or 5 mm). Third, the deformation was 
interpolated to the rest of the structure points using a thin-plate spline 15. Finally, the 
deformed structures were used in the non-rigid registration framework to generate 
the non-rigid transformation. We calculated a total of 9 non-rigid transformations per 
patient, using three random deformations per simulated maximum variation of 1, 3 
and 5 mm. Calculation of DVHs and gamma analyses were performed using the 
non-perturbed delineations in order to only assess the effects of the perturbations on 
the results of the dose addition.
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Figure 4:  Procedure to simulate delineation variations. A) A set of points is randomly selected 
(black dots) from the points in the original structure (light triangles). Then deforming vectors, 
restricted to the axial planes, are generated (thick lines) limiting their lengths to the delineation 
variation simulated (1, 3 or 5mm). B) The deformation is interpolated to the rest of the struc-
ture using a thin-plate spline. C) BT CT scan of patient 5 showing all 9 delineation variations 
simulated. The clinical delineation is shown in white.
Simple alternatives to full 3D non-rigid registration
We investigated the validity of approximating the mean dose, D99 and D1 by ad-
ding the separate mean dose, D99 and D1 for the EBRT and BT dose distributions 
without taking anatomical changes into account. We defined D99 and D1 as the 
dose received by the 99% and 1% of the organ’s voxels respectively, as read from 
the DVH data. We compared these approximations converted to EQD2 to the values 
obtained by non-rigid registration.
3D dose addition of EBRT and BT using nonrigid registration
-----------------------------------------------------------------------------------
272
..........
results
Total dose
Figures 5, 6 and 7 show the DVHs for the EBRT, BT and total dose distributions for 
the salivary glands, the chewing muscles and the swallowing muscles, respectively. 
The largest total doses were found for the constrictor muscles for patients 3 and 
4, and for the right submandibular gland for patient 3. For all patients, the largest 
contribution to the total dose came from the EBRT, and most organs at risk received 
low BT doses.
Perturbations analysis
Besides the DVHs for the reference EBRT, BT and total dose distributions, figures 5, 
6 and 7 also show the total dose DVHs for the 19 perturbations. Most perturbations 
produced only minor deviations with respect to the reference DVHs, to the point that 
most total dose DVHs blend into one single curve. The largest  variations were found 
in the superior, middle and inferior constrictor muscles. Figures 8 and 9 show distri-
butions of gamma indices using box and whisker diagrams categorizing the data by 
perturbation type and per patient, respectively. In general, the perturbations in the 
control point distributions produced the lowest gamma indices. The largest gamma 
Figure 5:  Dose volume histograms for the EBRT, BT and total dose distributions (reference 
and 19 perturbations) for the salivary glands. Perturbations on the total dose are shown in 
different shades of gray, and most of them blend with the reference DVH curve. All doses are 
biologically equivalent doses for 2Gy fractions (EQD2). Dose axes were cropped to the largest 
D1. The right submandibular glands for patient 1, 4 and 5, and the left submandibular gland 
for patient 4, were removed during neck dissection.
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indices were found for the perturbations using λ = 0.5 and delineation variations of 5mm. 
Results varied among patients. Patient 4 presented the largest variations and patient 
1 the smallest, while both were base of tongue cases. All chewing muscles, the paro-
tid glands, the  esophagus inlet and the cricopharyngeus muscles, presented small
gamma indices for all patients (median ≤ 0.2). The organs that presented the most 
variation were the constrictor muscles and the submandibular glands (median ≤ 1.5). 
These organs were close to the target volume in all patients, and some submandibu-
lar glands were treated as part of the clinical target volume. One example is shown in 
the last row of figure 1. Particularly for BT, the proximity to the target volume means 
a steep gradient within the organs.
Simple alternatives to full 3D non-rigid registration
For the organs at risk considered, the differences between calculating the D1 of 
the total dose versus adding D1 of the EBRT and BT dose distributions were large 
(average, range: -0.9Gy, -14.5 to 25.6Gy), for example 25.6Gy for the middle con-
strictor muscle for patient 3 and 14.5Gy for the right submandibular gland (shown in 
the lower column in figure 1). The differences for the mean doses were moderately 
small (-0.1Gy, -2.6 to 0.4Gy), as well as for D99 (0.1Gy, -1.7 to 1.5Gy). None of the 
DVH parameters were systematically underestimated or overestimated by the ap-
proximation.
discussion
In this paper we present a method for adding dose distributions of different modali-
ties taking into account anatomical changes and biological effects. The method was 
applied to organs at risk of 5 oropharyngeal patients. A robustness analysis was 
presented as an alternative to validation against ground truth. Overall, the method 
was robust against perturbations of the input parameters and delineation variations, 
as demonstrated by the overlapping total dose DVH curves in figures 5, 6 and 7. 
Robustness was also investigated by gamma analyses (figures 8 and 9), comparing 
perturbed and reference dose distributions using very strict criteria, i.e. DTA=1mm 
and DD=2Gy. Low gamma indices (median ≤ 0.2) for the esophagus inlet, cricop-
haryngeus and chewing muscles and the parotid glands indicate small deviations 
for the total doses resulting from the perturbations. Larger indices were found in 
the constrictor muscles and the submandibular glands (median ≤ 1.5). These last 
organs were located in areas with steep BT dose gradients, which explains the en-
hanced effect of the perturbations. When comparing the perturbation types (figure 
8), larger gamma indices were found for λ=0.5 and for the largest delineation va-
riations (5mm). The λ parameter controls the flexibility of the transformation, and 
a low λ produces a more flexible transformation. Compared to the reference dose 
distributions, total doses calculated by transformations using λ=0.5, showed larger 
local differences, resulting in larger gamma indices. The gamma indices were low for 
the perturbations in control point distributions, using λ=5 , and delineation variations 
below 5mm. Considering all analyses, we conclude that the presented method for 
adding EBRT and BT dose distributions is sufficiently insensitive to perturbations 
and renders reliable results.
3D dose addition of EBRT and BT using nonrigid registration
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Figure 6:  Dose volume histograms for the EBRT, BT and total dose distributions (reference 
and 19 perturbations) for the chewing muscles. Perturbations on the total dose are shown 
in different shades of gray, and most of them blend with the reference DVH curve. All doses 
are biologically equivalent doses for 2Gy fractions (EQD2). Dose axes were cropped to the 
largest D1. 
The robustness of the method could be explained by the fact that the correspon-
dence of each organ is optimized individually by correspondence filtering 10. Here 
the correspondence problem is limited to each individual organ, and the global trans-
formation is stable. In addition, correspondence filtering allows the inclusion of ana-
tomical landmarks, which increases control in localized positions, and fine-tunes 
the transformation locally. Therefore, if subunit information is available, it can be 
included in the registration.
In the present study, the total dose to the tumor was not calculated. Besides the 
large changes happening to the target volume due to catheter implantation, several 
studies have found that target volumes may shrink during EBRT treatment 18,19. 
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Figure 7:  Dose volume histograms for the EBRT, BT and total dose distributions (reference 
and 19 perturbations) for the swallowing muscles. Perturbations on the total dose are shown 
in different shades of gray, and most of them blend with the reference DVH curve, except for 
the constrictor muscles where slightly larger variability can be seen. All doses are biologically 
equivalent doses for 2Gy fractions (EQD2). Dose axes were cropped to the largest D1. 
Dose accumulation for a regressing mass requires further research to handle disap-
pearing tissue properly.
To further improve the method, octant interpolation for the dose mapping can be 
implemented for organs that lie in areas with steep dose gradient, as suggested 
by Rosu et al. 20. In their study, two interpolation approaches were investigated and 
compared: direct approximation, using one point to estimate the dose at each dose
grid position, and octant interpolation, where the dose of each grid position wasesti-
mated from 8 points. Rosu et al. concluded that octant interpolation is better suitable 
for areas with steep dose gradients.
3D dose addition of EBRT and BT using nonrigid registration
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Figure 8:  Distributions of gamma indices (DTA=1mm,DD=2Gy) for all organs and all patients, 
categorized by perturbation type. The dots represent the median, and the edges of each box 
are the 25th and 75th percentiles, the whiskers extend to the most extreme data points not 
considered outliers. 
We investigated whether an addition without non-rigid registration of D1, D99 and 
mean EBRT and BT dose is a valid approximation for the corresponding parameters 
of the total dose. We found large differences (≤ 25.6Gy) between this approximation 
and calculating D1 of the total dose. The differences were smaller for mean dose 
and D99 (≤ 2.6 Gy and 1.7 Gy respectively). For large quality of life studies where 
mean doses are summed up, such as 5, differences of this scale of magnitude are 
probably negligible. However, this approximation assumes not large deformations 
and may not hold for other sites where deformations are more complex.
The concept of accumulating dose using non-rigid registration has been explored 
in the literature. However to our knowledge, there is no previous attempt to add 3D 
dose distributions of EBRT and BT taking anatomical changes into account. Few 
reports are available that address the anatomical validity of dose addition. Schaly 
et al 21 proposed to track tissue elements (voxels) between daily CT scans and ac-
cumulate their dose distributions using thin-plate spline. In a sensitivity analysis of 
control point placement, they found dose differences up to 37% for bladder and 27% 
for rectum. An alternative approach for dose accumulation uses finite element ana-
lysis 22, 23. However, inclusion of anatomical landmarks inside or outside the surfaces 
is limited, and the mechanical properties for the tissue should be accurate 24.
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Figure 9:  Distributions of gamma indices (DTA=1mm,DD=2Gy) categorized by or-
gans and perturbation type per patient. The dots represent the median, and the ed-
ges of each box are the 25th and 75th percentiles, the whiskers extend to the most 
extreme data points not considered outliers. 
Apart from head and neck cases 12, our non-rigid registration framework has been 
used in a previous study to analyze the deformation of the prostate and the seminal 
vesicles in prostate cancer patients 25 and it was used for cervix cancer patients 
experiencing extreme deformations as a result of bladder filling variations 26. Based 
on this experience and the results described in this paper, we expect our method for 
dose addition to be applicable to other sites treated with combined modality treat-
3D dose addition of EBRT and BT using nonrigid registration
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ment, e.g. prostate and gynecological sites.
The method can also accumulate dose distributions from other radiation modalities. 
Dose accumulation can also be used to optimize radiation treatment plans consi-
dering dose previously delivered to the patient, e.g. optimizing BT plans taking the 
EBRT dose into account or for re-planning in adaptive strategies. Also, using a better 
approximation of the total dose, treatment related toxicity and dose-effect relation-
ships can be determined more accurately.
conclusion
The presented method allows adding 3D dose distributions of combined EBRT and 
BT for organs at risk in oropharyngeal patients. The method is reliable and robust 
with respect to placement of control points, choice of input parameters for the regi-
stration method and variations in organ delineation. Optimization of BT plans while 
taking into account the EBRT dose already delivered, and re-planning in adaptive 
strategies are promising new possibilities.
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AbstrAct
Purpose: To validate and clinically evaluate autocontouring using atlas-based au-
tosegmentation (ABAS) of computed tomography images.
Methods and Materials: The data from 10 head-and-neck patients were selec-
ted as input for ABAS, and neck levels I-V and 20 organs at risk were manually con-
toured according to published guidelines. The total contouring times were recorded. 
Two different ABAS strategies, multiple and single subject, were evaluated, and the 
similarity of the autocontours with the atlas contours was assessed using Dice coef-
ficients and the mean distances, using the leave-one-out method. For 12 clinically 
treated patients, 5 experienced observers edited the autosegmented contours. The 
editing times were recorded. The Dice coefficients and mean distances were calcu-
lated among the clinically used contours, autocontours, and edited autocontours. Fi-
nally, an expert panel scored all autocontours and the edited autocontours regarding 
their adequacy relative to the published atlas.
Results: The time to autosegment all the structures using ABAS was 7 min/pa-
tient. No significant differences were observed in the autosegmentation accuracy for 
stage N0 and N+ patients. The multisubject atlas performed best, with a Dice coef-
ficient and mean distance of 0.74 and 2 mm, 0.67 and 3 mm, 0.71 and 2 mm, 0.50 
and 2 mm, and 0.78 and 2 mm for the salivary glands, neck levels, chewing muscles, 
swallowing muscles, and spinal cord-brainstem, respectively. The mean Dice coef-
ficient and mean distance of the autocontours vs. the clinical contours was 0.8 and 
2.4 mm for the neck levels and salivary glands, respectively. For the autocontours 
vs. the edited autocontours, the mean Dice coefficient and mean distance was 0.9 
and 1.6 mm, respectively. The expert panel scored 100% of the autocontours as 
a “minor deviation, editable” or better. The expert panel scored 88% of the edited 
contours as good compared with 83% of the clinical contours. The total editing time 
was 66 min.
Conclusions: Multiple-subject ABAS of computed tomography images proved to 
be a useful novel tool in the rapid delineation of target and normal tissues. Although 
editing of the autocontours is inevitable, a substantial time reduction was achieved 
using editing, instead of manual contouring (180 vs. 66 min). 
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introduction
The large numbers of target and normal tissue structures that require manual deline-
ation in head-and-neck cancer patients has made contouring tedious and time consu-
ming. In addition, optimal sparing conditions for head-and-neck intensity-modulated 
radiotherapy require accurate delineation of those structures. To ensure consistent 
delineation of the target volume, a computed tomography (CT)-based atlas of neck 
levels I–V and guidelines for critical organs at risk (OARs) were developed and are in 
use 1-4. However, contouring still results in intra- and interobserver variations 5-7.
A promising new tool is auto-contouring using Atlas-Based Auto-Segmentation 
(ABAS) of CT-images 8,9,10. This tool automatically creates the contours for the neck 
levels and OARs in the CT images of a new patient. ABAS has the potential to lower 
the contouring burden and thus allow more normal tissues to be included in inverse 
treatment planning for high-dose intensity-modulated radiotherapy to fully exploit our 
knowledge of dose–volume effects. ABAS also has the potential to reduce the intra 
and interobserver variability in contouring.
In the present study, we have quantified the accuracy of autocontouring using ABAS 
and assessed the clinical applicability of this tool. This is, to our knowledge, the first 
report describing the validation of an ABAS tool (Elekta-CMS Software) for contou-
ring target tissues (including neck levels I–V) and all possible normal tissue struc-
tures (including the mastication and swallowing muscles) in the head and neck. We 
determined the accuracy and time reduction for contouring. The first part of the pre-
sent study assessed the geometric accuracy of the ABAS. Two ABAS approaches 
were evaluated: (1) selection of the atlas patient with the greatest similarity metric; 
and (2) combining multiple segmentations of all atlas patients into one segmentation. 
The comparison of a multiple-subject atlas with a single-subject atlas was quantified. 
The second part of the present study addressed the clinical implementation. The dif-
ferences among the clinically used contours, autocontours, and edited autocontours 
were quantified, and the quality of all contours was scored by an expert panel.
MAteriAl And Methods
Description of the ABAS tool
Atlas-based autosegmentation is the process of performing segmentation on novel 
data using the knowledge of a previous segmentation, a data set that has the struc-
tures of interest already labeled. The registration strategy incorporates the objects’ 
shape information in the atlas to help improve the registration efficiency and robust-
ness, while still accounting for large intersubject shape differences. The key com-
ponent of ABAS is a database (i.e., the so-called atlas) containing image data (e.g., 
CT scan data) with delineated contours of the structures (organs) of interest. These 
atlas contours must be transferred to the image data of a new patient who under-
going radiotherapy planning. The transfer is accomplished by nonrigidly registering 
the image data of the atlas to the image data of the new subject. Having obtained 
the transformation vectors from the atlas image data to the new subject image data, 
it is possible to transform the atlas contours to the new patient. The implementa-
Clinical validation of atlas-based auto-segmentation
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tion we tested used a hierarchical approach (ABAS, version 1.1) for the nonrigid 
registration. This approach makes the nonrigid registration procedure efficient and 
robust, while still able to register large shape differences present between different 
patients. Hierarchical atlas registration consists of three major steps: linear regi-
stration; object-driven “poly–smooth” nonlinear registration; and shape-constrained 
dense deformable registration 9,10.
Atlas patients
The CT data of 10 head-and-neck cancer patients (4 Stage N0 and 6 Stage N+) 
were used. An experienced staff member manually contoured the individual neck 
levels I–V (both necks) and 20 OARs (salivary glands, chewing and swallowing 
muscles, and spinal cord-brainstem) (table 1). First, the contouring was done by 
a research fellow and subsequently corrected by the supervisor. Contouring of 
the neck levels was done using the international consensus guidelines of Gregoi-
re and Levendag 11, and contouring of the normal tissues was done according to 
our guidelines for delineating the OARs 2-4,12. Those contours were used to con-
struct the atlas and were regarded as the reference standard. The total contou-
ring time needed to create the atlas was recorded. The contours of neck levels 
with invaded muscle in —N+ patients were not used for autosegmentation, be-
cause in our guideline, the anatomic border of those levels is defined differently 
than that for levels with noninvaded muscle. Other than the levels with inva-
ded muscle, all other contours of Stage N+ patients were used by the ABAS tool.
Tissue n
Submandibular glands 2
Parotid glands 2
Mastication muscles 5x2
Swallowing muscles 5
Spinal cord 1
Neck levels 5x2
Table 1: Tissues delineated for the atlas.
Atlas Selection
In theory, ABAS requires just one set of images from a patient as the atlas. In prac-
tice, however, the differences in the anatomy of patients merits the use of various 
atlas patients. In the present study, we evaluated two different atlas selection stra-
tegies to determine the best approach (figure 1). The first approach was selection 
of the atlas patient according to the greatest similarity metric among all the atlas pa-
tients and the new patient. The global mutual information similarity after global linear 
registration was used to choose the best atlas. The global correlation coefficient 
was only good for linear registration. The local correlation coefficient metric was 
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also evaluated. The local correlation coefficient is the usual correlation coefficient 
computed within a small neighborhood of each image voxel. The second approach 
for the atlas selection strategy was to apply multiple atlas data sets to the CT data 
of a new patient, thereby generating multiple autosegmentation sets. For the fusion 
of multiple single-atlas autosegmentation sets to one multiple-subject autosegmen-
tation, the simultaneous truth and performance level evaluation (STAPLE) algorithm 
was used 13. The STAPLE algorithm was introduced by Warfield et al. 13 and offers a 
more sophisticated strategy for multiple segmentation fusion in that it automatically 
estimates the segmentation quality of each classifier and also derives a weighted 
combination of the multiple classifiers according to their estimated segmentation 
quality. The STAPLE method was applied for each structure separately. For each 
structure, the STAPLE algorithm takes as input a collection of segmentation results, 
one for each atlas. It then simultaneously computes: a probabilistic estimate of the 
“true” segmentation and a measure of the performance level for each individual atlas 
result.
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Figure 1: Flow chart input ABAS and strategy evaluation. 
Atlas Evaluation
For evaluation, the mean distance and standard deviation around the mean dis-
tance between the autosegmented structure and the reference structure and the 
Dice coefficient were calculated. The mean distance measure was the mean dis-
tance between corresponding points on the surfaces of A, B. The surfaces were 
represented by triangular meshes consisting of sets of node points (triangle vertices) 
and edges (triangle sides) between the node points. Because the surfaces generally 
had different numbers of nodes, the distance d (A, B) was taken from the nodes on 
Clinical validation of atlas-based autosegmentation
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one surface A to the nearest node on the other structure. The mean distance was 
defined as
 
where    is the Euclidean distance from the i-th point on A, a, to b, 
the point on B closest to a, and N(A) is the number of surface mesh nodes on struc-
ture A. The standard deviation of the distances d(A,B) was defined as
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This is a measure of the degree to which the distances are spread out over their 
range. If the structures are in good agreement, the mean and standard deviation will 
both be small. The Dice coefficient is defined as follows:
Dice = 2 |A  B| / (|A|+|B|) 
where A and B are the two structures evaluated. This formula represents the 
size of the union of two structures divided by the average size of the two sets. 
A value of 0 indicates no overlap; a value of 1 indicates perfect agreement.
The leave-one-out cross-validation method was used to remove bias (i.e., the pa-
tient for whom the autocontours were generated was temporarily removed from the 
atlas). The levels with invaded muscle were excluded from the geometric validation, 
because the border of these levels differed, by definition, from the levels without 
invaded muscle. The levels with invaded muscle were evaluated in the clinical vali-
dation of ABAS (see the section “Clinical Validation of ABAS”). 
Clinical Validation of ABAS
First, for 12 N0 and N+ patients who had undergone intensity-modulated radiothe-
rapy by 10 experienced clinicians and residents, the clinically applied contours (le-
vels and salivary glands) were evaluated by an expert panel and compared with the 
published atlases 2-4, 11,12 using the following scores: 0=poor, 1=moderate, 2=good 
(figure 2). Next, autocontours were generated for those patients using the multiple-
subject ABAS tool. The accuracy of the autocontours relative to the published atlas 
was evaluated by the expert panel. For the autocontours, the following scoring sy-
stem was used: 0, poor; 1, major deviation, editable; 2, minor deviation, editable; and 
3, perfect. Generally, the expert panel scored the accuracy as a “minor deviation, 
editable” when the structures needed to be edited on a maximum of three CT slices, 
otherwise, it was scored as a “major deviation, editable.” Finally, for each patient, 
those autocontours were offered to 2 of a group of 5 experienced observers to edit, if 
needed, and the editing times were recorded. Contour editing was done using Focal, 
version 4.3.3 (Elekta - CMS Software, Maryland Heights, MO 63043). Those edited 
autocontours were also scored by the expert panel. The Dice coefficients and mean 
distance were calculated to quantify the differences among the clinical contours, 
autocontours, and edited autocontours of the observers (figure 2). In addition, other 
contours, i.e. mastication muscles, swallowing muscles, and spinal cord-brainstem) 
were autocontoured and edited, and the editing time was also recorded.
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Figure 2: Flow chart clinical validation.
results
Geometrical validation of ABAS
The time needed to autocontour all the structures using ABAS was approximately 
7 min/patient. The initial contouring time for the 30 structures delineated (Table 1) 
averaged 180 min/patient. Figure 3 shows an example of an autosegmentation of a 
neck level and swallowing muscle using a single-subject and multiple-subject atlas. 
In this example, the multiple-subject atlas contours were in better agreement with 
the reference contours than were the selected single-subject atlas contours. The 
comparison for all patients and structures is summarized in Fig. 4. Figure 4 shows 
the Dice coefficients and mean distances for the single-subject and multiple-subject 
approaches. The multiple-subject atlas method consistently performed superior to 
the selected single-subject atlas. These results and that the tested similarity metrics 
did not correlate, or moderately correlated, with the accuracy of the autosegmenta-
tion (median R2, 0.2; range, 0.1–0.6) were in agreement. Excluding the levels with 
invaded muscle, no significant differences were observed in the autosegmentation 
accuracy for the N0 and N+ patients.
For all patients, the mean Dice coefficient and mean distance of the multiple-subject 
method are listed in Table 2. Other results of the multiple-subject autosegmentation 
are shown in [Fig. 5] and [Fig. 6] through 7. In Fig. 5, an example of the application 
of auto-ABAS for the contouring of the OARs (i.e., masseter muscles, pterygoid 
muscles, temporalis muscles, and parotid glands) is shown. Figure 6 shows a coro-
nal view of the autocontours and reference contours of Levels II–IV. Figure 7 shows 
the autosegmentation of the levels vs. observer contouring. Figure 8 shows an au-
tosegmentation example for a neck level with invaded muscle (reference contour in 
green and multiple-subject autocontour in yellow). The muscle was not included in 
the autocontour, because the algorithm used the level of N0 atlas patients to auto- 
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Figure 3: Examples of single-subject autosegementation (yellow), multiple-subject autoseg-
mentation (turquoise), and reference contours (reference standard; green). (Left) level II; 
(Right) swallowing muscle.
segment the involved level of the N+ patient. At the medial site, some vessels were 
not encompassed. Both issues were quickly fixed by editing the autocontour.
Clinical validation
The mean editing time for the neck levels, parotid glands, submandibular glands, 
mastication muscles, swallowing muscles, and spinal cord-brainstem was 31, 7, 6, 
14, 7, and 1 min, respectively. The Dice coefficient and the mean distance of the 
clinical contours vs. the autocontours, the autocontours vs. the edited autocontours, 
and the observer 1 contours vs. observer 2 contours are listed in Table 3. 
The greatest variation was found for the neck levels, in particular, for the clinical con-
tours and autocontours of the neck levels. All autocontours (100%) were scored as 
a “minor deviation, editable” or better by the expert panel. The expert panel scored 
88% of the edited contours as good and 83% of the clinically used contours as good. 
The automatically generated contours still required editing, but the editing time was 
much less than that needed for manual delineation.
discussion
The present study reported on the development, validation, and use of the ABAS tool. 
As shown in Fig. 4, the comparison with the reference delineation clearly shows the 
advantage of using a multiple-subject atlas for segmentation. The multiple-subject 
atlas Dice coefficients and mean distances were more satisfactory than those with 
the single-subject atlas. As demonstrated by figures 3-6, the OARs (parotid glands 
and mastication muscles) were accurately segmented. From Fig. 6, the resemblance 
is apparent, but the autocontours still required editing to be used in the treatment 
planning process. The Dice coefficients for the different structures are listed in Table 
3. From these results, about 80–90% agreement between the autocontours and the
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Figure 4: Comparison of mean distance and Dice coefficient for single-subject and multiple-
subject approaches. Both metrics quantified agreement between autocontours and referen-
ce standard. Error bar indicates standard error; asterisk denotes significant difference for 
subgroup of structures at p = 0.01 (paired t test). Overall, multiple-subject method performed 
better (p < 0.001, paired t test). 
edited autocontours was found, similar or slightly better than that of other published 
data 14-16. Although our data showed considerable interpatient variability in intrave-
nous contrast uptake, head pose, dental artifacts, and the use of a tongue depres-
sor, all the autocontours were scored as “minor deviations, editable” or better by the 
expert panel, a promising result. The expert panel scored 88% of the edited contours 
as good and 83% of the clinically used contours as good. From these data, we can 
state that the edited contours (88% good) were closer to the published atlas than the 
ones used in clinic (83% good); the former might make the delineations for radiothe-
rapy plans for cancer patients more accurate.
Chao et al. (15) used a computer-assisted target volume delineation system and 
reference templates. They found that the variation was significantly reduced, but not 
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Neck
Levels
Parotid 
glands
Subman-
dibular 
glands
Chewing 
muscles
Swal-
lowing 
muscles
Cord-
brain-
stem
Dice 0.67 0.79 0.70 0.71 0.50 0.78
Mean distance* (mm) 3.4 ± 3.1 2.5 ± 2.8 1.9 ± 1.4 1.6 ± 1.4 2.0 ± 1.9 2.3 ± 1.4
* Mean ± standard deviation
Table 2: Dice coefficient and mean distance for multiple-subject autocontours vs. reference 
standard contours.
Figure 5: (Left) Autocontouring of organs at risk (mastication muscles and parotid glands) vs. 
(Right) reference contours (reference standard).
 
Figure 6: Coronal view of (Left) autocontours of neck levels vs. (Right) reference contours 
(reference standard).
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Figure 7: Autocontouring of levels (red) vs. observer contouring (blue and green).
necessarily the accuracy, which was beyond the scope of their study. It should be 
remembered that the border in N+ patients with invaded muscle in the present group 
was defined differently than those without invaded muscle. Therefore, the invaded 
muscle must be manually added to the autocontour of the level 12. Castadot et al. 14 
compared 12 voxel-based deformable registration strategies for adaptive radiothe-
rapy for head-and-neck tumors. Their data set contained 5 patients. They concluded 
that the level-set Demon’s algorithm (voxel-intensity-based registration) implemen-
ted in multiresolution is a good strategy for head-and-neck adaptive radiotherapy, 
because it was the best compromise in terms of the median and interquartile range 
for the Dice similarity index and correlation coefficient 14. 
Sims et al. 17 sought to establish the accuracy of ABAS, such that a priori information 
was used to delineate a limited set of organs of interest (e.g., brainstem, parotid 
glands, and mandible). The Dice coefficient for all OARs was 0.68 ± 0.25 for a first 
center and 0.82 ± 0.13 for a second center. Systematic oversegmentation of the pa-
rotids and undersegmentation of the brainstem occurred that required careful review 
and editing in most cases 17. They concluded that the autocontours and substantial 
time reduction in contouring proved that the ABAS would be a useful novel tool in the 
rapid delineation of neck levels and the limited number of OARs evaluated. Wang et 
al. 18 mapped contours from the planning CT scan onto daily CT or four-dimensional 
CT images using an image intensity-based deformable registration algorithm. They 
also only evaluated a limited set of contours (i.e., clinical target volume, parotid 
Clinical validation of atlas-based autosegmentation
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glands, and brain stem). The volume overlap index (A  B / (A+B) / 2))   and the 
mean absolute surface-to-surface distance was 83% and 1.3 mm, respectively. They 
concluded that a final review by physicians is highly recommended 18. Commowick et 
al. 8 presented a method for creating an anatomic atlas of the head-and-neck region 
from a database of 45 manually delineated CT images. They constructed a mean CT 
image set with atlas contours from a database of patients. The constructed mean at-
las was then applied to a new patient. The evaluation of the built atlas showed good 
results both qualitatively and quantitatively, although some important structures were 
not included in their database. Our report described an autosegmentation system 
with all possibly important (normal tissue) structures needed for treating head-and-
neck cancer included. Zhang et al. 16 showed for 7 patients that atlas-based image 
segmentation can automatically delineate the OARs (i.e., mandible, brainstem, and 
parotid glands only) on daily CT images. Quantitative validations demonstrated that 
the method was robust. Their Dice coefficients were slightly lower than ours.
Other studies 19 and 20 have shown anatomic changes in the parotid and submandi-
bular glands during radiotherapy, as assessed using nonrigid registration. The non-
rigid registration framework of Vásquez Osorio et al. 20 is an effective method to 
simultaneously register the anatomic changes of multiple organs with very different 
magnitudes and complexity. General shrinkage and deformation of the irradiated
Figure 8: Autosegmentation example for neck level with invaded muscle (reference contour 
in green and multiple-subject autocontour in yellow). Invaded muscle not included in autocon-
tour because algorithm used level of N0 atlas patients to autosegment involved level of N+ 
patient. At medial site, some vessels were not encompassed. Both issues were quickly fixed 
by editing the autocontour. 
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Variable Clinical con-tour vs. AC
Clinical vs. 
e-AC AC vs. e-AC
e-AC1 vs. 
e-AC2
Dice coefficient
Neck Levels 0.73 0.79 0.83 0.81
Parotid glands 0.80 0.81 0.91 0.89
Submandibular glands 0.72 0.77 0.83 0.86
Mean distance ± SD (mm)
Neck Levels 3.2 ±3.6 2.2 ± 2.8 1.5± 2.8 1.8 ± 2.5
Parotid glands 2.3 ± 3.8 2.1 ± 3.0 0.8 ± 1.2 1.1 ± 1.3
Submandibular glands 1.6 ± 1.4 1.2 ± 1.2 1.4 ± 1.8 1.0 ± 1.1
Table 3: Dice coefficient and mean distance around mean distance of different structures. 
e-AC= edited auto-contours, e-AC1 = edited auto-contour of observer 1 and e-AC2 = edited 
auto-contour of observer 2.
glands were observed. The spared glands showed few changes.Anatomic changes 
can be accommodated by repeat planning (adaptive radiotherapy); however, repeat 
planning requires recontouring of the new CT image or cone beam CT data set, 
which is tedious and time consuming. In the future, the ABAS tool might be used to 
ease adaptive radiotherapy. 
conclusions
Despite the large interpatient variability in the study population, the neck levels and 
OARs could be accurately contoured using the ABAS tool. The multisubject atlas 
performed better than the best single-subject atlas. Although the requirement for 
editing the autocontours was inevitable (66 min for 30 structures), a substantial time 
reduction was achieved by editing instead of manually contouring. Therefore, the 
new algorithm for autosegmentation could substantially reduce the clinical workload 
spent on organ delineation. This is even more relevant, because the edited contours 
were scored as having similar or better quality than the clinically used contours.
Clinical validation of atlas-based autosegmentation
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introduction
A brief summary of the treatment of head and neck cancer is given in the introduc-
tion section of this thesis. More detailed information about oropharyngeal cancer is 
described in chapter 2. In recent years intensification of therapy for head and neck 
cancers in general, either by altered fractionation radiotherapy (RT) schemes and/
or by the addition of concomitant chemotherapy (CHT), results in improved local–
regional tumor control 1,2. The 5-year survival rate (on the basis of SEER data) for all 
stages of head and neck cancer is about 60%, but for locally advanced disease still 
below 40%, despite the multi-modality treatment approaches 3. Data (actuarial local 
control (LC), disease free survival (DFS), and overall survival (OS)) at 5 years for 
cancer of the oropharynx and nasopharynx) from our institute showed a trend for a 
better outcome for the more recent time periods 2001–2007 as opposed to the time 
period 1991–1995. Most likely cause is that the treatment regimes used have been 
modified as per protocol and have become indeed more effective. As from 2000 on-
wards, all head and neck cancer (HNC) patients were treated by 6 fractions / week 
(accelerated); as from 1996, concurrent CHT for advanced cancers was introduced. 
The results obtained by more effective and aggressive treament modalities do not 
only impact tumor control outcome; for the patients being at least 1 year without evi-
dence of disease, quality of life was investigated for the items dysphagia, sticky sa-
liva, xerostomia, and pain. In short, best quality of life was observed for patients tre-
ated curatively and with maximal conformality that is in sequential treatments using 
boost techniques such as brachytherapy (BT) or stereotactic radiation (Cyberknife) 
(Chapters 8-10). 
Quality of Life: Dysphagia
Intensification of therapy for head and neck cancer in general, results in improved lo-
calregional tumor control, although unfortunately, late sequelae do increase as well. 
For example, the prevalence of dysphagia in organ preservation therapy is reported 
to be as high as 50% according to some papers on head and neck cancers 4-7, and 
an aspiration rate of 21–81% with chemoradiation 4,8-14 has been observed. Elevation 
of the larynx and pharynx during swallowing is essential for protection of the airway 
and propulsion of the bolus. Eisbruch et al.15 reported on the toxic effects of conco-
mitant chemotherapy and RT: several months after treatment, aspiration was expe-
rienced by 62% of patients 4. The types of impairments of the swallowing function 
after radiotherapy are described in the literature as follows: poor pharyngeal motility, 
with subsequent pharyngeal residue, epiglottic immobility, reduced laryngeal excur-
sion, poor closure of the laryngeal vestibule and aspiration 4,16-20. Chapter 3 analyzes 
the dose–volume effect relationships for dysphagia of patients with oropharyngeal 
cancer treated by 3DCRT and IMRT. The prevalence of grade 3 and 4 dysphagia for 
the items of the H&N35 ranged from 7% to 18%; the dysphagia RTOG grade 3 and 4 
equivalent scores for the M.D. Anderson dysphagia inventory (MDADI) ranged from 
21% to 32%. Patients were additionally seen in last follow-up at the outpatient clinic: 
severe xerostomia (VAS) and grade 3 and 4 dysphagia in long-term follow-up were 
present at the time of the last follow-up visit in 59% (30/51) and 12% (6/51), respecti-
vely. For the late dysphagia grade 3 and 4 (data taken from chart review) significant 
relationships were found for the superior constrictor muscle (scm)(p = 0.002), middle 
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constrictor muscle (mcm)(p = 0.003) and inferior constrictor muscle (icm)(0.006). In 
the multivariate analysis, if dose (received by the swallowing musculature) and BT 
are entered simultaneously in the logistic regression analysis for H&N35 (swallowing 
items), general MDADI, and late dysphagia taken from chart review, only BT remains 
a significant factor (p = 0.05). The responses obtained by the QoL questionnaires 
demonstrate that the probability of swallowing disorders increased significantly with 
dose (±19% per 10 Gy after 55 Gy) in paraticular with regard to the scm and mcm. 
Chapter 4 analyzes the dose–volume relationships for dysphagia. It relates the late 
side-effects to the different treatment techniques for widely separated anatomic lo-
cations. That is, the primary sites studied were base of tongue (BOT), tonsillar fossa 
(TF) and/or soft palate (SP), and the nasopharynx. From the series of 132 patients, 
chart review showed that 24 (18%) patients experienced moderate to severe dys-
phagia with more problems in patients with BOT (32%) cancer as opposed to pa-
tients with cancer of the TF/SP (22%) and NP (6%). Also according to the responses 
to the QoL questionnaires, swallowing problems are most frequently encountered 
in patients with tumors of the BOT. Moreover, patients seem to experience more 
complaints of dysphagia with longer follow-up. If grouped by treatment technique, 
most severe dysphagia was found in IMRT/3D-CRT compared with BT group and 
SRT/CBK group. Most significant were the relationships between EORTC H&N35 
‘Swallowing’ complaints and the dose in the superior constrictor muscles / middle 
constrictor muscles and the association of the PSS (normalcy of diet) and the dose 
in the scm (p values < 0.01). Xerostomia and dysphagia are strongly associated. 
Previous findings suggest that BT dose distributions are more sparing to the swal-
lowing musculature as opposed to the CBK/SRT and IMRT techniques. 
To differentiate between the intrinsic values of the irradiation techniques used, and 
whether it is simply because of margins, we computed for the six gross tumor volu-
mes of patients irradiated by CBK, the dose in the scm, mcm, left and right parotid 
glands, cord, and delineated the PTV with margins of 0, 2 and 5 mm, respectively. 
In a clinical situation, by comparing a PTV margin of 0 mm in case of BT vs. CBK 
with 2-mm margin and a 5-mm margin for IMRT, an advantage can be observed for 
the BT and CBK with respect to the dose contributed to the normal tissues. Mar-
gins do seem to have a substantial effect on the dose received by the swallowing 
muscles. When comparing IMRT, frameless stereotactic robotic radiosurgery and 
brachytherapy, these modalities can be considered as highly accurate techniques 
to boost a primary tumor (Chapter 9). Due to the smaller margins, one could arrive 
at smaller irradiated tumor volumes for BT and CBK, BT and CBK being somewhat 
more conformal as opposed to IMRT (Chapter 4). Because of the differences in tre-
ated volumes, smaller risks for overdosing critical normal tissues and potentially a 
lower risk for RT induced second malignancies for CBK as opposed to IMRT can be 
expected. Patients treated with a variety of disease sites (TF/BOT/NPC) and treated 
by various RT techniques (IMRT/3D-CRT/BT/SRT/CBK) vary in their prevalence of 
severe dysphagia. Although NPC patients receive the highest dose because of the 
treatment boost techniques used, sequentially, dysphagia is still less as opposed 
to patients with cancer of the BOT. The explanation of this phenomenon remains 
somewhat obscure; it is speculated that this might have to do with the infiltrative 
(muscles) nature of the BOT cancers.
Chapter 5 compared the Michigan, USA and Rotterdam, NL dysphagia studies. Both 
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studies found statistically significant correlations between the dysphagia endpoints, 
including aspiration, and the dose–volume parameters for the scm and mcm. The 
mechanisms of swallowing and protection from aspiration, as well as our results, 
suggest that the benefits from efforts to spare the swallowing structures are likely to 
be maximized if they include the superior constrictor muscles. They motivate efforts 
to reduce these doses as much as possible using either IMRT or BT, or both.
In chapter 6, the severity of dysphagia was measured by the FEES (Fiberoptic En-
doscopic Evaluation of Swallowing) procedure in tumors originating from the tonsillar 
fossa (TF) and/or SP or BOT. FEES for examining swallowing have some subjective 
nature. Kelly et al. investigated whether FEES and videofluoroscopy examinations 
influence the scoring of penetration and aspiration, penetration aspiration is per-
ceived to be greater (more severe) from FEES than for the videofluoroscopy recor-
dings 21. This has to be taken into account when looking at our data. A total of 24 
patients agreed to the FEES procedure. When calculating the total doses received, 
BT doses were added to EBRT by physical summation. The BT dose contributing 
to the target is only maximally one-third of the total dose, so the contribution of the 
BT is even less. Recently Vasquez-Osorio et al. did calculate the 3D summation of 
BT- and EBRT dose, and concluded that our ‘physical dose’ summation is a good 
estimation of the real 3D summation (Chapter 13). For the scm a dose–effect relati-
onship for the total FEES score was found. Also, the total FEES score is correlated 
well with the capability of swallowing of pureed and solid foods (H&N35), and with 
the normalcy of diet item from the PSS and total mean score of the MDADI.
Several dysphagia dose-effect relationships findings were reported in chapters 3-6. 
Because of the limited availability, its clinically silent nature and lack of awareness of 
objective measures to assess swallowing disorders, the incidence of this dysfunction 
was up to 2005 underreported 22, although recently there is increased focus on dys-
phagia as the last few years, more and more data regarding swallowing problems 
after radiotherapy are published in reputable journals. E.g. Feng et al. demonstrated 
significant relationships between dose–volume parameters of structures and objec-
tive and subjective measurements of swallowing dysfunction 23. Other groups also 
showed significant correlations of various dysphagia endpoints with dose: the su-
praglottic lesions 24 and glottic cancers 24,25. Other institutions at the same time or 
later had similar results although sometimes it is difficult to compare as we do not 
always have exactly the same definitions of the contoured organs at risks 24,26-34.
Quality of Life: Trismus
Xerostomia and dysphagia has been well documented in recent years in patients 
treated with CHT and/or RT. However few studies examined trismus as was the 
purpose of the analysis presented in chapter 7. Trismus has a significant impact on 
the QOL of head and neck cancer patients 35. Dijkstra et al reported that a reduced 
opening mouth of 18% (SD, 17%) was found in patients treated by RT involving the 
structures of the temporomandibular joint and/or pterygoid muscles 36. The authors 
found a cut-off point of 35 mm for the inter-incisal distance 37. Kent et al showed a 
high prevalence of trismus (47%) in cancer patients following >55 Gy to the mas-
seter and/or pterygoid muscles 38. Our population studied is based on 81 patients 
diagnosed with cancer of the oropharynx and treated curatively between 1999 and 
2005 by highly conformal radiation therapy techniques. According to the charts no-
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tes, 3 (4%) patients experienced trismus. Anatomical structures involved in masti-
cation were defined (masseter, temporalis, pterygoid muscle, condyl, and coronoid 
process), and the mean dose in each individual structure were computed. Less favo-
rable parameters for trismus complaints were tumors located in the BOT, and treat-
ment by 3DCRT, cCHT, non-BT, and high-dose radiation. None of these factors, ho-
wever, were found to be significant. The mean measured inter-incisal distance was 
39 mm (range, 10-65 mm). In the group of patients with a poor trismus-related QOL 
(H&N35), being defined as having a score of less or equal than 50%, the mean inter-
incisal distances were less (33 mm) as opposed to those patients with a good QOL 
score (40 mm). Similar conclusions about the inter-incisal distance can be drawn 
from the chart review (and last follow-up clinic), with chart review showing a signi-
ficant difference in inter-incisal distance (28 vs. 40 mm) between patients having 
trismus or no trismus (p = .0001). By univariate analysis, a significant relationship 
was found between dose in the masseter muscles as well as the pterygoid muscles 
and coronoid bone, and trismus complaints. In the multivariate analysis BT was the 
only remaining significant factor. For those patients whose trismus-related muscles 
were irradiated bilaterally, a significant increase of the probability of trismus was 
observed, but only with regard to the item opening mouth (H&N35, p = 0.02). For 
every additional 10 Gy in the pterygoid muscle, after a dose of 40 Gy, an increase of 
probability of trismus of 24% was observed. Currently having the availability of IMRT 
techniques, one may decrease the dose received by putting constraints on masseter 
and pterygoid muscles. Because of the several reported dose-effect relationships in 
HNC (chapters 3-7), specific attention deserves the balance between local control 
and late side-effects.
Brachytherapy
Chapters 8-10 describe BT techniques used in Erasmus MC. BT is an extremely 
conformal RT technique. Manual afterloading of the sources into applicators or af-
terloading tubes replaced direct loading of sources into the patient. In skillful, well-
trained hands, BT remains an extremely gratifying technique for applying high doses 
of radiation for small volume disease with highly conformal and accelerated proper-
ties. Results for local control of patients treated at the Erasmus MC between 1991 
and 2007 were at 5 years 88% for BT and 68% for non BT. Details are described 
in chapter 9. Selecting the right patients for BT, however, remains important. BT 
patients were found to have fewer swallowing problems compared with the non-BT 
group (chapters 9 and 10). Univariate analysis also demonstrated an advantage 
(ie, less dysphagia) related to T stage, boost treatment, neck surgery, and neck ir-
radiation. The multivariate analysis showed a significant effect for BT (implicating 
fewer swallowing complaints because of the lower doses of radiation received by the 
superior swallowing constrictor muscles). The tolerance of the swallowing muscles 
depends to some extent on the treatment modality used. In patients who receive BT 
as boost therapy, dysphagia is seen in 14% treated with an average dose of 53 Gy 
in the swallowing muscle. In contrast, dysphagia was seen in 40% of patients treated 
with EBRT to a mean dose of 68 Gy in the swallowing muscle. So far, no significant 
relationship has been seen between quality indices of BT implants and local control, 
overall survival and/or quality of life.
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Hyperbaric Oxygen
When radiation is used to treat cancer, it also (partly) affects a variety of critical 
surrounding normal tissues, as seen in previously, which can become hypocellular, 
hypovascular, and hypoxic, frequently eluded to as “3 H tissue.” The hypoxic sta-
tus of tissues can be counteracted to some extent by oxygenation of normal cells 
with hyperbaric oxygen treatment (HBOT). The effects of hyperbaric oxygen can be 
briefly summarized as follows: short-term effects are enhanced by oxygen delivery, 
reduction of edema, and phagocytosis activation, as well as anti-inflammatory ef-
fects. Long-term effects are neovascularization, osteoneogenesis, and stimulation 
of collagen formation by fibroblasts 39. So a lot of morbidity still exists after radiation 
therapy in HNC patients especially xerostomia and dysphagia although good results 
are reported when treating with brachytherapy (Chapters 8-10). It was recently found 
that a significant increase in mobilization of stem cells from the bone marrow occurs 
in the course of HBOT 40,41. Wound healing and recovery of normal-tissue radiation 
injury are the end result 42-44. In a review by Bennett et al. 40, the authors concluded 
that there is some evidence that hyperbaric oxygen improves outcomes in late radi-
ation tissue injury affecting bone and soft tissues of the head and neck, for proctitis, 
and to prevent the development of osteoradionecrosis following tooth extraction in 
an irradiated field. Although there are some conflicting experimental results 45, it is 
now believed that HBOT does not promote cancer growth (primary or metastasis). 
In the hyperbaric oxygen pilot trial described in chapter 11, we applied 30 sessions 
of hyperbaric oxygen after the series of radiotherapy. A great benefit for the quality 
of life of patients was seen in patients who were randomized for hyperbaric oxygen 
after radiotherapy. A significant difference of different aspects of quality of life was 
seen for H&N35 ‘swallowing problems’, H&N35 ‘sticky saliva’, H&N35 ‘dry mouth’, 
visual analogue scale (VAS) ‘Dry mouth’, PSS ‘eating in public’ and VAS ‘pain in 
mouth’ in favor of the hyperbaric oxygen group. No significant effect of hyperbaric 
oxygen was shown for early side effects (≤ 13 weeks post-treatment) as opposed to 
the late side effects (≥ 13 weeks post-treatment). The beneficial effects of how HBOT 
given shortly after radiotherapy is believed to work, is associated with a number of 
unknowns. It clearly demonstrates the need for a more detailed exploration of funda-
mental pathways 46. Because questions remain regarding HBOT after radiotherapy, 
currently, a larger randomized HBOT trial is running in a multi-institutional study for 
more sites in the head and neck, that is besides the oropharynx and nasopharynx 
also for the oral cavity, hypopharynx and larynx the roleof HBOT is investigated. This 
trial should confirm our promising results of the pilot randomized study.
Non-Rigid Registration / Atlas-Based Auto-Segmentation
To delineate all the described structures on CT in a busy clinic in this thesis on a 
daily basis, is extremely time-consuming. To solve this problem, we developed an 
auto-contouring program in cooperation with an industrial partner (Elekta – CMS 
Software). The basis of atlas-based auto segmentation (ABAS) is non-rigid regi-
stration which is presented in chapter 12. This non-rigid registration method is a po-
werful tool to accurately assess local shape and position changes in HNC patients. 
To keep the systematic component of the delineation error small, in this study, the 
same person delineated both CT scans. When the found transformation was app-
lied to CT scans, a good alignment between the transformed structures and original 
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contours was found. The local anatomic changes observed in this study were con-
sistent with the global measurements reported in published papers 47-50. When using 
the volume decrease rate found by Barker et al. 47 for 23 treatment days, a volume 
decrease of 13.8% is obtained. The average volume reduction for both parotids in 
our study was 14%. We observed asymmetric shifts in parotid gland surfaces, with 
average displacements of 1 ± 3 mm and 3 ± 3 mm for the medial and lateral regions 
of the irradiated glands, respectively. Our data showed that the planned mean dose 
is significantly related to the observed parotid gland volume reduction (p <0.001, r = 
0.68). We have demonstrated that for irradiated parotid glands, the lateral regions 
(with the lower planning doses) displace inward (i.e., toward the higher doses, with 
the spared parotid glands presenting little and near homogeneous deformation). Vo-
lume reduction and shape and position changes in glands belonging to non-treated 
necks showed few changes. Glands belonging to treated necks showed a general 
shrinkage and deformation. Non-rigid registration is an ideal tool with which to per-
form additional studies in larger patient series to investigate the relationship between 
the local dose and local shape and position changes in more detail. 
With ABAS, the clinician now only has to edit the auto-contour from any given struc-
ture: This has proven to be much faster, contouring time is down from 3 hours to 55 
minutes (chapter 14). Moreover, in retrospect, the edited auto-contours were some-
what more in concordance with the corresponding levels of this atlas as opposed to 
the originally contoured levels.  Auto-contouring thus seems to be an adquate way 
to go in daily radiotherapy practice.
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conclusion
Oropharyngeal Cancer (Chapter 2)
Good tumor control but late-side effects occur e.g. dysphagia.
Quality of Life: Dysphagia (Chapters 3-6)
Dose-effects relationships in base of tongue, tonsillar fossa and nasopharyngeal 
cancer are found for swallowing problems.
Quality of Lfe: Trismus (Chapter 7)
Dose-effects relationships in base of tongue and tonsillar fossa are found for trismus 
problems.
Brachytherapy (Chapters 8-10)
Patient treated by brachyhterapy have better local control, disease-free survival and 
overal survival than those treated with EBRT. Also BT patients were found to have 
fewer swallowing problems compared with the non-BT group of patients.
Hyperbaric Oxygen (Chapter 11)
A great benefit for the quality of life of patients was seen in patients who were rando-
mized for hyperbaric oxygen after radiotherapy. A significant difference of different 
aspects of quality of life was seen for H&N35 ‘swallowing problems’, H&N35 ‘sticky 
saliva’, H&N35 ‘dry mouth’, visual analogue scale (VAS) ‘Dry mouth’, PSS ‘eating in 
public’ and VAS ‘pain in mouth’ in favor of the hyperbaric oxygen group. 
Non-Rigid Registration / Atlas-Based Auto-Segmentation (Chapters 12-
14)
Non-rigid registration method is a powerful tool to accurately assess local shape and 
position changes in HNC patients. When using ABAS, edited auto-contours were so-
mewhat more in concordance with the corresponding levels of this atlas as opposed 
to the originally contoured levels.
Discussion
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Afgelopen jaren is de behandeling van hoofd hals kanker intensiever geworden door 
andere fractionerings-schema’s te gebruiken in de radiotherapie en / of door toe-
voeging van chemotherapie. Sinds 2000 krijgen alle patiënten met een hoofd hals 
kanker de bestraling in het Erasmus MC-Daniel den Hoed Kliniek, 6 fracties per 
weeek. Door middel van een licht geaccelereerd schema is er een verbetering in de 
locale controle van de tumor nagestreefd. Bijwerkingen na de radiotherapie blijven 
nog een punt van onderzoek. In hoofdstuk 1 is een samenvatting gegeven van de 
behandeling van hoofd hals kanker (HHK). Een meer gedetailleerde beschrijving 
van oropharynx kanker behandeling is in hooofdstuk 2 te lezen.
Kwaliteit van leven en bijwerkingen (slikklachten, droge mond en pijn) na bestraling 
zijn in de verdere hoofdstukken geanalyseerd in dit proefschrift. Slikproblemen zijn 
naast de droge mond een veel voorkomende bijwerking na bestraling van  HHK die 
echter tot een paar jaar geleden vaak onderbelicht bleef. In hoofdstuk 3 iwordt een 
dosis-effect relatie voor dysfagie beschreven: een signifacte relatie tussen de dosis 
die de musculus constrictor superior ontvangt bij de bestraling en de slikklachten 
van de patient. De kans op slikklachten stijgt met 19% per 10 Gy toename in de 
slikspier na 55 Gy. In hoofdstuk 4 is de dosis-effect relatie gerelateerd aan de ver-
schillende radiotherapie technieken en primaire hoofd hals tumor sites. 18% van 
de 132 patienten die geanalyseerd zijn hadden slikproblemen. Patienten met een 
tongbasis tumor hadden de meeste problemen (32%) gevolgd door patiënten met 
tonsiltumoren (22%) en nasopharynx tumoren (6%). Meer slikklachten komen voor 
bij patiënten die bestraald zijn met IMRT/3DCRT technieken in vergelijking tot bra-
chytherapie en stereotactie / Cybernknife technieken. Xerostomie en dysphagie zijn 
sterk gecorrelleerd aan elkaar. In hoofdstuk 5 zijn de bevindingen uit Michigan, USA 
en Roterdam beschreven. Beide instituten hebben min of meer gelijktijdig dezelfde 
dosis-effect relaties gerapporteerd. 
Hoofdstuk 6 presenteert data van de FEES (Fiberoptic Endoscopic Evaluation of 
Swallowing) in relatie tot de slikklachten ondervonden door de patiënten en de 
stralingsdosis in de slikspieren. Hierbij werden significante relaties gevonden. In 
de hoofdstukken 3 tot en met 6 zijn verschillende dysfagie dosis-effect relaties be-
schreven die tot 2005 ondergerapporteerd zijn gebleven. Nadien zijn er verschil-
lende publicaties verschenen in tijdschriften over slikklachten na de radiotherapie. 
Hoofdstuk 7 beschrijft het trismus probleem na bestraling van hoofd en hals kan-
ker patiënten. Uit status onderzoek blijkt dat 4% van de patiënten een beperkte 
mondopening hebben gehad. Anatomische structuren die de beperkte mondope-
ning kunnen veroorzaken zijn gedefinieerd en ingetekend op CT. De gemiddelde 
stralingsdosis die deze structuren hebben ontvangen zijn berekend en gecorreleerd 
aan de klacht beperkte mondopening. De gemiddelde mondopening gemeten is 39 
mm. Een significante relatie is gevonden tussen de musculus masseter, musculus 
pterygoid en trismus. Ook een significant verschil is beschreven tussen de patiënten 
die bilateraal bestraald zijn in vergelijking tot unilaterale bestraling. Voor elke 10 Gy 
die in de musculus pterygoideus terechtkomt is een toename in kans op trismus van 
24% na 40 Gy. 
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De hoofdstukken 8 tot en met 10 beschrijven de brachytherapie. Een zeer confor-
mele radiotherapie techniek. Goede lokale controle van de tumor is gerapporteerd 
met brachyhterapie. Minder bijwerkingen zijn gezien wanneer patiënten met een 
brachytherapie boost (14%) zijn behandeld. Een behandeling met brachytherapie 
boost geeft gemiddeld een stralings dosis van 53 Gy op de slikspier, in tegenstel-
ling tot een gemiddelde dosis van 68 Gy op de slikspier wanneer patiënten alleen 
uitwendig bestraald worden. 
De hyperbare zuurstof therapie trial om de bijwerkingen van bestraling in het hoofd 
hals gebied te reduceren is gepresenteerd in hoofdstuk 11. Wanneer normaal weef-
sel bestraald wordt dan kan deze “3 H weefsel” worden: hypocellular, hypovascular, 
and hypoxic. De hypoxische status van weefsels kan min of meer bestreden worden 
door hyperbare zuurstof therapie. In het kort samengevat zijn de korte termijn ef-
fecten: reductie van oedeem, fagocytose activatie en anti-inflammatoire effecten. 
Lange termijn effecten zijn neovascularisate, osteoneogenesis en stimulatie van col-
lageen formatie door fibroblasten. Hoewel er tegenstrijdige experimentele resultaten 
zijn, is nu min of meer consensus bereikt dat hyperbare zurstof niet tot vermenigvul-
diging van kankercellen zal leiden. In de beschreven trial kregen de patiënten met 
oropharynx of nasopharynx kanker wel of niet een extra behandeling met hyperbare 
zuurstof na de complete radiotherapie behandeling. De hyperbare zuurstof behan-
deling bestaat uit 30 sessies van ongeveer 2 uur. Een postief resultaat werd gezien 
in verschillende aspecten van kwaliteit van leven tussen de patient groepen die wel 
of niet de behandeling kregen. Vooral de late effecten (13 weken na behandeling) 
van bestraling zoals slikklachten, droge mond en pijn in de mond zijn duidelijk ver-
minderd in de groep patiënten die de hyperbare zuurstof behandeling hebben ge-
had. De exacte werking van hyperbare zuurstof in deze groep patiënten is nog in 
mist verhuld en er is daarom meer fundamenteel onderzoek nodig.
De verschillende normale weefsels die ingetekend moeten worden om het eventu-
eel te sparen bij de bestraling is arbeids intensief. Daarom is een auto-contouring 
programma een perfect hulpmiddel voor de arts. De basis van atlas-based auto seg-
mentation (ABAS) is non rigide registratie, welke gepresenteerd wordt in hoofdstuk 
12. De non-rigid registratie methode ontwikkeld door Vásquez-Osorio is een krachtig 
instrument om accuraat lokale vorm en positie veranderingen te presenteren in pa-
tiënten met hoofd hals kanker. Met ABAS worden de contouren van te voren be-
schikbaar gesteld aan de arts. Deze hoeft dan de auto-contour alleen nog te wijzigen 
indien nodig. Dit blijkt inderdaad veel sneller te gaan qua tijd die gespendeerd wordt 
met intekenen op CT in vergelijking tot het intekenen vanuit een nieuwe CT. De tijd 
die gereduceerd wordt is van 3 uur tot 55 minuten. De gewijzigde auto-contouren 
bleken ook nog dichter te staan bij de richtlijn voor hals level intekening. 
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Conclusies
Oropharyngeal Cancer (Hoofdstuk 2)
Goede tumor controle bij keelkanker bestraling maar late bijwerkingen zoals 
dysfagie ontstaan na radiotherapie.
Quality of Life: Dysphagia (Hoofdstukken 3-6)
Doisis-effect relaties in patiënten met tongbasis, tonsil en nasopharynx kanker 
zijn beschreven voor slikproblemen.
Quality of Lfe: Trismus (Hoofdstuk 7)
Doisis-effect relaties in patiënten met tongbasis, tonsil en nasopharynx kanker 
zijn beschreven voor beperkte mondopening (trismus).
Brachytherapy (Hoofdstukken 8-10)
Patiënten die zijn bestraald met brachytherapie (inwendige bestraling) hebben 
een betere lokale controle, ziektevrije overleving en totale overleving in vergelij-
king tot de patiënten die uitwendig bestraald zijn. Ook hebben patiënten behan-
deld met brachytherapie minder slikklachten.
Hyperbaric Oxygen (Hoofdstuk 11)
Patienten die gerandomiseerd waren voor hyperbare zuurstof behandeling na 
radiotherapie hebben in verschillende kwaliteit van leven items (oa. sliklkach-
ten, droge mond) een betere score dan degenen die geen hyperbare zuurstof 
behandeling hebben gehad.
Non-Rigid Registration / Atlas-Based Auto Segmentation (Hoofdstukken 12-14)
Non-rigide registratie methode is een krachtig instrument om accuraat lokale 
vorm en positie veranderingen te presenteren in hoofd hals kanker patiënten. 
Met ABAS wordt tijd die gespendeerd wordt met intekenen van CT gereduceerd 
en zijn de uiteindelijke gewijzigde ingetekende structuren meer in overeenkomst 
met de atlas richtlijn dan de oorspronkelijke intekeningen.
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